WO2023244775A1 - Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof - Google Patents
Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof Download PDFInfo
- Publication number
- WO2023244775A1 WO2023244775A1 PCT/US2023/025516 US2023025516W WO2023244775A1 WO 2023244775 A1 WO2023244775 A1 WO 2023244775A1 US 2023025516 W US2023025516 W US 2023025516W WO 2023244775 A1 WO2023244775 A1 WO 2023244775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- cycloalkyl
- halogen
- oxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims description 204
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title abstract description 6
- 229910052796 boron Inorganic materials 0.000 title abstract description 6
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 152
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 95
- 208000035475 disorder Diseases 0.000 claims abstract description 43
- 108010024121 Janus Kinases Proteins 0.000 claims abstract description 39
- 102000015617 Janus Kinases Human genes 0.000 claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 206010061218 Inflammation Diseases 0.000 claims abstract description 22
- 230000004054 inflammatory process Effects 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 18
- 230000005764 inhibitory process Effects 0.000 claims abstract description 13
- -1 -CHO Chemical group 0.000 claims description 393
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 235
- 229910052736 halogen Inorganic materials 0.000 claims description 221
- 150000002367 halogens Chemical group 0.000 claims description 221
- 229910052739 hydrogen Inorganic materials 0.000 claims description 182
- 239000001257 hydrogen Substances 0.000 claims description 181
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 165
- 150000002431 hydrogen Chemical group 0.000 claims description 127
- 125000001424 substituent group Chemical group 0.000 claims description 67
- 201000010099 disease Diseases 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 52
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- 201000008937 atopic dermatitis Diseases 0.000 claims description 32
- 125000001188 haloalkyl group Chemical group 0.000 claims description 30
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 239000013543 active substance Substances 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 22
- 201000004681 Psoriasis Diseases 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 21
- 230000007815 allergy Effects 0.000 claims description 21
- 208000026935 allergic disease Diseases 0.000 claims description 20
- 201000004624 Dermatitis Diseases 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241000282472 Canis lupus familiaris Species 0.000 claims description 13
- 230000001363 autoimmune Effects 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 208000026278 immune system disease Diseases 0.000 claims description 13
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 8
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 230000001668 ameliorated effect Effects 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010015218 Erythema multiforme Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 206010047642 Vitiligo Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 5
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000005962 mycosis fungoides Diseases 0.000 claims description 5
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims description 5
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims description 5
- 208000021781 secondary hypereosinophilic syndrome Diseases 0.000 claims description 5
- XOQABDOICLHPIS-UHFFFAOYSA-N 1-hydroxy-2,1-benzoxaborole Chemical compound C1=CC=C2B(O)OCC2=C1 XOQABDOICLHPIS-UHFFFAOYSA-N 0.000 claims description 4
- CKEWCFGVNDVQSC-UHFFFAOYSA-N 1-hydroxy-3,4-dihydro-2,1-benzoxaborinine Chemical compound C1=CC=C2B(O)OCCC2=C1 CKEWCFGVNDVQSC-UHFFFAOYSA-N 0.000 claims description 4
- KLJPGGCDUUNHPL-UHFFFAOYSA-N 2-hydroxy-1,2-benzoxaborinine Chemical compound OB1Oc2ccccc2C=C1 KLJPGGCDUUNHPL-UHFFFAOYSA-N 0.000 claims description 4
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 4
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 4
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- 230000004163 JAK-STAT signaling pathway Effects 0.000 claims description 4
- 241000282838 Lama Species 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 4
- 206010035116 pityriasis rubra pilaris Diseases 0.000 claims description 4
- 241000283074 Equus asinus Species 0.000 claims description 3
- 241001416177 Vicugna pacos Species 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 239000004243 E-number Substances 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 252
- 238000006243 chemical reaction Methods 0.000 description 170
- 238000002360 preparation method Methods 0.000 description 143
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 140
- 239000007787 solid Substances 0.000 description 127
- 238000005160 1H NMR spectroscopy Methods 0.000 description 106
- 235000019439 ethyl acetate Nutrition 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 80
- 229910001868 water Inorganic materials 0.000 description 79
- 230000002829 reductive effect Effects 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
- 239000011541 reaction mixture Substances 0.000 description 74
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 69
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 62
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 58
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 57
- 229910052938 sodium sulfate Inorganic materials 0.000 description 57
- 239000007832 Na2SO4 Substances 0.000 description 56
- 239000012267 brine Substances 0.000 description 53
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
- 239000012044 organic layer Substances 0.000 description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 41
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 41
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 41
- 239000003208 petroleum Substances 0.000 description 39
- 239000012071 phase Substances 0.000 description 35
- 229920006395 saturated elastomer Polymers 0.000 description 32
- 239000000377 silicon dioxide Substances 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 29
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 26
- 235000011152 sodium sulphate Nutrition 0.000 description 25
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 20
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 20
- 229910052681 coesite Inorganic materials 0.000 description 19
- 229910052906 cristobalite Inorganic materials 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- 229910052682 stishovite Inorganic materials 0.000 description 19
- 229910052905 tridymite Inorganic materials 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 239000012043 crude product Substances 0.000 description 18
- 239000012065 filter cake Substances 0.000 description 18
- MDNDJMCSXOXBFZ-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane Chemical compound O1CC(C)(C)COB1B1OCC(C)(C)CO1 MDNDJMCSXOXBFZ-UHFFFAOYSA-N 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 15
- VBWIZSYFQSOUFQ-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#CC1CCCCC1 VBWIZSYFQSOUFQ-UHFFFAOYSA-N 0.000 description 15
- 239000012299 nitrogen atmosphere Substances 0.000 description 15
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- 239000005457 ice water Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000012239 silicon dioxide Nutrition 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 9
- 239000004530 micro-emulsion Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 108010036949 Cyclosporine Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 8
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 150000003840 hydrochlorides Chemical class 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 7
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000004064 cosurfactant Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 5
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 5
- 150000003973 alkyl amines Chemical class 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- HVUWZJWTMFBHSG-UHFFFAOYSA-N methyl 5-amino-2-bromo-3-methylbenzoate Chemical compound COC(=O)C1=CC(N)=CC(C)=C1Br HVUWZJWTMFBHSG-UHFFFAOYSA-N 0.000 description 5
- OFDWPQOLEQDJIX-UHFFFAOYSA-N methyl 5-amino-2-bromobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1Br OFDWPQOLEQDJIX-UHFFFAOYSA-N 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- JBEUIYULCKXPPX-UOERWJHTSA-N (1r,2r)-2-aminocyclohexane-1-carbonitrile;hydrochloride Chemical compound Cl.N[C@@H]1CCCC[C@H]1C#N JBEUIYULCKXPPX-UOERWJHTSA-N 0.000 description 4
- IGDMNNQBPJHGOF-UHFFFAOYSA-N 2-(5-amino-2-bromophenyl)propan-2-ol Chemical compound CC(C)(C(C=C(C=C1)N)=C1Br)O IGDMNNQBPJHGOF-UHFFFAOYSA-N 0.000 description 4
- WQSNSIDIZKPPSS-UHFFFAOYSA-N 2-bromo-3-methyl-5-nitrobenzoic acid Chemical compound CC1=CC([N+]([O-])=O)=CC(C(O)=O)=C1Br WQSNSIDIZKPPSS-UHFFFAOYSA-N 0.000 description 4
- KCGSYHXXVLNFJN-UHFFFAOYSA-N 6-(4-methylphenyl)sulfonyl-6-azabicyclo[3.1.0]hexane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2CCCC21 KCGSYHXXVLNFJN-UHFFFAOYSA-N 0.000 description 4
- NIVBPVMTZHYBFT-UHFFFAOYSA-N 7-(4-methylphenyl)sulfonyl-7-azabicyclo[4.1.0]heptane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2CCCCC21 NIVBPVMTZHYBFT-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229910017906 NH3H2O Inorganic materials 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- DAWZEKCPPREGID-UHFFFAOYSA-N methyl 2-amino-3-cyano-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(C#N)=C1N DAWZEKCPPREGID-UHFFFAOYSA-N 0.000 description 4
- DHXPEVZMUAIGRK-UHFFFAOYSA-N methyl 2-bromo-3-chloro-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(Cl)=C1Br DHXPEVZMUAIGRK-UHFFFAOYSA-N 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 3
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229940075419 choline hydroxide Drugs 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 3
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- SWYGKKGFSVAHSW-UHFFFAOYSA-N methyl 2-amino-5-iodo-3-methoxybenzoate Chemical compound COC(=O)C1=CC(I)=CC(OC)=C1N SWYGKKGFSVAHSW-UHFFFAOYSA-N 0.000 description 3
- RSIFUNHBKKVOFE-UHFFFAOYSA-N methyl 2-bromo-3-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(C)=C1Br RSIFUNHBKKVOFE-UHFFFAOYSA-N 0.000 description 3
- HZUQFFJWNXKAJX-UHFFFAOYSA-N methyl 5-amino-2-bromo-3-chlorobenzoate Chemical compound COC(=O)C1=CC(N)=CC(Cl)=C1Br HZUQFFJWNXKAJX-UHFFFAOYSA-N 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000005825 oxyethoxy group Chemical group [H]C([H])(O[*:1])C([H])([H])O[*:2] 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910000367 silver sulfate Inorganic materials 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 3
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 3
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 2
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 2
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 2
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QOVTVIYTBRHADL-UHFFFAOYSA-N 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide Chemical compound NC1=CC(C(Cl)=C(Cl)Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O QOVTVIYTBRHADL-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940072359 anaprox Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229940107810 cellcept Drugs 0.000 description 2
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 229960004782 chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960000275 clorsulon Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 2
- 229960000465 dihydrotachysterol Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960002524 firocoxib Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 108010037743 hemoglobin glutamer-200 Proteins 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- NQVDYKOGHUVUGH-UHFFFAOYSA-N methyl 2-amino-3-chloro-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(Cl)=C1N NQVDYKOGHUVUGH-UHFFFAOYSA-N 0.000 description 2
- QDQYGNQBMQMIQK-UHFFFAOYSA-N methyl 2-bromo-5-[(2-methylpropan-2-yl)oxycarbonylamino]benzoate Chemical compound COC(=O)C1=CC(NC(=O)OC(C)(C)C)=CC=C1Br QDQYGNQBMQMIQK-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940072709 motrin Drugs 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 229960004955 oclacitinib Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229940063122 sandimmune Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- HBJOXQRURQPDEX-MHXMMLMNSA-N (2s,4r)-n-[(1s,2s)-2-chloro-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-ethylpiperidine-2-carboxamide Chemical compound C1[C@H](CC)CCN[C@@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 HBJOXQRURQPDEX-MHXMMLMNSA-N 0.000 description 1
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- CFRPSFYHXJZSBI-DHZHZOJOSA-N (E)-nitenpyram Chemical compound [O-][N+](=O)/C=C(\NC)N(CC)CC1=CC=C(Cl)N=C1 CFRPSFYHXJZSBI-DHZHZOJOSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- XFDJYSQDBULQSI-QFIPXVFZSA-N (R)-doxapram Chemical compound C([C@H]1CN(C(C1(C=1C=CC=CC=1)C=1C=CC=CC=1)=O)CC)CN1CCOCC1 XFDJYSQDBULQSI-QFIPXVFZSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- QWOZZTWBWQMEPD-UHFFFAOYSA-N 1-(2-ethoxypropoxy)propan-2-ol Chemical compound CCOC(C)COCC(C)O QWOZZTWBWQMEPD-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VVOIQBFMTVCINR-WWMZEODYSA-N 11-deoxycorticosterone pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)CC2 VVOIQBFMTVCINR-WWMZEODYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- WMDZKDKPYCNCDZ-UHFFFAOYSA-N 2-(2-butoxypropoxy)propan-1-ol Chemical compound CCCCOC(C)COC(C)CO WMDZKDKPYCNCDZ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 1
- MFWQXZZXOUIDTN-YGRLFVJLSA-N 3-(4-chloro-3-methoxyanilino)-1-[(3R,4S)-4-cyanooxan-3-yl]pyrazole-4-carboxamide Chemical compound ClC1=C(C=C(C=C1)NC1=NN(C=C1C(=O)N)[C@H]1COCC[C@@H]1C#N)OC MFWQXZZXOUIDTN-YGRLFVJLSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- DOSIONJFGDSKCQ-UHFFFAOYSA-N 3-amino-5-pyridin-4-yl-1h-pyridin-2-one;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 DOSIONJFGDSKCQ-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 1
- NARHAGIVSFTMIG-UHFFFAOYSA-N 4-(dimethylamino)-2,2-diphenylpentanamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC(C)N(C)C)C1=CC=CC=C1 NARHAGIVSFTMIG-UHFFFAOYSA-N 0.000 description 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-M 4-chlorobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ABYGSZMCWVXFCQ-UHFFFAOYSA-N 4-propylheptane Chemical compound CCCC(CCC)CCC ABYGSZMCWVXFCQ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- KEEYRKYKLYARHO-UHFFFAOYSA-N 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC(C)=C1CC1=CN=C(N)N=C1N KEEYRKYKLYARHO-UHFFFAOYSA-N 0.000 description 1
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RUCHWTKMOWXHLU-UHFFFAOYSA-M 5-nitroanthranilate Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C([O-])=O RUCHWTKMOWXHLU-UHFFFAOYSA-M 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical group C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- WGLYHYWDYPSNPF-RQFIXDHTSA-N Apramycin sulfate Chemical compound OS(O)(=O)=O.O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O WGLYHYWDYPSNPF-RQFIXDHTSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KSSJCVLNYHKPFZ-UHFFFAOYSA-N C1CCCCC1NC(N1)=NC=C2C1=CC=N2 Chemical compound C1CCCCC1NC(N1)=NC=C2C1=CC=N2 KSSJCVLNYHKPFZ-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 108010091893 Cosyntropin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-LNQMSSPSSA-N Cyotec Chemical compound CCCCC(C)(O)CC=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-LNQMSSPSSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 206010064769 Dactylitis Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 101100010343 Drosophila melanogaster lobo gene Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000005899 Fipronil Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- QZJIMDIBFFHQDW-LMLSDSMGSA-N Fosfomycin tromethamine Chemical compound C[C@@H]1O[C@@H]1P(O)([O-])=O.OCC([NH3+])(CO)CO QZJIMDIBFFHQDW-LMLSDSMGSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 239000005906 Imidacloprid Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 239000009471 Ipecac Substances 0.000 description 1
- ZFHZUGUCWJVEQC-FPUQOWELSA-M Ipodate Sodium Chemical compound [Na+].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I ZFHZUGUCWJVEQC-FPUQOWELSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- OJCZPLDERGDQRJ-UHFFFAOYSA-N Sufentanil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- AHMMSNQYOPMLSX-CNQKSJKFSA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] undec-10-enoate Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)OC(=O)CCCCCCCCC=C)[C@@H]4[C@@H]3CCC2=C1 AHMMSNQYOPMLSX-CNQKSJKFSA-N 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001946 acepromazine maleate Drugs 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000526 acetazolamide sodium Drugs 0.000 description 1
- MRSXAJAOWWFZJJ-UHFFFAOYSA-M acetazolamide sodium Chemical compound [Na+].CC(=O)NC1=NN=C(S([NH-])(=O)=O)S1 MRSXAJAOWWFZJJ-UHFFFAOYSA-M 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- LYCYLGFSIXIXAB-NUZRHMIVSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-h Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 LYCYLGFSIXIXAB-NUZRHMIVSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960001171 acetohydroxamic acid Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940013181 advil Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 229940057282 albuterol sulfate Drugs 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960000971 altrenogest Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960003683 amprolium Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940009192 apoquel Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940097776 arthrotec Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 229960002945 atracurium besylate Drugs 0.000 description 1
- XXZSQOVSEBAPGS-UHFFFAOYSA-L atracurium besylate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 XXZSQOVSEBAPGS-UHFFFAOYSA-L 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 125000003324 azulen-4-yl group Chemical group [H]C1=C([H])C2=C(*)C([H])=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 229940064856 azulfidine Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 229940040544 bromides Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229960000954 carbenicillin indanyl sodium Drugs 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960004445 cefotetan disodium Drugs 0.000 description 1
- 229960003016 cefoxitin sodium Drugs 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 229960004467 ceftiofur sodium Drugs 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229950006295 cerdulatinib Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940106265 charcoal Drugs 0.000 description 1
- VQIGDTLRBSNOBV-VQIYXBGXSA-N chembl2105739 Chemical compound OC(=O)\C=C/C(O)=O.C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 VQIGDTLRBSNOBV-VQIYXBGXSA-N 0.000 description 1
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 229960003716 cilastatin sodium Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 229960005098 clidinium bromide Drugs 0.000 description 1
- GKEGFOKQMZHVOW-KUTGSRRKSA-M clidinium bromide Chemical compound [Br-].C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKEGFOKQMZHVOW-KUTGSRRKSA-M 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960005351 cloprostenol sodium Drugs 0.000 description 1
- 229960001054 clorazepate dipotassium Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960003710 dantrolene sodium Drugs 0.000 description 1
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229940070230 daypro Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 229960001878 decoquinate Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001425 deferoxamine mesylate Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960004165 deslorelin acetate Drugs 0.000 description 1
- 229960002845 desmopressin acetate Drugs 0.000 description 1
- 229950008390 desoxycorticosterone pivalate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960001894 detomidine Drugs 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960004837 diethylcarbamazine citrate Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 229950001733 difloxacin Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 229960004280 dinoprost tromethamine Drugs 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- AXRWJSAOLNNBNI-UHFFFAOYSA-L disodium;2-[(4-carbamoylphenyl)-(carboxylatomethylsulfanyl)arsanyl]sulfanylacetate Chemical compound [Na+].[Na+].NC(=O)C1=CC=C([As](SCC([O-])=O)SCC([O-])=O)C=C1 AXRWJSAOLNNBNI-UHFFFAOYSA-L 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 1
- 229960001863 disopyramide phosphate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003218 dolasetron mesylate Drugs 0.000 description 1
- 229940072701 dolobid Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 229960002955 doxapram Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229940095629 edetate calcium disodium Drugs 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 229960002406 edrophonium chloride Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 208000020947 enthesitis Diseases 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 1
- 229960002346 eprinomectin Drugs 0.000 description 1
- LGUDKOQUWIHXOV-UHFFFAOYSA-N epsiprantel Chemical compound C1C(C2=CC=CC=C2CCC2)N2C(=O)CN1C(=O)C1CCCCC1 LGUDKOQUWIHXOV-UHFFFAOYSA-N 0.000 description 1
- 229960005362 epsiprantel Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960005416 estradiol cypionate Drugs 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229940011916 ethacrynate sodium Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- KVFVBPYVNUCWJX-UHFFFAOYSA-M ethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC[N+](C)(C)C KVFVBPYVNUCWJX-UHFFFAOYSA-M 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 229940065410 feldene Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950006663 filgotinib Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229940013764 fipronil Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 229960004285 fomepizole Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000000716 hydrazinylidene group Chemical group [*]=NN([H])[H] 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- PJBQYZZKGNOKNJ-UHFFFAOYSA-M hydron;5-[(2-methylpyridin-1-ium-1-yl)methyl]-2-propylpyrimidin-4-amine;dichloride Chemical compound Cl.[Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C PJBQYZZKGNOKNJ-UHFFFAOYSA-M 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 239000008146 hyperosmotic laxative Substances 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229940056881 imidacloprid Drugs 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960004683 imidocarb Drugs 0.000 description 1
- SCEVFJUWLLRELN-UHFFFAOYSA-N imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940068812 inamrinone lactate Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940083603 ipodate sodium Drugs 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004819 isoxsuprine Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940033992 kaolin / pectin Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 229960002018 liothyronine sodium Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940063718 lodine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- MGEOLZFMLHYCFZ-UHFFFAOYSA-N melarsomine Chemical compound C1=CC([As](SCCN)SCCN)=CC=C1NC1=NC(N)=NC(N)=N1 MGEOLZFMLHYCFZ-UHFFFAOYSA-N 0.000 description 1
- 229960002234 melarsomine Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- CTUAQTBUVLKNDJ-OBZXMJSBSA-N meropenem trihydrate Chemical compound O.O.O.C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 CTUAQTBUVLKNDJ-OBZXMJSBSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940001676 metacam Drugs 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 229960001620 methohexital sodium Drugs 0.000 description 1
- KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- WKGMRNVMTBOZIS-UHFFFAOYSA-N methyl 2-amino-3-bromo-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(Br)=C1N WKGMRNVMTBOZIS-UHFFFAOYSA-N 0.000 description 1
- YJEZEMGLLFLMDF-UHFFFAOYSA-N methyl 2-amino-3-methoxybenzoate Chemical compound COC(=O)C1=CC=CC(OC)=C1N YJEZEMGLLFLMDF-UHFFFAOYSA-N 0.000 description 1
- VBYFCWUBAVYLAY-UHFFFAOYSA-N methyl 5-amino-2-bromo-3-(trifluoromethyl)benzoate Chemical compound COC(=O)c1cc(N)cc(c1Br)C(F)(F)F VBYFCWUBAVYLAY-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229940099245 milbemycin oxime Drugs 0.000 description 1
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 229940112801 mobic Drugs 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- GVXPWRLSQCRZHU-UHFFFAOYSA-N n,n'-bis(3-methylphenyl)methanediimine Chemical compound CC1=CC=CC(N=C=NC=2C=C(C)C=CC=2)=C1 GVXPWRLSQCRZHU-UHFFFAOYSA-N 0.000 description 1
- VMEHWKYUBRIRFM-WCQYABFASA-N n-[(1r,2r)-2-cyanocyclopentyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H]1[C@H](C#N)CCC1 VMEHWKYUBRIRFM-WCQYABFASA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 229940089466 nalfon Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940100605 naprelan Drugs 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 229940079888 nitenpyram Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 229960004781 novobiocin sodium Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
- 229940072711 nuprin Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960004780 orbifloxacin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003068 ormetoprim Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960003994 oxacillin sodium Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940097084 pediacare fever Drugs 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940090663 penicillin v potassium Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960001635 pirlimycin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940014329 polysulfated glycosaminoglycan Drugs 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 229960003508 ponazuril Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 229960003456 pralidoxime chloride Drugs 0.000 description 1
- HIGSLXSBYYMVKI-UHFFFAOYSA-N pralidoxime chloride Chemical compound [Cl-].C[N+]1=CC=CC=C1\C=N\O HIGSLXSBYYMVKI-UHFFFAOYSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940106299 previcox Drugs 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 229960002151 pyridostigmine bromide Drugs 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229940018203 pyrilamine maleate Drugs 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000008147 saline laxative Substances 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 1
- 229960002245 selamectin Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 229960003693 sevelamer Drugs 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 229960001567 sodium stibogluconate Drugs 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- JMHCCAYJTTWMCX-QWPJCUCISA-M sodium;(2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 JMHCCAYJTTWMCX-QWPJCUCISA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
- ODWMXYHUKDMPTR-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-chloropyridazin-3-yl)azanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=CC=C(Cl)N=N1 ODWMXYHUKDMPTR-UHFFFAOYSA-N 0.000 description 1
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- CWCSCNSKBSCYCS-UHFFFAOYSA-M sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate Chemical compound [Na+].CCC(=C)C(=O)C1=CC=C(OCC([O-])=O)C(Cl)=C1Cl CWCSCNSKBSCYCS-UHFFFAOYSA-M 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005346 succimer Drugs 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940120904 succinylcholine chloride Drugs 0.000 description 1
- FFSBEIRFVXGRPR-UHFFFAOYSA-L succinylcholine chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C FFSBEIRFVXGRPR-UHFFFAOYSA-L 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960001204 sufentanil citrate Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960001423 tetracosactide Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229950004468 thiacetarsamide sodium Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960000340 thiopental sodium Drugs 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960004885 tiamulin Drugs 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 229940060693 tiletamine / zolazepam Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229940019127 toradol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- QTFFGPOXNNGTGZ-RCSCTSIBSA-N u3c8e5bwkr Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(OC3C[C@@H]4CC5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-RCSCTSIBSA-N 0.000 description 1
- 229950000088 upadacitinib Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229940045605 vanadium Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 description 1
- 229960004298 vecuronium bromide Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- Protein kinases are families of enzymes that catalyze the phosphorylation of specific residues in proteins, broadly classified into tyrosine and serine/threonine kinases. Inappropriate kinase activity, arising from mutation, over-expression, or inappropriate regulation, dys- regulation, or de-regulation, as well as over- or under-production of growth factors or cytokines has been implicated in many diseases, including but not limited to cancer, cardiovascular diseases, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative disorders such as Alzheimer's disease.
- Inappropriate kinase activity triggers a variety of biological cellular responses relating to cell growth, cell differentiation, survival, apoptosis, mitogenesis, cell cycle control, and cell mobility implicated in the aforementioned and related diseases.
- protein kinases have emerged as an important class of enzymes as targets for therapeutic intervention.
- JAK family of cellular protein tyrosine kinases (JAK-1, JAK-2, JAK-3, and Tyk- 2) play a central role in cytokine signaling (Kisseleva et al, Gene, 2002, 285, 1; Yamaoka et al. Genome Biology 2004, 5, 253)).
- cytokines Upon binding to their receptors, cytokines activate JAK, which then phosphorylate the cytokine receptor, thereby creating docking sites for signaling molecules, notably, members of the signal transducer and activator of transcription (STAT) family that ultimately lead to gene expression, which stimulates biologic responses such as an itch signal.
- STAT signal transducer and activator of transcription
- Activation of the JAK-STAT pathway also results in several other ancillary biologic activities that contribute to the inflammation and pruritic processes that contribute to acute allergy in animals but can also exacerbate clinical signs and contribute to chronic allergy.
- Atopic dermatitis also known as eczema
- AD is a common chronic inflammatory skin disease, affecting approximately 20% of children and up to 10% of adults and it imposes a significant financial and societal burden because of the direct medical costs and decreased productivity of individuals with AD.
- the burden of AD appears to be related mainly to the limited methods of treatment.
- Topical interventions are the mainstay of AD therapy.
- topical corticosteroids have been the first-line treatment. Their use, however, may be limited by potential local and systemic adverse effects.
- Topical calcineurin inhibitors are classified as second-line anti-inflammatory therapy for AD, with advantages in long-term maintenance and application to special sites.
- Topical calcineurin inhibitors inhibit calcineurin-dependent T-cell activation; however, a black box warning about the potential for developing malignant neoplasms with the use of topical calcineurin inhibitors reduces patients’ adherence to treatment.
- Psoriasis and psoriatic arthritis are associated with aberrant inflammation and the production of proinflammatory mediators. Psoriasis and psoriatic arthritis are inflammatory diseases with overlapping features and shared immunologic mechanisms.
- control of itching with antihistamines is usually ineffective, and while treatment with glucocorticoids can be effective, long term use is not ideal due to adverse side effects including excessive hunger, thirst, and urination, and increased risk of diabetes and urinary tract infections.
- JAK inhibition may provide a therapeutic strategy for various immune and inflammatory diseases, including rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), psoriasis, alopecia areata, atopic dermatitis, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft- versus-host disease, cutaneous lupus, transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer.
- RA rheumatoid arthritis
- IBD inflammatory bowel disease
- psoriasis
- JAK inhibitor compounds are described in published patent application nos. US 2020/0339585, WO 2009/114512 A1, WO 2021/003501 A1 and U.S. Patent No 7,598,257 B2.
- Published patent applications filed by Merck Sharp & Dohme Corporation and Intervet Inc. relating to pyrazole carboxamide compounds as JAK inhibitors include WO 2013/041042 A1, WO 2018/108969 A1, WO 2020/118597 A1, WO 2020/120673 A1, WO 2020/120679 A1, and WO2020221914 A1 (all incorporated by reference herein in their entirety).
- the present disclosure provides for boron containing pyrimidine compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses.
- the compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable.
- JAK Janus kinase
- One embodiment of the present disclosure includes a combination including a compound of the present disclosure, and one or more other pharmaceutical or veterinary active substances.
- the present disclosure provides methods of treating inflammation, auto- immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
- a method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound of the present disclosure.
- the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
- the disease or disorder is atopic dermatitis, psoriasis, or rheumatoid arthritis.
- One embodiment of the present disclosure includes a use of a compound of the present disclosure for the treatment of one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer.
- the disease or disorder is atopic dermatitis, psoriasis, or rheumatoid arthritis.
- One or more aspects and embodiments may be incorporated in a different embodiment although not specifically described. That is, all aspects and embodiments may be combined in any way or combination.
- the headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims.
- the word “may” is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must).
- the words “include”, “including”, and “includes” mean including but not limited to the described variable.
- the present disclosure provides for a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer thereof: a), b), wherein X1 is selected from the group consisting of -O-, -N(R 5 )-, and -C(R 6 )(R 7 )-; X2 is selected from the group consisting of -O-, -N(R 5 )-, and -C(R 6 )(R 7 )-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R 5 )-, and -C(
- A is selected from the group consisting of bcnzo[c][l,2]oxaborol-l(3H)-ol, 3,4-dihydro- lHbenzo[c][l,2]oxaborinin-l-ol, and 2H-benzo[e][l,2]oxaborinin-2-ol, 7,8 dihydro- 2H-l,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 :
- X1 is selected from the group consisting of -O-, and -C(R 6 )(R 7 )-;
- X2 is selected from the group consisting of -O-, and -C(R 6 )(R 7 )-, or X2 comprises a bond between X1 and X3;
- X3 is -C(R 6 )(R 7 )-, except X1 and X2 cannot both be -O-;
- R 1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen;
- R 2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R 2 group may optionally be substituted independently of one another with one or
- X1 is -C(R 6 )(R 7 )-;
- X2 is selected from -C(R 6 )(R 7 )-, or X2 comprises a bond between X1 and X3;
- X3 is-C(R 6 )(R 7 )-
- R 1 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen;
- R 2 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl, wherein the last two members of the above-mentioned R 2 group may optionally be substituted independently of one another with one or more halogen;
- each R 3 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cyclo
- X2 is -C(R 6 )(R 7 )-;
- X3 is -C(R 6 )(R 7 )-;
- R 1 , R 2 , and R 3 are hydrogen;
- R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl;
- R 6 and R 7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with one or more of halogen;
- each R 11 is independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R 11 group may optionally be substituted independently of one another with one or more halogen;
- each R 11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl,
- compositions of the present disclosure encompass any composition made by admixing a compound of formula (I), (Ia), and (Ib) or a mixture thereof, and pharmaceutically acceptable excipients.
- optionally substituted means "unsubstituted or substituted," and therefore, the generic structural formulas described herein encompasses compounds containing the specified optional substituent as well as compounds that do not contain the optional substituent.
- the following terms have the following meanings unless indicated otherwise. The following definitions are meant to clarify, but not limit, the terms defined. If a particular term used herein is not specifically defined, such term should not be considered indefinite. Rather, terms are used within their accepted meanings.
- alkyl refers to monovalent saturated aliphatic hydrocarbon groups having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably 1-6 carbon atoms.
- the hydrocarbon chain may be either straight-chained or branched.
- Illustrative alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and tert-butyl.
- an “alkenyl” group refers to an alkyl group having one or more double bonds present in the chain
- an “alkynyl” group refers to an alkyl group having one or more triple bonds present in the chain.
- Illustrative cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, as well as partially saturated versions thereof, such as cyclohexenyl, and cyclohexadienyl.
- heteroaryl or “heteroaromatic” refers to aromatic ring groups having 5 to 14 ring atoms selected from carbon and at least one (typically 1-4, more typically 1 or 2) heteroatom (e.g., oxygen, nitrogen, sulfur, or silicon). They include monocyclic rings and polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or more other carbocyclic aromatic or heteroaromatic rings.
- arylalkyl refers to those radicals in which an aryl, heteroaryl, or heterocyclyl group is linked through an alkyl group. Examples includes benzyl, phenethyl, pyridylmethyl, and the like.
- alkyl linking groups in which a carbon atom, for example, a methylene group, has been replaced by, for example, an oxygen atom. Examples include phenoxymethyl, pyrid-2-yloxymethyl, 3-(naphth- 1-yloxy)propyl, and the like.
- veterinary or veterinarily, or pharmaceutical or pharmaceutically acceptable salt refers to any salt of a compound disclosed herein which retains its biological properties and which is not toxic or otherwise undesirable for veterinary or pharmaceutical use.
- the general use of the terms pharmaceutical or pharmaceutically is intended to reach either veterinary or veterinarily, as well.
- the terms may be used interchangeably as context allows.
- Such salts may be derived from a variety of organic and inorganic counter-ions known in the art.
- Salts further include, by way of example only, salts of non-toxic organic or inorganic acids, such as halides, such as, chloride and bromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane- disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate),
- inorganic bases that may be used to form base addition salts include, but are not limited to, metal hydroxides, such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; metal amides, such as lithium amide and sodium amide; metal carbonates, such as lithium carbonate, sodium carbonate, and potassium carbonate; and ammonium bases such as ammonium hydroxide and ammonium carbonate.
- metal hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide
- metal amides such as lithium amide and sodium amide
- metal carbonates such as lithium carbonate, sodium carbonate, and potassium carbonate
- ammonium bases such as ammonium hydroxide and ammonium carbonate.
- Non-limiting examples of unsubstituted alkylamine bases that may be used in accordance with the present disclosure include methylamine, ethylamine, diethylamine, and triethylamine.
- a substituted alkylamine base may be substituted with one or more hydroxyl groups, and preferably one to three hydroxyl groups.
- Non-limiting examples of substituted alkylamine bases that may be used in accordance with the present disclosure include 2-(diethylamino)ethanol, ⁇ , ⁇ -dimethylethanolamine (deanol), tromethamine, ethanolamine, and diolamine.
- Stereoisomers and polymorphic forms [0073] In certain cases, the depicted substituents may contribute to optical isomers and/or stereoisomerism.
- isomers Compounds having the same molecular formula but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example when it is bonded to four different groups, a pair of enantiomers is possible.
- a molecule with at least one stereocenter may be characterized by the absolute configuration of its asymmetric center and is designated (R) or (S) according to the rules of Cahn and Prelog (Cahn et al., 1966, Angew. Chem. 78: 413-447, Angew. Chem., Int. Ed. Engl. 5: 385-414 (errata: Angew. Chem., Int. Ed. Engl. 5:511); Prelog and Helmchen, 1982, Angew. Chem. 94: 614-631, Angew. Chem. Internat. Ed. Eng.
- a chiral compound may exist as either an individual enantiomer or as a mixture thereof.
- a mixture containing equal proportions of enantiomers is called a “racemic mixture”.
- the compounds disclosed herein may possess one or more asymmetric centers, and such compounds may therefore be produced as a racemic mixture, an enantiomerically enriched mixture, or as an individual enantiomer.
- the compounds disclosed herein are “stereochemically pure”.
- a stereochemically pure compound has a level of stereochemical purity that would be recognized as “pure” by those of skill in the art. Of course, this level of purity may be less than 100%.
- “stereochemically pure” designates a compound that is substantially free, i.e. at least about 85% or more, of alternate isomers.
- the compound is at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or about 99.9% free of other isomers.
- active agents may exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form.
- the compositions of the disclosure may include hydrates and solvates of the active agents.
- a pharmaceutically acceptable prodrug of the compound represented by the formula (I), formula (Ia), and formula (Ib) is also included in the present disclosure.
- the pharmaceutically acceptable prodrug refers to a compound having a group which may be converted into an amino group, a hydroxyl group, a carboxyl group, or the like, by solvolysis or under a physiological condition. Examples of the groups forming the prodrug include those as described in Prog. Med., 5, 2157-2161 (1985) or “Pharmaceutical Research and Development” (Hirokawa Publishing Company, 1990), vol. 7, Drug Design, 163-198.
- prodrug is used throughout the specification to describe any pharmaceutically acceptable form of a compound which, upon administration to a patient, provides the active compound.
- Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present disclosure.
- Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
- Prodrugs include compounds that may be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound.
- the present disclosure includes all pharmaceutically acceptable isotopically-labelled compounds wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of the disclosure include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulfur, such as 35 S.
- isotopically- labelled compounds of the disclosure may be useful in drug or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of the disclosure may generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically- labeled reagent in place of the non-labeled reagent previously employed.
- the disclosure provides a process for preparing a compound of any embodiment of formula (I), formula (Ia) and formula (Ib) as described herein.
- compositions and Methods of Administration may be administered in certain embodiments using veterinary or pharmaceutical compositions including at least one compound of formula (I), formula (Ia) and formula (Ib), if appropriate in the salt form, either used alone or in the form of a combination with one or more compatible and veterinary or pharmaceutically acceptable carriers, such as diluents or adjuvants, or with another agent.
- veterinary or pharmaceutical compositions including at least one compound of formula (I), formula (Ia) and formula (Ib), if appropriate in the salt form, either used alone or in the form of a combination with one or more compatible and veterinary or pharmaceutically acceptable carriers, such as diluents or adjuvants, or with another agent.
- compositions which comprise a derivative of a compound of formula (I), formula (Ia) and formula (Ib) or a salt thereof, and an acceptable excipient, carrier or diluent.
- composition may also be in a variety of forms which include, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations.
- the particular route selected by the practitioner depends upon factors such as the physicochemical properties of the pharmaceutical or therapeutic agent, the condition of the host and economics.
- the disclosure provides for a method for treating a patient having a disease or disorder susceptible to modulation of JAK including administering a therapeutically effective amount of a compound as described herein, including any embodiment of a compound according formula (I), (Ia), or (Ib).
- the disclosure provides a method of treating a patient having a disease or disorder that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
- the disclosure provides for a method of treating a patient having a disease or disorder with a therapeutically effective amount of a compound which is an embodiment of formula (I), formula (Ia) and formula (Ib), wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease
- Formulations for oral use may be hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. Capsules may also be soft gelatin capsules, wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.
- the compositions may also be in the form of oil-in-water or water-in-oil emulsions.
- the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally- occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening agents, bittering agents, flavoring agents, and preservatives.
- the composition is in the form of a microemulsion. Microemulsions are well suited as the liquid carrier vehicle.
- Microemulsions are quaternary systems including an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids. Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions).
- the interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously.
- SA surface-active
- Co-SA co-surface-active
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as sucrose, saccharin or aspartame, bittering agents, and flavoring agents may be added to provide a palatable oral preparation.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol.
- a non-toxic parenterally-acceptable diluent or solvent for example, as a solution in 1,3-butane diol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. Preservatives, such as phenol or benzyl alcohol, may be used.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- the active agent is present in the formulation at a concentration of about 0.05 to 10% weight/volume.
- a compound of formula (I), formula (a) and formula (IVb) may be employed as such or in the form of their preparations or formulations as combinations.
- a compound of formula (I), formula (Ia) and formula (Ib) according to the disclosure may be combined with one or more agents having the same sphere of activity, for example, to increase activity, or with substances having another sphere of activity, for example, to broaden the range of activity.
- the compounds of formula (I), formula (Ia) or formula (Ib) according to the disclosure may be combined with one or more additional pharmaceutical or veterinary active agents.
- additional active agents which may be used in the methods provided herein in combination with a compound of formula (I), (Ia) or (Ib) include, but are not limited to, disease- modifying anti-rheumatic drugs (DMARDs such as cyclosporine A and methotrexate), anti- inflammatory agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), immnunosuppressants, mycophenolate mofetil, biologic agents, TNF-a inhibitors (such as etanercept), Cox-2 inhibitors (such as firocoxib), and analgesics.
- DMARDs disease- modifying anti-rheumatic drugs
- NSAIDs nonsteroidal anti-inflammatory drugs
- immnunosuppressants such as mycophenolate mofetil
- biologic agents such as TNF-a inhibitors (such as et
- Preferred intervals may be daily, weekly, monthly, quarterly, semi-annually, or annually.
- the dosages may be varied depending on the requirements of the patient, for example, the size of the human or mammal being treated, the severity of the condition being treated, the route of administration, and the potency of the compound(s) being used. Determination of the proper dosage and route of administration for a particular situation is within the skill of the practitioner. Generally, the treatment will be initiated with smaller dosages, which are less than the optimum dose of the compound, which may be increased in small increments until the optimum effect under the particular circumstances of the condition is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- the compound is administered orally; in one embodiment, the compound is administered parenterally; in one embodiment, the compound is administered topically.
- the present disclosure provides for a method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound according to any embodiment herein of formula (I), (Ia) or (Ib) wherein the subject is a mammal.
- reaction was allowed to warm to 20°C and stirred at 20°C for 1 h. TLC showed the reaction was complete.
- the mixture was extracted with EtOAc (10 mL x 3).
- the combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue.
- reaction mixture was heated and stirred at 95°C for 16 h. TLC showed the reaction was complete.
- the reaction mixture was adjusted pH to 7 with saturated aq. Na2CO3 (1L) at 0°C and extracted with ethyl acetate (500 mL x 3). The combined organic phase was washed with brine (300 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue.
- reaction was allowed to warm to 25°C and stirred at 25°C for 1 h. LCMS showed the reaction was complete and desired MS observed.
- the reaction mixture was quenched with aq. HCl (1 N, 5 mL) carefully and diluted with H 2 O (20 mL). The mixture was extracted with EtOAc (50 mL x 2). The combined organics were washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuum to give a residue.
- reaction was allowed to warm to 20°C and stirred at 20°C for 2 h.
- the mixture was extracted with EtOAc (10 mL x 3).
- the combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a residue.
- the reaction mixture was diluted with H 2 O (500 mL) and extracted with EtOAc (500 mL ⁇ 3). The combined organic layers were washed with brine (300mL ⁇ 2), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a residue.
- the residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, eluent of 0 ⁇ 25% ethyl acetate/petroleum ether gradient @ 100 mL/min) to obtain methyl 2-bromo-3-cyano-5-nitro-benzoate (32 g, 82.7% yield) as a yellow solid.
- the mixture was stirred at 35°C for 2h. LCMS showed the reaction was consumed completely and one main peak with desired mass was detected.
- the reaction mixture was diluted with H 2 O (100 mL) and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue.
- the crude product was further purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [water (NH 4 HCO 3 )-ACN]; B%: 35%-65%, 10 min) to give [2-[[tert- butyl(dimethyl)silyl]oxymethyl]-4-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5-methyl- pyrimidin-2-yl]amino]-6-fluoro-phenyl] boronic acid (2 g) as a white solid.
- reaction was allowed to warm to 25°C and stirred for 3 h. TLC showed the reaction was complete.
- the reaction mixture was quenched by addition saturated aq. NH4Cl (100 mL) at 0°C, and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a residue.
- the crude product was further purified by prep-HPLC (column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water ( NH 4 HCO 3 )-ACN]; B%: 30%-50%,10min) to give tert-butyl N-(2-hydroxy-1,2-benzoxaborinin-6-yl)carbamate (1 g, 28% yield) as a white solid.
- N'- [2-(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 12.8 g, 74.3 mmol, 15.5 mL, 2 eq) and 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]- 1,3,2-dioxaborolane (19.9 g, 74.3 mmol, 2 eq) at 0 o C.
- Comparator compounds which are derivatives of Compound (II) having Y 1-4 substituents (compounds C001-C020 as listed below) were prepared and the biological testing results for the comparator compounds are provided in Table 3b (Biological Examples).
- the comparator compounds may be made using the starting materials and synthetic procedures as outlined in PCT Application No. PCT/US2020/070234, which published as WO 2021/003501, and which is herein incorporated by reference with regard to such teaching.
- Y3 OH Y2 B I) Y 1 Y 2 3 4 Y Y C001 (Et)2CH- Me H H BIOLOGICAL EXAMPLES [0701] The compounds of the present disclosure were tested in multiple assays as described below.
- Cytokine inhibition Assay Protocol for IL-4 and IL-31 [0704] The test compounds are solubilized in DMSO, then diluted to make appropriate stocks for use in the assay, and diluted in culture medium to 20X assay concentrations.
- PBMC PBMC’s are plated and allowed to settle for 1 hour at 37 °C, 5% CO2. Test compounds and controls are added to the settled PBMC’s and incubated for 1 hour at 37 °C, 5% CO 2 . The PBMC’s are then be treated with PHA (10 ⁇ g/mL) and incubated for 24 hours at 37 °C, 5% CO 2 . DMSO is used as a positive control and dexamethasone (100 nM) was used as a reference inhibitor control. After the main incubation, cell culture supernatants are harvested and assayed for the cytokines listed above, using standard Luminex protocols.
- GM-CSF/pSTAT5 Whole blood from a healthy donor was lysed to remove red blood cells. Cells were plated onto a 96 well plate. Compound was added and incubated for 1 hour (at 37°C). After 1 hour, cells were stimulated with GM-CSF for 15 minutes. Cells were fixed and stained with anti- pSTAT5 antibody.
- IL-4/pSTAT6 PBMC from a healthy donor was plated onto a 96w plate. Compound was added and incubated for 1 hour (at 37°C). After 1 hour, cells were stimulated with IL-4 for 15 minutes. Cells were fixed and stained with anti-pSTAT6 antibody. After staining, cells were read on a Beckman-Coulter CytoFLEX. Cytokine Function assay protocol for IL-31 [0707] The protocol for the cytokine function assay for IL-31 is set forth below: 1.
- DH82 cells at a density of 125,000 cells per well in a 96-well plate and incubate overnight in EMEM medium (ATCC® 30-2003) containing 15% FBS and 10 ng/mL canine IFNr (R&D, Cat# 781-CG-050, Lot#DIA1320011) at 37 °C. 2. After 24 hr, wash with 37 °C pre-warmed PBS (100 uL/well). 3. Add serum-free MEM, 90 uL per well, 2 hr, 37 °C. 4. Add 10 uL 10x IL-31 (40, 10, 2.5 ug/mL) in duplicate, 5 min, 37 °C. 5. Remove medium, add 60 uL lysis buffer per well.
- Dog LM (liver microsome) Assay [0708] The metabolic degradation of the test compound is assayed at 37°C with pooled liver microsomes from dogs (Beagle). The final incubation volume of 100 ⁇ l per time point contains TRIS buffer pH 7.6 at RT (0.1 M), magnesium chloride (5 mM), microsomal protein (1 mg/ml) and the test compound at a final concentration of 1 ⁇ M. Following a short preincubation period at 37°C, the reactions were initiated by addition of beta-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 1 mM) and terminated by transferring an aliquot into solvent after different time points.
- TRIS buffer pH 7.6 at RT 0.1 M
- magnesium chloride 5 mM
- microsomal protein (1 mg/ml)
- the test compound at a final concentration of 1 ⁇ M. Following a short preincubation period at 37°C, the reactions were initiated by addition of beta-nico
- NADPH-independent degradation was monitored in incubations without NADPH, terminated at the last time point.
- the [%] remaining test compound after NADPH independent incubation is reflected by the parameter c(control) (metabolic stability).
- the quenched incubations are pelleted by centrifugation (10000 g, 5 min). An aliquot of the supernatant is assayed by LC-MS/MS for the amount of parent compound.
- the half-life (t1/2 INVITRO) is determined by the slope of the semilogarithmic plot of the concentration-time profile.
- the compounds of the present disclosure are potent JAK inhibitors. As such, the compounds may be used for the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable.
- All publications, patents, and patent applications cited in this specification are incorporated herein by reference for the teaching to which such citation is used.
- Test compounds for the experiments described herein were employed in free or salt form.
- R 1 is selected from the group consisting of hydrogen and C 1-6 alkyl
- R 2 is selected from the group consisting of hydrogen and C1-6 alkyl
- each R 3 is independently selected from the group consisting of hydrogen and C1-6 alkyl
- R 6 and R 7 are independently selected from the group consisting of hydrogen and C 1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen
- R 12 is hydrogen
- each R 13 is independently selected from the group consisting of hydrogen, halogen, cyano, C 1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven
- R 1 , R 2 , and R 3 are hydrogen;
- R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl;
- R 6 and R 7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen;
- each R 11 is independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen;
- each R 11a is independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, and C 3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen;
- R 1 is selected from the group consisting of hydrogen and C1-6 alkyl
- R 2 is selected from the group consisting of hydrogen and C 1-6 alkyl
- each R 3 is independently selected from the group consisting of hydrogen and C1-6 alkyl
- R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl
- R 6 and R 7 are independently selected from the group consisting of hydrogen and C 1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen
- R 12 is hydrogen
- each R 13 is independently selected from the group consisting of hydrogen, halogen, cyano, C 1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C)
- R 1 , R 2 , and R 3 are hydrogen;
- R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl;
- R 6 and R 7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C 1-6 alkyl may optionally be substituted with one or more of halogen;
- each R 11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen;
- each R 11a is independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen;
- the disease or disorder is a condition that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
- the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, inflammatory/autoimmune polyarthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic
- the mammalian cell is a cell from a subject having an inflammatory condition.
- #27 A composition including a compound of any one of paragraphs 1-17 and a pharmaceutically or veterinary acceptable carrier.
- #28 A combination including a compound of any one of paragraphs 1-17, and one or more other pharmaceutical or veterinary active substances.
- #29. A method for treating one or more diseases or disorders of inflammation, auto- immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound of any one of paragraphs 1-17. [0750] #30.
Abstract
The present disclosure describes boron containing pyrimidine compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the present disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.
Description
BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF
BACKGROUND OF THE DISCLOSURE
[0001] Protein kinases are families of enzymes that catalyze the phosphorylation of specific residues in proteins, broadly classified into tyrosine and serine/threonine kinases. Inappropriate kinase activity, arising from mutation, over-expression, or inappropriate regulation, dys- regulation, or de-regulation, as well as over- or under-production of growth factors or cytokines has been implicated in many diseases, including but not limited to cancer, cardiovascular diseases, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative disorders such as Alzheimer's disease. Inappropriate kinase activity triggers a variety of biological cellular responses relating to cell growth, cell differentiation, survival, apoptosis, mitogenesis, cell cycle control, and cell mobility implicated in the aforementioned and related diseases. Thus, protein kinases have emerged as an important class of enzymes as targets for therapeutic intervention. In particular, the JAK family of cellular protein tyrosine kinases (JAK-1, JAK-2, JAK-3, and Tyk- 2) play a central role in cytokine signaling (Kisseleva et al, Gene, 2002, 285, 1; Yamaoka et al. Genome Biology 2004, 5, 253)). Upon binding to their receptors, cytokines activate JAK, which then phosphorylate the cytokine receptor, thereby creating docking sites for signaling molecules, notably, members of the signal transducer and activator of transcription (STAT) family that ultimately lead to gene expression, which stimulates biologic responses such as an itch signal. Activation of the JAK-STAT pathway also results in several other ancillary biologic activities that contribute to the inflammation and pruritic processes that contribute to acute allergy in animals but can also exacerbate clinical signs and contribute to chronic allergy.
[0002] Atopic dermatitis (AD), also known as eczema, is a common chronic inflammatory skin disease, affecting approximately 20% of children and up to 10% of adults and it imposes a significant financial and societal burden because of the direct medical costs and decreased productivity of individuals with AD. The burden of AD appears to be related mainly to the limited methods of treatment. Furthermore, according to the AD treatment guidelines, there is no standard of care and treatment may be tailored to an individual’s needs. Topical interventions are the mainstay of AD therapy. Until now, topical corticosteroids have been the first-line
treatment. Their use, however, may be limited by potential local and systemic adverse effects. Topical calcineurin inhibitors are classified as second-line anti-inflammatory therapy for AD, with advantages in long-term maintenance and application to special sites. Topical calcineurin inhibitors inhibit calcineurin-dependent T-cell activation; however, a black box warning about the potential for developing malignant neoplasms with the use of topical calcineurin inhibitors reduces patients’ adherence to treatment. [0003] Psoriasis and psoriatic arthritis are associated with aberrant inflammation and the production of proinflammatory mediators. Psoriasis and psoriatic arthritis are inflammatory diseases with overlapping features and shared immunologic mechanisms. Psoriasis is a systemic disease in that it primarily affects the skin but up to 40% of individuals with psoriasis may go on to develop psoriatic arthritis. Psoriatic arthritis typically affects the peripheral joints and may occasionally affect the spine and sacroiliac area. Enthesitis, dactylitis, and nail changes such as pitting and discoloration are also common manifestations of psoriatic disease in patients with joint involvement. [0004] Pruritus is commonly a significant clinical sign associated with flea associated dermatitis in dogs. Medical management of for pruritis may be sought in cases where the cause of itching is not identifiable, or treatment of underlying disease does not eliminate itching. However, control of itching with antihistamines is usually ineffective, and while treatment with glucocorticoids can be effective, long term use is not ideal due to adverse side effects including excessive hunger, thirst, and urination, and increased risk of diabetes and urinary tract infections. [0005] JAK inhibition may provide a therapeutic strategy for various immune and inflammatory diseases, including rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), psoriasis, alopecia areata, atopic dermatitis, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft- versus-host disease, cutaneous lupus, transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer. Reference is made to Schwartz et al., JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Nat Rev Drug Discov., 2017 Dec 28., 17(1):78, herein incorporated by reference with regard to the rationale for targeting JAKs.
[0006] Various classes of compounds have been shown to inhibit JAK enzymes. For example, US 8,133,899 B2 (to Pfizer) discloses use of pyrrolo[2,3-D]pyrimidine compounds as JAK inhibitors. In particular, oclacitinib (APOQUEL®) is a cyclohexylamino pyrrolopyrimidine demonstrated to be a Janus kinase inhibitor that controls clinical signs of allergic skin disease in dogs (as disclosed in J. Vet. Pharmacol. Therap. 2014 Aug 37(4): 317-324). JAK inhibitor compounds are described in published patent application nos. US 2020/0339585, WO 2009/114512 A1, WO 2021/003501 A1 and U.S. Patent No 7,598,257 B2. [0007] Published patent applications filed by Merck Sharp & Dohme Corporation and Intervet Inc. relating to pyrazole carboxamide compounds as JAK inhibitors include WO 2013/041042 A1, WO 2018/108969 A1, WO 2020/118597 A1, WO 2020/120673 A1, WO 2020/120679 A1, and WO2020221914 A1 (all incorporated by reference herein in their entirety). [0008] Pyrazole carboxamide Janus Kinase 1 inhibitors are also described by Siu et al., The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3- yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties, J. Med. Chem. 2017 Dec 14; 60(23): 9676-9690 (incorporated herein by reference). [0009] There remains a need for therapies targeting and modulating JAK kinases for the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK modulation would be desirable. [0010] Any foregoing applications, and all documents cited therein or during their prosecution (“application cited documents”) and all documents cited or referenced in the application cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference. [0011] Citation or identification of any document in this application is not an admission that such document is available as prior art. SUMMARY OF THE DISCLOSURE [0012] The present disclosure provides boron-containing compounds, or their pharmaceutically
acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound of the disclosure. [0013] In a first aspect, the present disclosure provides for boron containing pyrimidine compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. [0014] In one embodiment, the present disclosure provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof; wherein A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro- 1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro-2H-1,6,9- trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 as defined herein, and the variables R1-11 , R11a, and R12-13 in respect of compounds of formula (I), (Ia) and (Ib) are defined herein. I),
, ).
[0015] One embodiment of the present disclosure includes a method for treating a patient having a disease or disorder susceptible to modulation of JAK including administering a therapeutically effective amount of a compound of the present disclosure. In one aspect, the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer. In one aspect, the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, psoriasis, and rheumatoid arthritis. In one aspect, the compound is administered in an amount to
perturb an immune regulatory pathway in a cell. In one aspect, the perturbation results in an effect on the JAK-STAT pathway. [0016] One embodiment of the present disclosure includes a method of inhibiting JAK in a mammalian cell including contacting the mammalian cell with a compound of the present disclosure. In one aspect, the mammalian cell is a cell from a subject having an inflammatory condition. [0017] One embodiment of the present disclosure includes a composition including a compound of the present disclosure and a pharmaceutically or veterinary acceptable carrier. [0018] One embodiment of the present disclosure includes a combination including a compound of the present disclosure, and one or more other pharmaceutical or veterinary active substances. [0019] In another aspect, the present disclosure provides methods of treating inflammation, auto- immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described. [0020] In one embodiment of the present disclosure, a method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer is provided including administering to a subject in need thereof an effective amount of a compound of the present disclosure. In one aspect, the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis. In one embodiment, the subject is a mammal. In one embodiment, the subject is a non-human animal. In one embodiment, the subject is selected from livestock mammals, domestic mammals, or companion animals. In one aspect, the subject is selected from cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs, and cats. In one aspect, the subject is a human. [0021] One embodiment of the present disclosure includes a compound of the present disclosure for use in medicine. [0022] One embodiment of the present disclosure includes a compound of the present disclosure for the manufacture of a medicament for the treatment of one or more diseases or disorder of inflammation, auto-immune dysfunction, and cancer. In one aspect, the disease or disorder is atopic dermatitis, psoriasis, or rheumatoid arthritis. [0023] One embodiment of the present disclosure includes a use of a compound of the present disclosure for the treatment of one or more diseases or disorders of inflammation, auto-immune
dysfunction, and cancer. In one aspect, the disease or disorder is atopic dermatitis, psoriasis, or rheumatoid arthritis. [0024] One or more aspects and embodiments may be incorporated in a different embodiment although not specifically described. That is, all aspects and embodiments may be combined in any way or combination. [0025] The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word "may" is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words “include”, “including”, and “includes” mean including but not limited to the described variable. [0026] These and other embodiments are disclosed or are obvious from and encompassed by the following Detailed Description. DETAILED DESCRIPTION [0027] In a first aspect, the present disclosure provides for boron containing pyrimidine compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. [0028] The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. [0029] In one embodiment, the present disclosure provides for a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer thereof:
a), b), wherein
X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be -O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R6)(R7)), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R6)(R7)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy),
wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen;
R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl,
A is selected from the group consisting of bcnzo[c][l,2]oxaborol-l(3H)-ol, 3,4-dihydro- lHbenzo[c][l,2]oxaborinin-l-ol, and 2H-benzo[e][l,2]oxaborinin-2-ol, 7,8 dihydro- 2H-l,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 :
R5 is selected from the group consisting of hydrogen, Ci-e alkyl, C3-7 cycloalkyl, C1-6
9
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1- 3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl); wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring; R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen members of the above-mentioned R10 group may optionally be substituted
independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0030] In one embodiment of the compound of formula I as described herein X1 is -C(R6)(R7)-; X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is-C(R6)(R7)-
R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0031] In yet another embodiment of the compound of formula I as described herein X1 is selected from the group consisting of -O-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0032] In one embodiment of the compound of formula I as described herein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be
substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0033] In one embodiment of the compound of formula I as described herein R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above- mentioned R13 group may optionally be substituted independently of one another by one or more halogen. [0034] In one embodiment, the present disclosure provides for a compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer thereof, wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be –O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R7)(R8)-), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6
alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl; A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro- 1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro- 2H-1,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 : 4, A6,
A7; R5 is sele loalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and - (C1-3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring;
R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen members of the above-mentioned R10 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted
independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0035] In one embodiment of the compound of formula (Ia) or (Ib) as described herein X1 is -C(R6)(R7)-; X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is-C(R6)(R7)- R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
[0036] In another embodiment of the compound of formula (Ia) or (Ib) as described herein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0037] In yet another embodiment of the compound of formula (Ia) or (Ib) as described herein R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen.
[0038] In yet another embodiment of the compound of formula (Ia) or (Ib) as described herein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl. [0039] In another embodiment of the compound of formula (Ia) or (Ib) as described herein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O- and -C(R6)(R7)-, except X1 and X2 may not both be -O-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-; R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl;
R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members said R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0040] In another embodiment of the compound of formula (Ia) or (Ib) as described herein X2 is -C(R6)(R7)-; X3 is -C(R6)(R7)-; R1, R2, and R3, are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R12 is hydrogen; and each R13 is independently selected from the group consisting hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen. [0041] In one embodiment, the present disclosure is a compound selected from the group shown in Table 1 below:
TABLE 1 Example Struc Example Number ture Number Structure
Example mber Str Example Nu ucture Number Structure
[0042] In one embodiment, the present disclosure is a compound selected from the group shown in Table 2 below:
TABLE 2 Example Struc Example Number ture Number Structure
Example Struc Example N b ture N b Structure
25
Example Struc Example Number ture Number Structure
, p p p g up consisting of Examples 1-24 and Examples 25-50 (Table 1 and Table 2) and the compound has trans relative stereochemistry as represented in formula (Ia) and (Ib): nd .
[0044] In one embodiment, the present disclosure provides a compound selected from the group consisting of Examples 1-25 (as shown in Table 1) and Examples 26-50 (as shown in Table 2) and has trans relative stereochemistry as represented in formula (Ia). [0045] In one embodiment, the present disclosure provides a compound selected from the group consisting of Examples 1-25 (as shown in Table 1) and Examples 26-50 (as shown in Table 2) and has trans relative stereochemistry as represented in formula (Ib).
Definitions [0046] Terms used herein will have their customary meaning in the art unless specified otherwise. The organic moieties mentioned in the definitions of the variables of the compound of formula (I), (Ia), and (Ib) are - like the term halogen – collective terms for individual listings of the individual group members. The prefix Cn-Cm (or Cn-m) indicates, in each case, the possible number of carbon atoms in the group. [0047] The term “animal” as used herein includes all mammals, birds and fish and also includes all vertebrate animals. Animals include, but are not limited to, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an individual animal in all stages of development, including embryonic and fetal stages. In some embodiments, the animal will be a non-human animal. [0048] By the term “enriched” is meant when the weight:weight ratio is at least approximately 1.05 or higher in favor of the enantiomer that displays significant in vitro and in vivo activity (the eutomer). [0049] In one embodiment, the compounds of the instant disclosure are selective JAK1 inhibitors relative to JAK2. The determination of relative selectivity for a given compound of JAK1 inhibition is defined as the relative ratio of the (JAK2 IC5o value/JAKl IC5o value). In one embodiment, for a given compound, the relative ratio of the (JAK2 IC5o value/JAKl IC5o value) is at least 2. In yet another embodiment, for a given compound, the relative ratios of the JAK2 IC5o value/JAKl IC5o value) is at least 5. In another embodiment, the relative ratios of the JAK2 IC50/JAK1 IC50 are preferably at least 10. In one embodiment the ratios of the JAK2 IC50/JAK1 IC50 are greater than 10. [0050] The term "treatment" or "treating" includes alleviating, ameliorating, relieving or otherwise reducing the signs and symptoms associated with a disease or disorder. [0051] "Therapeutically effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. [0052] The term "composition", as in pharmaceutical composition, is intended to encompass a product including the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which
results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present disclosure encompass any composition made by admixing a compound of formula (I), (Ia), and (Ib) or a mixture thereof, and pharmaceutically acceptable excipients. [0053] The term "optionally substituted" means "unsubstituted or substituted," and therefore, the generic structural formulas described herein encompasses compounds containing the specified optional substituent as well as compounds that do not contain the optional substituent. [0054] When referring to the compounds disclosed herein, the following terms have the following meanings unless indicated otherwise. The following definitions are meant to clarify, but not limit, the terms defined. If a particular term used herein is not specifically defined, such term should not be considered indefinite. Rather, terms are used within their accepted meanings. [0055] As used herein, “alkyl” refers to monovalent saturated aliphatic hydrocarbon groups having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably 1-6 carbon atoms. The hydrocarbon chain may be either straight-chained or branched. Illustrative alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and tert-butyl. Similarly, an “alkenyl” group refers to an alkyl group having one or more double bonds present in the chain, and an “alkynyl” group refers to an alkyl group having one or more triple bonds present in the chain. [0056] As used herein “halogen” or “halo” refers to a halogen. In some embodiments, the halogen is preferably Br, Cl, or F. [0057] As used herein, “haloalkyl” refers to monovalent saturated aliphatic hydrocarbon groups having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably 1-6 carbon atoms, wherein at least one hydrogen atom is substituted by a halogen, including but not limited to perhalo groups where all hydrogen atoms are replaced with halogen atoms. The haloalkyl chain can be either straight-chained or branched. Illustrative alkyl groups include trifluoromethyl, trifluoroethyl, trifluoropropyl, trifluorobutyl, and pentafluoroethyl. Similarly, a “haloalkenyl” group refers to a haloalkyl group having one or more double bonds present in the chain, and a “haloalkynyl” group refers to a haloalkyl group having one or more triple bonds present in the chain.
[0058] Moreover, an “alkylene” linker group refers to a divalent alkyl group, namely (CH2)x, where x is 1 to 20, preferably 1 to 8, preferably 1 to 6, and more preferably 1 to 3. [0059] As used herein, “hydroxyalkyl” refers to an alkyl group as herein defined substituted with one or more –OH group. Similarly, a “hydroxyalkenyl” group refers to a haloalkyl group having one or more double bonds present in the chain, and a “hydroxyalkynyl” group refers to a haloalkyl group having one or more triple bonds present in the chain. [0060] As used herein, “aryl” refers to a substituted or unsubstituted carbocyclic aromatic ring system, either pendent or fused, such as phenyl, naphthyl, anthracenyl, phenanthryl, tetrahydronaphthyl, indane, or biphenyl. A preferred aryl group is phenyl. [0061] As used herein, “cycloalkyl” refers to an unsaturated or partially saturated hydrocarbon ring, containing from 3 to 15 ring atoms. Illustrative cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, as well as partially saturated versions thereof, such as cyclohexenyl, and cyclohexadienyl. Moreover, bridged rings, such as adamantane, are included within the definition of “cycloalkyl.” [0062] As used herein, the term “heterocyclyl” refers to an unsaturated or partially saturated hydrocarbon ring, containing from 3 to 15 ring atoms, wherein one or more carbon atom is replaced with a heteroatom selected from O, N, S, or Si, where each N, S, or Si may be oxidized, and where each N may be quarternized. A heterocyclyl group may be attached to the remainder of the molecule through a heteroatom. Heterocyclyl does not include heteroaryl. [0063] As used herein, the term “heteroaryl” or “heteroaromatic” refers to aromatic ring groups having 5 to 14 ring atoms selected from carbon and at least one (typically 1-4, more typically 1 or 2) heteroatom (e.g., oxygen, nitrogen, sulfur, or silicon). They include monocyclic rings and polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or more other carbocyclic aromatic or heteroaromatic rings. Examples of monocyclic heteroaryl groups include furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- imidazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 2- oxadiazolyl, 5-oxadiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3-pyrazolyl, 4-pyrazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 2- pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl), tetrazolyl (e.g., tetrazolyl) and thienyl (e.g., 2-thienyl, 3-thienyl.
Examples of monocyclic six-membered nitrogen-containing heteroaryl groups include pyrimidinyl, pyridinyl and pyridazinyl. Examples of polycyclic aromatic heteroaryl groups include carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzisoxazolyl. [0064] The terms "arylalkyl," "heteroarylalkyl," and “heterocyclylalkyl” refers to those radicals in which an aryl, heteroaryl, or heterocyclyl group is linked through an alkyl group. Examples includes benzyl, phenethyl, pyridylmethyl, and the like. The terms also include alkyl linking groups in which a carbon atom, for example, a methylene group, has been replaced by, for example, an oxygen atom. Examples include phenoxymethyl, pyrid-2-yloxymethyl, 3-(naphth- 1-yloxy)propyl, and the like. Similarly, the term “benzyl” as used herein is a radical in which a phenyl group is attached to a CH2 group, thus, a CH2Ph group. Benzyl groups may be substituted or unsubstituted. The term substituted benzyl refers to radicals in which the phenyl group or CH2 contains one or more substituents. In one embodiment, the phenyl group may have 1 to 5 substituents, or in another embodiment 2 to 3 substituents. [0065] As used herein “optionally substituted” refers to a substitution of a hydrogen atom, which would otherwise be present for the substituent. When discussing ring systems, the optional substitution is typically with 1, 2, or 3 substituents replacing the normally-present hydrogen. When referencing straight and branched moieties, however, the number of substitutions may be more, occurring wherever hydrogen is present. The substitutions may be the same or different. [0066] Illustrative substituents, which with multiple substituents can be the same or different, include halogen, haloalkyl, R', OR', OH, SH, SR', NO2, CN, C(O)R', C(O)(alkyl substituted with one or more of halogen, haloalkyl, NH2, OH, SH, CN, and NO2), C(O)OR', OC(O)R', CON(R')2, OC(O)N(R')2, NH2, NHR', N(R')2, NHCOR', NHCOH, NHCONH2, NHCONHR', NHCON(R')2, NRCOR', NRCOH, NHCO2H, NHCO2R', NHC(S)NH2, NHC(S)NHR', NHC(S)N(R')2, CO2R', CO2H, CHO, CONH2, CONHR', CON(R')2, S(O)2H, S(O)2R', SO2NH2, S(O)H, S(O)R', SO2NHR', SO2N(R')2, NHS(O)2H, NR'S(O)2H, NHS(O)2R', NR'S(O)2R', Si(R')3, where each of the preceding may be linked through a divalent alkylene linker, (CH2)x, where x is 1, 2, or 3. In embodiments where a saturated carbon atom is optionally substituted with one or more substituent groups, the substituents may be the same or different and also include =O, =S, =NNHR', =NNH2, =NN(R')2, =N-OR', =N-OH, =NNHCOR',
=NNHCOH, =NNHCO2R', =NNHCO2H, =NNHSO2R', =NNHSO2H, =N-CN, =NH, or =NR'. For each of the preceding, each may be linked through an alkylene linker, (CH2)x, where x is 1, 2, or 3, Each occurrence of R’ is the same or different and , in some embodiments, represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, or, in some embodiments,when two R’ are each attached to a nitrogen atom, they may form a saturated or unsaturated heterocyclic ring containing from 4 to 6 ring atoms. [0067] As used herein, the phrase veterinary or veterinarily, or pharmaceutical or pharmaceutically acceptable salt refers to any salt of a compound disclosed herein which retains its biological properties and which is not toxic or otherwise undesirable for veterinary or pharmaceutical use. The general use of the terms pharmaceutical or pharmaceutically is intended to reach either veterinary or veterinarily, as well. The terms may be used interchangeably as context allows. [0068] Such salts may be derived from a variety of organic and inorganic counter-ions known in the art. Such salts include acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4- hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4- chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic, 3-phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid, and like acids. [0069] Salts further include, by way of example only, salts of non-toxic organic or inorganic acids, such as halides, such as, chloride and bromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane- disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-
methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, benzoate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, and the like. [0070] Examples of inorganic bases that may be used to form base addition salts include, but are not limited to, metal hydroxides, such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; metal amides, such as lithium amide and sodium amide; metal carbonates, such as lithium carbonate, sodium carbonate, and potassium carbonate; and ammonium bases such as ammonium hydroxide and ammonium carbonate. [0071] Examples of organic bases that may be used to form base addition salts include, but are not limited to, metal alkoxides, such as lithium, sodium, and potassium alkoxides including lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, and potassium tert-butoxide; quaternary ammonium hydroxides, such as choline hydroxide; and amines including, but not limited to, aliphatic amines (i.e., alkylamines, alkenylamines, alkynylamines, and alicyclic amines), heterocyclic amines, arylamines, heteroarylamines, basic amino acids, amino sugars, and polyamines. [0072] The base may be a quaternary ammonium hydroxide, wherein one or more of the alkyl groups of the quaternary ammonium ion are optionally substituted with one or more suitable substituents. Preferably, at least one alkyl group is substituted with one or more hydroxyl groups. Non-limiting examples of quaternary ammonium hydroxides that may be used in accordance with the present disclosure include choline hydroxide, trimethylethylammonium hydroxide, tetramethylammonium hydroxide, and is preferably choline hydroxide. An alkylamine base may be substituted or unsubstituted. Non-limiting examples of unsubstituted alkylamine bases that may be used in accordance with the present disclosure include methylamine, ethylamine, diethylamine, and triethylamine. A substituted alkylamine base may be substituted with one or more hydroxyl groups, and preferably one to three hydroxyl groups. Non-limiting examples of substituted alkylamine bases that may be used in accordance with the present disclosure include 2-(diethylamino)ethanol, Ν,Ν-dimethylethanolamine (deanol), tromethamine, ethanolamine, and diolamine.
Stereoisomers and polymorphic forms [0073] In certain cases, the depicted substituents may contribute to optical isomers and/or stereoisomerism. Compounds having the same molecular formula but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example when it is bonded to four different groups, a pair of enantiomers is possible. A molecule with at least one stereocenter may be characterized by the absolute configuration of its asymmetric center and is designated (R) or (S) according to the rules of Cahn and Prelog (Cahn et al., 1966, Angew. Chem. 78: 413-447, Angew. Chem., Int. Ed. Engl. 5: 385-414 (errata: Angew. Chem., Int. Ed. Engl. 5:511); Prelog and Helmchen, 1982, Angew. Chem. 94: 614-631, Angew. Chem. Internat. Ed. Eng. 21: 567-583; Mata and Lobo, 1993, Tetrahedron: Asymmetry 4: 657-668) or may be characterized by the manner in which the molecule rotates the plane of polarized light and is designated dextrorotatory or levorotatory (namely, as (+)- or (-)-isomers, respectively). A chiral compound may exist as either an individual enantiomer or as a mixture thereof. A mixture containing equal proportions of enantiomers is called a “racemic mixture”. [0074] In certain embodiments, the compounds disclosed herein may possess one or more asymmetric centers, and such compounds may therefore be produced as a racemic mixture, an enantiomerically enriched mixture, or as an individual enantiomer. Unless indicated otherwise, for example by designation of stereochemistry at any position of a formula, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. Methods for determination of stereochemistry and separation of stereoisomers are well-known in the art. [0075] In certain embodiments, the compounds disclosed herein are “stereochemically pure”. A stereochemically pure compound has a level of stereochemical purity that would be recognized as “pure” by those of skill in the art. Of course, this level of purity may be less than 100%. In certain embodiments, “stereochemically pure” designates a compound that is substantially free, i.e. at least about 85% or more, of alternate isomers. In particular embodiments, the compound is at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%,
about 96%, about 97%, about 98%, about 99%, about 99.5% or about 99.9% free of other isomers. [0076] In addition, the compounds disclosed herein (‘active agents’) may exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form. The compositions of the disclosure may include hydrates and solvates of the active agents. In some embodiments, the compositions of the disclosure may include up to 15% (w/w), up to 20% (w/w), or up to 30% (w/w) of a particular solid form. [0077] As used herein, the terms “subject” and “patient” may be used interchangeably herein. In one embodiment, the subject is a human. In one embodiment, the subject is a companion animal such as a dog or cat. In a further embodiment, the subject is an animal such as a sheep, cow, horse, goat, fish, pig, or domestic fowl (e.g., chicken, turkey, duck, or goose). In another embodiment, the subject is a primate such as a monkey such as a cynomolgous monkey or a chimpanzee. [0078] In addition, a pharmaceutically acceptable prodrug of the compound represented by the formula (I), formula (Ia), and formula (Ib) is also included in the present disclosure. The pharmaceutically acceptable prodrug refers to a compound having a group which may be converted into an amino group, a hydroxyl group, a carboxyl group, or the like, by solvolysis or under a physiological condition. Examples of the groups forming the prodrug include those as described in Prog. Med., 5, 2157-2161 (1985) or “Pharmaceutical Research and Development” (Hirokawa Publishing Company, 1990), vol. 7, Drug Design, 163-198. The term prodrug is used throughout the specification to describe any pharmaceutically acceptable form of a compound which, upon administration to a patient, provides the active compound. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present disclosure. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that may be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. [0079] The present disclosure includes all pharmaceutically acceptable isotopically-labelled compounds wherein one or more atoms are replaced by atoms having the same atomic number,
but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the disclosure include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S. Certain isotopically- labelled compounds of the disclosure, such as those incorporating a radioactive isotope, may be useful in drug or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, may be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of the disclosure may generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically- labeled reagent in place of the non-labeled reagent previously employed. In one aspect, the disclosure provides a process for preparing a compound of any embodiment of formula (I), formula (Ia) and formula (Ib) as described herein. Compositions and Methods of Administration [0080] The compounds of formula (I), formula (Ia) and formula (Ib) used in the methods disclosed herein may be administered in certain embodiments using veterinary or pharmaceutical compositions including at least one compound of formula (I), formula (Ia) and formula (Ib), if appropriate in the salt form, either used alone or in the form of a combination with one or more compatible and veterinary or pharmaceutically acceptable carriers, such as diluents or adjuvants, or with another agent. There are provided compositions which comprise a derivative of a compound of formula (I), formula (Ia) and formula (Ib) or a salt thereof, and an acceptable excipient, carrier or diluent. The composition may also be in a variety of forms which include, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations. The particular route selected by the practitioner depends upon factors
such as the physicochemical properties of the pharmaceutical or therapeutic agent, the condition of the host and economics. [0081] In one aspect, the disclosure provides for a method for treating a patient having a disease or disorder susceptible to modulation of JAK including administering a therapeutically effective amount of a compound as described herein, including any embodiment of a compound according formula (I), (Ia), or (Ib). [0082] In one embodiment, the disclosure provides a method of treating a patient having a disease or disorder that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2. [0083] In one embodiment, the disclosure provides for a method of treating a patient having a disease or disorder with a therapeutically effective amount of a compound which is an embodiment of formula (I), formula (Ia) and formula (Ib), wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer. [0084] In one embodiment, the disclosure provides a method of treating a patient as described above, wherein the the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis psoriasis, and rheumatoid arthritis. [0085] According to one embodiment, the disclosure provides for a method of treating a patient having a disease or disorder susceptible to modulating of JAK and including administering an amount of a compound according to the disclosure in an amount to perturb an immune regulatory pathway in a cell. In one such embodiment, the perturbation results in an effect on the JAK- STAT pathway. [0086] In one aspect, the disclosure provides a method of inhibiting JAK in a mammalian cell including contacting the mammalian cell with a compound according to any embodiment of
formula (I), (Ia), or (Ib). In certain embodiments, the mammalian cell is a cell from a subject having an inflammatory condition. [0087] In one aspect, the disclosure provides for a composition including a compound according to any embodiment of formula (I), formula (Ia) and formula (Ib) and a pharmaceutically or veterinary acceptable carrier. [0088] The composition may be in a form suitable for oral use, for example, as dietary supplements, troches, lozenges, chewables, tablets, hard or soft capsules, emulsions, aqueous or oily suspensions, aqueous or oily solutions, dispersible powders or granules, syrups, or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of veterinary or pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, bittering agents, flavoring agents, coloring agents and preserving agents in order to provide elegant and palatable preparations. In certain cases, it is convenient and efficient to administer veterinary medicines orally by placing the therapeutic agent in a solid or liquid matrix that is suitable for oral delivery. These methods include chewable drug-delivery formulations. The problem associated with administering oral formulations to animals is that the therapeutic agent often provides an unpleasant taste, aroma, or texture, which causes the animals to reject the composition. This is further exacerbated by compositions that are hard and difficult to swallow. [0089] Oral veterinary compositions in the form of soft chewable compositions (“soft chews”), or chewable tablets that are palatable are usually convenient to administer to certain animals, particularly cats and dogs, and may be used effectively to dose veterinary medicine to these animals. However, many oral compositions including active agents with a bitter or unpleasant taste are not well accepted by cats and dogs. Furthermore, when the bioavailability of an active agent from an oral dosage form is not sufficient or is variable, the required exposure of the animal to the active ingredient may not be sufficient to provide the desired efficacy. Problems such as these often lead to low or sub-optimal efficacy and control of parasites. [0090] Chewable dosage forms for drug delivery are well known to pharmaceutical technology. It is known in the pharmaceutical industry that the act of chewing increases the surface area of the available active ingredient and may increase the rate of absorption by the digestive tract. Chewable systems are also advantageous where it is desirable to make an active ingredient available topically to the mouth or throat areas for both local effects and/or systemic absorption.
Further, chewable dosage forms are also utilized to ease drug administration in pediatric and geriatric patients. Examples of chewable dosage forms may be found in U.S. Pat. Nos. 6,387,381; 4,284,652; 4,327,076; 4,935,243; 6,270,790; 6,060,078; 4,609,543; and 5,753,255, all incorporated herein by reference. [0091] Palatability and "mouth feel" are important characteristics to be considered in providing a dosage form, or matrix, for an active pharmaceutical or medicinal. Unfortunately, many pharmaceuticals and other active ingredients have a bitter or otherwise unpalatable taste, or an unacceptable mouth feel, due to the grittiness or chalkiness of the compound, or both. These characteristics make it difficult to incorporate such active ingredients into the current state of the art for chewable dosage forms because the objectionable taste and/or mouth feel make it less likely to obtain compliance by the user. Oral veterinary dosage forms that are not palatable to the animal treated result in low acceptance of the medicament by the animal and a low level of compliance. Thus, there is a need for improved oral veterinary dosage forms that are palatable and well accepted by the treated animal. [0092] Another challenge with oral veterinary compositions, particularly soft chewable compositions, is that the release and dissolution of the active agent from the composition after it is ingested by the animal can be variable and incomplete. This leads to variability in the amount of the drug that is absorbed from the digestive tract of the animal. [0093] US Patent No. 7,955,632 (incorporated herein by reference) describes palatable, edible soft chewable medication vehicles for the delivery of pharmaceutically acceptable active ingredients to an animal and processes of making the same. [0094] Furthermore, US 2004/0037869 A1, US 2004/0151759 A1, WO 2005/062782 and WO 2004/016252 to Cleverly et al. (incorporated herein by reference) describe chewable veterinary formulations and tablets that contain at least one pharmaceutical active agent, and WO 2009/02451A2 and US 2011/0059988 to Heckeroth et al. describe various compositions for oral administration to animals (all incorporated herein by reference). [0095] Traditionally, in veterinary formulations, palatability had been achieved by the inclusion of animal byproducts or flavors derived from animal sources into the formulation. For example, it is customary to include excipients, such as chicken powder, liver powder, beef, ham, fish, or rawhide-derived products in dog chews to make the chew attractive and palatable to the dog. See, e.g., U.S. Patent 6,086,940; U.S. Patent 6,093,441; U.S. Patent 6,159,516; U.S. Patent
6,110,521; U.S. Patent 5,827,565; U.S. Patent 6,093,427, all to Axelrod et at. (all incorporated herein by reference). [0096] Exceptionally palatable soft chewable oral veterinary compositions that provide high bioavailability of active agent are described in U.S. Patent 9,259,417; U.S. Patent 9,233,100; U.S. Patent 9,931,320; U.S. Patent 10,596,156; all to Soll et al. (all incorporated herein by reference). [0097] Lozenges are solid compositions containing one or more active ingredients intended to dissolve or disintegrate slowly in the oral cavity by passive incubation in the oral cavity, or actively by sucking or chewing. They may be used for systemic effect if the drug is absorbed through the buccal or esophageal lining or is swallowed. In particular, soft lozenges may be chewed or allowed to dissolve slowly in the mouth. These dosage forms have the advantage of being flavored and thus easy to administer to both human and animal patients; have formulas that are easy to change and may be patient specific; may deliver accurate amounts of the active ingredient to the oral cavity and digestive system; and allow for the drug to remain in contact with the oral or esophageal cavity for an extended period of time. [0098] Tablets may contain the active ingredient in admixture with non-toxic, pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. [0099] Formulations for oral use may be hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. Capsules may also be soft gelatin capsules, wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. [0100] The compositions may also be in the form of oil-in-water or water-in-oil emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-
occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening agents, bittering agents, flavoring agents, and preservatives. [0101] In one embodiment of the formulation, the composition is in the form of a microemulsion. Microemulsions are well suited as the liquid carrier vehicle. Microemulsions are quaternary systems including an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids. Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions). The interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously. In one embodiment of the oily phase, the oily phase may be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds. In one embodiment of the oily phase, the oily phase comprises of triglycerides; in another embodiment of the oily phase, the triglycerides are medium-chain triglycerides, for example, C8-C10 caprylic/capric triglyceride. In another embodiment, the oily phase will represent a % v/v range selected from the group consisting of about 2 to about 15%; about 7 to about 10%; and about 8 to about 9% v/v of the microemulsion. The aqueous phase includes, for example, water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol. In one embodiment of the glycol derivatives, the glycol is selected from the group consisting of propylene glycol, diethylene glycol monoethyl ether, dipropylene glycol monoethyl ether and mixtures thereof. Generally, the aqueous phase will represent a proportion from about 1 to about 4% v/v in the microemulsion. Surfactants for the microemulsion include diethylene glycol monoethyl ether, dipropylene glycol monomethyl ether, polyglycolyzed C8-C10 glycerides or polyglyceryl-6 dioleate. In addition to these surfactants, the cosurfactants include short-chain alcohols, such as ethanol and propanol. Some compounds are common to the three components discussed above, for example, aqueous phase, surfactant and cosurfactant. However, it is well within the skill level of the practitioner to use different compounds for each
component of the same formulation. In one embodiment, for example, for the amount of surfactant/cosurfactant, the cosurfactant to surfactant ratio may be from about 1/10 to about 1/2. In another embodiment for the amount of cosurfactant, there will be from about 25 to about 75% v/v of surfactant and from about 10 to about 55% v/v of cosurfactant in the microemulsion. [001] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as sucrose, saccharin or aspartame, bittering agents, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid, or other known preservatives. [0102] Aqueous suspensions may contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occuring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and/or bittering agents, such as those set forth herein. [0103] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, bittering, flavoring and coloring agents, may also be present.
[0104] Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and coloring agent(s). [0105] The compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. Preservatives, such as phenol or benzyl alcohol, may be used. [0106] In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. [0107] Topical, dermal and subdermal formulations may include emulsions, creams, ointments, gels or pastes. [0108] Organic solvents that may be used include but are not limited to: acetyltributyl citrate, fatty acid esters such as the dimethyl ester, diisobutyl adipate, acetone, acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetamide, dimethylformamide, dipropylene glycol n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, 2-pyrrolidone (e.g. N-methylpyrrolidone), diethylene glycol monoethyl ether, ethylene glycol and diethyl phthalate, or a mixture of at least two of these solvents. [0109] As vehicle or diluent, compositions of the present disclosure may include plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.; mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc.; aliphatic or cyclic hydrocarbons or alternatively, for example, medium-chain (such as C8-C12) triglycerides. [0110] Dosage forms may contain from about 0.5 mg to about 5 g of an active agent.
[0111] In one embodiment of the disclosure, the active agent is present in the formulation at a concentration of about 0.05 to 10% weight/volume. [0112] A compound of formula (I), formula (a) and formula (IVb) may be employed as such or in the form of their preparations or formulations as combinations. [0113] A compound of formula (I), formula (Ia) and formula (Ib) according to the disclosure may be combined with one or more agents having the same sphere of activity, for example, to increase activity, or with substances having another sphere of activity, for example, to broaden the range of activity. As an example, a combination of a compound of formula (I) (or of a formula (Ia) and formula (Ib)) with one or more of an additional JAK inhibitor or a JAK/Signal Transducer and Activator of Transcription (JAK/STAT) modulator may offer therapeutic advantage. Examples of JAK inhibitors that may be useful as combination agents include Baricitinib, Ruxolitinib, Filgotinib, CYT387, Upadacitinib, Fedratinib, Peficitinib, Lestaurtinib, Pacritinib, Oclacitinib, Cerdulatinib, and Tofacitinib. [0114] The compounds of formula (I), formula (Ia) or formula (Ib) according to the disclosure may be combined with one or more additional pharmaceutical or veterinary active agents. Further additional active agents which may be used in the methods provided herein in combination with a compound of formula (I), (Ia) or (Ib) include, but are not limited to, disease- modifying anti-rheumatic drugs (DMARDs such as cyclosporine A and methotrexate), anti- inflammatory agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), immnunosuppressants, mycophenolate mofetil, biologic agents, TNF-a inhibitors (such as etanercept), Cox-2 inhibitors (such as firocoxib), and analgesics. These agents may include but are not limited to cyclosporin A, e.g. Sandimmune® or Neoral®, rapamycin, FK-506 (tacrolimus), leflunomide, deoxyspergualin, mycophenolate, e.g., Cellcept®, azathioprine, e.g. Imuran®, daclizumab, e.g. Zenapax®, OKT3, e.g. Orthocolone®, AtGam, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and anti-inflammatory steroids, e.g. prednisolone or dexamethasone. [0115] In some embodiments, the second active agents may include, but are not limited to, anti- inflammatories such as NSAIDs including, but not limited to, diclofenac (e.g., ARTHROTEC®), diflunisal (e.g., DOLOBID®), etodolac (e.g., LODINE®), fenoprofen (e.g., NALFON®), ibuprofen (e.g., ADVIL®, CHILDREN'S ADVIL/MOTRIN®, MEDIPREN®, MOTRIN®, NUPRIN®, or PEDIACARE FEVER®), indomethacin (e.g., ARTHREXIN®), ketoprofen (e.g.,
ORUVAIL®), ketorolac (e.g., TORADOL®), fosfomycin tromethamine (e.g., MONURAL®), meclofenamate (e.g. , MECLOMEN®), nabumetone (e.g., RELAFEN®), naproxen (e.g. , ANAPROX®, ANAPROX® DS, EC-NAPROSYN®, NAPRELAN® or NAPROSYN®), oxaprozin (e.g., DAY PRO® ), piroxicam (e.g., FELDENE®), sulindac (e.g., CLINORIL®), and tolmetin (e.g., TOLECTIN® DS or TOLECTIN®). [0116] In other embodiments, the second active agents may include, but are not limited to, disease-modifying antirheumatic drugs (e.g., DMARDs) or immnunosuppressants such as, but not limited to, methotrexate (e.g., RHEUMATREX®), sulfasalazine (e.g., AZULFIDINE®), and cyclosporine (e.g., SANDIMMUNE® or NEROAL®; and including cyclosporine A). [0117] In other embodiments, the second active agents may include, but are not limited to, mycophenolate mofetil (e.g., CellCept®), an immunosuppressive agent widely used in organ transplantation and gaining favor in treating autoimmune and inflammatory skin disorders. [0118] In further embodiments, the second active agents may include, but are not limited to, biologic agents such as etanercept (e.g., ENBREL®), infliximab (e.g., REMICADE®) and adalimumab (e.g., HUMIRA®). [0119] In further embodiments of interest, the second active agents may include, but are not limited to Cox-2 inhibitors such as celecoxib (e.g., CELEBREX®), firocoxib (e.g. PREVICOX®), valdecoxib (e.g., BEXTRA®) and meloxicam (e.g., MOBIC®, METACAM®). [0120] In further embodiments, the second active agents may include veterinary therapeutic agents that are well-known in the art (see e.g. Plumb’s Veterinary Drug Handbook, 5th Edition, ed. Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9th Edition, (January 2005)) and include but are not limited to acarbose, acepromazine maleate, acetaminophen, acetazolamide, acetazolamide sodium, acetic acid, acetohydroxamic acid, acetylcysteine, acitretin, acyclovir, albendazole, albuterol sulfate, alfentanil, allopurinol, alprazolam, altrenogest, amantadine, amikacin sulfate, aminocaproic acid, aminopentamide hydrogen sulfate, aminophylline/theophylline, amiodarone, amitriptyline, amlodipine besylate, ammonium chloride, ammonium molybdenate, amoxicillin, clavulanate potassium, amphotericin B desoxycholate, amphotericin B lipid-based, ampicillin, amprolium, antacids (oral), antivenin, apomorphione, apramycin sulfate, ascorbic acid, asparaginase, aspiring, atenolol, atipamezole, atracurium besylate, atropine sulfate, aurnofin, aurothioglucose, azaperone, azathioprine, azithromycin, baclofen, barbituates, benazepril, betamethasone, bethanechol chloride, bisacodyl,
bismuth subsalicylate, bleomycin sulfate, boldenone undecylenate, bromides, bromocriptine mesylate, budenoside, buprenorphine, buspirone, busulfan, butorphanol tartrate, cabergoline, calcitonin salmon, calcitrol, calcium salts, captopril, carbenicillin indanyl sodium, carbimazole, carboplatin, carnitine, carprofen, carvedilol, cefadroxil, cefazolin sodium, cefixime, clorsulon, cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, ceftazidime, ceftiofur sodium, ceftiofur, ceftiaxone sodium, cephalexin, cephalosporins, cephapirin, charcoal (activated), chlorambucil, chloramphenicol, chlordiazepoxide, chlordiazepoxide, clidinium bromide, chlorothiazide, chlorpheniramine maleate, chlorpromazine, chlorpropamide, chlortetracycline, chorionic gonadotropin (HCG), chromium, cimetidine, ciprofloxacin, cisapride, cisplatin, citrate salts, clarithromycin, clemastine fumarate, clenbuterol, clindamycin, clofazimine, clomipramine, claonazepam, clonidine, cloprostenol sodium, clorazepate dipotassium, clorsulon, cloxacillin, codeine phosphate, colchicine, corticotropin (ACTH), cosyntropin, cyclophosphamide, cyclosporine, cyproheptadine, cytarabine, dacarbazine, dactinomycin/actinomycin D, dalteparin sodium, danazol, dantrolene sodium, dapsone, decoquinate, deferoxamine mesylate, deracoxib, deslorelin acetate, desmopressin acetate, desoxycorticosterone pivalate, detomidine, dexamethasone, dexpanthenol, dexraazoxane, dextran, diazepam, diazoxide (oral), dichlorphenamide, diclofenac sodium, dicloxacillin, diethylcarbamazine citrate, diethylstilbestrol (DES), difloxacin, digoxin, dihydrotachysterol (DHT), diltiazem, dimenhydrinate, dimercaprol/BAL, dimethyl sulfoxide, dinoprost tromethamine, diphenylhydramine, disopyramide phosphate, dobutamine, docusate/DSS, dolasetron mesylate, domperidone, dopamine, doramectin, doxapram, doxepin, doxorubicin, doxycycline, edetate calcium disodium.calcium EDTA, edrophonium chloride, enalapril/enalaprilat, enoxaparin sodium, enrofloxacin, ephedrine sulfate, epinephrine, epoetin/erythropoietin, eprinomectin, epsiprantel, erythromycin, esmolol, estradiol cypionate, ethacrynic acid/ethacrynate sodium, ethanol (alcohol), etidronate sodium, etodolac, etomidate, euthanasia agents w/pentobarbital, famotidine, fatty acids (essential/omega), felbamate, fentanyl, ferrous sulfate, filgrastim, finasteride, fipronil, florfenicol, fluconazole, flucytosine, fludrocortisone acetate, flumazenil, flumethasone, flunixin meglumine, fluorouracil (5-FU), fluoxetine, fluticasone propionate, fluvoxamine maleate, fomepizole (4-MP), furazolidone, furosemide, gabapentin, gemcitabine, gentamicin sulfate, glimepiride, glipizide, glucagon, glucocorticoid agents, glucosamine/chondroitin sulfate, glutamine, glyburide, glycerine (oral),
glycopyrrolate, gonadorelin, grisseofulvin, guaifenesin, halothane, hemoglobin glutamer-200 (OXYGLOBIN®), heparin, hetastarch, hyaluronate sodium, hydrazaline, hydrochlorothiazide, hydrocodone bitartrate, hydrocortisone, hydromorphone, hydroxyurea, hydroxyzine, ifosfamide, imidacloprid, imidocarb dipropinate, impenem-cilastatin sodium, imipramine, inamrinone lactate, insulin, interferon alfa-2a (human recombinant), iodide (sodium/potassium), ipecac (syrup), ipodate sodium, iron dextran, isoflurane, isoproterenol, isotretinoin, isoxsuprine, itraconazole, ivermectin, kaolin/pectin, ketamine, ketoconazole, ketoprofen, ketorolac tromethamine, lactulose, leuprolide, levamisole, levetiracetam, levothyroxine sodium, lidocaine, lincomycin, liothyronine sodium, lisinopril, lomustine (CCNU), lufenuron, lysine, magnesium, mannitol, marbofloxacin, mechlorethamine, meclizine, meclofenamic acid, medetomidine, medium chain triglycerides, medroxyprogesterone acetate, megestrol acetate, melarsomine, melatonin, meloxican, melphalan, meperidine, mercaptopurine, meropenem, metformin, methadone, methazolamide, methenamine mandelate/hippurate, methimazole, methionine, methocarbamol, methohexital sodium, methotrexate, methoxyflurane, methylene blue, methylphenidate, methylprednisolone, metoclopramide, metoprolol, metronidaxole, mexiletine, mibolerlone, midazolam milbemycin oxime, mineral oil, minocycline, misoprostol, mitotane, mitoxantrone, morphine sulfate, moxidectin, naloxone, mandrolone decanoate, naproxen, narcotic (opiate) agonist analgesics, neomycin sulfate, neostigmine, niacinamide, nitazoxanide, nitenpyram, nitrofurantoin, nitroglycerin, nitroprusside sodium, nizatidine, novobiocin sodium, nystatin, octreotide acetate, olsalazine sodium, omeprozole, ondansetron, opiate antidiarrheals, orbifloxacin, oxacillin sodium, oxazepam, oxibutynin chloride, oxymorphone, oxytretracycline, oxytocin, pamidronate disodium, pancreplipase, pancuronium bromide, paromomycin sulfate, parozetine, pencillamine, general information penicillins, penicillin G, penicillin V potassium, pentazocine, pentobarbital sodium, pentosan polysulfate sodium, pentoxifylline, pergolide mesylate, phenobarbital, phenoxybenzamine, pheylbutazone, phenylephrine, phenypropanolamine, phenytoin sodium, pheromones, parenteral phosphate, phytonadione/vitamin K-1, pimobendan, piperazine, pirlimycin, piroxicam, polysulfated glycosaminoglycan, ponazuril, potassium chloride, pralidoxime chloride, prazosin, prednisolone/prednisone, primidone, procainamide, procarbazine, prochlorperazine, propantheline bromide, propionibacterium acnes injection, propofol, propranolol, protamine sulfate, pseudoephedrine, psyllium hydrophilic mucilloid, pyridostigmine bromide, pyrilamine
maleate, pyrimethamine, quinacrine, quinidine, ranitidine, rifampin, s-adenosyl-methionine (SAMe), saline/hyperosmotic laxative, selamectin, selegiline /l-deprenyl, sertraline, sevelamer, sevoflurane, silymarin/milk thistle, sodium bicarbonate, sodium polystyrene sulfonate, sodium stibogluconate, sodium sulfate, sodum thiosulfate, somatotropin, sotalol, spectinomycin, spironolactone, stanozolol, streptokinase, streptozocin, succimer, succinylcholine chloride, sucralfate, sufentanil citrate, sulfachlorpyridazine sodium, sulfadiazine/trimethroprim, sulfamethoxazole/trimethoprim, sulfadimentoxine, sulfadimethoxine/ormetoprim, sulfasalazine, taurine, tepoxaline, terbinafline, terbutaline sulfate, testosterone, tetracycline, thiacetarsamide sodium, thiamine, thioguanine, thiopental sodium, thiotepa, thyrotropin, tiamulin, ticarcilin disodium, tiletamine /zolazepam, tilmocsin, tiopronin, tobramycin sulfate, tocainide, tolazoline, telfenamic acid, topiramate, tramadol, trimcinolone acetonide, trientine, trilostane, trimepraxine tartrate w/prednisolone, tripelennamine, tylosin, urdosiol, valproic acid, vanadium, vancomycin, vasopressin, vecuronium bromide, verapamil, vinblastine sulfate, vincristine sulfate, vitamin E/selenium, warfarin sodium, xylazine, yohimbine, zafirlukast, zidovudine (AZT), zinc acetate/zinc sulfate, and zonisamide and mixtures thereof. [0121] These one or more additional active agents may be administered as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art. [0122] The pharmaceutical preparation including the compounds of formula (Ia), (Ib), and (I) for delivery to a human or other mammal, is preferably in unit dosage form, in which the preparation is subdivided into unit doses containing an appropriate quantity of the active component. The unit dosage form may be a packaged preparation containing discrete quantities of the preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form may be a capsule, tablet or lozenge itself, or it may be an appropriate number of any of these in packaged form. [0123] The quantity of active component in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 1000 mg, according to the particular application and the potency of the active component. The composition may, if desired, also contain other compatible therapeutic agents. In therapeutic use for the treatment or alleviation of inflammation, auto- immune diseases, and cancer in a human or other mammal, the compounds utilized in the
method of treatment are administered at an initial dosage of about 0.1 mg/kg to about 100 mg/kg per interval, about 0.1 mg/kg to about 50.0 mg/kg per interval, about 0.1 mg/kg to about 10.0 mg/kg per interval, about 0.1 mg/kg to about 5.0 mg/kg per interval, about 0.1 mg/kg to about 2.5 mg/kg per interval, about 0.1 mg/kg to about 2.0 mg/kg per interval, about 0.1 mg/kg to about 1.0 mg/kg per interval, about 0.4 mg/kg to about 1.0 mg/kg per interval, or about 0.4 mg/kg to about 0.6 mg/kg per interval. Preferred intervals may be daily, weekly, monthly, quarterly, semi-annually, or annually. [0124] The dosages may be varied depending on the requirements of the patient, for example, the size of the human or mammal being treated, the severity of the condition being treated, the route of administration, and the potency of the compound(s) being used. Determination of the proper dosage and route of administration for a particular situation is within the skill of the practitioner. Generally, the treatment will be initiated with smaller dosages, which are less than the optimum dose of the compound, which may be increased in small increments until the optimum effect under the particular circumstances of the condition is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. [0125] In therapeutic use, the compounds of formula (Ia), (Ib), and (I) are useful in manufacture of a medicament for a method of the treating any indication where inhibition of JAK would be desirable, including but not limited to cancer, neuroinflammation, inflammatory airway diseases, ankylosing spondylitis, inflammatory bowel diseases, rheumatoid arthritis, psoriasis, and atopic dermatitis. In one or more embodiments, one or more of a compound of formula (Ia), (Ib), and (I) is useful in the treatment of one or more of atopic dermatitis, psoriasis, psoriatic arthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft- versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer. One route of administration may be oral. One route of administration may be topical. [0126] In one aspect, the present disclosure provides for a method of treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer including
administering to a subject in need thereof an effective amount of a compound that is an embodiment herein of formula (I), (Ia) or (Ib). [0127] In one embodiment, the present disclosure provides a method of treating atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis including administering to a subject in need thereof an effective amount of a compound that is an embodiment of formula (I), (Ia) or (Ib). In one embodiment, the compound is administered orally; in one embodiment, the compound is administered parenterally; in one embodiment, the compound is administered topically. [0128] In one embodiment, the present disclosure provides for a method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound according to any embodiment herein of formula (I), (Ia) or (Ib) wherein the subject is a mammal. [0129] In one embodiment, the present disclosure provides for method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound according to any embodiment herein of formula (I), (Ia) or (Ib) wherein the subject is selected from one or more of livestock mammals, domestic mammals, and companion animals. In one embodiment, the mammal is one or more of humans, cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs, and cats. In one embodiment, the mammal is a human, a dog, or a cat. [0130] In one aspect, the present disclosure provides a compound for use in medicine, wherein the compound is an embodiment of formula (I), (Ia), or (Ib) herein. In another aspect, the present disclosure provides for use of a compound according to any embodiment herein of any of formula (I), (Ia), and (Ib) for the manufacture of a medicament for the treatment of one or more diseases or disorder of inflammation, auto-immune dysfunction, and cancer. In one embodiment, the present disclosure provides for use of a compound according to any embodiment herein of formula (I), (Ia), or (Ib) for the manufacture of a medicament for the treatment of a disease or disorder that can be be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2. In one embodiment, the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis. In one aspect, the present disclosure provides for use of a compound according to an embodiment of formula (I), (Ia) or (Ib) herein and a second active agent in the manufacture of a medicament for the treatment of a disease or a disorder that can be
ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.In one aspect, the disclosure provides for use of a compound according to an embodiment of formula (I), (Ia), or (Ib) herein for the treatment of one or more diseases or disorders of inflammation, auto- immune dysfunction, and cancer. In one embodiment, the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis. [0131] The present disclosure explicitly encompasses compounds described herein, including salt forms thereof, and salt forms thereof. The present disclosure also encompasses those compounds presented herein, including stereoisomers thereof. The compounds encompassed by the present disclosure include, in some embodiments, compounds selected from Tables 1 and 2 as described herein. [0132] A composition including a therapeutically acceptable amount of any of the compounds described herein is within the scope of the disclosure. The composition may further comprise a pharmaceutically or veterinary acceptable excipient, diluent, carrier, or mixture thereof. Such a composition may be administered to a subject in need thereof to treat or control a disease or disorder mediated, in whole or in part, directly or indirectly, by JAK. The composition may further comprise an additional active agent, as described herein. EXAMPLES Experimental Procedures: [0133] The following examples provide a more detailed description of the process conditions for preparing compounds of the presentdisclosure. It is to be understood, however, that the disclosure, as fully described herein and as recited in the claims, is not intended to be limited by the details of the following schemes or modes of preparation. Certain abbreviations may be used in describing the examples of the present disclosure. The abbreviations are believed to be used consistently within commonly accepted use of those skilled in the art. CHEMISTRY EXAMPLES [0134] In the following schemes, general substituent groups are represented with assignments that may not align with the formulae of the present disclosure. The following schemes provide a
key for such substituent groups that should be followed for the schemes and not applied to the formulae of the present disclosure. [0135] The following abbreviations are used in the chemistry example schemes herein. Abbreviations: ACN acetonitrile NaHCO3 sodium bicarbonate Ag2SO4 Silver sulfate NaBH4 Sodium borohydride e y
MeOH methanol MeCN acetonitrile
Common Intermediate Syntheses. [0136] Preparation of (trans)-2-[(2-chloro-5-methyl-pyrimidin-4- yl)amino]cyclopentanecarbonitrile
[0137] Preparation of 6-(p-tolylsulfonyl)-6-azabicyclo[3.1.0]hexane [0138] Two reacti
e of cyclopentene (50 g, 734 mmol, 64.9 mL, 1 eq) and [chloro(p-tolylsulfonyl)amino]sodium (184 g, 807 mmol, 1.1 eq) in MeCN (2.5 L) was added Phenyltrimethylammonium tribromide (27.6 g, 73.4 mmol, 0.1 eq) in portions at 25°C under N2. The mixture was stirred at 25°C for 48 h. TLC showed the reaction was complete. The combined reactions were combined and concentrated under vacuum to give a residue. The residue was quenched with H2O (2 L) and extracted with EtOAc (1L x 2). The combined organic phases were washed with brine (1 L), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=5/1 to 4/1) to give 6-(p-tolylsulfonyl)-6- azabicyclo[3.1.0]hexane (125 g, 35.8% yield) as a white solid. 1H NMR (CDCl3, 400 MHz): 1.36 - 1.45 (m, 1 H) 1.57 - 1.69 (m, 3 H) 1.89 - 2.00 (m, 2 H) 2.44 (s, 3 H) 3.33 (s, 2 H) 7.29 - 7.38 (m, 2 H) 7.81 (d, J=8.25 Hz, 2 H). [0139] Preparation of N-(trans)-2-cyanocyclopentyl)-4-methylbenzenesulfonamide
[0140] Two reactions we
ried out n of 6-(p-tolylsulfonyl)-6-
azabicyclo[3.1.0]hexane (55 g, 231 mmol, 1 eq) in THF (550 mL) was added TMSCN (34.4 g, 347 mmol, 43.5 mL, 1.5 eq) and TBAF (1 M in THF, 46.3 mL, 0.2 eq) drop-wise at 20°C under N2. After the addition, the mixture was heated and stirred at 45°C for 16 h. TLC showed the reaction was complete. The two reaction mixtures were combined and poured into H2O (1L), and extracted with EtOAc (1L x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 300 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/petroleum ether gradient @ 200 mL/min) to give N- (trans)-(2-cyanocyclopentyl)-4-methyl- benzenesulfonamide (100 g, 81.8% yield) as a yellow solid.1H NMR (CDCl3, 400 MHz): δ = 7.82 (d, J=8.3 Hz, 2H), 7.35 (d, J=8.1 Hz, 2H), 5.64 (d, J=5.9 Hz, 1H), 3.76 (m, 1H), 2.84 (dt, J=8.5, 6.0 Hz, 1H), 2.45 (s, 3H), 2.04-2.16 (m, 1H), 1.82- 2.02 (m, 2H), 1.66-1.80 (m, 2H), 1.40-1.55 ppm (m, 1H). [0141] Preparation of tert-butyl ((trans)-2-cyanocyclopentyl)(tosyl)carbamate [0142] To a solution o
nesulfonamide (95 g, 359 mmol, 1 eq) in MeCN (1520 mL) was added Boc2O (117 g, 539 mmol, 124 mL, 1.5 eq) and DMAP (13.1 g, 108 mmol, 0.3 eq) at 20°C under N2. After the addition, the mixture was heated and stirred at 45°C for 2 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/petroleum ether gradient @ 200 mL/min) to give tert-butyl ((trans)-2- cyanocyclopentyl)(tosyl)carbamate (130 g, 99.2% yield) as an off-white solid. 1H NMR (CDCl3, 400 MHz): δ= 7.87 (d, J=8.3 Hz, 2H), 7.33 (d, J=8.1 Hz, 2H), 5.13 (m, 1H), 3.49-3.58 (m, 1H),
2.45 (s, 3H), 2.23-2.33 (m, 1H), 2.11-2.20 (m, 2H), 1.89-2.00 (m, 2H), 1.76-1.87 (m, 1H), 1.36 ppm (s, 9H). [0143] Preparation of tert-butyl ((trans)-2-cyanocyclopentyl)carbamate [0144] Three reactions were carried out in parallel. To each solution of tert-butyl ((trans)-2- cyanocyclopentyl)-N-(p-tolylsulfonyl)carbamate (32 g, 87.8 mmol, 1 eq) in MeOH (480 mL) was carefully added Mg (14.9 g, 612 mmol, 7 eq) at 20°C under N2 over 0.5 h. After the addition, the reaction was continue stirred at 20°C for 0.5 h. TLC showed the reaction was complete. The three reaction mixtures were combined and diluted with DCM (500 mL) and poured into 1N aq. HCl (500 mL). The mixture was adjusted pH to 5 with 2N aq. HCl at 0 °C and extracted with DCM (300 mL x 3). Then the organic phase was washed with saturated aq. NaHCO3 (100 mL x 3), the combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/petroleum ether gradient @ 100 mL/min) to give tert- butyl ((trans)-2-cyanocyclopentyl)carbamate (49 g, 88.4% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) ): δ = 4.12 (m, 1H), 2.82 (s, 1H), 2.06-2.20 (m, 2H), 1.88-2.00 (m, 1H), 1.81 (m, 2H), 1.38-1.50 ppm (m, 10H). [0145] Preparation of (trans)-2-aminocyclopentanecarbonitrile hydrochloride [0146] To a mixtu
2 g, 294 mmol, 1 eq) in EtOAc (900 mL)was added HCl/EtOAc (4 M, 221 mL, 3 eq) at 0°C. The mixture was stirred at 20°C for 1 h. White solid was formed after reaction for 30 min. TLC showed the reaction was complete. The reaction mixture was filtered and the filter cake was concentrated in vacuum to
give (trans)-2-aminocyclopentanecarbonitrile hydrochloride (36 g, 66% yield) as a white solid. 1H NMR (D2O-d6, 400 MHz) δ = 3.90 (m, 1H), 3.06 (m, 1H), 2.16-2.30 (m, 2H), 1.90-1.99 (m, 1H), 1.80 (m, 2H), 1.62-1.73 ppm (m, 1H). [0147] Preparation of (trans)-2-[(2-chloro-5-methyl-pyrimidin-4-yl)amino] cyclopentanecarbonitrile [0148] To a mixture ol, 1 eq) and (trans)-
2-aminocyclopentanecarbonitrile hydrochloride (20 g, 136.4 mmol, 1 eq) in DMA (200 mL) was added DIEA (105 mmol, 818 mL, 6 eq) at 20°C. The mixture was heated and stirred at 140°C for 8 h. TLC showed the reaction was complete. The reaction mixture was poured into H2O (1 L), then the precipitate was formed. The precipitate was filtered to give (trans)-2-[(2-chloro-5- methyl-pyrimidin-4-yl)amino]cyclopentanecarbonitrile (26 g, 80% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ = 7.84 (s, 1H), 5.13 (m, 1H), 4.64-4.72 (m, 1H), 2.87-3.02 (m, 1H), 2.14-2.36 (m, 2H), 1.96-2.06 (m, 4H), 1.88-1.93 (m, 2H), 1.61-1.72 (m, 1H). [0149] Preparation of (trans)-2-((2-chloro-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile
[0150] Preparation of 7-tosyl-7-azabicyclo[4.1.0]heptane [0151] Two reactions were c
arr ed out n para e . For eac a m xture of cyclohexene (25 g, 304 mmol, 30.8 mL, 1 eq) in MeCN (500 mL) was added [chloro(p-tolylsulfonyl) amino]sodium
(86.6 g, 380 mmol, 1.25 eq) and Phenyltrimethylammonium tribromide (11.4 g, 30.4 mmol, 0.1 eq) at 0 °C, and then the mixture was heated and stirred at 25°C for 16 h. TLC showed the reaction was complete. The two parallel reactions were combined and the reaction mixture was quenched by addition water (200 mL) at 0°C, and then extracted with DCM (200 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 20/1) to give 7-tosyl-7- azabicyclo[4.1.0]heptane (66 g, 43.1% yield) as colorless oil. 1H NMR (CDCl3-d6, 400 MHz) δ 7.82 (d, J=8.3 Hz, 2H), 7.33 (d, J=8.2 Hz, 2H), 2.98 (d, J=1.1 Hz, 2H), 2.45 (s, 3H), 1.79 (m, 4H), 1.48 - 1.35 (m, 2H), 1.25 - 1.17 (m, 2H). [0152] Preparation of N-((trans)-2-cyanocyclohexyl)-4-methylbenzenesulfonamide
[0153] To a mixture of 7-(p-tolylsulfonyl) -7-azabicyclo[4, 1, 0] heptane (60 g, 238 mmol, 1 eq) in THF (600 mL) was added TMSCN (35.5 g, 358 mmol, 1.5 eq) and TBAF (1 M in THF, 47.7 mL, 0.2 eq) at 25°C, and then the mixture was stirred at 25°C for 2 hr. TLC showed the reaction was complete. The reaction mixture was quenched by addition water (300 mL) at 0°C, and then extracted with DCM (300 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give N- ((trans)-2-cyanocyclohexyl)-4-methylbenzenesulfonamide (70 g, crude) as a brown solid. 1H NMR (CDCl3-d6, 400 MHz) δ 7.82 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 5.43-5.27 (m, 1H), 5.34 (br d, J = 8.0 Hz, 1H), 3.39-3.35 (m, 1H), 2.67-2.65 (1H), 2.44 (s, 3H), 2.05-2.00 (m, 1H), 1.98-1.87 (m, 1H), 1.69-1.62 (m, 2H), 1.37-1.29 (m, 2H). [0154] Preparation of tert-butyl ((trans)-2-cyanocyclohexyl) -N-(p-tolylsulfonyl) carbamate
[0155] Two reactions were carried out in parallel. For each a mixture of N-((trans)-2- cyanocyclohexyl) -4-methyl-benzenesulfonamide (30 g, 107 mmol, 1 eq) in MeCN (300 mL) was added Boc2O (35.2 g, 161 mmol, 1.5 eq) and DMAP (3.95 g, 32.3 mmol, 0.3 eq) at 20 °C, and then the mixture was stirred at 40°C for 2 hr. TLC showed the reaction was complete. The two parallel reactions were combined and quenched by addition water (300 mL) at 0°C, and then extracted with DCM (300 mL x 3). The combined organic layers were washed with brine (300 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 1/1) to give tert-butyl ((trans)-2-cyanocyclohexyl)-N-(p-tolylsulfonyl) carbamate (72 g, 88% yield) as white solid. 1H NMR (CDCl3-d6, 400 MHz) δ 7.93 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.55-4.48 (m, 1H), 3.66-3.59 (m, 1H), 2.43 (s, 3H), 2.27-2.23 (m, 2H), 2.05-1.97 (m, 1H), 1.80-1.68 (m, 3H), 1.53-1.48 (m, 1H), 1.34 (s, 9H), 1.33-1.22 (m, 1H). [0156] Preparation of tert-butyl ((trans)-2-cyanocyclohexyl) carbamate [0157] Two reactions w
ere carr e out n para e . or eac a m xture of tert-butyl ((trans)-2- cyanocyclohexyl)-N-(p-tolylsulfonyl) carbamate (26 g, 68.7 mmol, 1 eq) in MeOH (300 mL) was carefully added Mg (16.7 g, 687 mmol, 10 eq) at 20°C, and then the mixture was stirred at 20°C for 0.5 h under N2. TLC showed the reaction was complete. The two parallel reactions were combined the mixture was diluted with DCM (500 mL) and poured into aq. HCl (1N, 500 mL). Then, adjusted pH to 5 with aq. HCl (2N) at 0°C and extracted with DCM (300 mL x 3). Then the organic phase was washed with saturated aq. NaHCO3. The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 2/1) to give tert-butyl (trans)-2-cyanocyclohexyl) carbamate (28 g, 90% yield) as white solid. 1H NMR (CDCl3-d6, 400 MHz) δ 4.64 (s, 1H), 3.69 (d, J = 6.0 Hz, 1H), 2.60 (s, 1H), 2.15-1.96 (m, 2H), 1.81-1.61 (m, 3H), 1.47 (s, 9H), 1.42-1.22 (m, 3H).
[0158] Preparation of (trans)-2-aminocyclohexanecarbonitrile hydrochloride [0159] To a mixture of t ate (38 g, 169 mmol, 1 eq)
in EtOAc (100 mL) was added HCl/EtOAc (4 M, 300 mL) at 20 °C, and then the mixture was stirred at 20°C for 1 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give (trans)-2-aminocyclohexanecarbonitrile hydrochloride (27 g, 99.2% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.62 (s, 2H), 3.34 (s, 1H), 3.12-3.01 (m, 1H), 2.52 (d, J = 2.0 Hz, 1H), 2.13-2.00 (m, 2H), 1.74-1.55 (m, 3H), 1.50-1.22 (m, 3H). [0160] Preparation of (trans)-2-((2-chloro-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile
[0161] Two reactions were carried out in parallel. For each a mixture of (trans)-2- aminocyclohexanecarbonitrile hydrochloride (13 g, 80.9 mmol, 1 eq) in DMA (150 mL) was added 2,4-dichloro-5-methyl-pyrimidine (13.2 g, 80.9 mmol, 1 eq) and DIPEA (62.7 g, 485 mmol, 6 eq) at 20°C, and then the mixture was stirred at 140°C for 12 h. TLC showed the reaction was complete. The two parallel reactions were combined and quenched by addition water (100 mL) at 0°C, and then extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ Ethyl acetate = 1/ 0 to 0/ 1) to give (trans)-2-((2-chloro-5-methylpyrimidin-4- yl)amino)cyclohexane-1-carbonitrile (30 g, 73.9% yield) as a colorless oil. 1H NMR (CDCl3-d6, 400 MHz) δ 7.87 (s, 1H), 4.86 (d, J = 8.0 Hz, 1H), 4.44-4.30 (m, 1H), 2.85-2.75 (m, 1H), 2.17- 2.15 (m, 2H), 2.02 (s, 3H), 1.88-1.73 (m, 3H), 1.61-1.49 (m, 1H), 1.46-1.30 (m, 2H).
[0162] Preparation of (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran- 4-carbonitrile [0163] Preparation of 7-tosyl-3-oxa-7- ]heptane
[0164] Two reactions were carried out in parallel. A mixture of 3, ro-2H-pyran (100 g,
1.18 mol, 1 eq) in MeCN (2 L) was added phenyltrimethylammonium tribromide, (67 g, 179 mmol, 0.15 eq) and chloroamine-T (406 g, 1.78 mol, 1.5 eq) in portions under N2. Then the mixture was stirred at 25°C for 12 hr under N2 atmosphere. TLC showed the reaction was complete. The combined reaction mixtures were quenched by addition H2O (1 L) at 25°C and extracted with MTBE (2 L x 3) and the combined organic layers were washed with brine (1 L x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (1 L) at 25°C for 2 h, then filtered and the filtrate was concentrated under reduced pressure to give 7-tosyl-3-oxa-7-azabicyclo[4,1,0]heptane (750 g, crude) as yellow oil. [0165] Preparation of N-(trans)-(4-cyanotetrahydro-2H-pyran-3-yl)-4- methylbenzenesulfonamide [0166] Six reactions w
. tosyl-3-oxa-7- azabicyclo[4,1,0]heptane (100 g crude, 395 mmol, 1 eq) in THF (1 L) was added TBAF (1 M in THF, 178 mL, 0.45 eq) and TMSCN (137 g, 1.4 mol, 173 mL, 3.5 eq) in portions under N2. Then the mixture was stirred at 70°C for 3 hr under N2 atmosphere. TLC showed the reaction was complete. The six reaction mixtures were combined and quenched by addition H2O (3 L) at
25°C, and extracted with EtOAc (3 L x 3). The combined organic layers were washed with brine (3 L x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/1 to 0/1) to give crude product, which was triturated with MTBE (1 L) at 25°C for 2 h and filtered to give N-(trans)-(4-cyanotetrahydro-2H-pyran-3-yl)-4-methylbenzenesulfonamide (320 g) as a yellow solid.1H NMR (CDCl3, 400 MHz) δ =7.78 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 5.33 (d, J = 8.0 Hz, 1H), 3.85 (dd, J = 2.4, 12.0 Hz, 1H), 3.77 - 3.74 (m, 2H), 3.47 - 3.42 (m, 1H), 3.36 - 3.32 (m, 1H), 3.06 - 3.03 (m, 1H), 2.45 (s, 3H), 2.23 - 2.16 (m, 1H), 1.82 - 1.76 (m, 1H). [0167] Preparation of tert-butyl-((trans)-(4-cyanotetrahydro-2H-pyran-3-yl)(tosyl)carbamate [0168] Four reaction
(trans)-(4- cyanotetrahydro-2H-pyran-3-yl)-4-methylbenzenesulfonamide (80 g, 285 mmol, 1 eq) in MeCN (600 mL) was added Boc2O (93 g, 428 mmol, 98 mL, 1.5 eq) and DMAP (10.5 g, 86 mmol, 0.3 eq) in portions under N2. The mixture was stirred at 40°C for 2 hr. TLC showed the reaction was complete. The four reaction mixtures were combined and quenched by addition H2O (2 L) at 25°C and concentrated under reduced pressure to remove MeCN, then extracted with EtOAc (2 L x 3) and the combined organic layers were washed with brine (2 L x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 3/1) to give tert-butyl- ((trans)- (4-cyanotetrahydro-2H-pyran-3-yl)(tosyl)carbamate (300 g, 69.1% yield) as a yellow solid.1H NMR (CDCl3, 400 MHz) δ = 7.91 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.74 - 4.68 (m, 1H), 4.05 - 3.89 (m, 4H), 3.41 - 3.34 (m, 1H), 2.45 (s, 3H), 2.17 - 2.08 (m, 2H), 1.36 (s, 9H). [0169] Preparation of tert-butyl-((trans)-4-cyanotetrahydro-2H-pyran-3-yl)carbamate
[0170] Six reactions were carried out in parallel. To each solution of tert-butyl ((trans)(4- cyanotetrahydro-2H-pyran-3-yl)(tosyl)carbamate (50 g, 131 mmol, 1 eq) in MeOH (800 mL) was added Mg (26 g, 1.1 mol, 8.2 eq) in portions carefully at 25°C. Accompanied by generation of heat (exothermic) and bubbling, the resulting suspension was stirred at 25°C for 1 h. TLC showed the reaction was complete. The six reactions were combined and poured into ice-water (2.5 L), then adjusted pH to 5 with aq. HCl (2N) and extracted with EtOAc (1.5 L x 3). The combined organic layers were washed with brine (3 L x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give tert-butyl ((trans)-4-cyanotetrahydro-2H-pyran-3- yl)carbamate (170 g, 95.5% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ = 7.18 (d, J = 9.2 Hz, 1H), 3.78 (m, 1H), 3.71 (dd, J = 4.4, 11.2 Hz, 1H), 3.57 - 3.54 (m, 1H), 3.23 - 3.17 (m, 1H), 2.96 (t, J = 10.8 Hz, 1H), 2.88 - 2.81 (m, 1H), 2.06 - 2.01 (m, 1H), 1.83 - 1.72 (m, 1H), 1.39 (s, 9H). [0171] Preparation of (trans)-3-aminotetrahydro-2H-pyran-4-carbonitrile (hydrogen chloride) [0172] HCl/EtOAc (4 M,
-butyl ((trans)-4- cyanotetrahydro-2H-pyran-3-yl)carbamate (170 g, 751 mmol, 1 eq) at 25°C. After addition, the reaction was stirred at 25°C for 1 h. Solid precipitated out after 30 min reaction. TLC showed the reaction was complete. The reaction mixture was filtered and the filter cake was concentrated under reduced pressure to give (trans)-3-aminotetrahydro-2H-pyran-4-carbonitrile (91 g, 74.5% yield, HCl salt) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ = 8.74 (s, 3H), 3.89 (dd, J = 2.8, 12.0 Hz, 1H), 3.75-3.65 (m, 1H), 3.62-3.42 (m, 4H), 2.25 - 2.15 (m, 1H), 1.85 - 1.75 (m, 1H).
[0173] Preparation of (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran- 4-carbonitrile [0174] To a solutio (82 g, 504 mmol, 1
eq, HCl) in DMA (1 L) was added DIPEA (391 g, 3.02 mol, 525 mL, 6 eq) and 2,4-dichloro-5- methyl-pyrimidine (82.5 g, 504 mmol, 1 eq), and then the mixture was stirred at 135°C for 12 hr. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (4 L) at 20°C, then extracted with EtOAc (2 L x 3). The combined organic layers were washed with brine (2 L x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (500 mL) at 20oC for 12 hr to give (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (75 g, 58.9% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ = 7.92 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 4.38 - 4.29 (m, 1H), 3.89 - 3.81 (m, 2H), 3.28-3.27 (m, 1H), 3.23 - 3.16 (m, 1H), 3.10 (t, J = 10.8 Hz, 1H), 2.15 - 2.11 (m, 1H), 2.00 (s, 3H), 1.96 - 1.86 (m, 1H). This material (20 g) was separated by SFC (column: DAICEL CHIRALPAK IC(250 mm x 50 mm, 10um); mobile phase: [0.1%NH3H2O IPA]; B%: 60%-60%, 8.5 min) to give (trans)-3-((2-chloro-5- methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (8.95 g, 94.5% purity, 97.56% ee, first peak, Rt = 2.160 min) stereoisomer one (int-B05-P1) as a white solid. 1H NMR (DMSO- d6, 400 MHz) δ = 7.91 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 4.35 - 4.33 (m, 1H), 3.89 - 3.81 (m, 2H), 3.33 - 3.08 (m, 3H), 2.15 - 2.11 (m, 1H), 2.00 (s, 3H), 1.96 - 1.86 (m, 1H) and (trans)-3-((2- chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (9.05 g, 99.19% purity, 98.9% ee, second peak, Rt = 3.141 min) stereoisomer two (int-B05-P2) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ = 7.92 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 4.35 - 4.33 (m, 1H), 3.89 - 3.81 (m, 2H), 3.33 - 3.08 (m, 3H), 2.15 - 2.11 (m, 1H), 2.00 (s, 3H), 1.96 - 1.86 (m, 1H). [0175] Preparation of (trans)-3-((2,5-dichloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile
[0176] A mixture g, 15.8 mmol, 1 eq,
HCl salt), 2,4,5-trichloropyrimidine (2.91 g, 15.8 mmol, 1 eq), DIEA (4.10 g, 31.7 mmol, 5.52 mL, 2 eq) in DMA (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (200 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (80 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~65% Ethyl acetate/petroleum ether gradient @ 80 mL/min) to obtain (trans)-3-((2,5- dichloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (1.2 g, 27.7% yield) as light yellow oil. 1H NMR (400 MHz, DMSO-d6) δ = 8.29 (s, 1H), 7.98 (d, J = 8.8 Hz, 1H), 4.40 - 4.28 (m, 1H), 3.90 - 3.83 (m, 2H), 3.29 - 3.11 (m, 3H), 2.18 - 2.08 (m, 1H), 1.93 - 1.85 (m, 1H). [0177] Preparation of (trans)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)tetrahydro-2H-pyran- 4-carbonitrile [0178] To a soluti
on of (trans)-3-aminotetrahydro-2H-pyran-4-carbonitrile (500 mg, 3.07 mmol, 1 eq, HCl salt) in DMA (5 mL) was added DIEA (1.6 g, 12.3 mmol, 2 mL, 4 eq) and 2,4- dichloro-5-fluoro-pyrimidine (513 mg, 3.07 mmol, 1 eq) at 25°C and then the mixture was stirred at 100°C for 12 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (20 mL) at 25°C, then extracted with EtOAc (10 mL x 3) and the combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl
acetate/petroleum ethergradient @ 50 mL/min) to give (trans)-3-((2-chloro-5-fluoropyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (310 mg, 39% yield) as a yellow solid.1H NMR (DMSO-d6, 400 MHz) δ = 8.37 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 3.2 Hz, 1H), 4.27 - 4.24 (m, 1H), 3.88 - 3.84 (m, 2H), 3.31 - 3.07 (m, 3H), 2.14 - 2.10 (m, 1H), 1.98 - 1.87 (m, 1H). [0179] Preparation of (trans)-2-[(2-chloro-5-fluoro-pyrimidin-4-yl) amino]cyclohexanecarbonitrile [0180] A mixture ol, 1 eq, HCl salt) in
DMA (10 mL) was added DIEA (4.83 g, 37.3 mmol, 6.5 mL, 6 eq) and 2,4-dichloro-5-fluoro- pyrimidine (1.04 g, 6.22 mmol, 1 eq) at 25°C, and then the mixture was stirred at 140°C for 12 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (40 mL) at 25°C, and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a crude product. The crude product was triturated with MTBE (10 mL) at 25oC for 30 min to afford (trans)-2-[(2-chloro-5-fluoro-pyrimidin-4-yl) amino]cyclohexanecarbonitrile (1.2 g, 75.8% yield) as a brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.34 (d, J = 8.8 Hz, 1H), 8.15 (d, J = 3.2 Hz, 1H), 4.21-4.14 (m, 1H), 2.86-2.79 (m, 1H), 2.13-2.09 (m, 1H), 1.89-1.85 (m, 1H), 1.72-1.64 (m, 3H), 1.36-1.25 (m, 2H), 1.21-1.10 (m, 1H). [0181] Preparation of (trans)-2-((2,5-dichloropyrimidin-4-yl)amino)cyclohexanecarbonitrile [0182] A mixture o
(trans)- -am nocyc o exanecar on tr e ( .00 g, . mmol, 1 eq, HCl salt), 2,4,5-trichloropyrimidine (2.28 g, 12.4 mmol, 1 eq), DIEA (9.65 g, 74.7 mmol, 13.0 mL, 6 eq) in DMA (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at
140°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (50 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40g SepaFlash® Silica Flash Column, Eluent of 0~35% Ethyl acetate/petroleum ether gradient @80 mL/min) to obtain (trans)-2-((2,5-dichloropyrimidin-4- yl)amino)cyclohexanecarbonitrile (2 g, 59.2% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.24 (s, 1H), 7.98 (d, J = 9.2 Hz, 1H), 4.30 - 4.17 (m, 1H), 2.99 (m, 1H), 2.16 - 2.05 (m, 1H), 1.88 - 1.78 (m, 1H), 1.73 - 1.58 (m, 3H), 1.44 - 1.30 (m, 2H), 1.21 - 1.06 (m, 1H). [0183] Preparation of 3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile [0184] To a solut
y py g, . mol, 1 eq, HCl) in THF (20 mL) was added DIEA (4.77 g, 36.9 mmol, 6.4 mL, 3 eq) and 2,4-dichloro-5- (trifluoromethyl)pyrimidine (3.20 g, 14.7 mmol, 1.2 eq) at 25°C. The mixture was stirred at 25°C for 16 hr. LCMS showed the reaction was complete and 2 peaks with desired MS observed. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Xtimate C1810u 250mm*80mm; mobile phase: [water ( NH4HCO3)-ACN]; B%: 20%-55%,30min) to give (trans)-2-[[2-chloro-5- (trifluoromethyl)pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (800 mg, 21.2% yield) as a yellow solid 1H NMR (400 MHz, DMSO-d6) δ = 8.56 - 8.44 (m, 1H), 7.85 (d, J = 8.4 Hz, 1H), 4.60 - 4.43 (m,
1H), 3.91 - 3.78 (m, 2H), 3.45 - 3.40 (m, 1H), 3.28 - 3.17 (m, 2H), 2.18 - 2.07 (m, 1H), 1.96 - 1.86 (m, 1H). [0185] Preparation of 2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexane-1- carbonitrile
[0186] To a solutio mmol, 1 eq, HCl) in
THF (20 mL) was added DIEA (4.83 g, 37.3 mmol, 3 eq) and 2,4-dichloro-5- (trifluoromethyl)pyrimidine (3.24 g, 14.9 mmol, 1.2 eq) at 25°C. The mixture was stirred at 25°C for 16 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Xtimate C1810u 250mm*80mm;mobile phase: [water ( NH4HCO3)-ACN]; B%: 35%-75%,35min) to give (trans)-2-((2-chloro-5- (trifluoromethyl)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (900 mg, 23.7% yield) as a yellow solid 1H NMR (400 MHz, DMSO-d6) δ = 8.47 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 4.47 - 4.34 (m, 1H), 3.08 (m, 1H), 2.17 - 2.06 (m, 1H), 1.85 - 1.75 (m, 1H), 1.75 - 1.57 (m, 3H), 1.51 - 1.28 (m, 2H), 1.21 - 1.06 (m, 1H). [0187] Preparation of (trans)-2-[[2-chloro-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclopentanecarbonitrile [0188] To a solutio
mmol, 1 eq, HCl) in THF (20 mL) was added 2,4-dichloro-5-(trifluoromethyl)pyrimidine (2.96 g, 13.6 mmol, 1 eq) and DIEA (5.29 g, 40.9 mmol, 7.13 mL, 3 eq) at 25°C. The mixture was stirred at 25°C for 16 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Agela DuraShell C18250*70 mm*10 um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-60%, 20 min) to afford (trans)-2-[[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino] cyclopentanecarbonitrile (1.37 g, 34.5% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 8.34 (s, 1H), 5.35 (s, 1H),
4.85-4.75 (m, 1H), 2.92-2.83 (m, 1H), 2.42-2.31 (m, 1H), 2.27-2.17 (m, 1H), 2.14-2.03 (m, 1H), 2.01-1.88 (m, 2H), 1.71-1.61 (m, 1H). [0189] Synthetic Examples (for compounds in Table 1 and Table 2) [0190] 1. Preparation of (trans)-2-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile
[0191] 1.1 Preparation of methyl 2-bromo-5-((4-(((trans)-2-cyanocyclopentyl)amino)-5- methylpyrimidin-2-yl)amino)benzoate [0192]
yl)amino]cyclopentanecarbonitrile (2.00 g, 8.45 mmol, 1 eq), methyl 5-amino-2-bromo-benzoate (2.14 g, 9.29 mmol, 1.1 eq) and TsOH.H2O (3.21 g, 16.9 mmol, 2 eq) in dioxane (60 mL) was heated and stirred at 80 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was cooled to room temperature and concentrated in vacuum to give a residue. The residue was quenched with saturated aq. Na2CO3 (50 mL) and extracted with EtOAc (20 mL x 3). The combined organics were dried over Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of MTBE (50 mL) and EtOAc (10 mL) to give methyl 2-bromo-5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2- yl)amino)benzoate (1.50 g, 41% yield) as a gray solid. 1H NMR (CDCl3, 400 MHz) δ 8.05 (s, 1H), 7.80 (s, 1H), 7.76-7.73 (m, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.12 (s, 1H), 4.68-4.62 (m, 1H), 4.50-4.48 (m, 1H), 3.94 (s, 3H), 2.88-2.84 (m, 1H), 2.36-2.34 (m, 1H), 2.15-2.08 (m, 2H), 1.97 (s, 3H), 1.93-1.91 (m, 1H), 1.64-1.62 (m, 1H).
[0193] 1.2 Preparation of methyl 5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin- 2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate
methylpyrimidin-2-yl)amino)benzoate (500 mg, 1.16 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)- 5,5-dimethyl-1,3,2-dioxaborinane (656 mg, 2.90 mmol, 2.5 eq), Pd(PPh3)2Cl2 (81 mg, 116 umol, 0.1 eq) and KOAc (285 mg, 2.90 mmol, 2.5 eq) in dioxane (20 mL) was heated and stirred at 120 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was cooled to room temperature and filtered. Then the filtrate was concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of MTBE (50 mL), EtOAc (5 mL) and Petroleum ether (10 mL) to give methyl 5-((4-(((trans)-2- cyanocyclopentyl)amino)-5-methylpyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)benzoate (300 mg, crude) as a gray solid. 1H NMR (CDCl3, 400 MHz) δ 8.14 (s, 1H), 7.82- 7.80 (m, 2H), 7.51-7.49 (m, 1H), 7.15 (s, 1H), 4.68-4.65 (m, 1H), 4.46-4.45 (m, 1H), 3.92 (s, 3H), 3.79 (s, 4H), 3.61-3.60 (m, 6H), 2.92-2.87 (m, 1H), 2.36-2.35 (m, 1H), 2.15-2.13 (m, 1H), 2.13-2.05 (m, 1H), 1.96 (s, 3H), 1.93-1.92 (m, 2H), 1.63-1.62 (m, 1H), 1.10 (s, 6H). [0195] 1.3 Preparation of (trans)-2-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile
y y y p y y py midin- 2-yl]amino] -2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (500 mg, 1.08 mmol, 1 eq) in THF (10 mL) and MeOH (2 mL) was added NaBH4 (204 mg, 5.40 mmol, 5 eq) portion-wise at
0oC. After the addition, the reaction was allowed to warm to 25°C and stirred at 25oC for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was quenched with aq. HCl (1 N, 5 mL) carefully and diluted with H2O (10 mL). The mixture was extracted with EtOAc (10 mL x 3). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of MeCN (5 mL) and H2O (2 mL) to give (trans)-2-((2-((1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1- carbonitrile (48.3 mg, 11.6% yield) as a white solid. 1HNMR (DMSO-d6, 400 MHz) δ 12.27 (s, 1H), 10.63 (s, 1H), 9.14 (s, 1H), 8.43 (s, 1H), 7.84 (s, 1H), 7.75-7.73 (m, 2H), 7.48-7.46 (m, 1H), 5.00 (s, 2H), 4.76-4.74 (m, 1H), 3.26-3.24 (m, 1H), 2.18-2.17 (m, 1H), 2.12-2.09 (m, 1H), 2.04 (s, 3H), 1.86-1.71 (m, 4H). MS (ESI): mass calcd. For C18H21BClN5O2349.17, m/z found 350.1 [M+H]+. HPLC: 94.26% (220 nm), 92.97% (254 nm). [0197] 2. Preparation of (trans)-2-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol- 5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile OH N B O [0198] 2.1 Preparation of meth
anocyclopentyl)amino]-5-methyl - pyrimidin-2-yl]amino]-3-methyl-benzoate
yl)amino]cyclopentanecarbonitrile (1.40 g, 5.91 mmol, 1 eq) and methyl 5-amino-2-bromo-3- methyl-benzoate (1.59 g, 6.51 mmol, 1.1 eq) in dioxane (15 mL) was added TsOH·H2O (2.25 g, 11.8 mmol, 2 eq) in one portion at 20°C under N2. The mixture was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was filtered and the
white filter cake was washed with EtOAc (10 mL) to give methyl 2-bromo-5-[[4-[(trans)-(2- cyanocyclopentyl)amino]-5-methyl-pyrimidin-2-yl]amino]-3-methyl-benzoate (1.2 g, 45.6% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 10.41 (s, 1H), 8.36 (s, 1H), 7.83 (s, 1H), 7.82 (s, 1H), 7.64 (s, 1H), 4.76-4.68 (m, 1H), 3.86 (s, 3H), 3.21-3.19 (m, 1H), 2.42 (s, 3H), 2.20- 2.18 (m, 1H), 2.06-2.03 (m, 4H), 1.85-1.69 (m, 4H). [0200] 2.2 Preparation of methyl 5-[[4-[(2-cyanocyclopentyl)amino]-5-methyl -pyrimidin-2- yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate [0201] methyl-
pyrimidin -2-yl]amino]-3-methyl-benzoate (600 mg, 1.35 mmol, 1 eq) and 2-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (762 mg, 3.38 mmol, 2.5 eq) in dioxane (6 mL) was added KOAc (331 mg, 3.38 mmol, 2.5 eq) and Pd(PPh3)2Cl2 (94 mg, 135 umol, 0.1 eq) in one portion at 20°C under N2. The mixture was stirred at 120°C for 1 h. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (20 mL) at 20oC for 10 min to give methyl 5-[[4-[((trans)-2-cyanocyclopentyl)amino]-5- methyl -pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate (900 mg, crude) as an off-white solid. [0202] 2.3 Preparation of (trans)-2-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol- 5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile OH O
y y y p y y py imidin-2- yl]amino] -2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate (900 mg, 1.89 mmol, 1
eq) in THF (10 mL) and MeOH (1 mL) was added NaBH4 (178 mg, 4.71 mmol, 2.5 eq) in portions at 0°C . After the addition, the reaction was allowed to warm to 20°C and stirred at 20°C for 1 h. TLC showed the reaction was complete. The reaction mixture was adjusted pH = 6 by aq. HCl (2N). The mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C1880*40mm*3 um; mobile phase: [water (0.04%HCl)-ACN]; B%: 15%-35%,7min) to give (trans) 2-[[2-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-5-yl)amino] - 5-methyl-pyrimidin-4-yl]amino]cyclopentanecarbonitrile (30 mg) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.62 (s, 1H), 10.47 (s, 1H), 8.88 (s, 1H), 8.42 (d, J = 8.0 Hz, 1H), 7.82 (s, 1H), 7.46 (s, 1H), 7.28 (s, 1H), 4.96 (s, 2H), 4.80-4.72 (m, 1H), 3.27-3.22 (m, 1H), 2.44 (s, 3H), 2.23-2.19 (m, 1H), 2.12-2.10 (m, 1H), 2.03 (s, 3H), 1.88-1.70 (m, 4H).MS (ESI): mass calcd. For 19H23BClN5O2, 363.11, m/z found 364.2 [M+H]+. HPLC: 96.69% (220 nm), 96.77% (254 nm). [0204] 3. Preparation of (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile [0205] 3.1 Preparation of met
enzoate [0206] Three rea
. thyl 2-amino-5- nitro-benzoate (10 g, 51.0 mmol, 1 eq) in DMF (100 mL) was added NCS (8.85 g, 66.2 mmol, 1.3 eq) at 25°C. The mixture was stirred at 25°C for 14 h. TLC showed the reaction was complete. The contents of three parallel reactions were combined and the mixture was poured into water (300 mL) at 0°C, then the yellow precipitate formed and was collected. The yellow
precipitate was washed with H2O (80 mL x 2) and petroleum ether (50 mL x 2) to give methyl 2- amino-3-chloro-5-nitro-benzoate (34.1 g, 96.7% yield) as a yellow solid.1H NMR (DMSO-d6, 400 MHz) δ 8.58 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 2.4 Hz, 1H), 3.89 (s, 3H). [0207] 3.2 Preparation of methyl 2-bromo-3-chloro-5-nitro-benzoate [0208] Three re uONO (8.94 g,
86.7 mmol, 10.3 mL, 2 eq) and CuBr2 (14.5 g, 65.1 mmol, 3.1 mL, 1.5 eq) in MeCN (100 mL) was added methyl 2-amino-3-chloro-5-nitro-benzoate (10 g, 43.3 mmol, 1 eq) in portions at 65°C. The mixture was stirred at 65°C for 30 min. TLC showed the reaction was complete. The three parallel reactions were combined and poured into H2O (350 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with saturated aq. Na2SO3 (100 mL x 3). Then the combined organic layers were washed with brine (100 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give methyl 2-bromo-3- chloro-5-nitro-benzoate (33 g, 86.1% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 8.44-8.42 (m, 2H), 4.02 (s, 3H). [0209] 3.3 Preparation of methyl 5-amino-2-bromo-3-chloro-benzoate [0210] Three reacti
. methyl 2-bromo-3- chloro-5-nitro-benzoate (11 g, 37.3 mmol, 1 eq) in EtOH (120 mL) and H2O (40 mL) was added Fe (6.26 g, 112 mmol, 3 eq) and NH4Cl (3.00 g, 56.0 mmol, 1.5 eq) in one portion at 25°C. The mixture was heated to 80°C and stirred at 80°C for 2 h. TLC showed the reaction was complete. The three parallel reactions were combined and filtered followed by concentration under reduced pressure to give a residue. The residue was quenched with water (500 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with brine (250 mL x 3), dried
over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-amino-2- bromo-3-chloro-benzoate (28 g, 94.5% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 6.90 (d, J = 2.8 Hz, 1H), 6.86 (d, J = 2.8 Hz, 1H), 3.92 (s, 3H), 3.90-3.80 (m, 2H). [0211] 3.4 Preparation of (5-amino-2-bromo-3-chloro-phenyl)methanol [0212] To a solutio , 37.8 mmol, 1 eq) in
THF (150 mL) was added DIBAL-H (1 M, 113 mL, 3 eq) drop-wise at -60°C. The mixture was stirred at -60 °C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition aq. seignette salt (500 mL) at 0°C, and then extracted with EtOAc (70 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (30 mL) at 25oC for 5 min to give (5-amino-2-bromo-3-chloro-phenyl)methanol (8.2 g, 91.7% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 6.76 (d, J = 2.8 Hz, 1H), 6.65 (d, J = 2.8 Hz, 1H), 5.54 (s, 2H), 5.39 (t, J = 5.6 Hz, 1H), 4.37 (d, J = 5.6 Hz, 2H). [0213] 3.5 Preparation of (trans)-2-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]cyclopentanecarbonitrile
. -bromo-3- chloro-phenyl)methanol (0.5 g, 2.11 mmol, 1 eq) and (trans)-2-[(2-chloro-5-methyl-pyrimidin-4- yl)amino]cyclopentanecarbonitrile (525 mg, 2.22 mmol, 1.05 eq) in dioxane (15 mL) was added TsOH·H2O (603 mg, 3.17 mmol, 1.5 eq) at 25°C. The mixture was heated to 90°C and stirred at 90°C for 5 h. TLC showed the reaction was complete. The five parallel reactions were combined
and quenched by addition of saturated aq. NaHCO3 (80 mL) at 0°C and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (80 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (15 mL) at 25oC for 10 min to give (trans)-2-[[2-[4-bromo-3-chloro-5- (hydroxymethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclopentanecarbonitrile (2.8 g, 60.6% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.29 (s, 1H), 8.12 (s, 1H), 7.91 (d, J = 2.8 Hz, 1H), 7.76 (s, 1H), 6.81 (d, J = 8.8 Hz, 1H), 5.50 (t, J = 5.6 Hz, 1H), 4.87-4.78 (m, 1H), 4.48 (d, J = 5.6 Hz, 2H), 3.15-3.08 (m, 1H), 2.24-2.12 (m, 2H), 1.94 (s, 3H), 1.89-1.83 (m, 1H), 1.82-1.74 (m, 2H), 1.57-1.47 (m, 1H). [0215] 3.6 Preparation of (trans)-2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- chloro-anilino] -5-methyl-pyrimidin-4-yl]amino]cyclopentanecarbonitrile [
l- pyrimidin -4-yl]amino]cyclopentanecarbonitrile (2.8 g, 6.41 mmol, 1 eq) and 2,6- dimethylpyridine (2.08 g, 19.2 mmol, 2.3 mL, 3 eq) in THF (60 mL) was added TBSOTf (2.54 g, 9.62 mmol, 2.2 mL, 1.5 eq) at 0°C. The mixture was stirred at 25°C for 3 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturated aq. NH4Cl (80 mL) at 0°C, and then extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (40 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (30 mL) at 25oC for 20 min to give (trans)-2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-methyl- pyrimidin-4-yl]amino]cyclopentanecarbonitrile (2.5 g, 70.7% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.39 (s, 1H), 8.30 (d, J = 2.8 Hz, 1H), 7.75 (s, 1H), 7.72 (d, J = 2.8 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.78 (m, 1H), 4.66 (s, 2H), 3.13 (q, J = 8.4 Hz, 1H), 2.25-2.09 (m, 2H), 1.95 (s, 3H), 1.87-1.73 (m, 3H), 1.60-1.51 (m, 1H), 0.92 (s, 9H), 0.10 (s, 6H).
[0217] 3.7 Preparation of [2-[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-4-[[4-[(trans)-(2- cyanocyclopentyl)amino]-5-methyl-pyrimidin-2-yl]amino]phenyl]boronic acid [0218] bromo-3-
[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino] -5-methyl-pyrimidin-4- yl]amino]cyclopentanecarbonitrile (0.4 g, 726 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan- 2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (492 mg, 2.18 mmol, 3 eq), KOAc (214 mg, 2.18 mmol, 3 eq) and Pd(PPh3)2Cl2 (51 mg, 72.6 umol, 0.1 eq) in dioxane (6 mL) was degassed and purged with N2 for 3 times. Then the mixture was heated to 120°C and stirred at 120°C for 40 min under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The six parallel reactions were cooled to room temp, combined and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18250*50mm*10um; mobile phase: [water ( NH4HCO3)- ACN]; B%: 50%-90%,10min) to give [2-[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-4-[[4- [(trans)-(2-cyanocyclopentyl)amino]-5-methyl-pyrimidin-2-yl]amino]phenyl]boronic acid and 2- ((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclopentane-1-carbonitrile (1.2 g, mixture) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.11 (s, 1H), 8.04 (s, 2H), 7.91 (s, 1H), 7.73 (s, 1H), 7.51 (s, 1H), 6.78 (d, J = 8.0 Hz, 1H), 4.80-4.70 (m, 1H), 4.63 (s, 2H), 3.20-3.10 (m, 1H), 2.25-2.09 (m, 2H), 1.95 (s, 3H), 1.87- 1.73 (m, 3H), 1.60-1.51 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H). [0219] 3.8 Preparation of (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile
[02
cyanocyclopentyl)amino]-5-methyl-pyrimidin-2-yl]amino]phenyl]boronic acid and 2-((2-((7- chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclopentane-1-carbonitrile (mixture, 1.2 g, 1.16 mmol, 1 eq) in THF (10 mL) was added HCl (6 M, 775 uL, 4 eq) at 0°C. The mixture was heated to 40°C and stirred at 40°C for 1 h. LCMS showed the reaction was complete and one main peak with desired mass was detected. The reaction was concentrated under reduced pressure to give a residue. The residue was triturated with MeCN (15 mL) at 25oC for 10 min to give racemic product (trans)-2-((2-((7- chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclopentane-1-carbonitrile (880 mg). The racemic product (trans)-2-((2-((7-chloro-1- hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclopentane-1-carbonitrile (880 mg) was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 40%- 40%,6min) to give (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile (stereoisomer one) (335.9 mg, 97.10% purity, 98.96% ee, first peak, Rt = 3.898 min) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.39 (s, 1H), 8.84 (s, 1H), 7.81 (s, 1H), 7.78 (s, 1H), 7.76 (s, 1H), 6.88 (d, J = 8.0 Hz, 1H), 4.94 (s, 2H), 4.85-4.75 (m, 1H), 3.13 (q, J = 8.4 Hz, 1H), 2.25-2.10 (m, 2H), 1.96 (s, 3H), 1.90-1.73 (m, 3H), 1.62-1.53 (m, 1H). MS (ESI): mass calcd. For C18H19BClN5O2383.13, m/z found 384.1 [M+H]+. HPLC: 97.10% (220 nm), 98.17% (254 nm); and 370 mg of stereoisomer two, containing isopropanol residue), which was further purified by pre-HPLC (column: Phenomenex Luna 80*30mm*3um;mobile phase: [water(HCl)-ACN];B%: 5%- 35%,8min) to remove isopropanol residue to obtain (trans)-2-((2-((7-chloro-1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1- carbonitrile (stereoisomer two) (332.9 mg, 97.31% purity, 97.80% ee, second peak, Rt = 4.470 min) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.40 (br s, 1H), 9.05 (br s, 1H), 8.10 (br s, 1H), 7.84 (s, 1H), 7.71 (s, 1H), 7.62 (s, 1H), 4.99 (s, 2H), 4.80-4.70 (m, 1H), 3.26-3.19 (m, 1H), 2.26-2.19 (m, 1H), 2.15-2.09 (m, 1H), 2.03 (s, 3H), 1.90-1.75 (m, 3H), 1.71-1.63 (m, 1H).
MS (ESI): mass calcd. For C18H19BClN5O2383.13, m/z found 384.1 [M+H]+. HPLC: 97.31% (220 nm), 97.90% (254 nm). [0221] 4. Preparation of (trans)-2-((2-((7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo [cd]azulen-4- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile
[0223] To a solution mol, 1 eq) in MeOH
(500 mL) was drop-wise added a solution of H2SO4 (1.32 mol, 70 mL, 5.5 eq) at 0°C over 5 mins under N2 at 0oC. After the addition, the reaction mixture was heated and stirred at 95°C for 16 h. TLC showed the reaction was complete. The reaction mixture was adjusted pH to 7 with saturated aq. Na2CO3 (1L) at 0°C and extracted with ethyl acetate (500 mL x 3). The combined organic phase was washed with brine (300 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2-amino-3-methoxy-benzoate (43 g, 99% yield) as a white solid.1H NMR (CDCl3, 400 MHz) δ 7.40 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H), 6.50 (t, J = 8.0 Hz, 1H), 5.94 (s, 2H), 3.79 (s, 6H). [0224] 4.2 Preparation of methyl 2-amino-5-iodo-3-methoxy-benzoate [0225] To a mixture o
y y . g, 7 mmol, 1 eq) in EtOH (500 mL) was added Ag2SO4 (77.6 g, 249 mmol, 1.05 eq) and I2 (63.2 g, 249 mmol, 1.05 eq) in one portion at 20°C. The mixture was stirred at 20°C for 5 h. TLC showed the reaction was
complete. The mixture was poured into ice-water (1 L) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (600 mL x 3). The combined organic phase was washed with saturated aq. Na2SO3 (400 mL x 2) and brine (150 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2-amino-5- iodo-3-methoxy-benzoate (45.0 g, 61% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.61 (s, 1H), 7.15 (s, 1H), 6.45 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H). [0226] 4.3 Preparation of methyl 2-bromo-5-iodo-3-methoxy-benzoate [0227] To a sol
46 mmol, 1 eq) in MeCN (600 mL) was added CuBr2 (66.4 g, 297 mmol, 2.03 eq) at 25°C. The mixture was stirred at 25°C for 20 min, and then, tert-butyl nitrite (264 mmol, 31 mL, 1.8 eq) was added dropwise over 10 min at 10°C. The reaction mixture was stirred at 10°C for additional 30 min, and the mixture was heated and stirred at 60°C for 12 h. The residue was poured into ice-water (1L) and saturated aq. Na2CO3 (600 mL). The aqueous phase was extracted with ethyl acetate (500 mL x 3). The combined organic phase was washed with saturated aq. Na2SO3 (500 mL) and brine (500 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2-bromo -5-iodo-3-methoxy-benzoate (33 g, 60% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.47 (s, 1H), 7.44 (s, 1H), 3.92 (s,3H), 3.85 (s, 3H). [0228] 4.4 Preparation of methyl 2,5-dibromo-3-hydroxy-benzoate [0229] To a solutio
o e y - o o- - o o- - e o y- e oa e .0 g, 88.9 mmol, 1 eq) in DCM (400 mL) was slowly added BBr3 (267 mmol, 25.7 mL, 3 eq) at 0°C under N2. After
the addition, the reaction was allowed to warm to 20°C and stirred for 1 h. TLC showed the reaction was complete. To the reaction mixture was slowly added MeOH (2.67 mol, 108 mL, 30 eq) and the resulting mixture was stirred at 20°C for 30 min. The mixture was poured into ice- water (600 mL) and stirred for 5 min. The aqueous phase was extracted with DCM (350 mL x 3). The combined organic phase was washed with brine (400 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2,5- dibromo-3-hydroxy-benzoate (17.0 g, 62% yield) as a white solid.1H NMR (DMSO-d6,, 400 MHz) δ 11.16 (s, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 3.83 (s, 3H). [0230] 4.5 Preparation of methyl 2,5-dibromo-3-[2-[tert-butyl(dimethyl)silyl]oxyethoxy] benzoate [0231] To a mi
mmol, 1 eq) and 2- bromoethoxy-tert-butyl-dimethyl-silane (9.26 g, 38.7 mmol, 1.5 eq) in DMF (80 mL) was added K2CO3 (7.13 g, 51.6 mmol, 2 eq) and NaI (774 mg, 5.16 mmol, 0.2 eq) in one portion at 20°C under N2. The mixture was heated to 60°C and stirred for 16 h. TLC showed the reaction was complete. The mixture was poured into ice-water (150 mL) and stirred for 10 min. Then aqueous phase was extracted with ethyl acetate (80 mL x 3). The combined organic phase was washed with brine (50 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2,5-dibromo-3-[2-[tert- butyl(dimethyl)silyl]oxyethoxy]benzoate (12.0 g, 99% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.41 (d, J = 2.4 Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 4.14 (t, J = 4.8 Hz, 2H), 4.02 (t, J = 5.2 Hz, 2H), 3.94 (s, 3H), 0.91 (s, 9H), 0.11 (s, 6H). [0232] 4.6 Preparation of methyl 2-bromo-5-(tert-butoxycarbonylamino)-3-[2-[tert- butyl(dimethyl) silyl]oxyethoxy]benzoate
[0233] To a mixture of methyl 2,5-dibromo-3-[2-[tert-butyl(dimethy
enzoate (5.0 g, 10.6 mmol, 1 eq) and NH2Boc (1.38 g, 11.7 mmol, 1.1 eq) in dioxane (80 mL) was added Pd(OAc)2 (239 mg, 1.07 mmol, 0.1 eq), (5-diphenylphosphanyl-9,9-dimethyl-xanthen-4-yl) - diphenyl-phosphane (617 mg, 1.07 mmol, 0.1 eq) and Cs2CO3 (6.96 g, 21.36 mmol, 2 eq) in one portion at 20°C under N2. The mixture was heated to 100°C and stirred for 16 h. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2-bromo-5-(tert-butoxycarbonylamino)-3-[2-[tert- butyl(dimethyl)silyl]oxyethoxy]benzoate (3.3 g, 61% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.40 (s, 1H), 7.14 (d, J = 2.4 Hz, 1H), 6.53 (s, 1H), 4.13 (t, J =
.8 Hz, 2H), 4.02 (t, J = 5.2 Hz, 2H), 3.92 (s, 3H), 1.52 (s, 9H), 0.91 (s, 9H), 0.12 (s, 6H). [0234] 4.7 Preparation of tert-butyl N-[4-bromo-3-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5- (hydroxymethyl)phenyl]carbamate [0235] To a mixtur
[2-[tert-butyl (dimethyl) silyl]oxyethoxy]benzoate (4.0 g, 7.93 mmol, 1 eq) in THF (40 mL) was added MeOH (49.4 mmol, 2.00 mL, 6.23 eq) and LiBH4 (2 M in THF, 15 mL, 3.78 eq) drop-wise at 0°C under N2. After the addition, the reaction was allowed to warm to 20°C and stirred for 4 h. TLC showed the reaction was complete. The mixture was poured into ice-water (100 mL) and the aqueous phase was adjusted pH to 7-8 with aq. HCl (2N). The aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with brine (50 mL), dried
with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=5/1 to 3/1) to give tert- butyl N-[4-bromo-3-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-(hydroxymethyl) phenyl]carbamate (4 g, crude) as a white solid.1H NMR (CDCl3, 400 MHz) δ 7.26 (s, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.56 (s, 1H), 4.70 (s, 2H), 4.12 (t, J = 4.8 Hz, 2H), 4.01 (t, J = 4.8 Hz, 2H),
1.52 (s, 9H), 0.92 (s, 9H), 0.12 (s, 6H). [0236] 4.8 Preparation of tert-butyl N-[7-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-1-hydroxy-3H -2,1-benzoxaborol-5-yl]carbamate
]oxyethoxy]-5- (hydroxymethyl)phenyl]carbamate (4.0 g, 8.39 mmol, 1 eq) in dioxane (120 mL) was added KOAc (2.47 g, 25.2 mmol, 3 eq), Pd(dppf)Cl2 (614 mg, 840 umol, 0.1 eq) and 2-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (4.74 g, 20.9 mmol, 2.5 eq) in one portion at 25°C under N2. Then the mixture was heated to 100°C and stirred for 16 h. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=3/1 to 2/1) to give tert-butyl N-[7-[2-[tert- butyl(dimethyl)silyl]oxyethoxy]-1-hydroxy-3H-2,1-benzoxaborol -5-yl]carbamate (2.5 g, crude) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 7.04 (s, 1H), 6.90 (s, 1H), 6.60 (s, 1H), 5.85 (s, 1H), 5.31 (s, 1H), 5.00 (s, 2H), 4.14 (t, J = 4.4 Hz, 2H), 3.98 (t, J = 4.8 Hz, 2H), 1.53 (s, 9H), 0.93 (s, 9H), 0.13 (s, 6H). [0238] 4.9 Preparation of tert-butyl (7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-4- yl)carbamate
[0239] To a mixture of te
rt-butyl N-[7-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-1-hydroxy-3H- 2,1 -benzoxaborol-5-yl]carbamate (250 mg, 590 umol, 1 eq) in THF (10 mL) was added aq. HCl (3 M, 1.18 mL, 6 eq) drop-wise at 0°C. After the addition, the reaction was heated and stirred at 40°C for 30 min. TLC showed the reaction was complete. The mixture was poured into ice- water (6 mL). The aqueous phase was extracted with ethyl acetate (5 mL x 3). The combined organic phase was washed with brine (5 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was purified by prep-TLC (SiO2, Petroleum ether/ethyl acetate= 2:1) and further purified by prep-HPLC (column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 30%- 60%,10min) to give tert-butyl (7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-4- yl)carbamate (43.2 mg, 99.58% purity) as a off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.57 (s, 1H), 7.22 (s, 1H), 6.95 (s, 1H), 5.05 (s, 2H), 4.63-4.59 (m, 1H), 4.30-4.29 (m, 1H), 4.26- 4.12 (m, 2H), 1.47 (s, 9H). MS (ESI): mass calcd. For C14H18BNO5291.13, m/z found 290.2[M- H]-. HPLC: 99.58% (220 nm), 99.68% (254 nm). [0240] 4.10 Preparation of 7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-4-amine hydrochloride [0241] To a mixture
, , , enzo[cd]azulen-4- yl)carbamate (1.0 g, 3.44 mmol, 1 eq) in EtOAc (10 mL) was added HCl/EtOAc (4 M, 40 mL, 46.58 eq) drop-wise at 20°C. After the addition, the reaction was heated and stirred at 40°C for 2 h. Then, the mixture was cooled to 10°C and stirred, solid was precipitate out. The solid was filtered, and filter cake was washed with ethyl acetate (10 mL x 2) and dried in vacuuo to give
crude product. The crude product was triturated with acetonitrile (10 mL) at 20oC for 10 min to give 7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-4-amine hydrochloride (550 mg, 96.86% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.60 (s, 3H), 6.63(s, 1H), 6.43 (s, 1H), 5.04 (s, 2H), 4.63-4.60 (m, 1H), 4.30-4.25 (m, 1H), 4.21-4.15 (m, 2H). MS (ESI): mass calcd. For C9H11BClNO3227.05, m/z found 192.2 [M+H]+. HPLC: 96.86% (220 nm), 98.77% (254 nm). [0242] 4.11 Preparation of (trans)-2-((2-((7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo [cd]azulen-4-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclopentanecarbonitrile
hydrochloride (50 mg, 219 umol, 1 eq, HCl salt) and (trans)-2-((2-chloro-5-methylpyrimidin-4- yl)amino) cyclopentanecarbonitrile (57.2 mg, 241 umol, 1.1 eq) in 2-methylbutan-2-ol (2 mL) was added BrettPhos Pd G3 (19.9 mg, 21.9 umol, 0.1 eq), Brettphos (11.8 mg, 21.9 umol, 0.1 eq) and Cs2CO3 (214 mg, 659 umol, 3 eq) in one portion at 20°C under N2. The mixture was heated to 100°C and stirred for 16 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filtrate was concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 25%-55%,10min) to give (trans)-2-((2-((7,8-dihydro-2H-1,6,9- trioxa-9a-borabenzo[cd]azulen-4-yl)amino)-5- methylpyrimidin-4-yl)amino)cyclopentanecarbonitrile (63 mg, 99.18% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.19-9.16 (m, 1H), 7.76 (d, J = 3.2 Hz, 1H), 7.53 (d, J = 46 Hz, 1H) 7.29 (d, J = 25.2 Hz, 1H), 6.85-6.75 (m, 1H), 5.09 (s, 2H), 4.79-4.47 (m, 2H), 4.30-4.25 (m, 2H), 4.16-4.12 (m, 1H), 3.63-3.10 (m, 1H), 2.17-2.05 (m, 2H), 2.01-1.84 (m, 5H), 1.64-1.61 (m, 2H). MS (ESI): mass calcd. For C20H22BN5O3391.18, m/z found 392.0 [M+H]+. HPLC: 99.18% (220 nm), 98.79% (254 nm).
[0244] 5. Preparation of (trans)-2-[[5-chloro-2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl) amino]pyrimidin -4-yl]amino]cyclopentane-1-carbonitrile [0245] 5.1 Preparation of methyl rans)(2-cyanocyclopentyl)amino]
pyrimidin-2-yl]amino]benzoate [024
nitrile (2.20 g, 8.56 mmol, 1 eq), methyl 5-amino-2-bromo-benzoate (2.17 g, 9.41 mmol, 1.1 eq) and TsOH.H2O (3.26 g, 17.1 mmol, 2 eq) in dioxane (60 mL) was heated and stirred at 80 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was cooled to room temperature and concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of EtOAc (50 mL) and saturated aq. Na2CO3 (50 mL) and the resulting suspension was filtered. The filter cake was dried in vacuum to give methyl 2-bromo-5-[[5-chloro-4-[(trans)-(2-cyano cyclopentyl)amino]pyrimidin-2-yl]amino]benzoate (2.05 g, 64.8% yield) as a gray solid. [0247] 5.2 Preparation of methyl 5-[[5-chloro-4-[(trans)-(2-cyanocyclopentyl)amino]pyrimidin - 2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate [02
] m x ure o me y - romo- -[[ -c oro- -[ -cyanocyc open y am no]pyr m n-2- yl] amino]benzoate (2.00 g, 4.44 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (2.51 g, 11.0 mmol, 2.5 eq), Pd(PPh3)2Cl2 (311 mg, 443 umol, 0.1
eq) and KOAc (1.09 g, 11.0 mmol, 2.5 eq) in dioxane (60 mL) was heated and stirred at 120 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of MTBE (50 mL), EtOAc (5 mL) and petroleum ether (10 mL) to give methyl 5-[[5-chloro-4-[(trans)-(2- cyanocyclopentyl)amino]pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)benzoate (2.0 g, crude) as a brown solid. 1H NMR (CDCl3, 400 MHz) δ 8.16 (s, 1H), 8.08 (s, 1H), 7.89 (s, 1H), 7.71 (d, J=7.6 Hz, 2H), 7.50-7.48 (m, 1H), 5.26-5.24 (m, 1H), 4.73-4.66 (m, 1H), 3.90 (s, 3H), 3.77 (s, 4H), 3.57-3.56 (m, 1H), 2.88-2.84 (m, 1H), 2.33-2.31 (m, 1H), 2.15- 2.13 (m, 1H), 2.05-2.04 (m, 1H), 1.92-1.86 (m, 2H), 1.65-1.61 (m, 1H), 1.08 (s, 6H). [0249] 5.3 Preparation of (trans)-2-[[5-chloro-2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl) amino]pyrimidin -4-yl]amino]cyclopentanecarbonitrile [0250
cyanocyclopentyl) amino]pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)benzoate (5.00 g, 10.3 mmol, 1 eq) in THF (100 mL) and MeOH (5 mL) was added NaBH4 (1.96 g, 51.6 mmol, 5 eq) portion-wise at 0oC. After the addition, the reaction was allowed to warm to 25°C and stirred at 25°C for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was quenched with aq. HCl (1 N, 5 mL) carefully and diluted with H2O (20 mL). The mixture was extracted with EtOAc (50 mL x 2). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of MeCN (10 mL) and H2O (3 mL) to give (trans)-2-[[5-chloro-2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]pyrimidin-4- yl]amino]cyclopentanecarbonitrile (118.6 mg) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.57 (s, 1H), 9.07 (s, 1H), 8.06 (s, 1H), 7.92 (s, 1H), 7.62-7.54 (m, 2H), 7.48-7.46 (m, 1H), 4.95 (s, 2H), 4.83-4.75 (m, 1H), 3.26-3.20 (m, 1H), 2.19-2.09 (m, 2H), 1.89-1.80 (m, 3H), 1.64-1.54 (m, 1H).. MS (ESI): mass calcd. For C17H17BClN5O2369.11, m/z found 370.1 [M+H]+. HPLC: 92.18% (220 nm), 93.35% (254 nm).
[0251] 6. Preparation of (trans)2-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol-5- yl]amino] -5-methyl -pyrimidin-4-yl]amino]cyclopentanecarbonitrile [0252] 6.1 Preparation of meth lopentyl)amino]-5-methyl-
pyrimidin -2-yl]amino]-3-(trifluoromethyl)benzoate [0253
nitrile (2.00 g, 8.45 mmol, 1 eq) and methyl 5-amino-2-bromo-3-(trifluoromethyl)benzoate (2.77 g, 9.29 mmol, 1.1 eq) in dioxane (20 mL) was added TsOH·H2O (3.21 g, 16.9 mmol, 2 eq) in one portion at 20°C. The mixture was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was adjusted pH = 9 by saturated aq. Na2CO3. The mixture was extracted with EtOAc (40 mL x 3). The combined organic layers were washed with brine (40 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (30 mL) at 20oC for 20 min to give methyl 2-bromo-5-[[4-[(2-cyanocyclopentyl) amino]-5-methyl-pyrimidin-2-yl]amino]-3- (trifluoromethyl) benzoate (1.1 g, 26.1% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 11.16 (s, 1H), 8.62-8.60 (m, 1H), 8.30 (s, 1H), 8.16 (s, 1H), 7.89 (s, 1H), 4.75-4.67 (m, 1H), 3.91 (s, 3H), 3.30-3.26 (m, 1H), 2.27-2.23 (m, 1H), 2.06-2.03 (m, 4H), 1.80-1.79 (m, 2H), 1.72-1.68 (m, 2H). [0254] 6.2 Preparation of 2-[[2-[4-bromo-3-(hydroxymethyl)-5-(trifluoromethyl)anilino] -5- methyl-pyrimidin-4-yl]amino]cyclopentanecarbonitrile
[025 imidin-
2-yl] amino]-3-(trifluoromethyl)benzoate (0.65 g, 1.30 mmol, 1 eq) in THF (15 mL) was dropwise added LiBH4 (4 M in THF, 1.63 mL, 5 eq) at 0°C. The mixture was heated and stirred at 50°C for 8 h. TLC showed the reaction was complete. The reaction was quenched with ice water (30 mL), and adjusted pH = 2 by aq. HCl (2N). The white solid was precipitated and filtered. The filter cake was washed with H2O (10 mL) to give 2-[[2-[4-bromo-3- (hydroxymethyl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclopentane carbonitrile (0.45 g, crude) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 8.54 (s, 1H), 8.21 (s, 1H), 8.13 (s, 1H), 7.82 (s, 1H), 7.75-7.73 (m, 1H), 5.68-5.65 (m, 1H), 4.81-4.72 (m, 1H), 4.60- 4.54 (m, 2H), 3.32 (s, 3H), 3.13-3.08 (m, 1H), 2.19-2.14 (m, 2H), 2.00 (s, 3H), 1.73-1.72 (m, 1H), 1.71-1.65 (m, 2H), 1.58-1.55 (m, 1H). [0256] 6.3 Preparation of (trans)-2-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol-5- yl]amino] -5-methyl -pyrimidin-4-yl]amino]cyclopentanecarbonitrile [0
(hydroxymethyl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino] cyclopentanecarbonitrile (60 mg, 127 umol, 1 eq) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)- 5,5-dimethyl-1,3,2-dioxaborinane (72 mg, 318 umol, 2.5 eq) in dioxane (2 mL) was added KOAc (31 mg, 318 umol, 2.5 eq) and Pd(PPh3)2Cl2 (8.95 mg, 12.7 umol, 0.1 eq) in one portion at 20°C under N2. The mixture was heated and stirred at 120°C for 10 h. LCMS showed the reaction was complete and desired MS observed. The five parallel reactions were combined and the mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18100*25mm*3um; mobile phase:
[water (0.04%HCl)-ACN]; B%: 20%-30%,8min) to give 2-[[2-[[1-hydroxy-7-(trifluoromethyl)- 3H-2,1-benzoxaborol-5-yl]amino]-5-methyl -pyrimidin-4-yl]amino]cyclopentanecarbonitrile (77.1 mg, 30.2% yield) a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.61 (s, 1H), 9.09 (s, 1H), 8.10 (m, 2H), 7.86 (s, 1H), 5.06 (s, 2H), 4.79-4.75 (m, 1H), 3.25-3.13 (m, 1H), 2.22-2.21 (m, 1H), 2.05-2.03 (m, 4H), 1.82-1.65 (m, 4H). MS (ESI): mass calcd. For C15H15BO4, 417.16, m/z found 418.2 [M+H]+. HPLC: 99.09% (220 nm), 99.29 (254 nm). [0258] 7. Preparation of (trans)-2-((2-((2-hydroxy-2H-benzo[e][1,2]oxaborinin-6-yl)amino)-5- methylpyrimidin-4-yl)amino)cyclopentane-1-carbonitrile [0259
yl)amino]cyclopentanecarbonitrile (100 mg, 422 umol, 1 eq) and 2-hydroxy-1,2-benzoxaborinin- 6-amine (83.4 mg, 422 umol, 1 eq, HCl) in dioxane (5 mL) was added TsOH·H2O (121 mg, 634 umol, 1.5 eq) at 20°C, the mixture was stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 15%-45%,10min) to give (trans)-2-((2- ((2-hydroxy-2H-benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclopentane-1-carbonitrile (17 mg, 95.13% purity) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.03 (s, 1H), 8.83 (s, 1H), 7.88 (s, 1H), 7.76-7.68 (m, 2H), 7.60 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.94-6.70 (m, 1H), 6.11 (d, J = 11.6 Hz, 1H), 4.79-4.72 (m, 1H), 3.19-3.09 (m, 1H), 2.20-2.15 (m, 1H), 2.12-2.07 (m, 1H), 1.94 (s, 3H), 1.85-1.77 (m, 2H), 1.73-1.66 (m, 1H), 1.62-1.57 (m, 1H). MS (ESI): mass calcd. For C19H20BN5O2361.17, m/z found 362.2 [M+H]+. HPLC: 95.13% (220 nm), 97.25% (254 nm). [0260] 8. Preparation of (trans)2-[[2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-methyl- pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
[0261] 8.1 Preparation of methy cyanocyclohexyl)amino]-5-methyl-
pyrimidin -2-yl]amino]benzoate [0262]
yl)amino]cyclohexanecarbonitrile (1.30 g, 5.18 mmol, 1 eq) and methyl 5-amino-2-bromo- benzoate (1.43 g, 6.22 mmol, 1.2 eq) in dioxane (20 mL) was added TsOH·H2O (1.97 g, 10.3 mmol, 2 eq) in one portion at 20°C. The mixture was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (10 mL) at 20oC for 10 min to give methyl 2-bromo-5-[[4-[(2-cyanocyclohexyl) amino]- 5-methyl-pyrimidin-2-yl]amino]benzoate (0.8 g, 34% yield) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.29 (s, 1H), 8.26 (d, J = 2.8 Hz, 1H), 7.76-7.73 (m, 2H), 7.55 (d, J = 8.8 Hz, 1H), 6.74 (d, J = 8.8 Hz, 1H), 4.27 (br d, J = 5.2 Hz, 1H), 3.85 (s, 3H), 3.31 (s, 3H), 2.93 (dt, J=3.6, 11.6 Hz, 1H), 2.21 - 2.10 (m, 1H), 1.97 - 1.84 (m, 4H), 1.80 - 1.52 (m, 3H), 1.38 - 1.13 (m, 4H). [0263] 8.2 Preparation of methyl 5-[[4-[((trans)-2-cyanocyclohexyl)amino]-5-methyl-pyrimidin- 2-yl]amino]-2-(5,5-dimethyl-1,3,2 –dioxaborinan-2-yl)benzoate
[0264] To a mixture of methyl 2-bromo-5-[[4-[((trans)-2-cyanocyclohexyl)amino]-5-methyl- pyrimidin-2-yl]amino] benzoate (800 mg, 1.80 mmol, 1 eq) and 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl- 1,3,2-dioxaborinane (1.02 g, 4.50 mmol, 2.5 eq) in dioxane (10 mL) was added KOAc (442 mg, 4.50 mmol, 2.5 eq) and Pd(PPh3)2Cl2 (253 mg, 360 umol, 0.2 eq) in one portion at 20°C under N2. The mixture was heated and stirred at 120°C for 1 h. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (10 mL) at 20oC for 15 min to give methyl 5-[[4-[((trans)2-cyanocyclohexyl)amino]-5- methyl-pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2 –dioxaborinan-2-yl)benzoate (0.8 g, crude) as an off-white solid. [0265] 8.3 Preparation of (trans)-2-[[2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-methyl- pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
din-2- yl]amino] -2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (800 mg, 1.68 mmol, 1 eq) in THF (10 mL) and MeOH (1 mL) was added NaBH4 (159 mg, 4.19 mmol, 2.5 eq) in portions at 0°C. After the addition, the reaction was allowed to warm to 20°C and stirred at 20°C for 2 h. The reaction mixture was adjusted pH = 6 by aq. HCl (2N). The mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C1880*40mm*3 um; mobile phase: [water (0.04%HCl)-ACN]; B%: 18%-43%,7min) to give (trans)-2-[[2-[(1-hydroxy-3H- 2,1-benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (80 mg, 13% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.37 (s, 1H), 10.76 (s, 1H), 9.17 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 7.76-7.72 (m, 2H), 7.48 (dd, J = 1.6, 8.0 Hz, 1H),
5.05-4.96 (m, 2H), 4.32-4.23 (m, 1H), 3.08 (m, 1H), 2.19 (d, J = 12.8 Hz, 1H), 2.05 (s, 3H), 1.96-1.94 (m, 1H), 1.80-1.71 (m, 2H), 1.66-1.56 (m, 1H), 1.46-1.37 (m, 1H), 1.33-1.15 (m, 2H). MS (ESI): mass calcd. For C19H23BClN5O2, 363.19, m/z found 364.2 [M+H]+. HPLC: 96.51% (220 nm), 99.68 (254 nm). [0267] 9. Preparation of (trans)-2-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol- 5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
[0268] 9.1 Preparation of 2-bromo-3-methyl-5-nitro-benzoic acid [0269] To a mixture o
ol, 1 eq) in H2SO4 (70 mL, 98% purity) was added a solution of KNO3 (4.70 g, 46.5 mmol, 1 eq) in H2SO4 (30 mL, 98% purity) at 0°C over 0.5 h, and the mixture was stirred at 0°C for 2.5 h. TLC showed the reaction was complete. The reaction mixture was poured into ice H2O (200 mL), the resulting solid was filtered and the filter cake was extracted with ethyl acetate (100 mL). The combined organic phase was washed with brine (150 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give 2-bromo-3-methyl-5-nitro-benzoic acid (10.5 g, 86% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 8.58 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 2.63 (s, 3H). [0270] 9.2 Preparation of methyl 2-bromo-3-methyl-5-nitro-benzoate
[0271] To a mixture of 2-bromo-3-methyl-5-nitro-benzoic acid (8.00 g, 30.8 mmol, 1 eq) in MeOH (80 mL) was added SOCl2 (61.5 mmol, 4.46 mL, 2 eq) at 0°C. After the addition, the reaction was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction was concentrated under reduced pressure to give a residue. The residue was dissolved in H2O (80 mL) and adjusted pH to 7 with saturated aq. NaHCO3 and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~15% Ethyl acetate/petroleum ether gradient @ 100 mL/min) to give methyl 2-bromo-3- methyl-5-nitro-benzoate (6 g, 71% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) 8.35 (d, J = 2.4 Hz, 1H), 8.21 (d, J = 2.4 Hz, 1H), 4.00 (s, 3H) 2.59 (s, 3H). [0272] 9.3 Preparation of methyl 5-amino-2-bromo-3-methyl-benzoate [0273] To a mixt
9 mmol, 1 eq) in EtOH (80 mL) and H2O (20 mL) was added NH4Cl (4.68 g, 87.6 mmol, 4 eq) and Fe (4.89 g, 87.6 mmol, 4 eq) at 25°C under N2. The mixture was stirred at 80°C for 1 h. TLC showed the reaction was complete. The reaction was filtered and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-amino-2-bromo-3-methyl-benzoate (5 g, 93% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 6.80 (d, J = 2.8 Hz, 1H), 6.68 (d, J = 3.2 Hz, 1H), 3.91 (s, 3H), 3.72 (s, 2H), 2.36 (s, 3H). [0274] 9.4 Preparation of methyl 2-bromo-5-[[4-[((trans)-2-cyanocyclohexyl)amino]-5-methyl- pyrimidin-2-yl]amino]-3-methyl-benzoate
[0275] ane-1-
carbonitrile (2.00 g, 7.98 mmol, 1 eq) and methyl 5-amino-2-bromo-3-methyl-benzoate (2.14 g, 8.77 mmol, 1.1 eq) in dioxane (40 mL) was added 4-methylbenzenesulfonicacid·hydrate (3.03 g, 16.0 mmol, 2 eq) in one portion at 20°C under N2. The mixture was heated to 80°C and stirred for 16 h. TLC showed the reaction was complete. The mixture was poured into ice-water (80 mL) and the aqueous phase was adjusted pH to 5-6 with saturated aq. Na2CO3. The resulting mixture was diluted with EtOAc (30 mL x 3) and then the suspension was filtered. The filter cake was washed with water (30 mL x 2) and dried in vacuum to give residue. The residue was purified by trituration with MTBE (30 mL) at 20oC for 0.5 h to give methyl 2-bromo-5-[[4- [((trans)-2-cyanocyclohexyl)amino]-5-methyl- pyrimidin-2-yl]amino]-3-methyl-benzoate (1.5 g, 41% yield) as an off-white solid. [0276] 9.5 Preparation of methyl 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methylbenzoate
[0 77] ree react ons were carr e out n para e . or eac a m xture o met y - romo-5-[[4- [((trans)-2-cyanocyclohexyl)amino]-5-methyl-pyrimidin- 2-yl]amino]-3-methyl-benzoate (200 mg, 436 umol, 1 eq) and 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2- dioxaborinane (246 mg, 1.09 mmol, 2.5 eq) in dioxane (6 mL) was added AcOK (107 mg, 1.09 mmol, 2.5 eq) and Pd(PPh3)2Cl2 (15.3 mg, 21.8 umol, 0.05 eq) in one portion at 20°C under N2. The mixture was heated and stirred at 120°C for 1 h. TLC showed the reaction was complete. The three parallel reactions were combined and the reaction mixture was filtered and concentrated in vacuum to give a residue. The crude product was triturated with MTBE (20 mL)
at 20oC for 0.5 h to give methyl 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methylbenzoate (300 mg, 46% yield) as a gray solid.1H NMR (CDCl3, 400 MHz) δ 7.97 (s, 1H), 7.77 ( s, 1H), 7.61 (s, 1H), 4.59-4.48 (m, 1H), 4.44-4.37 (m, 1H), 3.94 (s, 3H), 3.82 (s, 4H), 2.86-2.76 (m, 1H), 2.48 (s, 3H), 2.21-2.18 (m, 1H), 1.99 (s, 3H), 1.84-1.71 (m, 4H), 1.60-1.49 (m, 2H), 1.42-1.36 (m, 2H), 1.15 (s, 6H). [0278] 9.6 Preparation of (trans)-2-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
methylpyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methylbenzoate (150 mg, 305 umol, 1 eq) and MeOH (0.5 mL) in THF (6 mL) was added NaBH4 (57.7 mg, 1.53 mmol, 5 eq) at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 1 h. The reaction was quenched by H2O (10 mL), adjusted pH to 5 with aq. HCl (2N). EtOAc (10 mL) was added to the reaction mixture, then precipitate formed. The precipitate was filtered to give (trans)-2-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5- methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (28 mg, 95.47% purity) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.03 (s, 1H), 8.57 (s, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.37 (s, 1H), 6.68 (d, J = 8.8 Hz,, 1H), 4.94-4.85 (m, 2H), 4.38-4.25 (m, 1H), 2.99-2.91 (m, 1H), 2.38 (s, 3H), 2.18 (d, J = 12.4 Hz, 1H), 1.98-1.96 (m, 1H), 1.94 (s, 3H), 1.81-1.70 (m, 2H), 1.65- 1.56 (m, 1H), 1.37-1.30 (m, 2H), 1.24-1.15 (m, 1H). MS (ESI): mass calcd. For C20H24BN5O2 377.20, m/z found 378.2 [M+H]+. HPLC: 95.47% (220 nm), 94.36% (254 nm). [0280] 10. Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-1,3dihydrobenzo[c][1,2] oxaboroll-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
[0281] 10.1 Preparation of (tra -(hydroxymethyl)anilino]-5-
methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile N OH eq) in i-
PrOH (30 mL) was added TFA (2.89 g, 25.37 mmol, 1.90 mL, 2 eq) and 2-((2-chloro-5- methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (3.50 g, 13.95 mmol, 1.1 eq) at 20°C. The mixture was heated to 90oC and stirred at 90°C for 16 hrs. Solid precipitated out after 3 hours reaction time. TLC showed the reaction was complete. The reaction was filtered to give the crude product. The crude product was triturated with aqueous NaHCO3 (40 mL) at 20oC for 30 min, then filtered. The filtered cake was washed with THF (100 mL) to give (trans)-2-[[2-[4- bromo-3-chloro-5-(hydroxymethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1- carbonitrile (5 g, 87% purity) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.12 - 7.89 (m, 2H), 7.85 (s, 1H), 7.73 (s, 1H), 5.69 (s, 1H), 4.52 (s, 2H), 4.41 - 4.28 (m, 1H), 3.84 - 3.72 (m, 1H), 3.00 (dt, J = 2.4, 12.0 Hz, 1H), 2.16 (d, J = 12.4 Hz, 1H), 2.02 (s, 3H), 1.90 - 1.80 (m, 1H), 1.77 - 1.52 (m, 3H), 1.50 - 1.30 (m, 2H), 1.27 - 1.10 (m, 1H). [0283] 10.2 Preparation of 2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro- anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
[0284] To a solution of (trans)-2-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]cyclohexanecarbonitrile (6 g, 13.3 mmol, 1 eq) and 2,6-dimethylpyridine (5.76 g, 53.2 mmol, 4 eq) in THF (60 mL) was added TBSOTf (7.04 g, 26.6 mmol, 6.12 mL, 2 eq) dropwise at 0oC. The mixture was stirred at 25°C for 3 h. LCMS showed the reaction was complete. The reaction mixture was quenched by addition saturated. aq. NH4Cl (100 mL) at 0°C and extracted with Ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with a solution of petroleum ether (15 mL) and ethyl acetate (15mL) at 20oC for 30 min to give (trans)-2-[[2-[4-bromo-3-[[tert- butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-methyl-pyrimidin-4-yl]amino]cyclo hexane-1-carbonitrile (5.2 g, 69.1% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.45 (s, 1H), 8.32 (s, 1H), 7.75 (s, 1H), 7.66 (s, 1H), 6.77 (d, J = 8.0 Hz, 1H), 4.65 (s, 2H), 4.43 - 4.21 (m, 1H), 2.95 - 2.85 (m, 1H), 2.27 - 2.08 (m, 1H), 2.03 - 1.85 (m, 4H), 1.83 - 1.67 (m, 2H), 1.65 - 1.52 (m, 1H), 1.47 - 1.12 (m, 3H), 0.94 (s, 9H), 0.13 (s, 6H). [0285] 10.3 Preparation of (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1- carbonitrile [028
-bromo- 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexane-1-carbonitrile (0.4 g, 708 umol, 1 eq) in dioxane (12 mL) was added 2- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (800 mg, 3.54 mmol, 5 eq), KOAC (208 mg, 2.12 mmol, 3 eq) and Pd(PPh3)2Cl2 (50 mg, 70.8 umol, 0.1 eq) at 20oC. Then the mixture was stirred at 120°C for 40 min under N2 atmosphere. LCMS showed the reaction was complete. The reactions were cooled to room temperature and the five parallel reactions were combined and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC(column: Welch Xtimate C18
250*70mm#10um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 45%-75%,20min) to give 2- [[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (1 g, 47.2% yield, 95% purity) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.20 (s, 1H), 7.98 (s, 1H), 7.74 (s, 1H), 7.43 (s, 1H), 6.73 (d, J = 8.8 Hz, 1H), 4.63 (s, 2H), 4.42 - 4.26 (m, 1H), 3.70 (s, 4H), 2.95 - 2.90 (m, 1H), 2.18 (d, J = 11.6 Hz, 1H), 1.98 - 1.87 (m, 4H), 1.80 - 1.67 (m, 2H), 1.68 - 1.53 (m, 1H), 1.46 - 1.27 (m, 2H), 1.47 - 1.12 (m, 1H), 1.04 (s, 6H), 0.92 - 0.87 (m, 9H), 0.06 (s, 6H). [0287] 10.4 Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
oro-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1- carbonitrile (1.8 g, 3.40 mmol, 1 eq) in THF (20 mL) was added HCl (6 M, 2.26 mL, 4 eq) at 20°C. The mixture was stirred at 40 for 1hr. LCMS showed the reaction was complete and one main peak with desired mass was detected. The reaction was concentrated under reduced pressure to give a residue. The residue was triturated with MeCN (15 mL) at 25oC for 10 min to give racemic product (1.5 g). The racemic product (1.5 g) was purified by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [Neu-IPA]; B%: 42%- 42%,8min) to give (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5- methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile (90.5 mg, 95.79% purity, 98.80% ee, first peak, Rt = 1.280 min) stereoisomer one as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.37 (s, 1H), 8.84 (s, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.71 (s, 1H), 6.79 (d, J = 8.8 Hz, 1H), 5.00 - 4.85 (m, 2H), 4.40 - 4.26 (m, 1H), 2.93 (dt, J = 3.2, 11.2 Hz, 1H), 2.19 (d, J = 11.2 Hz, 1H), 2.00 - 1.90 (m, 4H), 1.90 - 1.76 (m, 2H), 1.75 - 1.62 (m, 1H), 1.53 - 1.33 (m, 2H), 1.33 - 1.19 (m, 1H) MS (ESI): mass calcd. For C19H21BClN5O2397.15, m/z found 398.0 [M+H]+. HPLC: 95.79% (220 nm), 95.88% (254 nm).and (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1- benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (206 mg,
96.14% purity, 98.78% ee, second peak, Rt = 1.841 min) stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.37 (s, 1H), 8.84 (s, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.71 (s, 1H), 6.78 (d, J = 8.8 Hz, 1H), 5.07 - 4.78 (m, 2H), 4.46 - 4.13 (m, 1H), 2.93 (dt, J = 3.6, 12.0 Hz, 1H), 2.18 (d, J = 11.2 Hz, 1H), 2.00 - 1.90 (s, 4H), 1.83 - 1.69 (m, 2H), 1.68 - 1.56 (m, 1H), 1.46 - 1.27 (m, 2H), 1.26 - 1.13 (m, 1H). MS (ESI): mass calcd. For C19H21BClN5O2397.15, m/z found 398.1 [M+H]+. HPLC: 96.14% (220 nm), 99.69% (254 nm). [0289] 11. Preparation of (trans)-2-((2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile [0290] 11.1 Preparation of (tr
ethyl)-5- (trifluoromethyl)anilino]-5- methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile
[0291] To a mixture of [5-amino-2-bromo-3-(trifluoromethyl)phenyl]methanol (3.6 g, 13.3 mmol, 1 eq) and 2-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]cyclohexanecarbonitrile (3.34 g, 13.3 mmol, 1 eq) in i-PrOH (40 mL) was added TFA (2.28 g, 20.0 mmol, 1.5 mL, 1.5 eq) in one portion at 25°C. The mixture was stirred at 90°C for 5 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was cooled to room temperature and large amount of precipitate formed. The mixture was filtered and the filter cake was triturated with saturated aq. NaHCO3 to afford 2-[[2-[4-bromo-3-(hydroxymethyl)-5- (trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (5.2 g, 80.5% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.43 (s, 1H), 8.30 (d, J = 2.8 Hz, 1H),
8.18 (d, J = 2.4 Hz, 1H), 7.77 (s, 1H), 6.71 (d, J = 8.8 Hz, 1H), 5.57 (t, J = 5.2 Hz, 1H), 4.54 (d, J = 5.2 Hz, 2H), 4.42-4.32 (m, 1H), 2.95-2.88 (m, 1H), 2.18-2.12 (m, 1H), 1.95 (s, 3H), 1.90- 1.85 (m, 1H), 1.75-1.65 (m, 2H), 1.66-1.56 (m, 1H), 1.37-1.29 (m, 2H), 1.20-1.10 (m, 1H). [0292] 11.2 Preparation of (trans)-2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- (trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile [ o]-5-
methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (3.5 g, 7.23 mmol, 1 eq) and 2,6- dimethylpyridine (2.34 g, 21.7 mmol, 2.6 mL, 3 eq) in THF (100 mL) was added TBSOTf (2.87 g, 10.8 mmol, 2.5 mL, 1.5 eq) at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 3 h. TLC showed the reaction was complete. The reaction mixture was quenched with saturated aq. NH4Cl (80 mL) at 0°C, and then extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (40 mL) at 25oC for 30 min to obtain (trans)-2-[[2-[4-bromo-3-[[tert- butyl(dimethyl)silyl]oxymethyl]-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (4.1 g, 94.8% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.55 (s, 1H), 8.45 (s, 1H), 8.04 (s, 1H), 7.75 (s, 1H), 6.74 (d, J = 9.2 Hz, 1H), 4.72 (s, 2H), 4.37-4.28 (m, 1H), 2.97-2.89 (m, 1H), 2.20-2.14 (m, 1H), 1.95 (s, 3H), 1.88-1.80 (m, 1H), 1.76-1.68 (m, 2H), 1.60-1.50 (m, 1H), 1.39-1.14 (m, 4H), 0.95 (s, 9H), 0.14 (s, 6H). [0294] 11.3 Preparation of (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile
[0 omo-
3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (1 g, 1.67 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)-5,5-dimethyl-1,3,2-dioxaborinane (1.8 g, 7.97 mmol, 4.8 eq), Pd(PPh3)2Cl2 (117 mg, 167 umol, 0.1 eq), KOAc (492 mg, 5.01 mmol, 3 eq) in dioxane (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 40 min under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The four parallel reactions were combined, filtered and the filter cake was washed with EtOAc (90 mL x 2). The filtrate was concentrated under reduced pressure to give a residue (6 g, crude). The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/petroleum ether gradient @ 75 mL/min) to give crude product, which was purified by prep-HPLC (column: C18 (250*50mm*10 um);mobile phase: [water ( NH4HCO3)- ACN]; B%: 75%-95%,10min) to give 2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (2.4 g) as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 9.34 (s, 1H), 8.27 (s, 1H), 7.79 (s, 1H), 7.75 (s, 1H), 6.69 (d, J = 9.2 Hz, 1H), 4.73 (s, 2H), 4.37-4.30 (m, 1H), 3.70 (s, 4H), 2.92 (m, 1H), 2.20-2.15 (m, 1H), 1.95 (s, 3H), 1.90-1.85 (m, 1H), 1.76- 1.68 (m, 2H), 1.60-1.50 (m, 1H), 1.36-1.26 (m, 2H), 1.24-1.13 (m, 1H), 1.03 (s, 6H), 0.90 (s, 9H), 0.07 (s, 6H). [0296] 11.4 Preparation of (trans)-2-((2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile
[0297] To a mixture of (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (2 g, 3.17 mmol, 1 eq) in THF (20 mL) was added HCl (6 M, 2.64 mL, 5 eq) drop-wise at 0°C. The mixture was stirred at 40°C for 0.5 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was cooled to room temperature and large amount of precipitate formed. The reaction was filtered. The filter cake was washed with deionized water to give crude product. The crude product was triturated with MeCN (20 mL) at 25oC for 20 min to give (trans)-2-((2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (1.2 g) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.91 (s, 1H), 9.17 (s, 1H), 8.44 (d, J = 7.2 Hz, 1H), 8.04 (s, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 5.13-5.04 (m, 2H), 4.32-4.22 (m, 1H), 3.04 (m, 1H), 2.18 (d, J = 11.2 Hz, 1H), 2.06 (s, 3H), 1.88 (d, J = 12.8 Hz, 1H), 1.78- 1.72 (m, 2H), 1.60-1.38 (m, 2H), 1.27-1.16 (m, 2H). Material was separated by prep-SFC (column: DAICEL CHIRALPAK IG(250mm*50mm,10um);mobile phase: [0.1%NH3H2O MEOH]; B%: 40%-40%,5min) to give (trans)-2-((2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (557 mg, 99.90% ee, first peak, Rt = 1.246 min) stereoisomer one as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, 1H), 8.89 (s, 1H), 8.14 (s, 1H), 8.04 (s, 1H), 7.79 (s, 1H), 6.76 (d, J = 8.8 Hz, 1H), 5.06-4.97 (m, 2H), 4.37-4.28 (m, 1H), 2.93 (m, 1H), 2.18 (d, J = 11.6 Hz, 1H), 1.96 (s, 3H), 1.95-1.90 (m, 1H), 1.78-1.70 (m, 2H), 1.65-1.54 (m, 1H), 1.39-1.28 (m, 2H), 1.25-1.14 (m, 1H). MS (ESI): mass calcd. For C20H21BF3N5O2431.17, m/z found 432.3 [M+H]+. HPLC: 99.25% (220 nm), 99.33% (254 nm) and (trans)-2-((2-((1-hydroxy-7- (trifluoromethyl)-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclohexane-1-carbonitrile (551.7 mg, 99.34% ee, second peak, Rt = 1.443 min) stereoisomer two as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.54 (s, 1H), 8.90 (s, 1H), 8.13 (s, 1H), 8.03 (s, 1H), 7.79 (s, 1H), 6.81 (d, J = 8.8 Hz, 1H), 5.06-4.97 (m, 2H), 4.37- 4.28 (m, 1H), 2.94 (m, 1H), 2.20-2.15 (m, 1H), 1.97 (s, 3H), 1.95-1.90 (m, 1H), 1.78-1.69 (m, 2H), 1.65-1.54 (m, 1H), 1.39-1.29 (m, 2H), 1.26-1.15 (m, 1H). MS (ESI): mass calcd. For C20H21BF3N5O2431.17, m/z found 432.3 [M+H]+. HPLC: 97.52% (220 nm), 98.26% (254 nm)
[0298] 12. Preparation of 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile [0299] 12.1 Preparation of methy benzoate
[030
(60 g, 305 mmol, 1 eq) in DMF (700 mL) was added NBS (70.7 g, 397 mmol, 1.3 eq) at 35oC. The mixture was stirred at 35°C for 12 h. Solid was precipitate out after 3 h reaction. TLC showed the reaction was complete. The reaction mixture was filtered to give crude product (filter cake). The crude product was triturated with MTBE (50 mL) at 25oC for 1 h to obtain methyl 2-amino-3-bromo-5-nitro- benzoate (70 g, 83.2% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 8.61 (d, J = 2.8 Hz, 1H), 8.47 (d, J = 2.8 Hz, 1H), 3.90 (s, 3H). [0301] 12.2 Preparation of methyl 2-amino-3-cyano-5-nitrobenzoate [0302] A mixt
, ol, 1 eq), Zn (3.50 g, 53.5 mmol, 0.21 eq), Zn(CN)2 (59.7 g, 508 mmol, 2 eq), Pd2(dba)3 (6.99 g, 7.63 mmol, 0.03 eq) and 1,1-Bis(diphenylphosphino)ferrocene (DPPF, 8.47 g, 15.2 mmol, 0.06 eq) in DMA (600 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 110°C for 1 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (3 L) and extracted with EtOAc (1 L × 3). The combined organic layers were washed with brine (500 mL × 2), dried over anhydrous Na2SO4, filtered, and concentrated under
reduced pressure to give a residue. The residue was triturated with DCM (60 mL) at 25oC for 1 h to obtain methyl 2-amino-3-cyano-5-nitro-benzoate (30 g, 55.3% yield) as a gray solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.74 - 8.67 (m, 2H), 8.20 (s, 2H), 3.90 (s, 3H) [0303] 12.3 Preparation of methyl 2-bromo-3-cyano-5-nitrobenzoate [0304] To a mixtu and CuBr2 (45.4 g,
203 mmol, 1.5 eq) in MeCN (100 mL) was added methyl 2-amino-3-cyano-5-nitro-benzoate (30 g, 135 mmol, 1 eq) in portions at 65°C. The mixture was stirred at 65°C for 1 h. LCMS showed the reaction was complete and desired mass was detected. The reaction mixture was diluted with H2O (500 mL) and extracted with EtOAc (500 mL × 3). The combined organic layers were washed with brine (300mL × 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, eluent of 0~25% ethyl acetate/petroleum ether gradient @ 100 mL/min) to obtain methyl 2-bromo-3-cyano-5-nitro-benzoate (32 g, 82.7% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.98 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H), 3.94 (s, 3H). [0305] 12.4 Preparation of methyl 5-amino-2-bromo-3-cyanobenzoate [0306] To a solu
, mmol, 1 eq) in EtOH (200 mL) and H2O (100 mL) was added Fe (13.5 g, 242 mmol, 2.3 eq) and NH4Cl (12.9 g, 242 mmol, 2.3 eq). The mixture was stirred at 70°C for 2 h. LCMS showed the reaction was complete and desired mass was detected. The reaction mixture was diluted with H2O (500 mL) and extracted with ethyl acetate (500 mL × 3). The combined organic layers were washed with
brine (300 mL × 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (80 mL) at 25oC for 1 h to obtain methyl 5- amino-2-bromo-3-cyano-benzoate (22 g, 81.9% yield) as a gray solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.27 - 7.00 (m, 2H), 6.05 (s, 2H), 3.84 (s, 3H). [0307] 12.5 Preparation of 5-amino-2-bromo-3-(hydroxymethyl)benzonitrile [0308] To a soluti 86.2 mmol, 1 eq) in
THF (200 mL) was added LiBH4 (4 M in THF, 64.7 mL, 259 mmol, 3 eq) at 25°C. The mixture was stirred at 35°C for 12 h. LCMS showed the reaction was complete and desired mass was detected. The reaction mixture was quenched by addition H2O (300 mL) at 0°C, and adjusted pH to 2 with aq. HCl (2M). The resulting solution was extracted with ethyl acetate (300 mL × 3). The combined organic layers were washed with brine (200 mL × 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (50 mL) at 25oC for 1 h to obtain 5-amino-2-bromo-3-(hydroxymethyl)benzonitrile (10 g, 51.0% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 7.07 (d, J = 2.8 Hz, 1H), 6.84 (d, J = 2.8 Hz, 1H), 5.79 (s, 2H), 5.52 (t, J = 5.6 Hz, 1H), 4.39 (d, J = 5.6 Hz, 2H). [0309] 12.6 Preparation of 2-bromo-5-((4-(((trans)-2-cyanocyclohexyl)amino)-5- methylpyrimidin-2-yl)amino)-3-(hydroxymethyl)benzonitrile
y y y . g, . mmol, 1.3 eq), 2-((2-chloro-5-methylpyrimidin-4-yl)amino)cyclohexanecarbonitrile (3.5 g, 13.9 mmol, 1 eq), TFA (2.39 g, 20.9 mmol, 1.55 mL, 1.5 eq) in i-PrOH (40 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 85°C for 12 h under N2 atmosphere. LCMS
showed the reaction was complete and desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was triturated with saturated aq. NaHCO3 (20 mL) at 25oC for 2 h to obtain 2-bromo-5-((4-(((trans)-2- cyanocyclohexyl) amino)-5-methylpyrimidin-2-yl)amino)-3-(hydroxymethyl)benzonitrile (2.3 g, 37.3% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.50 (s, 1H), 8.37 (d, J = 2.4 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.78 (s, 1H), 6.79 (d, J = 8.8 Hz, 1H), 5.63 (s, 1H), 4.50 (s, 2H), 4.41 - 4.26 (m, 1H), 2.95 - 2.85 (m, 1H), 2.16 (d, J = 11.2 Hz, 1H), 1.99 - 1.86 (m, 4H), 1.79 - 1.59 (m, 3H), 1.50 - 1.27 (m, 2H), 1.25 - 1.10 (m, 1H). [0311] 12.7 Preparation of 2-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2- cyanocyclohexyl)amino)-5-methylpyrimidin-2-yl)amino)benzonitrile
[0312] To a solution of 2-bromo-5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin- 2-yl)amino)-3-(hydroxymethyl)benzonitrile (2.3 g, 5.21 mmol, 1 eq) in THF (50 mL) was added 2,6-dimethylpyridine (1.78 g, 16.6 mmol, 1.94 mL, 3 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (2.20 g, 8.33 mmol, 1.91 mL, 1.5 eq) at 25oC. The mixture was stirred at 35°C for 2h. LCMS showed the reaction was consumed completely and one main peak with desired mass was detected. The reaction mixture was diluted with H2O (100 mL) and extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (50 mL) at 25oC for 30 min to obtain 2-bromo-3- (((tert-butyldimethylsilyl)oxy)methyl)-5-((4-((2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)benzonitrile (3 g, 97.2% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.67 (s, 1H), 8.51 (d, J = 2.4 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.76 (s, 1H), 6.90 (d, J = 8.4 Hz, 1H), 4.67 (s, 2H), 4.38 - 4.22 (m, 1H), 3.00 - 2.95 (m, 1H), 2.17 (d, J = 13.6 Hz, 1H), 1.96 (s,
3H), 1.92 - 1.84 (m, 1H), 1.80 - 1.54 (m, 3H), 1.43 - 1.29 (m, 2H), 1.26 - 1.08 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H). [0313] 12.9 Preparation of (2-(((tert-butyldimethylsilyl)oxy)methyl)-6-cyano-4-((4-(((trans)-2- cyanocyclohexyl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid [031 -
butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)benzonitrile (500 mg, 899 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (1.42 g, 6.30 mmol, 7 eq), KOAc (264 mg, 2.70 mmol, 3 eq), Pd(PPh3)2Cl2 (63.1 mg, 90.0 umol, 0.1 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 h under N2 atmosphere. LCMS showed the reaction was consumed completely and desired compound was detected. The six parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (neutral condition; column: Waters Xbridge BEH C18250*50mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 50%-80%,10 min) to give (2-(((tert-butyldimethylsilyl)oxy)methyl)-6-cyano-4-((4-(((trans)2-cyanocyclohexyl) amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid (400 mg, 12.5% yield) as a white solid. [0315] 12.10 Preparation of 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile
[0316] To a solution of (2-(((tert-butyldimethylsilyl)oxy)methyl)-6-cyano-4-((4-((trans)-2- cyanocyclohexyl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid (400 mg, 679 umol, 1 eq) in THF (10 mL) was added aq. HCl (6 M, 640 uL, 4 eq) at 25oC. The mixture was stirred at 25°C for 2 h. Solid was precipitate out after. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered to obtain compound 5-((4-(((trans)- 2-cyanocyclohexyl)amino)-5-methylpyrimidin-2-yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborole-7-carbonitrile (360 mg, yield 95%, purity 99%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 11.11 (s, 1H), 9.49 - 9.35 (m, 1H), 8.65 - 8.55 (m, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.82 (s, 1H), 5.06 (s, 2H), 4.33 - 4.21 (m, 1H), 3.64 - 3.56 (m, 1H), 3.12 - 2.98 (m, 1H), 2.20 - 2.14 (m, 1H), 2.06 (s, 3H), 1.95 - 1.87 (m, 1H), 1.74 - 1.57 (m, 2H), 1.50 - 1.30 (m, 2H), 1.27 - 1.13 (m, 1H). The racemic material was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 36%-36%,6min) to obtain 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile (80.8 mg, 99.62% purity, 99.42% ee, first peak, Rt = 1.108 min) stereoisomer one as a white solid; 1H NMR (400 MHz, DMSO-d6) δ = 9.55 (s, 1H), 9.17 (s, 1H), 8.23 (s, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 6.82 (d, J = 8.8 Hz, 1H), 5.05 - 4.95 (m, 2H), 4.37 - 4.25 (m, 1H), 3.00 - 2.90 (m, 1H), 2.22 - 2.11 (m, 1H), 2.00 - 1.95 (s, 4H), 1.81 - 1.57 (m, 3H), 1.45 - 1.27 (m, 2H), 1.26 - 1.12 (m, 1H). MS (ESI): mass calcd. For C20H21BN6O2388.18, m/z found 389.2 [M+H]+. HPLC: 99.62% (220 nm), 99.60% (254 nm). and 5-((4-(((trans)-2-cyanocyclohexyl)amino)-5-methylpyrimidin-2-yl)amino)-1- hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile (72.0 mg, 99.62% purity, 98.64% ee, second peak, Rt = 1.499 min) stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.58 (s, 1H), 9.19 (s, 1H), 8.23 (s, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 6.84 (d, J = 8.8 Hz, 1H), 5.05 - 4.95 (m, 2H), 4.38 - 4.25 (m, 1H), 2.98 - 2.86 (m, 1H), 2.22 - 2.13 (m, 1H), 2.00 - 1.95 (s, 4H), 1.82 - 1.57 (m, 3H), 1.44 - 1.27 (m, 2H), 1.25 - 1.12 (m, 1H). MS (ESI): mass calcd. For C20H21BN6O2388.18, m/z found 387.1 [M-H]-. HPLC: 99.62% (220 nm), 100.0% (254 nm). [0317] 13. Preparation of (trans)-2-((2-((7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen- 4-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
[0318]
e of
, y , , (50 mg, 219 umol, 1 eq, HCl) and 2-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]cyclohexanecarbonitrile (60.6 mg, 241 umol, 1.1 eq) in 2-methylbutan-2-ol (3 mL) was added BrettPhos Pd G3 (19.9 mg, 21.9 umol, 0.1 eq), BRETTPHOS (11.8 mg, 21.9 umol, 0.1 eq) and Cs2CO3 (214 mg, 659 umol, 3 eq) in one portion at 20°C under N2. The mixture was heated to 100°C and stirred for 16 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filtrate was concentrated in vacuum to give a redisue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 30%-60%,10min) to give 2-((2-((7,8-dihydro-2H-1,6,9-trioxa- 9a-borabenzo[cd]azulen-4-yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (24 mg, 95.34% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.23 (s, 1H), 7.77 (s, 1H), 7.39 (s, 1H), 7.33 (s, 1H), 6.65 (d, J = 6.4 Hz, 1H), 5.06 (s, 2H), 4.66-4.57 (m, 1H), 4.35- 4.24 (m, 2H), 4.22-4.12 (m, 1H), 4.03-3.98 (m, 1H), 3.76-3.74 (m, 1H), 2.03-1.99 (m, 1H), 1.98 (s, 3H), 1.88-1.77 (m, 3H), 1.74-1.65 (m, 2H), 1.45-1.39 (m, 2H). MS (ESI): mass calcd. For C21H24BN5O3405.20, m/z found 404.3 [M-H]-. HPLC: 95.34% (220 nm), 90.93% (254 nm). [0319] 14. Preparation of (trans)-2-[[2-[(1-hydroxy-3,3-dimethyl -2,1-benzoxaborol-5-yl)amino] -5-methyl-pyrimidin-4-yl]amino]cyclohexanecarbonitrile hydrochloride [0320] 14.1 Preparation of methyl
y rbonylamino)benzoate
[0321] To a mixture of methyl 5-amino-2-bromo-benzoate (5.00 g, 21.7 mmol, 1 eq) in MeOH (35 mL) was added Boc2O (10.4 g, 47.8 mmol, 2.2 eq) and Na2CO3 (6.91 g, 65.2 mmol, 3 eq) at 20°C. The mixture was stirred at 20°C for 24 h. TLC showed the reaction was complete. The reaction was removed methanol under reduced pressure and the resulting residue was quenched with H2O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~13% Ethyl acetate/petroleum ether gradient @ 75 mL/min) to give methyl 2-bromo-5-(tert-butoxycarbonylamino)benzoate (6.00 g, 83.6% yield) as a yellow solid.1H NMR (CDCl3, 400 MHz) δ 7.84 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.40 (dd, J = 8.4 Hz, 2.4 Hz, 1H), 6.69 (br s, 1H), 3.91 (s, 3H), 1.51 (s, 9H). [0322] 14.2 Preparation of 2-(5-amino-2-bromo-phenyl)propan-2-ol [0323] To a sol
F (40 mL) was added methyl 2-bromo-5-(tert-butoxycarbonylamino)benzoate (4.00 g, 12.1 mmol, 1 eq) at 0°C over 0.5 h. After the addition, the reaction was warmed to 35°C and stirred for 5.5 h. TLC showed the reaction was complete. The reaction mixture was poured into saturate aq. NH4Cl (100 mL), adjusted pH to 6 with 2N HCl at 0 °C and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/petroleum ether gradient @ 75 mL/min) to give 2-(5-amino-2-bromo-phenyl) propan-2-ol (2.3 g, 82% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.31 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 2.8 Hz, 1H), 6.44 (dd, J = 8.4 Hz, 2.8Hz, 1H), 1.72 (s, 6H).
[0324] 14.3 Preparation of 2-[[2-[4-bromo-3-(1-hydroxy-1-methyl-ethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]cyclohexanecarbonitrile [0325] To a ecarbonitrile
(700 mg, 2.79 mmol, 1 eq) in dioxane (20 mL) was added 2-(5-amino-2-bromo-phenyl)propan- 2-ol (697 mg, 3.03 mmol, 1.09 eq) and TsOH·H2O (797 mg, 4.19 mmol, 1.5 eq) at 25°C under N2, the mixture was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was quenched with H2O (20 mL), adjusted pH to 7 with saturated aq. NaHCO3 at 0°C and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (20 mL) at 25oC to give 2-[[2-[4-bromo-3-(1-hydroxy-1- methyl-ethyl)anilino]-5-methyl-pyrimidin-4-yl] amino]cyclohexanecarbonitrile (700 mg, 56.4% yield) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.99 (s, 1H), 8.13 (d, J = 2.4 Hz, 1H), 7.71 (s, 1H), 7.64 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.8 Hz, 1H), 5.13 (s, 1H), 4.39-4.31 (m, 1H), 2.97-2.90 (m, 1H),2.16-2.11 (m, 1H), 1.93 (s, 3H), 1.92- 1.88 (m, 1H), 1.75-1.66 (m, 3H), 1.61 (s, 6H), 1.45-1.23(m, 3H). [0326] 14.4 Preparation of (trans)-2-[[2-[(1-hydroxy-3,3-dimethyl -2,1-benzoxaborol-5- yl)amino] -5-methyl-pyrimidin-4-yl]amino]cyclohexane-1-carbonitrile hydrochloride [0327]
. 4-bromo- 3-(1-hydroxy-1-methyl-ethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]cyclohexanecarbonitrile (100 mg, 225 umol, 1 eq) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2- dioxaborinane (127 mg, 563 umol, 2.5 eq) in dioxane (5 ml) was added KOAc (44.2 mg, 450
umol, 2 eq), Pd(PPh3)2Cl2 (15.8 mg, 22.5 umol, 0.1 eq) at 25°C under N2. The mixture was heated and stirred at 120°C for 0.5 h. TLC showed the reaction was complete. The five parallel reactions were combined and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 80*40mm*3 um; mobile phase: [water (0.04%HCl)-ACN]; B%: 18%-32%,7min) to give (trans)- 2-[[2-[(1-hydroxy-3,3-dimethyl -2,1-benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4- yl]amino]cyclohexanecarbonitrile hydrochloride (163.3 mg, 35.2% yield, 95.81% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.17 (s, 1H), 10.42 (s, 1H), 9.03 (s, 1H), 8.36 (s, 1H), 7.84 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.47 (dd, J = 9.6 Hz, 8.0 Hz 1H), 4.34- 4.25 (m, 1H), 3.08-2.99 (m, 1H), 2.24-2.17 (m, 1H), 2.04 (s, 3H), 1.93-1.85 (m, 1H), 1.78-1.69 (m, 2H), 1.61-1.51 (m, 1H), 1.48 (d, J = 10.4 Hz, 6H), 1.44-1.37 (m, 1H), 1.28-1.14 (m, 2H) . MS (ESI): mass calcd. For C21H27BClN5O2391.22, m/z found 392.3 [M+H]+. HPLC: 95.81% (220 nm), 96.45% (254 nm) [0328] 15. Preparation of (trans)-2-[[2-[(2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-5-methyl- pyrimidin -4-yl]amino]cyclohexanecarbonitrile [0329] 15.1 Preparation of 2-[
no]-5-methyl-pyrimidin-4-yl] amino]cyclohexanecarbonitrile [0330] A mixtu
ohexane-1- carbonitrile (600 mg, 2.39 mmol, 1 eq) and PMBNH2 (6.36 g, 46 mmol, 6 mL, 19 eq) was stirred at 100°C for 4 h. TLC showed the reaction was complete. The reaction was poured into saturated aq. NH4Cl (20 mL) and adjusted pH to 5 with aq. HCl (2N). The aqueous was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The
residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=5/1 to 0/1) to give (trans)-2-[[2-[(4-methoxyphenyl)methylamino]-5-methyl-pyrimidin-4- yl]amino]cyclohexane-1-carbonitrile (370 mg, 44% yield) as a white solid.1H NMR (CDCl3, 400 MHz) δ 12.16 (s, 1H), 8.45 (s, 1H), 8.23 (q, J = 8.4 Hz, 1H), 7.65 (s, 1H), 8.28 (q, J = 8.8 Hz, 2H), 6.89 (q, J = 8.4 Hz, 2H), 4.55-4.25 (m, 2H), 4.40-4.20 (m, 1H), 3.72 (s, 3H), 3.10-2.90 (m, 1H), 2.20-2.10 (m, 1H), 1.95 (s, 3H), 1.75-1.65 (m, 2H), 1.63-1.50 (m. 1H), 1.40-1.20 (m, 2H), 1.20-1.00 (m, 1H). [0331] 15.2 Preparation of 2-[(2-amino-5-methyl-pyrimidin-4-yl)amino]cyclohexane-1- carbonitrile [0332] A m
imidin-4- yl]amino] cyclohexane-1-carbonitrile (300 mg, 853 umol, 1 eq) in TFA (3 mL) was stirred at 20°C for 3 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove TFA. The residue was diluted with water 20 mL and extracted with DCM (10 mL x 3). The aqueous layer was lyophilized to give (trans)-2-[(2-amino-5-methyl-pyrimidin-4-yl)amino]cyclohexane-1-carbonitrile (200 mg, 96% yield) as a white solid. [0333] 15.3 Preparation of (trans)-2-[[2-[(2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-5-methyl- pyrimidin -4-yl]amino]cyclohexane-1-carbonitrile [0
y y , g, , q , ans)- 2-[(2-amino-5-methyl-pyrimidin-4-yl)amino]cyclohexane-1-carbonitrile (103 mg, 444 umol, 1 eq), K2CO3 (123 mg, 889 umol, 2 eq), Pd2(dba)3 (20 mg, 22 umol, 0.05 eq) and t-Bu Xphos (19 mg, 44 umol, 0.1 eq) in i-PrOH (6 mL) was degassed and purged with N2 for 3 times, and then
the mixture was stirred at 80°C for 2 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturated aq. NH4Cl (10 mL) at 20°C, and then extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 25%-50%,10min) to give (trans)-2-[[2-[(2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-5-methyl-pyrimidin-4-yl]amino] cyclohexane-1-carbonitrile (31.8 mg, 19% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.85 (s, 1H), 8.80 (s, 1H), 7.89 (s, 1H), 7.80-7.65 (m, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 6.63 (d, J = 8.8 Hz, 1H), 6.11 (d, J = 12.0 Hz, 1H), 4.35-4.25 (m, 1H), 3.00- 2.90 (m, 1H), 2.18 (d, J = 11.6 Hz, 1H), 2.00-1.90 (m, 4H), 1.85-1.70 (m, 2H), 1.65-1.50 (m, 1H), 1.40-1.25 (m, 2H), 1.25-1.10 (m, 1H). MS (ESI): mass calcd. For C20H22BN5O2375.19, m/z found 374.3 [M-H]-. HPLC: 98.55% (220 nm), 99.53% (254 nm). [0335] 16. Preparation of (trans)-2-((2-((2-hydroxy-3-methyl-2H-benzo[e][1,2]oxaborinin-6- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [0336] 16.1 Preparation of t
enzoxaborinin-6-yl)carbamate [0337]
T ree react ons were carr ed out n para e . For eac a m xture o 6-bromo-2- ydroxy-3- methyl-1,2-benzoxaborinine (200 mg, 837 umol, 1 eq) and tert-butyl carbamate (118 mg, 1.0 mmol, 1.2 eq) in dioxane (3 mL) was added t-Bu Xphos (36 mg, 83.7 umol, 0.1 eq), K3PO4 (355 mg, 1.67 mmol, 2 eq) and [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium;ditert-butyl- [2-(2,4,6-triisopropylphenyl)phenyl]phosphane (t-Bu Xphos Pd G3, 66 mg, 83.7 umol, 0.1 eq) in one portion at 25°C under N2. The mixture was heated and stirred at 100°C for 10 h. TLC showed the reaction was complete. The three parallel reactions were combined, filtered and the
filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 70~80% Ethyl acetate/petroleum ether gradient @ 60 mL/min) to give tert-butyl N-(2-hydroxy - 3-methyl-1,2-benzoxaborinin-6-yl)carbamate (600 mg, 60% yield, 70% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.26 (s, 1H), 8.81 (s, 1H), 7.53 (s, 1H), 7.39 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.07 (d, J = 8.8 Hz, 1H), 2.00 (s, 3H), 1.48 (s, 9H). [0338] 16.2 Preparation of 2-hydroxy-3-methyl-1,2-benzoxaborinin-6-amine hydrochloride [0339] To a m
-yl)carbamate (500 mg, 1.27 mmol, 70% purity, 1 eq) in EtOAc (3 mL) was added HCl/EtOAc (4N, 6.36 mL, 20 eq) in one portion at 25°C under N2. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The mixture was concentrated to give a residue. The residue was triturated with EtOAc (2 mL) to give 2-hydroxy-3-methyl-1,2-benzoxaborinin-6-amine hydrochloride (150 mg, 55% yield, HCl salt) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.12 (s, 3H), 9.09 (s, 1H), 7.52 (s, 1H), 7.38 (s, 1H), 7.32-7.27 (m, 2H), 2.03 (s, 3H). [0340] 16.3 Preparation of (trans)-2-((2-((2-hydroxy-3-methyl-2H-benzo[e][1,2]oxaborinin-6- yl)amino)-5-methylpyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [0341
wo eac o s we e ca e ou pa a e . o eac a u e o - y o y- - ethyl- 1,2-benzoxaborinin-6-amine hydrochloride (100 mg, 472 umol, 1 eq, HCl salt) and 2-[(2-chloro- 5-methyl-pyrimidin-4-yl)amino]cyclohexanecarbonitrile (119 mg, 472 umol, 1 eq) in dioxane (5 mL) was added TsOH·H2O (81 mg, 472 umol, 1 eq) in one portion at 25°C under N2. The mixture was heated and stirred at 80°C for 15 h. TLC showed the reaction was complete. The
two parallel reactions were combined and concentrated under reduced pressure to give a residue. The residue was dissolved in EtOAc (10 mL) and washed with saturated aq. NaHCO3 (5 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to get the residue. The residue was triturated with a mixture solvent of MeCN (5 mL) and H2O (5 mL) to give 2-((2-((2- hydroxy-3-methyl-2H-benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4- yl)amino)cyclohexane-1-carbonitrile (102 mg, 27% yield, 99.68% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.79 (s, 1H), 7.80 (s, 1H), 7.70 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.8 Hz, 1H), 4.31-4.28 (m, 1H), 2.98-2.91 (m, 1H), 2.19-2.16 (m, 1H), 1.99 (s, 3H), 1.93 (s, 3H), 1.82-1.90 (m, 1H), 1.76-1.69 (m, 2H), 1.59- 1.56 (m, 1H), 1.32-1.24 (m, 2H), 1.21-1.14 (m, 1H). MS (ESI): mass calcd. For C21H24BN5O2 389.20, m/z found 390.3 [M+H]+. HPLC: 99.68% (220 nm), 99.75% (254 nm). [0342] 17. Preparation of (trans)-2-((5-chloro-2-((1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [0343] 17.1 Preparation of methy
(trans)-2–cyanocyclohexyl) amino)pyrimidin-2-yl)amino)benzoate
[0344] A mixture of (trans)-2-[(2,5-dichloropyrimidin-4-yl)amino]cyclohexane-1-carbonitrile (2.30 g, 8.48 mmol, 1 eq), methyl 5-amino-2-bromo-benzoate (2.15 g, 9.33 mmol, 1.1 eq) and TsOH·H2O (3.23 g, 16.9 mmol, 2 eq) in dioxane (60 mL) was heated and stirred at 80 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was cooled and concentrated in vacuum to give a residue. The residue was triturated with a mixture solvent of EtOAc (50 mL) and saturated aq. Na2CO3 (50 mL) to give methyl 2-bromo-5-[[5-chloro-4-[(2-cyanocyclo
hexyl)amino]pyrimidin-2-yl]amino]benzoate (2.1 g, 53% yield) as a gray solid. 1H NMR (CDCl3, 400 MHz) δ 8.02 (s, 1H), 7.95 (s, 1H), 7.59-7.54 (m, 2H), 7.15 (s, 1H), 5.27-5.25 (m, 1H), 4.38- 4.32 (m, 1H), 3.92 (s, 3H), 2.76-2.73 (m, 1H), 2.12-2.10 (m, 2H), 1.80-1.77 (m, 3H), 1.62-1.58 (m, 1H), 1.47-1.43 (m, 2H). [0345] 17.2 Preparation of methyl 5-((5-chloro-4-(((trans)-2-cyanocyclohexyl)amino) pyrimidin- 2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate
[ ] o a m x ure o me y - romo- - -c oro- - rans - -cyanocyc o exy amino)pyrimidin-2-yl)amino)benzoate (500 mg, 1.08 mmol, 1 eq) in dioxane (15 mL) was added KOAc (264 mg, 2.69 mmol, 2.5 eq), Pd(PPh3)2Cl2 (75.5 mg, 107umol, 0.1 eq) and 2-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (608 mg, 2.69 mmol, 2.5 eq) in one portion at 25°C under N2. Then the mixture was heated to 120°C and stirred for 3 hours. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (20 mL) at 20oC for 30 min to give methyl 5-((5-chloro-4-(((trans)-2-cyanocyclohexyl)amino) pyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (500 mg, crude) as a off-white solid, which was used directly for next step. [0347] 17.3 Preparation of (trans)-2-((5-chloro-2-((1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
[0348] To a mixture of methyl methyl 5-((5-chloro-4-(((trans)-2-cyanocyclohexyl)amino) pyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (500 mg, 1.00 mmol, 1 eq) in THF (10 mL) was added MeOH (12.3 mmol, 0.5 mL, 12.3 eq) and NaBH4 (95.0 mg, 2.51 mmol, 2.5 eq) in portions at 0°C under N2. The mixture was stirred at 0°C for 1 h. TLC showed the reaction was complete. The mixture was poured into ice-water (20 mL) and the aqueous phase was adjusted pH to 5-6 with aq. HCl (2N). The resulting mixture was diluted with ethyl acetate (20 mL) and then the suspension was filtered. The filter cake was washed with water (10 mL x 3) and dried in vacuum to give a crude product. The crude product was purified by trituration with THF (10 mL) at 20oC for 0.5 h to give (trans)-2-((5-chloro-2-((1-hydroxy-1,3- dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (132.4 mg, 32% yield, 95.1% purity) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.52 (s, 1H), 8.94 (br s, 1H), 8.04 (s, 1H), 7.91 (s, 1H), 7.57 (q, J = 8.0 Hz, 2H), 7.35 (d, J = 8.8 Hz, 1H), 4.99-4.90 (m, 2H), 4.33-4.27 (m, 1H), 3.05-3.04 (m, 1H), 2.20-2.17 (m, 1H), 1.95-1.91 (m, 1H), 1.80-1.79 (m, 1H), 1.76-1.71 (m, 1H), 1.63-1.59 (m, 1H), 1.37-1.35 (m, 1H), 1.34-1.20 (m, 2H). MS (ESI): mass calcd. For C18H19BClN5O2383.64, m/z found 384.0 [M+H]+. HPLC: 95.1% (220 nm), 93.88% (254 nm). [0349] 18. Preparation of 5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile N OH O [0350] 18.1 Preparation of 2-
opentyl)amino)-5- methylpyrimidin-2-yl)amino)-3-(hydroxymethyl)benzonitrile
[0351] To a solution of 5-amino-2-bromo-3-(hydroxymethyl)benzonitrile (3 g, 13.2 mmol, 1 eq) in i-PrOH (25 mL) was added TFA (2.26 g, 19.8 mmol, 1.47 mL, 1.5 eq) and 2-((2-chloro-5- methylpyrimidin-4-yl)amino)cyclopentanecarbonitrile (3.13 g, 13.3 mmol, 1 eq) at 25°C. The mixture was stirred at 80°C for 12 h. Solid was precipitate out after 3 h reaction. TLC showed the reaction was complete. The reaction mixture was filtered to give a filter cake. The filter cake was triturated with saturated aq. NaHCO3 (20 mL) at 25oC for 30 min to give 2-bromo-5- ((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2-yl)amino)-3-(hydroxymethyl) benzonitrile (3.6 g, 63.7% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.51 (s, 1H), 8.36 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 7.80 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 5.63 (s, 1H), 4.90 - 4.80 (m, 1H), 4.51 (s, 2H), 3.13 (q, J = 8.8 Hz, 1H), 2.26 - 2.10 (m, 2H), 1.98 (s, 3H), 1.94 - 1.74 (m, 3H), 1.63 - 1.50 (m, 1H). [0352] 18.2 Preparation of 2-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2- cyanocyclopentyl)amino)-5-methylpyrimidin-2-yl)amino)benzonitrile [0353
yrimidin- 2-yl)amino)-3-(hydroxymethyl)benzonitrile (3.6 g, 8.43 mmol, 1 eq) in THF (35 mL) was added 2,6-dimethylpyridine (2.71 g, 25.2 mmol, 2.94 mL, 3 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (3.34 g, 12.6 mmol, 2.90 mL, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of saturated aq. NH4Cl (80 mL) at 0°C, and then extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with Petroleum ether (10 mL) at 25oC for 30 min to give compound 2-bromo-3-(((tert- butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin- 2-yl)amino)benzonitrile (3 g, 65.7% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 9.60 (s, 1H), 8.51 (d, J = 2.8 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.77 (s, 1H), 6.86 (d, J = 8.0 Hz,
1H), 4.85 - 4.75 (m, 1H), 4.67 (s, 2H), 3.11 (q, J = 8.4 Hz, 1H), 2.26 - 2.06 (m, 2H), 1.96 (s, 3H), 1.89 - 1.73 (m, 3H), 1.63 - 1.52 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H). [0354] 18.3 Preparation of 3-(((tert-butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2- cyanocyclopentyl)amino)-5-methylpyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)benzonitrile [0
butyldimethylsilyl)oxy)methyl)-5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin- 2-yl)amino)benzonitrile (500 mg, 923 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (834 mg, 3.69 mmol, 4 eq), KOAc (271 mg, 2.77 mmol, 3 eq), Pd(PPh3)2Cl2 (64.8 mg, 92.3 umol, 0.1 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 h under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The six parallel reactions were combined, diluted with H2O (150 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (70 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (neutral condition; column: Waters Xbridge BEH C18250*50mm*10um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 40%-70%,10min) to give 3-(((tert-butyldimethylsilyl)oxy)methyl)-5- ((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)benzonitrile (900 mg, 28.2% yield) as a white solid. [0356] 18.4 Preparation of 5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile
[0357
cyanocyclopentyl) amino)-5-methylpyrimidin-2-yl)amino)-2-(5,5-dimethyl-1,3,2-dioxaborinan- 2-yl)benzonitrile (900 mg, 1.57 mmol, 1 eq) in THF (5 mL) was added HCl (6 M, 2 mL, 7.66 eq). The mixture was stirred at 25°C for 2 h. LCMS showed the reaction was complete and one main peak with desired mass was detected. The reaction was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (formic acid (FA) condition; column: Phenomenex luna C18 (250*70mm,15 um); mobile phase: [water (FA)-ACN]; B%: 15%-45%, 20min) to give 5-((4-(((trans)-2-cyanocyclopentyl)amino)-5-methylpyrimidin-2- yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile (160.5 mg, 28.5% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 9.55 (s, 1H), 9.17 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 8.09 (s, 1H), 7.80 (s , 1H), 6.88 (d, J = 8.0 Hz, 1H), 5.01 (s, 2H), 4.84 - 4.75 (m, 1H), 3.32 - 3.07 (m, 1H), 2.25 - 2.08 (m, 2H), 1.97 (s, 3H), 1.92 - 1.72 (m, 3H), 1.66 - 1.51 (m, 1H). MS (ESI): mass calcd. For C19H19BN6O2374.17, m/z found 375.1 [M+H]+. HPLC: 96.77% (220 nm), 95.94% (254 nm). [0358] 19. Preparation of (trans)-2-((5-chloro-2-((7-chloro-1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [0359] 19.1 Preparation of 2-((
xymethyl)phenyl)amino)-5- chloropyrimidin-4-yl)amino)cyclohexanecarbonitrile
[0360] To a .38 mmol, 1 eq)
in i-PrOH (10 mL) was added TFA (578 mg, 5.07 mmol, 375 uL, 1.5 eq) and (trans)-2-[(2,5- dichloropyrimidin-4-yl)amino]cyclohexanecarbonitrile (917 mg, 3.38 mmol, 1 eq) at 25°C. The mixture was stirred at 80°C for 5 h. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered to give a filter cake. The filter cake was triturated with saturated aq. NaHCO3 (10 mL) to give (trans)-2-((2-((4-bromo-3-chloro-5- (hydroxymethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino) cyclohexanecarbonitrile (1 g, 62.7% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 9.65 (s, 1H), 8.09 - 8.03 (m, 1H), 7.83 (s, 1H), 7.36 (d, J = 9.2 Hz, 1H), 5.56 (s, 1H), 4.49 (s, 2H), 4.41 - 4.29 (m, 1H), 3.60 (t, J = 6.4 Hz, 1H), 3.08 - 2.96 (m, 1H), 2.20 - - 2.10 (m, 1H), 1.95 - 1.85 (s, 1H), 1.75 - 1.58 (m, 3H), 1.46 - 1.31 (m, 2H), 1.24 - 1.09 (m, 1H). [0361] 19.2 Preparation of (trans)-2-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- chlorophenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexanecarbonitrile [0362] T
amino)-5- chloropyrimidin-4-yl)amino) cyclohexanecarbonitrile (900 mg, 1.91 mmol, 1 eq) in THF (20 mL) was added 2,6-dimethylpyridine (818 mg, 7.64 mmol, 4 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (757 mg, 2.87 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 3 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of saturated aq. NH4Cl (30 mL) at 0°C, and then extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with
petroleum ether (10 mL) to give (trans)-2-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy) methyl)-5-chlorophenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexanecarbonitrile (600 mg, 53.6% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.78 (s, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.03 (s, 1H), 7.62 (s, 1H), 7.39 (d, J = 8.8 Hz, 1H), 4.66 (s, 2H), 4.36 - 4.25 (m, 1H), 3.02 (t, J = 2.8, 12.4 Hz, 1H), 2.22 - 2.13 (m, 1H), 1.95 - 1.85 (m, 1H), 1.79 - 1.67 (m, 2H), 1.64 - 1.50 (m, 1H), 1.48 - 1.28 (m, 2H), 1.24 - 1.10 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H). [0363] 19.3 Preparation of (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino) cyclohexane-1-carbonitrile [03
romo- 3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chlorophenyl)amino)-5-chloropyrimidin-4- yl)amino)cyclohexanecarbonitrile (200 mg, 341 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (540 mg, 2.39 mmol, 7 eq), KOAc (100 mg, 1.02 mmol, 3 eq), Pd(PPh3)2Cl2 (24 mg, 34.1 umol, 0.1 eq) in dioxane (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 h under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The two parallel reactions were combined and filtered, then the residue was purified by prep-HPLC (neutral condition; column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 50%-90%,8min) to give (trans)-2-((2-((3-(((tert- butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (60 mg, 15 % yield) as a white solid. [0365] 19.4 Preparation of (trans)-2-((5-chloro-2-((7-chloro-1-hydroxy-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
[0366 o-4-(5,5-
dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (60 mg, 109 umol, 1 eq) in THF (5 mL) was added aq. HCl (6 M, 0.2 mL) at 25°C. The mixture was stirred at 25°C for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction was concentrated under reduced pressure to give a residue. The residue was triturated with n-pentane (1 mL) to give (trans)-2-((5-chloro-2-((7-chloro-1- hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (18.9 mg, 41.4% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.72 (s, 1H), 8.91 (s, 1H), 8.07 (s, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.43 (d, J = 8.8 Hz, 1H), 5.05 - 4.95 (m, 2H), 4.36 - 4.24 (m, 1H), 3.03 (t, J = 2.8, 12.0 Hz, 1H), 2.20 - 2.15 (d, J = 12.4 Hz, 1H), 1.95 - 1.87 (m, 1H), 1.81 - 1.68 (m, 2H), 1.67 - 1.55 (m, 1H), 1.44 - 1.29 (m, 2H), 1.24 - 1.13 (m, 1H) MS (ESI): mass calcd. For C18H18BCl2N5O2417.09, m/z found 418.0 [M+H]+. HPLC: 97.31% (220 nm), 98.50% (254 nm). [0367] 20. Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]- 5-fluoro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile
[0368] 20.1 Preparation of (trans)-2-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-fluoro- pyrimidin-4-yl]amino]cyclohexanecarbonitrile
[0369] To ol, 1 eq) and
(trans)-2-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]cyclohexanecarbonitrile (1.07 g, 4.22 mmol, 1 eq) in i-PrOH (10 mL) was dropwise added TFA (1.44 g, 12.7 mmol, 3 eq) at 25°C. The resulting mixture was stirred at 80°C for 12 h. Solid was precipitate out after 3 hour reaction. TLC showed the reaction was complete. The reaction mixture was filtered to give a residue. The residue was triturated with saturated aq. NaHCO3 (20 mL) and filtered to give (trans)-2-[[2- [4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-fluoro-pyrimidin-4-yl]amino] cyclohexanecarbonitrile (1 g, 52% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.37 (s, 1 H), 8.76 (s, 1 H), 8.20 (d, J = 4.4 Hz, 1 H), 7.97 (d, J = 2.8 Hz, 1 H), 7.79 (d, J = 2.8 Hz, 1 H), 4.52 (s, 2 H), 4.32-4.20 (m, 1 H), 2.93-2.75 (m, 1 H), 2.20-2.10 (m, 1 H), 2.02-1.93 (m, 1 H), 1.78-1.61 (m, 3 H), 1.41-1.35 (m, 2 H), 1.34-1.23 (m, 1 H). [0370] 20.2 Preparation of (trans)-2-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- chlorophenyl)amino)-5-fluoropyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [03
oro- pyrimidin-4-yl]amino]cyclohexanecarbonitrile (803 mg, 1.77 mmol, 1 eq) in THF (10 mL) was added 2,6-dimethylpyridine (757 mg, 7.07 mmol, 820 uL, 4 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (700 mg, 2.65 mmol, 600 uL, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2, Petroleum ether/ethyl acetate = 10/1 to 5/1) to give (trans)-2-((2-((4- bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chlorophenyl)amino)-5-fluoropyrimidin-4- yl)amino)cyclohexane-1-carbonitrile (0.8 g, 79.6% yield) as a white solid. [0372] 20.3 Preparation of (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-fluoropyrimidin-4- yl)amino)cyclohexane-1-carbonitrile romo-
3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-fluoro-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (100 mg, 175 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (198 mg, 878 umol, 5 eq), KOAc (52 mg, 527 umol, 3 eq) and Pd(PPh3)2Cl2 (12 mg, 17.5 umol, 0.1 eq) in dioxane (5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The five parallel reactions were combined, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (0.5 g, crude) as a white solid. [0374] 20.4 Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-fluoro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile
[0375] To a solution of (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (0.5 g, 830 umol, 1 eq) in THF (10 mL) was added aq. HCl (4 M, 2.0 mL, 9.6 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitate out. The reaction mixture was filtered to give a residue. The residue was triturated with MeCN (5 mL) and filtered to give 2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-fluoro-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (81 mg, 24.3% yield, 98.07% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.59 (s, 1 H), 8.89 (s, 1 H), 8.01 (d, J = 3.6 Hz, 1 H), 785-7.75
(m, 2 H), 7.69 (s, 1 H), 5.00 - 4.90 (m, 2 H), 4.32-4.20 (m, 1 H), 2.92-2.63 (m, 1 H), 2.38-2.30 (m, 1 H), 1.86-1.77 (m, 1 H), 1.76-1.75 (m, 2 H), 1.74-1.70 (m, 1 H), 1.41-1.35 (m, 2 H), 1.34- 1.30 (m, 1 H). MS (ESI): mass calcd. For C18H18BClFN5O2401.12, m/z found 402.2 [M+H]+. HPLC: 98.07% (220 nm), 98.08% (254 nm). [0376] 21. Preparation of (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile [0377] 21.1 Preparation of (tra
-(hydroxymethyl)phenyl) amino)- 5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile F3C N Cl OH [0378]
, . mol, 1 eq) in i-PrOH (5 mL) was added TFA (361 mg, 3.17 mmol, 1.5 eq) and (trans)-2-[[2-chloro-5- (trifluoromethyl)pyrimidin-4-yl]amino]cyclohexanecarbonitrile (643 mg, 2.11 mmol, 1 eq) at 25°C. The mixture was stirred at 80°C for 4 hrs. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered and the filter cake was triturated with
saturated aq. NaHCO3 (30 mL) and filtered to give (trans)-2-((2-((4-bromo-3-chloro-5- (hydroxymethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino) cyclohexane carbonitrile (800 mg, 75.1% yield) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.36 (s, 1H), 8.36 (s, 1H), 8.05 (s, 1H), 7.79 (s, 1H), 7.51 (d, J = 6.0 Hz, 1H), 4.51 (s, 2H), 4.50 - 4.40 (m, 1H), 3.20 - 3.10 (m, 1H), 2.20 - 2.09 (m, 1H), 1.90 - 1.79 (m, 1H), 1.78 - 1.54 (m, 3H), 1.52 - 1.28 (m, 2H), 1.21 - 1.05 (m, 1H). [0379] 21.2 Preparation of (trans)-2-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- chlorophenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile [03
(trifluoromethyl)pyrimidin-4-yl]amino]cyclohexanecarbonitrile (500 mg, 990 umol, 1 eq) in THF (20 mL) was added 2,6-dimethylpyridine (424 mg, 3.96 mmol, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (393 mg, 1.49 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 hr. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 10/1 to 3/1) to give (trans)-2-((2- ((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chlorophenyl)amino)-5-(trifluoromethyl) pyrimidin-4-yl)amino)cyclohexanecarbonitrile (500 mg, 81.5% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 10.14 (s, 1H), 8.28 (s, 2H), 7.62 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 4.68 (s, 2H), 4.54 - 4.38 (m, 1H), 3.19 - 3.04 (m, 1H), 2.22 - 2.09 (m, 1H), 1.90 - 1.80 (m, 1H), 1.79 - 1.65 (m, 2H), 1.65 - 1.51 (m, 1H), 1.51 - 1.40 (m, 1H), 1.40 - 1.29 (m, 1H), 1.22 - 1.08 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H).
[0381] 21.3 Preparation of (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclohexane carbonitrile l)-5-
chlorophenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile (400 mg, 646 umol, 1 eq) in dioxane (8 mL) was added Pd(PPh3)2Cl2 (45.3 mg, 64.6 umol, 0.1 eq) and KOAc (190 mg, 1.94 mmol, 3 eq) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl- 1,3,2-dioxaborinane (729 mg, 3.23 mmol, 5 eq) at 25°C. The mixture was stirred at 120°C for 10 min. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (10 mL× 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18100*40mm*3 um; mobile phase: [water (FA formic acid)-ACN]; B%: 30%-80%,8min) to give 2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]cyclohexanecarbonitrile (110 mg, 26.1% yield) as a white solid. [0383] 21.4 Preparation of (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile [03
y y y y y -(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino] cyclohexanecarbonitrile (110 mg, 168 umol, 1 eq) in THF (2 mL) was added aq. HCl (6 M, 2
mL) at 25°C. The mixture was stirred at 25°C for 1 hr. Solid was precipitated out. TLC showed the reaction was complete. The reaction mixture was filtered and the filter cake was triturated with THF (5 mL) to give (trans)-2-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol- 5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)cyclohexanecarbonitrile (13.6 mg, 17.8% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.09 (s, 1H), 8.31 (s, 1H), 7.84 (s, 1H), 7.65 (s, 1H), 7.25 (d, J = 8.4 Hz, 1H), 5.03 - 4.89 (m, 2H), 4.52 - 4.40 (m, 1H), 3.19 - 3.05 (m, 1H), 2.25 - 2.15 (m, 1H), 1.91 - 1.84 (m, 1H), 1.81 - 1.67 (m, 2H), 1.67 - 1.54 (m, 1H), 1.52 - 1.29 (m, 2H), 1.27 - 1.06 (m, 1H). MS (ESI): mass calcd. For C19H18BClF3N5O2451.12, m/z found 449.9 [M-H]-. HPLC: 98.10% (220 nm), 100% (254 nm). [0385] 22. Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]- 5-(trifluoromethyl)pyrimidin-4-yl]amino]cyclopentanecarbonitrile [0386] 22.1 Preparation of (tr
hydroxymethyl)anilino]-5- (trifluoromethyl)pyrimidin-4-yl]amino]cyclopentanecarbonitrile [0387]
mmol, 1 eq) in i-PrOH (10 mL) was added (trans)-2-[[2-chloro-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclopentanecarbonitrile (614 mg, 1.83 mmol, 1 eq) and TFA (360 mg, 3.17 mmol, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 12 h. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered to give the crude product (filter cake). The crude product was triturated with saturated aq. NaHCO3 (30 mL) and filtered to give (trans)-2-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-(trifluoromethyl)pyrimidin-4-
yl]amino]cyclopentanecarbonitrile (820 mg, 79.1% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 10.16 (s, 1 H), 8.33 (s, 1 H), 8.02 (s, 1 H), 7.94 (s, 1 H), 7.42 (d, J = 8.0 Hz, 1 H), 5.02-4.91 (m, 1 H), 4.51 (s, 2 H), 3.35 - 3.20 (m, 1 H), 2.23-2.07 (m, 2 H), 1.93-1.71 (m, 3 H), 1.64-1.52 (m, 1 H). [0388] 22.2 Preparation of (trans)-2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- chloro-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]cyclopentanecarbonitrile [0
(trifluoromethyl) pyrimidin-4-yl]amino]cyclopentanecarbonitrile (820 mg, 1.67 mmol, 1 eq) in THF (20 mL) was added 2,6-dimethylpyridine (716 mg, 6.68 mmol, 780 uL, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (662 mg, 2.51 mmol, 580 uL, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give (trans)-2-[[2- [4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5- (trifluoromethyl)pyrimidin-4-yl]amino] cyclopentanecarbonitrile (840 mg, 83.0% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.14 (s, 1 H), 8.29 (s, 2 H), 7.66 (s, 1 H), 7.28 (d, J = 8.0 Hz, 1 H), 4.98-4.86 (m, 1 H), 4.68 (s, 2 H), 3.31-3.24 (m, 1 H), 2.26-2.05 (m, 2 H), 1.90- 1.70 (m, 3 H), 1.67-1.54 (m, 1 H), 0.94 (s, 9 H), 0.13 (s, 6 H). [0390] 22.3 Preparation of (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclopentanecarbonitrile
[03 omo-
3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclopentanecarbonitrile (400 mg, 661 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (746 mg, 3.31 mmol, 5 eq), Pd(PPh3)2Cl2 (69.6 mg, 99.1 umol, 0.15 eq) and KOAc (142 mg, 1.45 mmol, 2.2 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The two parallel reactions were combined, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-2-[[2-[3-[[tert-butyl(dimethyl)silyl] oxymethyl]-5-chloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-(trifluoromethyl) pyrimidin-4-yl]amino]cyclopentanecarbonitrile (0.5 g, 59.2% yield) as a yellow solid. [0392] 22.4 Preparation of (trans)-2-[[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]cyclopentanecarbonitrile
-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)anilino]-5-(trifluoromethyl)pyrimidin-4- yl]amino]cyclopentanecarbonitrile (0.5 g, 783 umol, 1 eq) in THF (5 mL) was added aq. HCl (4 M, 2 mL, 10 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitated out. TLC showed the reaction was complete. The reaction mixture was filtered to give crude product (filter cake). The crude product was triturated with THF (5 mL) and filtered to give (trans)-2- [[2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-
yl]amino]cyclopentanecarbonitrile (157.5 mg, 45.9% yield, 97.36% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.10 (s, 1 H), 8.33 (s, 1 H), 7.83 (s, 1 H), 7.72 (s, 1 H), 7.33 (d, J = 8.4 Hz, 1 H), 5.00-4.87 (m, 3 H), 3.35 - 3.25 (m, 1 H), 2.26-2.04 (m, 2 H), 1.92-1.70 (m, 3 H), 1.68-1.55 (m, 1 H). MS (ESI): mass calcd. For C18H16BClF3N5O2437.10, m/z found 435.9 [M- H]-. HPLC: 97.36% (220 nm), 97.17% (254 nm). [0394] 23. Preparation of (trans)-2-((5-chloro-2-((7-fluoro-1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile [0395] 23.1 Preparation of (tran
-(hydroxymethyl)phenyl)amino)-5- chloropyrimidin-4-yl)amino)cyclohexanecarbonitrile [0396] T
mmol, 1 eq) in i-PrOH (10 mL) was added TFA (388 mg, 3.41 mmol, 1.5 eq) and (trans)-2-[(2,5- dichloropyrimidin-4-yl)amino]cyclohexanecarbonitrile (616 mg, 2.27 mmol, 1 eq) at 25°C. The mixture was stirred at 80°C for 5 h. Solid was precipitated out. TLC showed the reaction was complete. The reaction mixture was filtered to obtained filter cake. The filter cake was triturated with saturated aq. NaHCO3 (10 mL) at 25oC for 30 min to give (trans)-2-[[2-[4-bromo- 3-fluoro-5-(hydroxymethyl)anilino]-5-chloro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (850 mg, 82.2% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.67 (s, 1H), 8.05 (s, 1H), 7.80 (dd, J = 2.4, 12.0 Hz, 1H), 7.71 (s, 1H), 7.38 (d, J = 9.2 Hz, 1H), 5.52 (s, 1H), 4.50 (s, 2H), 4.40 - 4.24 (m, 1H), 3.08 - 2.96 (m 1H), 2.16 (d, J = 12.0 Hz, 1H), 1.94 - 1.86(m, 1H), 1.76 - 1.56 (m, 3H), 1.40 - 1.35 (m, 2H), 1.24 - 1.09 (m, 1H).
[0397] 23.2 Preparation of (trans)-2-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- fluorophenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexanecarbonitrile [0 -
pyrimidin-4-yl]amino]cyclohexanecarbonitrile (850 mg, 1.87 mmol, 1 eq) and 2,6- dimethylpyridine (801 mg, 7.48 mmol, 870 uL, 4 eq) in THF (10 mL) was added TBSOTf (741 mg, 2.80 mmol, 640 uL, 1.5 eq) at 25°C. Then the mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of saturated aq. NH4Cl (20 mL) at 0°C, and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with Petroleum ether (20 mL) at 25oC for 30 min to give 2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-fluoro- anilino]-5-chloro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (570 mg, 53.5% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.81 (s, 1H), 8.03 (s, 1H), 7.99 (dd, J = 2.8, 12.4 Hz, 1H), 7.52 (s, 1H), 7.42 (d, J = 9.2 Hz, 1H), 4.67 (s, 2H), 4.36 - 4.20 (m, 1H), 3.09 - 2.97 (m, 1H), 2.21 - 2.15(m, 1H), 1.94 - 1.87 (m, 1H), 1.81 - 1.67 (m, 2H), 1.62 - 1.49 (m, 1H), 1.44 - 1.25 (m, 2H), 1.25 - 1.11 (m, 1H), 0.93 (s, 9H), 0.13 (s, 6H). [0399] 23.3 Preparation of (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluorophenyl)amino)-5-chloropyrimidin-4- yl)amino)cyclohexane-1-carbonitrile [0
p . mo- 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-fluoro-anilino]-5-chloro-pyrimidin-4-
yl]amino]cyclohexanecarbonitrile (100 mg, 175 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (277 mg, 1.23 mmol, 7 eq), KOAc (51.7 mg, 527 umol, 3 eq), Pd(PPh3)2Cl2 (12.3 mg, 17.5 umol, 0.1 eq) in dioxane (5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 h under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The five parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. Then the residue was purified by prep-HPLC (column: Phenomenex Luna C18 75*30mm*3um; mobile phase: [water (formic acid FA)-ACN]; B%: 40%-70%,8min) to give (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)-5-fluorophenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (200 mg, 42.6% yield) as a white solid. [0401] 23.4 Preparation of (trans)-2-((5-chloro-2-((7-fluoro-1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile
ro-4- ((2-cyanocyclohexyl)amino)pyrimidin-2-yl)amino)-6-fluorophenyl)boronic acid (200 mg, 374 umol, 1 eq) in THF (3 mL) was added aq. HCl (6 M, 0.3 mL, 5 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitate out. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered to give a residue. The residue was triturated with THF (2 mL) and filtered to give (trans)-2-((5-chloro-2-((7-fluoro-1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)cyclohexane-1-carbonitrile (65.5 mg, 43.1% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.91 (s, 1H), 8.11 (s, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.51 (d, J = 11.2 Hz, 1H), 5.00 - 4.95 (m, 2H), 4.34 - 4.22 (m, 1H), 3.10 - 2.99 (m, 1H), 2.19 (d, J = 11.6 Hz, 1H), 1.98 - 1.89 (m, 1H), 1.82 - 1.68 (m, 2H), 1.65 - 1.52 (m, 1H), 1.46 - 1.26 (m, 2H), 1.25 - 1.12 (m, 1H). MS (ESI): mass calcd. For C18H18BClFN5O2401.12, m/z found 402.1 [M+H]+. HPLC: 99.09% (220 nm), 99.70% (254 nm).
[0403] 24. Preparation of 2-[[5-chloro-2-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]cyclohexanecarbonitrile
[0404] 24.1 Preparation of 2-bromo-3-methyl-5-nitro-benzoic acid [0405] The compound
mol, 1 eq) was dissolved in concentrated H2SO4 (70 mL). KNO3 (4.61 g, 45.5 mmol, 0.98 eq) dissolved in H2SO4 (30 mL) was drop-wise added to the solution at 0°C. The mixture was stirred for 3 h at 0°C. TLC showed the reaction was complete. The reaction mixture was poured into ice-water (200 mL) and filtered to give 2-bromo-3-methyl-5-nitro-benzoic acid (10.6 g, crude) as a brown solid. 1H NMR (CDCl3, 400 MHz) δ 8.55 (d, J = 2.8 Hz, 1H), 8.27 (d, J = 2.8 Hz, 1H), 2.63 (s, 3H). [0406] 24.2 Preparation of methyl 2-bromo-3-methyl-5-nitro-benzoate [0407] To a mixtu
, mmol, 1 eq) in MeOH (100 mL) was drop-wise added thionyl chloride (65.3 mmol, 4.7 mL, 2 eq) at 0°C. The mixture was heated to 80°C and stirred for 15 h. TLC showed the reaction was complete. The reaction mixture was concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=10/1 to 5/1) to give methyl 2-
bromo-3-methyl-5-nitro-benzoate (8.5 g, 94.9% yield) as an off-white solid.1H NMR (CDCl3, 400 MHz) δ 8.35 (d, J = 2.4 Hz, 1H), 8.20 (d, J = 2.4 Hz, 1H), 3.99 (s, 3H), 2.59 (s, 3H). [0408] 24.3 Preparation of methyl 5-amino-2-bromo-3-methyl-benzoate [0409] To a mol, 1 eq) in
EtOH (100 mL) and H2O (20 mL) was added NH4Cl (5.86 g, 109 mmol, 4 eq) and Fe powder (6.11 g, 109 mmol, 4 eq) at 25°C. The mixture was stirred at 80°C for 1 h. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was diluted with H2O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-amino-2- bromo-3-methyl-benzoate (5.5 g, 82.3% yield) as brown oil. 1H NMR (CDCl3, 400 MHz) δ 6.80 (s, 1 H), 6.68 (s, 1 H), 3.91 (s, 3 H), 3.72 (s, 2 H), 2.36 (s, 3 H). [0410] 24.4 Preparation of (5-amino-2-bromo-3-methyl-phenyl)methanol [0411] To a solutio
g, 22.5 mmol, 1 eq) in THF (50 mL) was added DIBAL-H (1 M in THF, 90.1 mL, 4 eq) drop-wise at 0°C. The mixture was stirred at 0°C for 1 h. TLC showed the reaction was complete. The reaction mixture was poured into saturated.aq.seignette salt (100 mL) at 0°C and stirred at room temperature for 1 h, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (30 mL) and filtered to give (5-amino-2-bromo-3-methyl- phenyl)methanol (1.5 g, 30.8% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 6.67 (d, J = 2.8 Hz, 1 H), 6.54 (d, J = 2.8 Hz, 1 H), 4.66 (s, 2 H), 3.58 (s, 2 H), 2.33 (s, 3 H).
[0412] 24.5 Preparation of (trans)-2-[[2-[4-bromo-3-(hydroxymethyl)-5-methyl-anilino]-5- chloro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile [0413] T mmol, 1
eq) in i-PrOH (5 mL) was added (trans)-2-[(2,5-dichloropyrimidin-4- yl)amino]cyclohexanecarbonitrile (627 mg, 2.31 mmol, 1 eq) and TFA (395 mg, 3.47 mmol, 256 uL, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 12 h. Solid was precipitated out. TLC showed the reaction was complete. The reaction mixture was filtered to give a residue. The residue was triturated with saturated aq. NaHCO3 (30 mL) and filtered to give (trans)-2-[[2-[4- bromo-3-(hydroxymethyl)-5-methyl-anilino]-5-chloro-pyrimidin-4- yl]amino]cyclohexanecarbonitrile (875 mg, 83.8% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.95 (s, 1 H), 7.67 (d, J = 2.8 Hz, 1 H), 7.34 (d, J = 2.4 Hz, 1 H), 7.02 (s, 1 H), 5.25 (d, J = 8.4 Hz, 1 H), 4.76 (s, 2 H), 4.49-4.40 (m, 1 H), 2.84-2.74 (m, 1 H), 2.43 (s, 3 H), 2.19- 2.06 (m, 2 H), 1.85-1.69 (m, 3 H), 1.62-1.35 (m, 3 H). [0414] 24.6 Preparation of (trans)-2-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- methyl-anilino]-5-chloro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile
ro- pyrimidin-4-yl]amino]cyclohexanecarbonitrile (460 mg, 1.02 mmol, 1 eq) in THF (5 mL) was added 2,6-dimethylpyridine (437 mg, 4.08 mmol, 4 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (404 mg, 1.53 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (20 mL x 3). The combined organic
layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 10/1 to 5/1) to give (trans)-2-[[2-[4-bromo-3-[[tert- butyl(dimethyl)silyl]oxymethyl]-5-methyl-anilino]-5-chloro-pyrimidin-4-yl]amino]cyclohexan ecarbonitrile (500 mg, 86.7% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.43 (s, 1 H), 7.98 (s, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 7.27 (d, J = 9.2 Hz, 1 H), 4.66 (s, 2 H), 4.35-4.24 (m, 1 H), 3.10 - 3.00 (m, 1 H), 2.35 (s, 3 H), 2.22-2.13 (m, 1 H), 1.92-1.83 (m, 1 H), 1.79-1.66 (m, 2 H), 1.62-1.49 (m, 1 H), 1.37-1.10 (m, 3 H), 0.94 (s, 9 H), 0.12 (s, 6 H). [0416] 24.7 Preparation of (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-methylphenyl)amino)-5-chloropyrimidin-4- yl)amino)cyclohexane-1-carbonitrile
methyl- anilino]-5-chloro-pyrimidin-4-yl]amino]cyclohexanecarbonitrile (500 mg, 884 umol, 1 eq), 2- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (999 mg, 4.42 mmol, 5 eq), Pd(PPh3)2Cl2 (93 mg, 132 umol, 0.15 eq) and KOAc (191 mg, 1.95 mmol, 2.2 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-2-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5-methylphenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (0.4 g, 75.5% yield) as a yellow solid. [0418] 24.8 Preparation of (trans)-2-[[5-chloro-2-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]cyclohexanecarbonitrile
[0 ethyl-
1,3,2-dioxaborinan-2-yl)-5-methylphenyl)amino)-5-chloropyrimidin-4-yl)amino)cyclohexane-1- carbonitrile (0.4 g, 668 umol, 1 eq) in THF (5 mL) was added aq. HCl (4 M, 1.67 mL, 10 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered to give a residue. The residue was triturated with THF (5 mL) and filtered to give (trans)-2-[[5-chloro-2-[(1-hydroxy-7-methyl-3H- 2,1-benzoxaborol-5-yl)amino]pyrimidin-4-yl]amino]cyclohexanecarbonitrile (99.0 mg, 37.2% yield, 98.68% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.98 (s, 1 H), 8.16 (s, 1 H), 8.01 (d, J = 4.4 Hz, 1 H), 7.55 (s, 1 H), 7.34 (s, 1 H), 4.99-4.88 (m, 2 H), 4.32-4.21 (m, 1 H), 3.10 - 3.00 (m, 1 H), 2.42 (s, 3 H), 2.23-2.14 (m, 1 H), 1.95-1.86 (m, 1 H), 1.82-1.67 (m, 2 H), 1.64-1.51 (m, 1 H), 1.48-1.36 (m, 1 H), 1.34-1.10 (m, 2 H). MS (ESI): mass calcd. For C19H21BClN5O2397.15, m/z found 398.2 [M+H]+. HPLC: 98.68% (220 nm), 98.78% (254 nm). [0420] 25. Preparation of 3-[[2-[(7-cyclopropyl-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5- methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0421] 25.1 Preparation of methyl 2-hydroxy-3-methyl-benzoate
[0422] Four reactions were carried out in parallel. For each a solution of methyl 3-bromo-2- hydroxy-benzoate (8.75 g, 37.8 mmol, 1 eq) in toluene (360 mL) and water (36 mL) was added cyclopropylboronic acid (13.0 g, 151 mmol, 4 eq), tricyclohexylphosphane (4.25 g, 15.1 mmol, 4.91 mL, 0.4 eq), K3PO4 (16.0 g, 75.7 mmol, 2 eq), and Pd(OAc)2 (850 mg, 3.79 mmol, 0.1 eq) at 20°C. The mixture was stirred at 100°C for 12 h. TLC showed the reaction was complete. The four parallel reactions were combined and poured into H2O (150 mL) and extracted with MTBE (200 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 99/1 to 3/1) to give methyl 2-hydroxy-3-methyl-benzoate (11.5 g, 45.6% yield) as yellow oil.1H NMR (CDCl3, 400 MHz) δ 11.17 (s, 1 H), 7.67 (d, J = 7.6 Hz, 1 H), 7.05 (d, J = 7.6 Hz, 1 H), 6.78 (t, J = 8.0 Hz, 1 H), 3.95 (s, 3 H), 2.25-2.18 (m, 1 H), 1.00-0.95 (m, 2 H), 0.70-0.65 (m, 2 H). [0423] 25.2 Preparation of methyl 3-cyclopropyl-2-hydroxy-5-nitro-benzoate [0424] Two reactions w
ethyl 3-cyclopropyl-2- hydroxy-benzoate (8.4 g, 43.7 mmol, 1 eq) in DCM (35 mL) was cooled to -10°C, then mixed acid of HNO3 (6.35 g, 65.5 mmol, 4.5 mL, 65% purity, 1.5 eq) and H2SO4 (15.4 g, 157 mmol, 8.4 mL, 3.61 eq) was added dropwise at -10°C. After the addition, the reaction was allowed to warm to 0oC and stirred at 0oC for 2 hr. TLC showed the reaction was complete. The two parallel reactions were combined and poured into H2O (100 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 20/1 to 3/1) to give methyl 3- cyclopropyl-2-hydroxy-5-nitro-benzoate (10.6 g, 51.1% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 11.85 (s, 1 H), 8.62 (s, 1 H), 7.91 (s, 1 H), 4.04 (s, 3 H), 2.28-2.20 (m, 1 H), 1.15-1.01 (m, 2 H), 0.81-0.74 (m, 2 H).
[0425] 25.3 Preparation of methyl 5-amino-3-cyclopropyl-2-hydroxy-benzoate [0426] To a solution e (3.5 g, 14.7 mmol, 1
eq) in EtOH (53 mL) and water (17 mL) was added Fe powder (2.47 g, 44.2 mmol, 3 eq) and NH4Cl (1.18 g, 22.1 mmol, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 2 hr. TLC showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated to give a residue. The residue was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 2/1 to 3/1) to give methyl 5-amino-3- cyclopropyl-2-hydroxy-benzoate (2.7 g, 87.2% yield) as a yellow solid.1H NMR (CDCl3, 400 MHz) δ 10.62 (s, 1 H), 7.00 (s, 1 H), 6.48 (s, 1 H), 3.93 (s, 3 H), 3.41 (s, 2 H), 2.24-2.15 (m, 1 H), 1.01-0.90 (m, 2 H), 0.70-0.60 (m, 2 H). [0427] 25.4 Preparation of methyl 5-((4-(((trans)-4-cyanotetrahydro-2H-pyran-3-yl)amino)-5- methylpyrimidin-2-yl)amino)-3-cyclopropyl-2-hydroxybenzoate [0428] To a
g, 4.10 mmol, 1 eq) and (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (1.04 g, 4.10 mmol, 1 eq) in i-PrOH (34 mL) was added TFA (935 mg, 8.20 mmol, 2 eq) at 20°C. The mixture was stirred at 90°C for 12 h. TLC showed the reaction was complete. The residue was poured into H2O (35 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2, petroleum ether/ethyl acetate = 2/1 to 0/1) to give methyl 5-((4-(((trans)- 4-cyanotetrahydro-2H-pyran-3-yl)amino)-5-methylpyrimidin-2-yl)amino)-3-cyclopropyl-2- hydroxybenzoate (1.25 g, 71.9% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 11.49 (br s, 1 H), 11.11 (s, 1 H), 7.86 (s, 1 H), 7.49 (s, 1 H), 7.05 (s, 1 H), 5.99 (d, J = 7.2 Hz, 1 H), 4.25-4.22 (m, 1 H), 4.08-4.03 (m, 1 H), 3.96 (s, 3 H), 3.86-3.83 (m, 1 H), 3.78-3.74 (m, 2 H), 3.42-3.30 (m, 1 H), 2.13-2.06 (m, 1 H), 2.05-2.01 (m, 4 H), 1.85-1.79 (m, 1 H), 1.01-0.90 (m, 2 H), 0.70-0.60 (m, 2 H). [0429] 25.5 Preparation of methyl 5-((4-(((trans)-4-cyanotetrahydropyran-3-yl]amino]-5- methyl-pyrimidin-2-yl]amino]-3-cyclopropyl-2-(trifluoromethylsulfonyloxy)benzoate
ethyl- pyrimidin-2-yl]amino]-3-cyclopropyl-2-hydroxy-benzoate (1.15 g, 2.72 mmol, 1 eq) in THF (20 mL) was added NaH (325 mg, 8.15 mmol, 60% purity, 3 eq) at 0°C and stirred for 10 min. Then, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (PhNTf2, 2.91 g, 8.15 mmol, 3 eq) in THF (30 mL) was added to the reaction. The mixture was stirred at 25°C for 1 hr. TLC showed the reaction was complete. The residue was poured into ice-water (100 mL) and extracted with EtOAC (50 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 3/1 to 0/1) to give methyl 5-((4-(((trans)-4-cyanotetrahydropyran-3-yl]amino]-5- methyl-pyrimidin-2-yl]amino]-3-cyclopropyl-2-(trifluoromethylsulfonyloxy)benzoate (1.2 g, 79.5% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ, 8.15 (s, 1 H), 7.84 (s, 1 H), 7.32 (s, 1 H), 7.07 (s, 1 H), 5.05 (d, J = 7.2 Hz, 1 H), 4.45-4.38 (m, 1 H), 3.95 (s, 3 H), 3.89-3.85 (m, 2 H), 3.81-3.78 (m, 1 H), 3.32-3.25 (m, 1 H), 2.20-2.11 (m, 2 H), 2.03 (s, 3 H), 1.89-1.81 (m, 1 H), 1.15-1.11 (m, 2 H), 0.82-0.78 (m, 2 H).
[0431] 25.6 Preparation of methyl 5-((4-(((trans)-4-cyanotetrahydropyran-3-yl]amino]-5- methyl-pyrimidin-2-yl]amino]-3-cyclopropyl-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate
pyrimidin-2-yl]amino]-3-cyclopropyl-2-(trifluoromethylsulfonyloxy)benzoate (0.5 g, 900 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (609 mg, 2.70 mmol, 3 eq), KOAc (265 mg, 2.70 mmol, 3 eq), Pd(dppf)Cl2 (32.9 mg, 45.0 umol, 0.05 eq) and Pd(PPh3)4 (52.0 mg, 45.0 umol, 0.05 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times. Then the mixture was heated to 120°C and stirred at 120°C for 2 h under N2 atmosphere. TLC showed the reaction was complete. The residue was poured into water (10 mL) and extracted with EtOAC (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (HCl condition) to give methyl 5-((4-(((trans)- 4-cyanotetrahydropyran-3-yl]amino]-5-methyl-pyrimidin-2-yl]amino]-3-cyclopropyl-2-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (160 mg, 34.2% yield) as a yellow solid. [0433] 25.7 Preparation of (trans)-3-[[2-[(7-cyclopropyl-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
thyl- pyrimidin-2-yl]amino]-3-cyclopropyl-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (0.13 g, 250 umol, 1 eq) in THF (2 mL) was added NaBH4 (28.4 mg, 750 umol, 3 eq) at 0°C. The mixture was stirred at 25°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (2 mL) at 0°C and adjust pH = 6 with aq. HCl (2N), then
filtered to give (trans)-3-[[2-[(7-cyclopropyl-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5- methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (70.8 mg, 69.8% yield, 96.9% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.91 (s, 1 H), 8.23 (s, 1 H), 7.83 (s, 1 H), 7.62 (d, J = 8.8 Hz, 1 H), 7.53 (s, 1 H), 6.87 (s, 1 H), 4.99-4.88 (m, 2 H), 4.39-4.28 (m, 1 H), 3.92-3.81 (m, 2 H), 3.31-3.19 (m, 2 H), 3.14 (t, J = 10.4 Hz, 1 H), 2.48-2.41 (m, 1 H), 2.22-2.14 (m, 1 H), 1.99 (s, 3 H), 1.93-1.80 (m, 1 H), 1.03-0.95 (m, 2 H), 0.87-0.77 (m, 2 H). MS (ESI): mass calcd. For C21H24BN5O3405.20, m/z found 406.2 [M+H]+. HPLC: 96.90% (220 nm), 96.88% (254 nm). [0435] 26. Preparation of (trans)-3-[[2-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0436] 26.1 Preparation of (5-am
ol [0437] To a solution of mmol, 1 eq) in THF (50
mL) was drop-wise added DIBAL-H (1 M in THF, 86.9 mL, 4 eq) at 0°C, and then stirred at 0°C for 1h. TLC showed the reaction was complete. The reaction mixture was quenched with saturated aq. Na2CO3 (200 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: EtOAc = 100:1 to 1:1) to obtain (5-amino-2- bromophenyl) methanol (4.3 g) as a yellow solid. [0438] 26.2 Preparation of (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl) phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0439] A mixt
), (trans)-3-[(2- chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (2.5 g, 9.90 mmol, 1 eq) and TFA (1.69 g, 14.8 mmol, 1.5 eq) in i-PrOH (40 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (20 mL) to give (trans)-3-((2-((4-bromo-3- (((tert-butyldimethylsilyl)oxy)methyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile (5 g, crude) as yellow oil. [0440] 26.3 Preparation of (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl) phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0441]
y y y y py midin-4- yl]amino]tetrahydropyran-4-carbonitrile (4.9 g, 11.7 mmol, 1 eq), and 2,4-dimethylpyridine (5 g, 46.8 mmol, 4 eq) in THF (40 mL) was added [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (6.2 g, 23.4 mmol, 2 eq) under N2, and then the mixture was stirred at 0°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched with aq. NH4Cl (100 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: EtOAc = 100:1 to 1:1) to give (trans)-3-((2-((4-bromo-3- (((tert-butyldimethylsilyl)oxy)methyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile (5 g, 80% yield) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 9.18 (s, 1H), 7.97 (d, J = 2.4 Hz, 1H), 7.73 (s, 1H), 7.64 (dd, J = 2.8, 8.8 Hz, 1H), 7.37 (d, J = 8.8 Hz,
1H), 6.66 (d, J = 8.4 Hz, 1H), 4.64 (s, 2H), 4.55 - 4.35 (m, 1H), 3.87 (m, 2H), 3.30 - 3.19 (m, 2H), 3.13 (t, J = 10.8 Hz, 1H), 2.22 - 2.10 (m, 1H), 1.91 - 1.77 (m, 1H), 0.94 (s, 9H), 0.12 (s, 6H). [0442] 26.4 Preparation of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile [04 omo-
3-[[tert-butyl(dimethyl)silyl]oxymethyl]anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (1 g, 1.88 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (1.70 g, 7.51 mmol, 4 eq), KOAc (552 mg, 5.63 mmol, 3 eq) and Pd(PPh3)2Cl2 (131 mg, 187 umol, 0.1 eq) in dioxane (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 hr under N2 atmosphere. TLC showed the reaction was complete. The five parallel reactions were combined and concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (column: C18 (250*50mm*10 um);mobile phase: [water ( NH4HCO3)-ACN]; B%: 40%- 70%,10min) to give (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (5 g, crude) as yellow oil. [002] 26.5 Preparation of (3R,4S)-3-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0444] ethyl-
1,3,2-dioxaborinan-2-yl)anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (4.5 g, 7.96 mmol, 1 eq) in THF (50 mL) was added aq. HCl (6 M, 5.3 mL, 4 eq), and then the mixture was stirred at 40°C for 1 h under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filter cake was washed with MeCN (10 mL), dried in vacuum to give (trans)-3-((2-((1-hydroxy-1,3- dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (1.5 g, 51% yield) as a white solid, which was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O EtOH]; B%: 60%-60%,6min) to give (trans)-3-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (343 mg, 99.34% purity, 100% ee, first peak, RT = 1.424 min) stereoisomer one as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.28 (s, 1H), 8.90 (s, 1H), 7.96 (s, 1H), 7.79 (d, J = 0.8
, 1H), 7.61 - 7.50 (m, 2H), 6.83 (m, 1H), 4.99 - 4.87 (m, 2H), 4.50 - 4.40 (m, 1H), 3.95 - 3.84 (m, 2H), 3.31 - 3.19 (m, 2H), 3.14 (t, J = 10.8 Hz, 1H), 2.23 - 2.14 (m, 1H), 1.96 (s, 3H), 1.91 - 1.78 (m, 1H) MS (ESI): mass calcd. For C18H20BN5O3, 365.17 m/z found 364.0[M-H]-. HPLC: 99.34% (220 nm), 99.9% (254 nm) and (trans)-3-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (185 mg, 99.40% purity, 99.90% ee, second peak, RT = 1.737 min) stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.40 (s, 1H), 8.93 (s, 1H), 7.93 (s, 1H), 7.79 (s, 1H), 7.61 - 7.55 (m, 1H), 7.54 - 7.49 (m, 1H), 6.99 (m, 1H), 4.99 - 4.86 (m, 2H), 4.52 - 4.39 (m, 1H), 3.90 (m, 2H), 3.29 - 3.20 (m, 2H), 3.15 (t, J = 10.8 Hz, 1H), 2.18 (m, 1H), 1.97 (s, 3H), 1.92 - 1.79 (m, 1H) MS (ESI): mass calcd. For C18H20BN5O3, 365.17 m/z found 364.1[M-H]-. HPLC: 99.40% (220 nm), 99.95% (254 nm). [0445] 27. Preparation of (trans)-3-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol- 5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0446] 27.1 Preparation of methyl -4-cyanotetrahydro-2H-pyran-3-
yl)amino)-5-methylpyrimidin-2-yl)amino)-3-methylbenzoate rahydropyran-4-
carbonitrile (700 mg, 2.49 mmol, 90% purity, 1 eq) in dioxane (10 mL) was added TsOH·H2O (711 mg, 3.74 mmol, 1.5 eq) and methyl 5-amino-2-bromo-3-methyl-benzoate (730 mg, 2.99 mmol, 1.2 eq). The mixture was stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (30mL) at 0°C and adjust pH=7, then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over with Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, eluent of 100~0% ethyl acetate/petroleum ether gradient @ 50 mL/min) to give methyl 2-bromo-5-((4-(((trans)-4-cyanotetrahydro-2H-pyran-3-yl)amino)-5- methylpyrimidin-2-yl)amino)-3-methylbenzoate (950 mg, 82% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.82 (s, 1H), 7.79 (d, J = 2.8 Hz, 1H), 7.64 (d, J = 2.4 Hz, 1H), 6.96 (s, 1H), 5.06-5.04 (m, 1H), 4.39-4.37 (m, 1H), 4.16-4.10 (m, 1H), 3.95 (s, 3H), 3.89-3.86 (m, 2H), 3.82-3.79 (m, 1H), 3.32-3.29 (m, 1H), 2.48 (s, 3H), 2.18-2.11 (m, 1H), 2.02 (s, 3H), 1.86-1.82 (m, 1H). [0448] 27.2 Preparation of methyl 5-[[4-[(4-cyanotetrahydropyran-3-yl)amino]-5-methyl- pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate
[0449] Nine reactions were carried out in parallel. For each a mixture of 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (123 mg, 543 umol, 2.5 eq), methyl 2- bromo-5-[[4-[(4-cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-3-methyl- benzoate (100 mg, 217 umol, 1 eq), KOAc (53 mg, 543 umol, 2.5 eq) and Pd(PPh3)2Cl2 (15 mg, 21.7 umol, 0.1 eq) in dioxane (5 mL) was stirred at 120°C for 1 h under N2 atmosphere. The nine parallel reactions were combined and the mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, eluent of 0~50% ethyl acetate/petroleum ether gradient @ 50 mL/min) to give methyl 5-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5- methyl-pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate (1.1 g, crude) as a brown solid, which was used directly for next step. [0450] 27.4 Preparation of (trans)-3-((2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
ethyl- pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-benzoate (1 g, 2.03 mmol, 1 eq) in THF (10 mL) and MeOH (2 mL) was added NaBH4 (767 mg, 20.2 mmol, 10 eq) in portions at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 1 h. The mixture was adjusted pH = 4 with aq. HCl (2N), added H2O (30 mL) and then extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (10 mL x 3), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give the residue. The residue was purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (0.04%HCl)-MEOH]; B%: 10%-30%,8min) to give (trans)-3-((2-((1-hydroxy-7-methyl- 1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (127.4 mg, 16% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 10.16 (s, 1H), 8.86 (s, 1H), 8.10 (s, 1H), 7.82 (s, 1H), 7.44 (s, 1H), 7.31 (s, 1H), 4.94-4.93 (m, 2H), 4.43-4.38 (m, 1H), 4.91-3.85 (m, 2H), 3.23-3.14 (m, 3H), 2.44 (s, 3H), 2.20-2.13 (m, 1H),
2.02 (s, 3H), 1.87-1.83 (m, 1H). MS (ESI): mass calcd. For C19H22BN5O3379.22, m/z found 380.2 [M+H]+. HPLC: 92.4% (220 nm), 89.52% (254 nm). [0452] 28. Preparation of (trans)-3-[[2-[(1-hydroxy-3-methyl-3H-2,1-benzoxaborol-5-yl)amino]- 5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0453] 28.1 Preparation of (trans henyl)amino-5-methylpyrimidi-4-
yo)amino)tetrahydro-2H-pyran-4-carbonitrile [0454] Two r
ino-2-bromo- phenyl)ethanone (212 mg, 989 umol, 1 eq) and (trans)-3-[(2-chloro-5-methyl-pyrimidin-4- yl)amino]tetrahydropyran-4-carbonitrile (250 mg, 989 umol, 1 eq) in dioxane (3 mL) was added TsOH (256 mg, 1.48 mmol, 1.5 eq) at 20°C. The mixture was heated and stirred at 80°C for 16 h. TLC showed the reaction was complete. The two parallel reactions were combined and concentrated under reduced pressure to give a residue. The residue was diluted with EtOAc (10 mL) and adjusted pH to 7 with saturated aq. NaHCO3. The resulting mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0~100% ethyl acetate/petroleum ether gradient @ 36 mL/min) to give (trans)-3-[[2-(3- acetyl-4-bromo-anilino)-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (450 mg) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.30 (s, 1H), 8.11 (s, 1H), 7.80 (s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 4.50-4.40 (m, 1H), 3.90-3.80 (m, 2H), 3.30-3.10 (m, 2H), 2.55 (s, 3H), 2.17 (q, J = 10.4 Hz, 1H), 2.20-1.80 (m, 5H).
[0455] 28.2 Preparation of (trans)-3-[[2-[4-bromo-3-(1-hydroxyethyl)anilino]-5-methyl- pyrimidin -4-yl]amino]tetrahydropyran-4-carbonitrile To a solu mino]
tetrahydropyran-4-carbonitrile (300 mg, 697 umol, 1 eq) in THF (3 mL) was added NaBH4 (380 mg, 10.0 mmol, 14 eq) and MeOH (0.3 mL) at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 1 h. The reaction mixture was added saturated aq. NH4Cl (10 mL) at 0°C and adjust pH to 5 with aq. HCl (2N), and then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (15 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 3-[[2-[4-bromo-3-(1-hydroxyethyl)anilino]-5- methyl-pyrimidin-4-yl] amino]tetrahydropyran-4-carbonitrile (200 mg, 66.3% yield) as a brown solid. [0456] 28.3 Preparation of (trans)-3-[[2-[(1-hydroxy-3-methyl-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0457] F
2-[4-bromo- 3-(1-hydroxyethyl)anilino]-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (50 mg, 115 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (52 mg, 231 umol, 2 eq), Pd(PPh3)2Cl2 (16 mg, 23.1 umol, 0.2 eq), KOAc (28 mg, 289 umol, 2.5 eq) in dioxane (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 30 min under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The four parallel reactions were combined and the mixture was poured into saturated aq. NH4Cl (10 mL) at 0°C, and then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (15 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC
(column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (0.04%HCl)-ACN]; B%: 15%-45%,8min) to give crude product (100 mg, crude). The crude product was further purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (0.04%HCl)- MEOH]; B%: 15%-20%,8min) to give (trans)-3-[[2-[(1-hydroxy-3-methyl-3H-2,1- benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (36.7 mg) mixture of isomers as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.45 (s, 1H), 9.09 (s, 1H), 8.29 (s, 1H), 7.86 (s, 1H), 7.76-7.65 (m, 2H), 7.39 (d, J = 8.8 Hz, 1H), 5.25-5.15 (m, 1H), 4.50-4.40 (m, 1H), 3.95-3.85 (m, 2H), 3.30-3.20 (m, 3H), 2.25-2.10 (m, 1H), 2.06 (s, 3H), 1.85- 1.70 (m, 1H), 1.45-1.40 (m, 3H). MS (ESI): mass calcd. For C19H22BN5O3379.18, m/z found 380.2 [M+H]+. HPLC:99.96% (220 nm), 99.97% (254 nm). [0458] 29. Preparation of (trans)-3-[[2-[(7-fluoro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0459] 29.1 Preparation of (5-a
l)methanol [0460] To a solution
g, 23.0 mmol, 1 eq) in THF (60 mL) was added DIBAL-H (1 M in THF, 57.5 mL, 2.5 eq) drop-wise at -60 °C. The mixture was stirred at -60 °C for 0.5 h. After the addition, the reaction was allowed to warm to 0°C and stirred at 0°C for 1.5 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition aq. seignette salt (100 mL) at 0°C, and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with Petroleum ether at 25oC for 30 min to give (5-amino-2-bromo-3-fluoro- phenyl)methanol (5 g, 98% yield) as a brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 6.63 (s, 1
H), 6.34 (dd, J = 2.8, 7.6 Hz, 1 H), 5.57 (s, 2 H), 5.33 (t, J = 6.0 Hz, 1 H), 4.38 (d, J = 6.0 Hz, 2 H). [0461] 29.2 Preparation of (trans)-3-[[2-[4-bromo-3-fluoro-5-(hydroxymethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0462] To mol, 1 eq)
and (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (2.87 g, 11.36 mmol, 1 eq) in i-PrOH (30 mL) was added TFA (1.94 g, 17.0 mmol, 1.26 mL, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. After cooling the reaction to room temperature, large amount of solid formed. The reaction mixture was filtered and the filter cake was washed respectively with EtOAc (20 mL), saturated aq. NaHCO3 (20 mL) and MeCN (20 mL) to give (trans)-3-[[2-[4-bromo-3- fluoro-5-(hydroxymethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydr-opyran-4- carbonitrile (3.7 g, 74% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.40 (s, 1 H), 7.90 (dd, J = 2.4, 12.4 Hz, 1 H), 7.80 (s, 1 H), 7.68 (s, 1 H), 6.76 (d, J = 8.8 Hz, 1 H), 5.44 (s, 1 H), 4.56-4.40 (m, 3 H), 3.92-3.82 (m, 2 H), 3.32-3.19 (m, 2 H), 3.18-3.11 (m, 1 H), 2.20-2.12 (m, 1 H), 1.95 (s, 3 H), 1.92-1.80 (m, 1 H). [0463] 29.3 Preparation of (trans)-3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- fluoro-anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0464] To a solution of (trans)-3-[[2-[4-bromo-3-fluoro-5-(hydroxymethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (2.1 g, 4.81 mmol, 1 eq) and 2,6- dimethylpyridine (1.55 g, 14.4 mmol, 1.68 mL, 3 eq) in THF (30 mL) was added [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (1.91 g, 7.22 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 3 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (30 mL) at 0°C and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (40 mL) to give (trans)-3-[[2-[4-bromo-3-[[tert- butyl(dimethyl)silyl]oxymethyl]-5-fluoro-anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (2.54 g, 95% yield) as a white solid. 1H NMR (DMSO- d6, 400 MHz) δ 9.52 (s, 1 H), 7.93 (dd, J = 2.0, 12.0 Hz, 1 H), 7.78 (s, 1 H)
764 (s, 1 H), 6.84 (d, J = 8.4 Hz, 1 H), 4.67 (s, 2 H), 4.54-4.42 (m, 1 H), 3.92-3.83 (m, 2 H), 3.27-3.10 (m, 3 H), 2.22-2.14 (m, 1 H), 1.96 (s, 3 H), 1.89-1.75 (m, 1 H), 0.94 (s, 9 H), 0.13 (s, 6 H). [0465] 29.4 Preparation of [2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-[[4-[((trans)-4- cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-6-fluoro-phenyl]boronic acid [0
mo- 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-fluoro-anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (0.5 g, 908 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (1.23 g, 5.45 mmol, 6 eq), Pd(PPh3)2Cl2 (95.6 mg, 136 umol, 0.15 eq) and KOAc (196 mg, 2.00 mmol, 2.2 eq) in dioxane (10 mL) was stirred at 100°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. The five parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (20 mL) and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2, Petroleum ether/ethyl acetate = 1/1 to 0/1) to give a crude product. The crude product was further purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [water (NH4HCO3)-ACN]; B%: 35%-65%, 10 min) to give [2-[[tert- butyl(dimethyl)silyl]oxymethyl]-4-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5-methyl- pyrimidin-2-yl]amino]-6-fluoro-phenyl] boronic acid (2 g) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.18 (s, 1 H), 7.99 (s, 2 H), 7.77 (s, 1 H), 7.52-7.47 (m, 2 H), 6.69 (d, J = 8.8 Hz, 1 H), 4.68 (s, 2 H), 4.53-4.43 (m, 1 H), 3.92-3.83 (m, 2 H), 3.28-3.10 (m, 3 H), 2.22-2.15 (m, 1 H), 1.95 (s, 3 H), 1.88-1.75 (m, 1 H), 0.92 (s, 9 H), 0.09 (s, 6 H). [0467] 29.5 Preparation of (trans)-3-[[2-[(7-fluoro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0468
cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-6-fluoro-phenyl]boronic acid (2 g, 3.87 mmol, 1 eq) in THF (20 mL) was added aq. HCl (2 M, 19.4 mL, 10 eq) at 25°C. The mixture was stirred at 25°C for 2 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filter cake was triturated with MTBE (20 mL) to give (trans)-3-((2-((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (1.8 g), which was separated by SFC (column: DAICEL CHIRALPAK AD (250 mm x 50 mm, 10 um); mobile phase: [0.1% NH3H2O ETOH]; B%: 40%-40%, 6 min) to give (trans)-3-[[2-[(7-fluoro-1- hydroxy-3H-2,1-benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4- carbonitrile (367.9 mg, 98.91% purity, 97.08% ee, first peak, Rt = 1.393 min) stereoisomer one as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.44 (s, 1 H), 8.97 (s, 1 H), 7.82 (s, 1 H), 7.68 (s, 1 H), 7.47 (d, J = 11.6 Hz, 1 H), 6.80 (d, J = 8.8 Hz, 1 H), 4.99-4.88 (m, 2 H), 4.52-4.41 (m, 1 H), 3.92-3.85 (m, 2 H), 3.28-3.24 (m, 1 H), 3.23-3.10 (m, 2 H), 2.22-2.14 (m, 1 H), 1.96 (s, 3 H), 1.91-1.79 (m, 1 H). MS (ESI): mass calcd. For C18H19BFN5O3383.16, m/z found 382.0 [M-H]-. HPLC: 98.91% (220 nm), 98.55% (254 nm) and (trans)-3-[[2-[(7-fluoro-1-hydroxy-3H-2,1-
benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (470.2 mg, 98.93% purity, 96.96% ee, second peak, Rt = 1.516 min) stereoisomer two as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.44 (s, 1 H), 8.97 (s, 1 H), 7.82 (s, 1 H), 7.68 (s, 1 H), 7.47 (d, J = 10.8 Hz, 1 H), 6.80 (d, J = 8.4 Hz, 1 H), 4.99-4.88 (m, 2 H), 4.52-4.41 (m, 1 H), 3.92-3.85 (m, 2 H), 3.28-3.24 (m, 1 H), 3.23-3.10 (m, 2 H), 2.22-2.14 (m, 1 H), 1.96 (s, 3 H), 1.91-1.79 (m, 1 H). MS (ESI): mass calcd. For C18H19BFN5O3383.16, m/z found 382.0 [M-H]-. HPLC: 98.93% (220 nm), 98.83% (254 nm). [0469] 30a. Preparation of (R)-7-chloro-5-((5-methyl-4-((tetrahydro-2H-pyran-3- yl)amino)pyrimidin-2-yl)benzo[c][1,2]oxaborol-1(3H)-ol [0470] 30a.1 Preparation of 2
ropyran-3-yl]pyrimidin-4-amine [0471] To a mixt
- dichloro-5-methyl-pyrimidine (1.18 g, 7.27 mmol, 1 eq) in DMA (10 mL) was added DIEA (5.64 g, 43.6 mmol, 7.6 mL, 6 eq) at 20°C. The mixture was stirred at 140°C for 8 h. TLC showed the reaction was complete. The residue was poured into H2O (30 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4 and filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=20/1 to 1/1) to give 2-chloro-5-methyl-N-[(3R)-tetrahydropyran-3-yl]pyrimidin-4-amine (1.4 g, 84.6% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1 H), 5.09 (d, J=7.2 Hz, 1 H), 4.35 - 4.28 (m, 1 H), 3.86 - 3.77 (m, 2 H), 3.67 - 3.60 (m, 2 H), 2.03 (s, 3 H), 1.92 - 1.87 (m, 1 H), 1.80 - 1.73 (m, 1 H), 1.65 - 1.59 (m, 1 H).
[0472] 30a.2 Preparation of [2-bromo-3-chloro-5-[[5-methyl-4-[[(3R)-tetrahydropyran-3- yl]amino] pyrimidin-2-yl]amino]phenyl]methanol [0473] amine (1.2
g, 5.27 mmol, 1 eq) and (5-amino-2-bromo-3-chloro-phenyl)methanol (1.25 g, 5.27 mmol, 1 eq) in i-PrOH (20 mL) was added TFA (1.20 g, 10.5 mmol, 780 uL, 2 eq) at 20°C, the mixture was stirred at 90°C for 12 h. Solid was precipitate out. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered, and the filter cake was washed with aq. NaHCO3 (20mL) to give [2-bromo-3-chloro-5-[[5-methyl-4-[[(3R)-tetrahydropyran-3- yl]amino]pyrimidin-2-yl]amino]phenyl]methanol (1.85 g, 82.0% yield) as white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.50 - 12.10 (m, 1 H), 10.35 (s, 1 H), 8.04 (s, 1 H), 7.77 (
H), 7.64 (s, 1 H), 5.64 - 5.58 (m, 1 H), 4.51 (s, 2 H), 4.25 - 4.15 (m, 1 H), 3.85 - 3.75 (m, 2 H), 3.5 - 3.30 (m, 2 H), 1.99 (s, 4 H), 1.70 - 1.63 (m, 3 H). [0474] 30a.3 Preparation of N2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro- phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3-yl]pyrimidine-2,4-diamine [04
mino] pyrimidin-2-yl]amino]phenyl]methanol (1.6 g, 3.74 mmol, 1 eq) and 2,6-dimethylpyridine (1.20 g, 11.2 mmol, 1.31 mL, 3 eq) in THF (32 mL) was added TBSOTf (1.48 g, 5.61 mmol, 1.29 mL, 1.5 eq) at 0°C.The reaction was stirred it at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturatedaq. NH4Cl (30 mL) at 0°C, and extracted with EtOAc (30 mL x 4). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (15 mL) to give N2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-
phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3-yl]pyrimidine-2,4-diamine (1.8 g, 88.7% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1 H), 8.23 (d, J=2.4 Hz, 1 H), 7.76 (s, 1 H), 7.70 (s, 1H), 6.31 (d, J=7.6 Hz, 1 H), 4.65 (s, 2 H), 4.20 - 4.15 (m, 1 H), 3.89 - 3.79 (m, 2 H), 3.20 (t, J=10.0 Hz, 2 H), 1.93 (s, 3 H), 1.71 - 1.61 (m, 3 H), 0.94 (s, 9 H), 0.13 (s, 6 H). [0476] 30a.4 Preparation of N2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3-yl]pyrimidine- 2,4-diamine [ rt-
butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3- yl]pyrimidine-2,4-diamine (450 mg, 830 umol, 1 eq),2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)- 5,5-dimethyl-1,3,2-dioxaborinane (938 mg, 4.15 mmol, 5 eq),KOAc (244 mg, 2.49 mmol, 3 eq) and Pd(PPh3)2Cl2 (58 mg, 83.0 umol, 0.1 eq) in dioxane (6 mL) was degassed and purged with N2 for 3 times. Then the mixture was heated to 120°C and stirred at 120°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The five parallel reactions were combined, filtered and washed with EtOAc (30 mL). The filtrate was concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/1 to 0/1) to give N2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3-yl]pyrimidine- 2,4-diamine (1.8 g, 75.3% yield) as a white solid. [0478] 30a.5 Preparation of (R)-7-chloro-5-((5-methyl-4-((tetrahydro-2H-pyran-3- yl)amino)pyrimidin-2-yl)benzo[c][1,2]oxaborol-1(3H)-ol
[0479] To a solution of N2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-4-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)phenyl]-5-methyl-N4-[(3R)-tetrahydropyran-3-yl]pyrimidine-2,4- diamine (2.2, 3.83 mmol, 1 eq) in THF (22 mL) was added aq. HCl (6 M, 2.55 mL, 4 eq) at 25°C, the reaction mixture was stirred at 40°C for 1h. Solid was precipitated out. LCMS showed the reaction was complete. The mixture was filtered. The filter cake was triturated with a mixture solvent of MeOH (3 mL) and DCM (25 mL) at 25oC for 20 min to give (R)-7-chloro-5- ((5-methyl-4-((tetrahydro-2H-pyran-3-yl)amino)pyrimidin-2-yl)benzo[c][1,2]oxaborol-1(3H)-ol (400 mg, 97.69% purity, 97.38% ee, second peak, Rt = 1.284 min) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1 H), 9.19 (s, 1 H), 8.06 - 8.14 (m, 1 H), 7.85 (s, 1 H), 7.69 (s, 1 H), 7.58 (s, 1 H), 4.98 (s, 2 H), 4.18 - 4.12 (m, 1 H), 3.89 - 3.81 (m, 2 H), 3.35 - 3.29 (m, 2 H), 2.05 - 1.95 (m, 4 H), 1.80 - 1.60 (m, 3 H). MS (ESI): mass calcd. For C17H20BClN4O3374.13, m/z found 375.1 [M+H]+. HPLC: 97.69% (220 nm), 99.16% (254 nm). [0480] 30b.1 Preparation of (S)-7-chloro-5-((5-methyl-4-((tetrahydro-2H-pyran-3-yl)amino) pyrimidin-2-yl)amino)benzo[c][1,2]oxaborol-1(3H)-ol [0481]
butyldimethylsilyl)oxy)methyl)-6-chloro-4- ((5-methyl-4-((tetrahydro-2H-pyran-3- yl)amino)pyrimidin-2-yl)amino)phenyl)boronic acid (1 g, 1.97 mmol, 1 eq) in THF (10 mL) was added HCl (6 M, 1.32 mL, 4 eq) at 25oC. The mixture was stirred at 40°C for 1 hr. Solid was precipitate out after 30 min reaction. TLC showed the reaction was complete. The mixture was filtered and the filter cake was washed with MeCN (20 mL) to give (S)-7-chloro-5-((5-methyl-4- ((tetrahydro-2H-pyran-3-yl)amino)pyrimidin-2-yl)amino)benzo[c][1,2]oxaborol-1(3H)-ol (500 mg, 67.5 yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.33 (br s, 1H), 8.83 (s, 1H), 7.82 (s, 1H), 7.77 (s, 1H), 7.73 (s, 1H), 6.33 (d, J=7.2 Hz, 1H), 4.92 (s, 2H), 4.25 - 4.15 (m, 1H), 3.95 - 3.75 (m, 2H), 3.30 - 3.25 (m, 1H), 3.25 - 3.10 (m, 1H), 2.10 - 1.80 (m, 4H), 1.75 - 1.50 (m, 3H). MS (ESI): mass calcd. For C17H20BClN4O3374.13, m/z found 375.1 [M+H]+. HPLC: 98.24% (220 nm), 99.57% (254 nm).
[0482] 31. Preparation of (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0483] 31.1 Preparation of (tr (hydroxymethyl)anilino]-5-
methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0484]
1 eq), (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (2.67 g, 10.5 mmol, 1 eq) and TFA (1.81 g, 15.8 mmol, 1.17 mL, 1.5 eq) in i-POH (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80°C for 12 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturated aq. NaHCO3 (50 mL) at 0°C and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was
ted with MTBE (30 mL) at 25oC for 10 min to give (trans)-3-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]- 5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (3.5 g, 73% yield) as a white solid. [0485] 31.2 Preparation of (trans)-3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- chloro- anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0486] To a solution of (trans)-3-[[2-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (4.4 g, 9.72 mmol, 1 eq) in THF (50 mL) was added 2,6-dimethylpyridine (4.20 g, 38.8 mmol, 4.57 mL, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (3.85 g, 14.5 mmol, 3.35 mL, 1.5 eq). The mixture was stirred at 25°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturated aq. NH4Cl (50 mL) at 0°C and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (40 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (30 mL) at 25oC for 20 min to give (trans)-3-[[2-[4-bromo-3-[[tert- butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (4.5 g, 81% yield) as a white solid. [0487] 31.3 Preparation of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro- 4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino) tetrahydro-2H-pyran-4-carbonitrile [0
omo- 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-methyl-pyrimidin-4-yl]amino] cyclopentanecarbonitrile (0.5 g, 881 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (1.02 g, 4.4 mmol, 5 eq), KOAc (267 mg, 2.72 mmol, 3 eq) and Pd(PPh3)2Cl2 (63.6 mg, 88.1 umol, 0.1 eq) in dioxane (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 h under N2 atmosphere. TLC showed the reaction was complete. The reactions were cooled to room temperature and filtered. The nine parallel reactions were combined and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=10/1 to 5/1) to give (trans)-3-((2-((3-(((tert-butyldimethylsilyl) oxy)methyl)-5-chloro- 4-(5,5-dimethyl-1,3,2-dioxa borinan-2-yl)phenyl)amino)-5-methyl pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (4.1 g, 84% yield) as a white solid.
[0489] 31.4 Preparation of (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile ro-4-(5,5-
dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (3 g, 5.00 mmol, 1 eq) in THF (30 mL) was added aq. HCl (4 M, 7.95 mL, 6 eq). The mixture was stirred at 25°C for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and triturated with EtOAc (30 mL) to give racemic product (1g). The racemic product (1g) was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 40%- 40%,6min) to give (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (313.7 mg, 98.88% purity, 100% ee, first peak, Rt = 0.685 min) stereoisomer one as a white solid.1H NMR (DMSO- d6, 400 MHz) δ 9.42 (s, 1H), 8.84 (s, 1H), 7.83 -7.74 (m, 3H), 6.78 (d, J = 8.8 Hz, 1H), 4.94 (m, 2H), 4.60-4.45 (m, 1H), 4.00-3.84 (m, 2H), 3.34-3.12 (m, 3H), 2.35-2.05 (m, 1H), 1.96 (s, 3H), 1.90-1.81 (m, 1H). MS (ESI): mass calcd. For C18H19BCl2N5O2399.13, m/z found 400.1 [M+H]+. HPLC: 98.88% (220 nm), 99.25% (254 nm) and (trans)-3-((2-((7-chloro-1-hydroxy- 1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (333.9 mg, 98.20% purity, 98.06% ee, second peak, Rt = 0.874 min) stereoisomer two as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.42 (s, 1H), 8.84 (s, 1H), 7.83 -7.74 (m, 3H), 6.78 (d, J = 8.8 Hz, 1H), 4.94 (m, 2H), 4.60-4.45 (m, 1H), 4.00-3.84 (m, 2H), 3.34-3.12 (m, 3H), 2.35-2.05 (m, 1H), 1.96 (s, 3H), 1.90-1.81 (m, 1H). MS (ESI): mass calcd. For C18H19BCl2N5O2399.13, m/z found 400.2 [M+H]+. HPLC: 98.20% (220 nm), 99.33% (254 nm). [0491] 32. Preparation of (trans)-3-[[2-[(1-hydroxy-3,3-dimethyl-2,1 -benzoxaborol-5- yl)amino]-5 -methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0492] 32.1 Preparation of (tran oxy-1-methyl-ethyl)anilino]-5-
methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile Br O O Br N H 2 N OH N OH [0493] To a so
lution of (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4- carbonitrile (600 mg, 2.37 mmol, 1 eq) in dioxane (10 mL) was added 2-(5-amino-2-bromo- phenyl) propan-2-ol (437 mg, 1.90 mmol, 0.8 eq) and TsOH.H2O (677 mg, 3.56 mmol, 1.5 eq) at 25°C under N2. The mixture was heated and stirred at 80°C for 12 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was triturated with DCM (20 mL) at 25oC to give (trans)-3-[[2-[4-bromo-3- (1-hydroxy-1-methyl-ethyl)anilino]-5-methyl-pyrimidin -4-yl]amino]tetrahydropyran-4- carbonitrile (400 mg, 37.7% yield) as an off-white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.08 (s, 1H), 8.13 (d, J = 2.8 Hz, 1H), 7.75 (s, 1H), 7.61 (dd, J = 8.4 Hz, 2.8 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.08 (s, 1H), 4.53-4.44 (m, 1H), 3.87-3.83 (m, 2H), 3.30-3.20 (m, 2H), 3.12 (t, J = 10.8 Hz, 1H), 2.16-2.12 (m, 1H), 1.94 (s, 3H), 1.61 (d, J = 2.8 Hz, 6H). [0494] 32.2 Preparation of (trans)-3-[[2-[(1-hydroxy-3,3-dimethyl-2,1 -benzoxaborol-5- yl)amino]-5 -methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0495] Fo
u eac o s we e ca e ou pa a e . o eac a so u o o ans - - [2-[4-bromo- 3-(1-hydroxy-1-methyl-ethyl)anilino]-5-methyl-pyrimidin-4-yl] amino]tetrahydropyran-4-
carbonitrile (100 mg, 224 umol, 1 eq) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (127 mg, 560 umol, 2.5 eq) in dioxane (3 mL) was added KOAc (44.0 mg, 448 umol, 2 eq), Pd(PPh3)2Cl2 (15.7 mg, 22.4 umol, 0.1 eq) at 25°C under N2. The mixture was heated and stirred at 120°C for 1 h. TLC showed the reaction was complete. The four parallel reactions were combined and filtered The reaction filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (0.04%HCl)-MEOH]; B%: 10%- 30%,8min) to give (trans)-3-[[2-[(1-hydroxy-3,3-dimethyl-2,1 -benzoxaborol-5-yl)amino]-5- methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (59 mg, 94.03% purity) as an off- white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.74 (s, 1H), 8.52 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.32 (dd, J = 8.0 Hz, 1.6 Hz, 1H), 4.49-4.40 (m, 1H), 3.93-3.86 (m, 2H), 3.32-3.23 (m, 3H), 2.24-2.20 (m, 1H), 2.06 (d, J = 7.2 Hz,3H), 1.82-1.71 (m, 1H), 1.48 (d, J = 4.8 Hz, 6H). MS (ESI): mass calcd. For C20H24BN5O3393.20, m/z found 394.3 [M+H]+. HPLC: 94.03% (220 nm), 96.18% (254 nm). [0496] 33. Preparation of (trans)-3-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol- 5- yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0497] 33.1 Preparation of meth
)benzoate [0498] A mixture of 2-am
, 24.4 mmol, 1 eq) in MeOH (100 mL) was added H2SO4 (7.36 g, 75.1 mmol, 4.0 mL, 3.1 eq) at 25°C under N2, and then the mixture was stirred 80°C for 24 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was added saturated aq. NaHCO3 (200 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under
reduced pressure to give methyl 2-amino-3-(trifluoromethyl)benzoate (4 g, 75% yield) as brown oil. 1H NMR (CDCl3, 400 MHz) δ 8.06 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 6.67 (t, J = 8.0 Hz, 1H), 6.47 (s, 2H), 3.89 (s, 3H). [0499] 33.2 Preparation of methyl 2-bromo-3-(trifluoromethyl)benzoate [0500] To a stirred so ate (5 g, 22.8 mmol, 1
eq) in MeCN (30 mL) was added HBr (50.0 g, 247 mmol, 33.6 mL, 40% purity, 10.9 eq) drop- wise over 10 min at 0°C. Then a solution of NaNO2 (1.73 g, 25.1 mmol, 1.1 eq) in H2O (7.5 mL) was added drop-wise to the reaction over 1 h at 0°C. After addition, the solution was stirred at 0°C for 20 min, then added CuBr (3.76 g, 26.2 mmol, 1.15 eq) in portions over 30 min at 0oC. The mixture was heated and stirred at 70°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched with H2O (100 mL) at 0°C, and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate/petroleum ethergradient @ 80 mL/min) to give methyl 2-bromo- 3-(trifluoromethyl)benzoate (5 g, 77% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.80 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 3.97 (s, 3H). [0501] 33.3 Preparation of methyl 2-bromo-5-nitro-3-(trifluoromethyl)benzoate [0502] To a solutio
g, 45.9 mmol, 1 eq) in H2SO4 (110 mL) was drop-wise added fuming nitric acid (10.8 g, 163 mmol, 7.75 mL, 95% purity, 3.56 eq) at 0°C. After the addition, the reaction was allowed to warm to 20°C and stirred at 20°C for 2 h under N2 atmosphere. TLC showed the reaction was complete. The reaction
mixture was poured into ice-water (80 mL) at 0°C, and large amount of precipitate formed. The mixture was filtered and the filter cake was washed with H2O (50 mL x 3) to give methyl 2- bromo-5-nitro-3-(trifluoromethyl)benzoate (10 g, 66% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 8.65-8.60 (m, 2H), 4.04 (s, 3H). [0503] 33.4 Preparation of methyl 5-amino-2-bromo-3-(trifluoromethyl)benzoate [0504] A mixture 5 g, 15.2 mmol, 1 eq)
in EtOH (60 mL) and H2O (20 mL) was added Fe (2.55 g, 45.7 mmol, 3.00 eq) and NH4Cl (2.45 g, 45.8 mmol, 3.00 eq) at 25°C, and then the mixture was stirred at 70°C for 2 h. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was added H2O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-amino-2- bromo-3-(trifluoromethyl)benzoate (4 g, 88% yield) as a brown solid.1H NMR (CDCl3, 400 MHz) δ 7.08 (d, J = 2.8 Hz, 1H), 7.00 (d, J = 2.8 Hz, 1H), 4.13-3.96
m, 2H), 3.95 (s, 3H). [0505] 33.5 Preparation of [5-amino-2-bromo-3-(trifluoromethyl)phenyl]methanol CF3 CF3 Br OH [0506] To a solutio
oate (6 g, 20.1 mmol, 1 eq) in THF (60 mL) was added DIBAL-H (1 M in THF, 50.3 mL, 2.5 eq) drop-wise at -60°C. The mixture was stirred at -60°C for 0.5 h. Then the reaction was allowed to warm to 0°C and stirred at 0°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition aq. seignette salt (100 mL) at 0°C, and then extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated
with Petroleum ether at 25oC for 30 min to give [5-amino-2-bromo-3- (trifluoromethyl)phenyl]methanol (5.2 g, 95% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.01 (d, J = 2.8 Hz, 1H), 6.34 (d, J = 2.8 Hz, 1H), 4.74 (d, J = 5.6 Hz, 2H), 3.90 (s, 2H). [0507] 33.6 Preparation of (trans)-3-[[2-[4-bromo-3-(hydroxymethyl)-5- (trifluoromethyl)anilino]- 5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0508] To , 11.1 mmol,
1 eq) and (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (2.81 g, 11.1 mmol, 1 eq) in i-PrOH (30 mL) was added TFA (1.90 g, 16.7 mmol, 1.23 mL, 1.5 eq) in one portion at 25°C. The mixture was stirred at 25°C for 10 min, then heated to 80 °C and stirred for 5 hours. TLC showed the reaction was complete. The reaction mixture was filtered, and the filter cake was triturated with saturated aq. NaHCO3 (50 mL) to give 3-[[2-[4-bromo-3- (hydroxymethyl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4- carbonitrile (5.3 g, 98% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.78 (s, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.10 (s, 1H), 7.83 (s, 1H), 7.09 (s, 1H), 5.57 (s, 1H), 4.55 (s, 2H), 4.51- 4.48 (m, 1H), 3.86-3.81 (m, 2H), 3.25-3.12 (m, 3H), 2.15 (d, J = 10.0 Hz, 1H), 1.98 (s, 3H), 1.87-1.82 (m, 1H). [0509] 33.7 Preparation of (trans)-3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- (trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0510]
o a so u o o ans - - - - o o- - y o y e y - - uo o e y anilino]-5- methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (4 g, 8.2 mmol, 1 eq) and 2,6-
dimethylpyridine (2.64 g, 24.7 mmol, 2.9 mL, 3 eq) in THF (60 mL) was added [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (3.26 g, 12.3 mmol, 2.8 mL, 1.5 eq) at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 3 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition saturated aq. NH4Cl (100 mL) at 0°C, and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with Petroleum ether (50 mL) to give (trans)-3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(trifluoromethyl)anilino] -5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (4.5 g, 91% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.62 (s, 1H), 8.40 (d, J = 2.8 Hz, 1H), 8.12 (s, 1H), 7.80 (d, J = 10.8 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 4.73 (s, 2H), 4.51-4.48 (m, 1H), 3.86-3.83 (m, 2H), 3.28-3.24 (m, 2H), 3.23-3.12 (m, 1H), 2.17 (d, J = 9.6 Hz, 1H), 1.97-1.96 (m, 3H),1.81-1.79 (m, 1H), 0.95 (s, 9H), 0.14 (s, 6H). [0511] 33.8 Preparation of (trans)-3-[[2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(5,5- dimethyl-1,3,2- dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile [051
5- (trifluoromethyl) anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (700 mg, 1.2 mmol, 1 eq) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2- dioxaborinane (1.84 g, 8.2 mmol, 7 eq) in dioxane (30 mL) was added KOAc (343 mg, 3.5 mmol, 3 eq) and Pd(PPh3)2Cl2 (82 mg, 117 umol, 0.1 eq) at 25°C under N2. The mixture was stirred at 120°C for 2 h. LCMS showed the reaction was complete and desired MS observed. 6 parallel reactions were combined for work up. The reaction mixture was filtered and the filtrate concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (column: C18 (250 x 50mm x 10 um); mobile phase: [water ( NH4HCO3)-ACN]; B%: 75%-90%,10min) to give (trans)-3-[[2-[3-[[tert-butyl(dimethyl)silyl] oxymethyl]-4-(5,5-dimethyl-1,3,2-
dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran- 4-carbonitrile (1.4 g) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.39 (s, 1H), 8.17 (s, 1H), 8.12 (s, 1H), 7.90 (s, 1H), 7.79 (s, 1H), 6.70 (d, J = 8.8 Hz, 1H), 4.74 (s, 2H), 4.50-4.46
(m, 1H), 3.89-3.85 (m, 2H), 3.70 (s, 4H), 3.32-3.24 (m, 2H), 3.16-3.12 (m, 1H), 2.19 (d, J = 8.0 Hz, 1H), 1.96 (s, 3H), 1.87-1.83 (m, 1H), 1.03 (s, 6H), 0.90 (s, 9H), 0.07 (s, 6H). [0513] 33.9 Preparation of (trans)-3-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol- 5-yl] amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0514]
imethyl- 1,3,2- dioxaborinan-2-yl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (700 mg, 1.1 mmol, 1 eq) in THF (8 mL) was added HCl (6 M, 0.9 mL, 5 eq) drop-wise at 0°C. The mixture was stirred at 40°C for 0.5 h. LCMS showed the reaction was complete and desired MS observed. 2 parallel reactions were combined for work up. The reaction mixture was filtered and the filter cake was wished with H2O (10 mL). The crude product was triturated with MeCN (10 mL) at 25oC for 30 min to give (trans)-3-[[2- [[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol-5-yl]amino]-5-methyl-pyrimidin-4- yl]amino] tetrahydropyran-4-carbonitrile (800 mg, 97.53% purity) as a white solid. This material was separated by prep-SFC (column: ChiralPak IH, 250 x 30mm, 10um; mobile phase: [0.1%NH3H2O IPA]; B%: 25%-25%,9min) to give (trans)-3-[[2-[[1-hydroxy-7- (trifluoromethyl)-3H-2,1-benzoxaborol-5-yl]amino]-5-methyl-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (345.4 mg, 98.39% purity, 95.36% ee, first peak, Rt = 1.824 min) stereoisomer one as a white solid 1H NMR (DMSO-d6, 400 MHz) δ 9.74 (s, 1H), 8.93 (s, 1H), 8.06 (s, 2H), 7.84 (s, 1H), 7.05 (broad doublet, 1H), 5.06-5.00 (m, 2H), 5.49-4.44 (m, 1H), 3.90-3.85 (m, 2H), 3.27-3.21 (m, 2H), 3.17-3.11 (m, 1H), 2.19 (d, J = 10.0 Hz, 1H), 1.98 (s, 3H), 1.86-1.83 (m, 1H). MS (ESI): mass calcd. For C19H19BF3N5O3433.15, m/z found 434.2 [M+H]+. HPLC: 98.39% (220 nm), 97.98% (254 nm) and (trans)-3-[[2-[[1-hydroxy-7- (trifluoromethyl)-3H-2,1-benzoxaborol-5-yl] amino]-5-methyl-pyrimidin-4-
yl]amino]tetrahydropyran-4-carbonitrile (285.4 mg, 98.34% purity, 97.14% ee, second peak, Rt = 1.963 min) stereoisomer two as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.64 (s, 1H), 8.90 (s, 1H), 8.09 (d, J = 5.2 Hz, 2H), 7.83 (s, 1H), 6.88 (d, J = 7.6 Hz, 1H), 5.06-4.96 (m, 2H),
4.48-4.44 (m, 1H), 3.90-3.85 (m, 2H), 3.30-3.22 (m, 2H), 3.17-3.10 (m, 1H), 2.19 (d, J = 10.0 Hz, 1H), 1.97 (s, 3H), 1.87-1.83 (m, 1H). MS (ESI): mass calcd. For C19H19BF3N5O3433.15, m/z found 434.2 [M+H]+. HPLC: 98.34% (220 nm), 99.50% (254 nm). [0515] 34. Preparation of (trans)-3-[[2-[(2-hydroxy-1,2- benzoxaborinin-7-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile N H H OH [0516] 34.1 Preparation of (t
)methylamino]-5-methyl- pyrimidin -4-yl]amino]tetrahydropyran-4-carbonitrile
[0517] Three reactions were carried out in parallel. For each a mixture of (trans)-3-[(2-chloro-5- methyl-pyrimidin-4-yl)amino]tetrahydropyran -4-carbonitrile (650 mg, 2.57 mmol, 1 eq) and (2,4-dimethoxyphenyl)methanamine (6.45 g, 38.5 mmol, 5.81 mL, 15 eq) was stirred at 100°C for 9 h. TLC showed the reaction was complete. The three parallel reactions were combined and the mixture was adjusted pH=4-5 with aq. HCl (2N), and added H2O (20 mL). The aqueous layer was extracted with EtOAc (20 mL x 2). The aqueous layers were adjusted pH=8-9 with saturated aq. NaHCO3 and extracted with EtOAc (10 mL x 4). The combined organics was dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with DCM (10 mL) to give (trans)-3-[[2-[(2,4-dimethoxyphenyl)methylamino]-5- methyl -pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (2.00 g, 67% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 7.53 (s, 1H), 7.06 (d, J = 8.0 Hz, 1H), 6.54-6.50 (m, 2H), 6.42-6.39 (m, 2H), 4.35-4.33 (m, 1H), 4.32-4.26 (m, 2H), 3.84-3.82 (m, 2H), 3.81 (s, 3H),
3.71 (s, 3H), 3.25-3.21 (m, 2H), 3.20-3.18 (m, 1H), 2.08-2.05 (m, 1H), 1.84 (s, 3H), 1.81-1.77 (m, 1H). [0518] 34.2 Preparation of (trans)-3-[(2-amino-5-methyl-pyrimidin -4-yl)amino] tetrahydropyran -4-carbonitrile [0519] To hyl-pyrimidin -
4-yl]amino]tetrahydropyran-4-carbonitrile (1.80 g, 4.69 mmol, 1 eq) in DCM (20 mL) was added TFA (5.35 g, 46.9 mmol, 3.48 mL, 10 eq) in one portion at 25°C under N2. The mixture was stirred at 25°C for 12 h. TLC showed the reaction was complete. The mixture was adjusted pH=8 with saturated aq. NaHCO3 and diluted with H2O (20 mL). The aqueous layer was extracted with EtOAc (20 mL x 4). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (trans)-3- [(2-amino-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (750 mg, 68% yield) as a white solid, which used directly into next step without further purification.1H NMR (DMSO-d6, 400 MHz) δ 7.54 (s, 1H), 6.54 (d, J = 8.8 Hz, 1H), 6.06 (s, 2H), 4.40-4.36 (m, 1H), 3.81-3.77 (m, 2H), 3.25-3.22 (m, 2H), 3.08-3.05 (m, 1H), 2.12-2.11 (m, 1H), 1.86 (s, 3H), 1.83- 1.79 (m, 1H). [0520] 34.3 Preparation of 5-bromo-2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) vinyl]phenol O O B B O [0521] To a mixture o
, . , q L) was added 4,4,5,5- tetramethyl -2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane (20.0 g, 74.6 mmol, 3 eq) and N'-[2-(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (8.62
g, 49.7 mmol, 10.4 mL, 2 eq) drop-wise at 0°C under N2. The mixture was stirred at 0°C for 30 min. The reaction mixture was added 4-bromo-2-hydroxy-benzaldehyde (5 g, 24.8 mmol, 1 eq) and stirred for 30 min at 0°C. TLC showed the reaction was complete. The mixture was quenched with saturated aq. NH4Cl (100 mL) and extracted with EtOAc (1000 mL x 3). The combined organic layers were washed by brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 10~15% Ethyl acetate/petroleum ethergradient @100mL/min) to give 5-bromo-2-[2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)vinyl]phenol (5 g, 61% yield) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.56 (d, J = 18.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 84 Hz, 1H), 7.00 (s, 1H), 6.16
(d, J = 18.4 Hz, 1H), 5.49 (br d, 1H), 1.29 (s, 12H). [0522] 34.4 Preparation of 7-bromo-2-hydroxy-1,2-benzoxaborinine [0523] Three
mo-2-[2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]phenol (500 mg, 1.54 mmol, 1 eq) in MeCN (11 mL) was added tris[2-(2-pyridyl)phenyl]iridium (10 mg, 15 umol, 0.01 eq) in one portion at 25°C under N2. The reaction was stirred and irradiated using 34W blue LED lamps for 15 h. TLC showed the reaction was complete. The three parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 30%-60%,8min) to obtain 7-bromo-2-hydroxy-1,2-benzoxaborinine (240 mg, 23% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.17 (s, 1H), 7.78 (d, J = 12.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 2 Hz, 1H), 7.33 (dd, J = 8, 2 Hz, 1H), 6.17 (d, J = 12.0 Hz, 1H). [0524] 34.5 Preparation of (trans)-3-[[2-[(2-hydroxy-1,2- benzoxaborinin-7-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[05
no-5- methyl-pyrimidin-4-yl)amino]tetrahydropyran -4-carbonitrile (150 mg, 643 umol, 1 eq) and 7- bromo-2-hydroxy-1,2-benzoxaborinine (231 mg, 1.03 mmol, 1.6 eq) in i-PrOH (3 mL) was added K2CO3 (160 mg, 1.16 mmol, 1.8 eq), Pd2(dba)3 (82.4 mg, 90 umol, 0.14 eq) and t-Bu Xphos (191 mg, 450 umol, 0.7 eq) in one portion at 25°C under N2. The mixture was stirred at 80°C for 5 h. LCMS showed the reaction was complete and desired MS observed. The five parallel reactions were combined and the mixture was adjusted pH=6 with aq. HCl (2N) and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (HCl)-ACN]; B%: 10%- 30%,8min) to give (trans)-3-[[2-[(2-hydroxy-1,2- benzoxaborinin-7-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (383 mg, 31% yield, 99.45% purity) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.40 (s, 1H), 9.00 (s, 1H), 8.26 (s, 1H), 7.81 (s, 1H), 7.78 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.40 (s, 1H), 7.35 (d, J=8.4 Hz, 1H), 6.06 (d, J=11.6 Hz, 1H), 4.49-4.43 (m, 1H), 3.88-3.83 (m, 2H), 3.29-3.26 (m, 3H), 2.20-2.17 (m, 1H), 2.04 (s, 3H), 1.88-1.85 (m, 1H). MS (ESI): mass calcd. For C19H20BN5O3377.17, m/z found 378.2 [M+H]+. HPLC: 99.45% (220 nm), 99.18% (254 nm). [0526] 35. Preparation of 3-[[2-[(2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0527] 35.1 Preparation of 6
- romo- - y roxy- , - enzoxa or nine
[0528] To a mixtu dded 4,4,5,5-
tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane (10.0 g, 37.3 mmol, 2.5 eq) and N'-[2-(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (7.76 g, 44.7 mmol, 9.35 mL, 3 eq) drop-wise at 0°C under N2. The mixture was stirred at 0°C for 30 min. To the resulting mixture was added a solution of 5-bromo-2-hydroxy-benzaldehyde (3 g, 14.9 mmol, 1 eq) in THF (10 mL) drop-wise at 0°C. The mixture was stirred for 30 min at 0°C. TLC showed the reaction was complete. The mixture was quenched with saturated aq. NH4Cl (30 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 20~40% Ethyl acetate/petroleum ethergradient @ 75 mL/min) to get 6-bromo-2-hydroxy-1,2-benzoxaborinine (500 mg, 14% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.69 (d, J = 12 Hz, 1H), 7.55 (d, J = 2.4 Hz, 1H), 7.46 (dd, J = 8.8, 2.4 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H), 6.28 (d, J = 12 Hz, 1H). [0529] 35.2 Preparation of tert-butyl N-(2-hydroxy-1,2-benzoxaborinin-6-yl)carbamate [0
. xy- 1,2-benzoxaborinine (1 g, 4.45 mmol, 1 eq) and tert-butyl carbamate (625 mg, 5.34 mmol, 1.2 eq) in i-PrOH (30 mL) was added K2CO3 (1.54 g, 11.1 mmol, 2.5 eq), t-Bu Xphos (188 mg, 444 umol, 0.1 eq) and Pd2(dba)3 (81.5 mg, 89 umol, 0.02 eq) in one portion at 25°C under N2. The mixture was heated and stirred at 85°C for 0.5 h. TLC showed the reaction was complete. The three parallel reactions were combined and quenched with H2O (20 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column,
Eluent of 20~30% Ethyl acetate/petroleum ether gradient @ 100 mL/min) to give a crude product. The crude product was further purified by prep-HPLC (column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 30%-50%,10min) to give tert-butyl N-(2-hydroxy-1,2-benzoxaborinin-6-yl)carbamate (1 g, 28% yield) as a white solid.1H NMR (CDCl3, 400 MHz) δ 7.73 (d, J = 12 Hz, 1H), 7.58 (s, 1H), 7.23 (dd, J = 8.8, 2.8 Hz, 1H), 7.16 (d, J = 8.8 Hz, 1H), 6.22 (d, J = 12 Hz, 1H), 1.54 (s, 9H). [0531] 35.3 Preparation of 2-hydroxy-1,2-benzoxaborinin-6-amine hydrochloride [0532] To
te (1 g, 3.83 mmol, 1 eq) in EtOAc (5 mL) was added HCl/EtOAc (4 N, 38.3 mL, 80 eq) in one portion at 25°C under N2. The mixture was stirred at 25°C for 15 h. TLC showed the reaction was complete. The mixture was filtered to give 2-hydroxy-1,2-benzoxaborinin-6-amine hydrochloride (601 mg, 78% yield, HCl) as an off-white solid.1H NMR (DMSO-d6, 400 MHz) δ 10.03 (s, 3H), 9.12 (s, 1H), 7.83 (d, J = 12 Hz, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.4, 2.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.22 (d, J = 12 Hz, 1H). [0533] 35.4 Preparation of (trans)-3-[[2-[(2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0534] Five reactions were carried out in parallel. For each a mixture of 2-hydroxy-1,2- benzoxaborinin-6-amine hydrochloride (100 mg, 506 umol, 1 eq, HCl) and (trans)-3-[(2-chloro- 5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (141 mg, 557 umol, 1.1 eq) in dioxane (2 mL) was stirred at 130°C for 1 h. TLC showed the reaction was complete. The five parallel reactions were combined and quenched with a mixture solvent of H2O (0.5 mL) and THF
(3 mL) and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 2 g SepaFlash® Silica Flash Column, Eluent of 7~10% DCM/MeOH @ 60mL/min) to give (trans)-3-[[2-[(2-hydroxy-1,2-benzoxa borinin-6-yl)amino]-5-methyl- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (535 mg, 50% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.25 (s, 1H), 10.28 (s, 1H), 9.02 (s, 1H), 8.20 (s, 1H), 7.80-7.68 (m, 3H), 7.44 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 6.17 (d, J = 12 Hz, 1H), 4.41-4.38 (m, 1H), 3.89-3.85 (m, 2H), 3.40-3.37 (m, 1H), 3.27-3.22 (m, 2H), 2.19-2.15 (m, 1H), 2.03 (s, 3H), 1.81-1.79 (m, 1H). MS (ESI): mass calcd. For C19H20BN5O3377.17, m/z found 378.2 [M+H]+. HPLC: 98.25% (220 nm), 98.43% (254 nm). [0535] 36. Preparation of (trans)-3-((2-((8-fluoro-2-hydroxy-2H-benzo[e][1,2] oxaborinin-6- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0536] 36.1 Preparation of 5-
ehyde [0537] To a solution of
3- uoro- - y roxy- enza e y e ( 0 g, 7 .3 mmol, 1 eq) in MeCN (100 mL) was added NBS (12.8 g, 72.0 mmol, 1.01 eq) and NH4OAc (550 mg, 7.14 mmol, 0.1 eq) at 25oC. The mixture was stirred at 25°C for 2 hrs. LCMS showed 3-fluoro-2-hydroxy- benzaldehyde was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition saturated aq. NH4Cl (100 mL) at 0°C and then diluted with H2O (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate/petroleum ether gradient @100 mL/min) to give compound 5-bromo-3-fluoro-2-hydroxy-benzaldehyde
(14.5 g, 92% yield) as a light yellow solid. 1H NMR (400 MHz, CHLOROFORM-d) δ = 10.89 (s, 1H), 9.88 (s, 1H), 7.55-7.47 (m, 2H). [0538] 36.2 Preparation of (E)-4-bromo-2-fluoro-6-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -yl)vinyl)phenol [0539] To a mixt ) was drop-wise
added N'-[2-(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 22.9 g, 132 mmol, 27.6 mL, 2 eq) and 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)methyl]-1,3,2-dioxaborolane (35.4 g, 132 mmol, 2 eq) at 0oC. After addition, the mixture was stirred at 0oC for 20 min, and then a solution of 5-bromo-3-fluoro-2-hydroxy-benzaldehyde (14.5 g, 66.2 mmol, 1 eq) in THF (20 mL) was drop-wise added at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 40 min. LCMS showed 5-bromo-3-fluoro- 2-hydroxy-benzaldehyde was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched with aq. NH4Cl (100 mL) and extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®;120 g SepaFlash® Silica Flash Column, eluent of 0~15% ethyl acetate/petroleum ether gradient @ 100 mL/min) to obtain compound 4-bromo-2-fluoro-6-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]phenol (24 g, 60% purity) as light yellow oil . [0540] 36.3 Preparation of 6-bromo-8-fluoro-2-hydroxy-1,2-benzoxaborinine
[0541] Six reactions were carried out in parallel. For each a solution of 4-bromo-2-fluoro-6- [(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl] phenol (4 g, 6.98 mmol, 60% purity, 1 eq) in MeCN (30 mL) was added tris[2-(2-pyridyl)phenyl]iridium (114 mg, 175 µmol, 0.025 eq). The reaction was stirred and irradiated using 34 W blue LED lamps at 25°C for 16 h. TLC showed the reaction was complete. The six parallel reactions were combined for work up. The reaction mixture was diluted with H2O (100 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (40 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0~25% ethyl acetate/petroleum ethergradient @ 100 mL/min) to obtain 6-bromo-8-fluoro-2-hydroxy- 1,2-benzoxaborinine (10 g, 85% purity) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.44 (s, 1H), 7.79 (d, J = 12.0 Hz, 1H), 7.68-7.60 (m, 2H), 6.26 (d, J = 12.0 Hz, 1H). [0542] 36.4 Preparation of tert-butyl (8-fluoro-2-hydroxy-2H-benzo[e][1,2]oxaborinin-6-yl) carbamate [0543] A mmol, 85%
purity, 1 eq), tert-butyl carbamate (4.92 g, 42.0 mmol, 1.2 eq), Pd2(dba)3 (3.21 g, 3.50 mmol, 0.1 eq), K3PO4 (11.1 g, 52.50 mmol, 1.5 eq) and ditert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl] phosphane (1.49 g, 3.50 mmol, 0.1 eq) in i-PrOH (150 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80°C for 2 h under N2 atmosphere. LCMS showed the reaction was complete and one peak with desired mass was detected. The reaction mixture was quenched by addition H2O (250 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~24% ethyl acetate/petroleum ether gradient @ 90 mL/min) to obtain tert-butyl (8-fluoro-2-hydroxy-2H- benzo[e][1,2]oxaborinin-6-yl)carbamate (1.8 g, 18.6% yield) as a gray solid. 1H NMR (400
MHz, DMSO-d6) δ = 9.48 (s, 1H), 9.17 (s, 1H), 7.74 (d, J = 12.0 Hz, 1H), 7.45-7.35 (m, 2H), 6.20 (d, J = 12.0 Hz, 1H), 1.47 (s, 9H). [0544] 36.5 Preparation of 6-amino-8-fluoro-2H-benzo[e][1,2]oxaborinin-2-ol hydrochloride [0545] To a solu orinin-6-
yl)carbamate (1.7 g, 6.09 mmol, 1 eq) in EtOAc (10 mL) was added HCl/EtOAc (4 M, 54 mL) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (15 mL) at 25oC for 10 min to obtain 6-amino-8-fluoro-2H- benzo[e][1,2]oxaborinin-2-ol hydrochloride (1.4 g, HCl salt) as a gray solid.1H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 12.0 Hz, 1H), 7.41-7.23 (m, 2H), 6.28 (d, J = 12.0 Hz, 1H). [0546] 36.6 Preparation of 3-((2-((8-fluoro-2-hydroxy-2H-benzo[e][1,2]oxaborinin-6-yl) amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [05
mol, 1 eq, HCl) in i-PrOH (18 mL) was added (trans)-3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino] tetrahydropyran-4-carbonitrile (1.52 g, 6.03 mmol, 1 eq) and TFA (1.03 g, 9.05 mmol, 1.5 eq). The mixture was stirred at 80°C for 12 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was quenched by addition H2O (5 mL) and THF (4 mL), and then concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (15 mL) at 25oC for 30 min to obtain (trans)3-((2-((8-fluoro-2-hydroxy-2H- benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-
carbonitrile (780 mg, 32% yield) as a gray solid. 1H NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.1 (s, 1H), 8.15 (s, 1H), 7.84-7.76 (m, 2H), 7.60-7.52 (m, 2H), 6.25 (d, J = 12.0 Hz, 1H), 4.45- 4.34 (m, 1H), 3.90-3.85 (m 2H), 3.28-3.21 (m, 3H), 2.23-2.15 (m, 1H), 2.03 (s, 3H), 1.84-1.71 (m, 1H). This material was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 30%-30%,5min) to obtain (trans)-3-((2-((8-fluoro-2-hydroxy-2H-benzo[e][1,2] oxaborinin-6-yl)amino)-5- methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (195.9 mg, 98.80% purity, 97.40% ee, first peak, Rt = 3.435 min) stereoisomer one as a white solid, 1H NMR (400 MHz, DMSO-d6) δ = 9.10 (s, 2H), 7.79 - 7.65 (m, 4H), 6.71 (d, J = 8.4 Hz, 1H), 6.17 (d, J = 11.6 Hz, 1H), 4.52 - 4.40 (m, 1H), 3.95-3.85 (m 2H), 3.29 - 3.09 (m, 3H), 2.23 - 2.15 (m, 1H), 1.95 (s, 3H), 1.90-1.80 (m 1H). MS (ESI): mass calcd. For C19H19BFN5O3395.16, m/z found 396.0 [M+H]+. HPLC: 98.80% (220 nm), 99.37% (254 nm)’ and (trans)-3-((2-((8-fluoro-2-hydroxy- 2H-benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (299.1 mg, 98.23% purity, 95.72% ee, second peak, Rt = 3.670 min) stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.10 (s, 2H), 7.80 - 7.65 (m, 4H), 6.72 (d, J = 8.4 Hz, 1H), 6.17 (d, J = 12.0 Hz, 1H), 4.54 - 4.39 (m, 1H), 3.5 - 3.85 (m, 2H), 3.30 - 3.10 (m, 3H), 2.23 - 2.15 (m, 1H), 1.95 (s, 3H), 1.90-1.80 (m, 1H). MS (ESI): mass calcd. For C19H19BFN5O3395.16, m/z found 396.1 [M+H]+. HPLC: 98.23% (220 nm), 99.34% (254 nm). [0548] 37. Preparation of (trans)-3-[[2-[[2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinin-6- yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0549] 37.1 Preparation of 2-
dehyde CF3 CF3 OH (HCHO)n MgCl 2 TEA OH O [0550] To a solution
o - uo o e y p e o g, . o , eq) in THF (300 mL) was added paraformaldehyde (20.7 g, 690 mmol, 19.0 mL, 8 eq), MgCl2 (12.3 g, 129 mmol, 1.5 eq)
and TEA (30.5 g, 302 mmol, 42.1 mL, 3.5 eq) at 25°C. The mixture was heated and stirred at 70°C for 12 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (100 mL) at 0°C and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 20/1 to 5/1) to give 2-hydroxy-3-(trifluoromethyl)benzaldehyde (10.7 g, 65.1% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 11.74 (s, 1 H), 9.97 (s, 1 H), 7.84 (d, J = 8.0 Hz, 1 H), 7.78 (d, J = 7.6 Hz, 1 H), 7.13 (t, J = 7.6 Hz, 1 H). [0551] 37.2 Preparation of 5-bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde To a solution of 2-hydro
56.3 mmol, 1 eq) in MeCN (150 mL) was added NBS (12.0 g, 67.5 mmol, 1.2 eq) at 0oC. The mixture was stirred at 0°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition H2O (200 mL) at 0°C and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with saturated aq. Na2SO3 (60 mL) and brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 10/1) to give 5-bromo-2-hydroxy- 3-(trifluoromethyl)benzaldehyde (10 g, 66.0% yield) as brown oil.1H NMR (CDCl3, 400 MHz) δ 11.63 (s, 1 H), 9.91 (s, 1 H), 7.93 (d, J = 2.4 Hz, 1 H), 7.89 (d, J = 2.4 Hz, 1 H). [0552] 37.3 Preparation of 4-bromo-2-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)vinyl]-6-(trifluoromethyl)phenol [0553] To a solu
, . , . q op-wise added N'- [2-(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 12.8 g, 74.3 mmol, 15.5 mL, 2 eq) and 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-
1,3,2-dioxaborolane (19.9 g, 74.3 mmol, 2 eq) at 0oC. After addition, the mixture was stirred at 0°C for 20 min, and then a solution of 5-bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde (10 g, 37.1 mmol, 1 eq) in THF (50 mL) was added drop-wise at 0°C. The resulting mixture was stirred at 0°C for 10 min. The reaction mixture was quenched by addition H2O (70 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 3/1) to give 4-bromo-2-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]-6- (trifluoromethyl)phenol (11.5 g, 78.7% yield) as yellow oil. [0554] 37.4 Preparation of 6-bromo-2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinine [0555] Two reac
omo-2-[(E)-2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]-6-(trifluoromethyl)phenol (5.65 g, 14.4 mmol, 1 eq) in MeCN (20 mL) was added tris[2-(2-pyridyl)phenyl]iridium (94 mg, 143 umol, 0.01 eq). The reaction was stirred and irradiated using 34 W blue LED lamps at 25°C for 16 h. TLC showed the reaction was complete. The two parallel reactions were combined and the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 1/1) to give 6-bromo-2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinine (4.4 g, 52.2% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.75 (s, 1 H), 7.71 (s, 1H), 7.68 (d, J = 12.0 Hz, 1 H), 6.40 (d, J = 12.0 Hz, 1 H). [0556] 37.5 Preparation of tert-butyl N-[2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinin-6- yl]carbamate
182
[0557] Two reactions were carried out in parallel. For each a mixture of 6-bromo-2-hydroxy-8- (trifluoromethyl)-1,2-benzoxaborinine (0.5 g, 1.71 mmol, 1 eq), tert-butyl carbamate (300 mg, 2.56 mmol, 1.5 eq), t-Bu XPhos (72 mg, 170 umol, 0.1 eq), K2CO3 (353 mg, 2.56 mmol, 1.5 eq) and Pd2(dba)3 (156 mg, 170 umol, 0.1 eq) in i-PrOH (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was heated and stirred at 70°C for 2 h under N2 atmosphere. TLC showed the reaction was complete. The two parallel reactions were combined for work up. The reaction mixture was filtered, quenched by addition H2O (20 mL) at 0°C, and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1) to give tert- butyl N-[2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinin-6-yl]carbamate (0.8 g) as a brown solid. [0558] 37.6 Preparation of 2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinin-6-amine (hydrogen chloride) [0559] To a solution
benzoxaborinin-6- yl]carbamate (0.8 g, 2.44 mmol, 1 eq) in EtOAc (20 mL) was added HCl/EtOAc (4 M, 6.1 mL, 10 eq). The mixture was stirred at 25°C for 1 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was triturated with MTBE (10 mL) and filtered to give 2-hydroxy-8-(trifluoromethyl)-1,2- benzoxaborinin-6-amine (hydrogen chloride) (0.6 g, 92.99% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.34 (s, 1 H), 7.83 (d, J = 12.0 Hz, 1 H), 7.50 (s, 2 H), 7.22 (s, 1 H), 6.92 (s, 1 H), 6.27 (d, J = 12.0 Hz, 1 H). [0560] 37.7 Preparation of (trans)-3-[[2-[[2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinin-6- yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile
[0561] Fo oxy-8-
(trifluoromethyl)-1,2-benzoxaborinin-6-amine (hydrogen chloride) (0.3 g, 1.13 mmol, 1 eq) in i- PrOH (5 mL) was added TFA (193 mg, 1.70 mmol, 1.5 eq) and (trans)-3-[(2-chloro-5-methyl- pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (285 mg, 1.13 mmol, 1 eq). The mixture was heated and stirred at 80°C for 12 h. LCMS showed the reaction was complete and desired MS observed. The four parallel reactions were combined for work up. The reaction mixture was added H2O (0.4 mL), the resulting mixture was concentrated under reduced pressure to give a crude product. The crude product was further purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/1 to 0/1) to give (trans)-3-[[2-[[2-hydroxy-8-(trifluoromethyl)- 1,2-benzoxaborinin-6-yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (558.6 mg, 1.25 mmol, 27.7% yield, 97.33% purity) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.37 (s, 1 H), 9.37 (s, 1 H), 8.20 (s, 1 H), 7.88 (d, J = 6.4 Hz, 2 H), 7.82-7.76 (m, 2 H), 6.24 (d, J = 11.6 Hz, 1 H), 4.35-4.25 (m, 1 H), 3.83-3.75 (m, 2 H), 3.20-3.12 (m, 3 H), 2.12 (d, J = 10.8 Hz, 1 H), 1.98 (s, 3 H), 1.74-1.62 (m, 1 H). MS (ESI): mass calcd. For C20H19BF3N5O3445.15, m/z found 444.1 [M-H]-. HPLC: 97.33% (220 nm), 98.72% (254 nm). [0562] 38. Preparation of (trans)-3-[[2-[(2-hydroxy-3-methyl-1,2-benzoxaborinin-6-yl)amino] - 5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0563
. ethyl- 1,2-benzoxaborinin-6-amine hydrochloride (180 mg, 851 umol, 1 eq, HCl salt) and (trans)-3-[(2- chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4- carbonitrile (215 mg, 851 umol, 1 eq) in dioxane (8 mL) was added TsOH·H2O (146 mg, 851 umol, 1 eq). The mixture was heated and
stirred at 80°C for 15 h. TLC showed the reaction was complete. The two parallel reactions were combined and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3um; mobile phase: [water (0.04%HCl)- ACN]; B%: 10%-40%,8min) to give 3-[[2-[(2-hydroxy-3- methyl-1,2-benzoxaborinin-6- yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (157.2 mg, 23% yield, 99.97% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.27 (s, 1H), 10.49 (s, 1H), 9.00 (s, 1H), 8.47 (d, J = 8 Hz, 1H), 7.79 (s, 1H), 7.66 (s, 1H), 7.48 (s, 1H), 7.34 (dd, J= 8.8, 2.4 Hz, 1H), 7.22 (d, J= 8.8 Hz, 1H), 4.39-4.37 (m, 1H), 3.89-3.85 (m, 2H), 3.42-3.39 (m, 1H), 3.28- 3.25 (m, 2H), 2.20-2.17 (m, 1H), 2.04 (s, 3H), 2.02 (s, 3H), 1.80-1.76 (m, 1H). MS (ESI): mass calcd. For C20H22BN5O3391.18, m/z found 392.2 [M+H]+. HPLC: 99.97% (220 nm), 99.98% (254 nm). [0564] 39. Preparation of (trans)-3-((2-((2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin-6- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0565] 39.1 Preparation of 1
ylpropan-1-one [0566] i-PrMgCl (
rred solution of 5- bromo-2-hydroxybenzonitrile (30 g, 151 mmol, 1 eq) in THF (300 mL) at 0°C under N2 in 30 mins. The resulting solution was allowed to warm to 20°C and stirred for 2 h. TLC showed the reaction was complete. The solution was then cooled to 0°C, and aq. HCl (2 M, 100 mL) was added. Then the mixture was stirred and heated at 50°C for 1 h. After cooling to room temperature, the reaction was added EtOAc (300 mL) and water (10 mL). The organic layer was washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash column chromatography to obtain
1-(5-bromo-2-hydroxyphenyl)-2-methylpropan-1-one (35 g, 95% yield) as light yellow gum. 1H NMR (400 MHz, CDCl3) δ 12.42 (s, 1H), 7.88 (s, 1H), 7.54 (dd, J = 2.4, 8.8 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 3.61 - 3.45 (m, 1H), 1.26 (d, J = 6.8 Hz, 6H). [0567] 39.2 Preparation of 6-bromo-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol [0568] To a sol was added N'-[2-
(dimethylamino)ethyl]-N,N,N'-trimethylethane-1,2-diamine (PMDTA, 20.0 g, 115 mmol, 24 mL, 2 eq) and a solution of 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)methyl]-1,3,2-dioxaborolane (30.9 g, 115 mmol, 2 eq) in THF (40 mL) at 0°C under N2. The mixture was stirred at 0°C for 20 min. Then drop-wise added a solution of 1-(5-bromo-2- hydroxyphenyl)-2-methylpropan-1-one (14 g, 57.5 mmol, 1 eq) in THF (2 mL) at 25°C, and then the mixture was stirred at 25°C for 40 min. TLC showed the reaction was complete. The reaction mixture was quenched with aq. NH4Cl (150 mL) and extracted with EtOAc (250 mL x3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a redisue, which was purified by silica gel chromatography (petroleum ether/ethyl acetate=100:5 to 1:1) to give 6-bromo-4- isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol (10 g, 65% yield) as light yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.82 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 6.03 (s, 1H), 3.31 - 3.11 (m, 1H), 1.21 - 1.16 (m, 6H). [0569] 39.3 Preparation of tert-butyl (2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin-6- yl)carbamate [0570] A
u e o e - u y ca a a e . g, . o , . eq , 3 . g, 61.7 mmol, 1.64 eq), Pd2(dba)3 (1.88 g, 2.06 mmol, 0.055 eq) and t-BuXphos (1.75 g, 4.11 mmol,
0.11 eq) and 6-bromo-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol (10 g, 37.5 mmol, 1 eq) in 2- propanol (50 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80°C for 2 h. TLC showed the reaction was complete. The reaction was quenched with H2O (100 ml) and extracted with EtOAc (250 ml x 2). The combined organic phases were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica column (petrolum ether: EtOAc=10:1 to 1:1) to give tert-butyl (2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin-6-yl)carbamate (7.5 g, 66% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.27 (s, 1H), 8.70 (s, 1H), 7.86 (s, 1H), 7.51 - 7.39 (m, 1H), 7.14 - 7.07 (m, 1H), 5.95 (s, 1H), 3.14 - 3.03 (m, 1H), 1.49 - 1.43(m, 9H), 1.22 - 1.17 (m, 6H). [0571] 39.4 Preparation of 6-amino-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol (hydrogen chloride) [0572] To a s orinin-6-
yl)carbamate (1.8 g, 5.94 mmol, 1 eq) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL, 6.74 eq) at 25°C for 1h. TLC showed the reaction was complete. The reaction was concentrated to give 6-amino-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol (hydrogen chloride) (1.4 g, 98% yield, HCl salt) as a yellow solid, which used in next step directly with-out further purification. [0573] 39.5 Preparation of (trans)-3-((2-((2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin- 6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0574
u e o -a o- - sop opy - - e o e , o a o - -o . g, . mmol, 1 eq, HCl), (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
(633 mg, 2.51 mmol, 1 eq) and TFA (428 mg, 3.76 mmol, 278 uL, 1.5 eq) in i-PrOH (10 mL) was heated to 80°C and stirred for 12 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was cooled to 25°C and quenched with H2O (50 mL) and then extracted with EtOAc (50 mL x 2). The combined organic phases were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica column to give (trans)-3-((2-((2-hydroxy-4-isopropyl-2H- benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile as a white solid (954 mg, 96.10 % purity).1H NMR: (400 MHz, DMSO-d6) δ =10.35 (s, 1H), 8.90 (s, 1H), 8.38 - 8.23 (m, 1H), 7.83 - 7.71 (m, 2H), 7.50 (dd, J = 2.0, 8.8 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 6.04 (s, 1H), 4.40 - 4.27 (m, 1H), 3.93 - 3.73 (m, 2H), 3.30 - 3.16 (m, 4H), 2.23 - 2.11 (m, 1H), 2.04 (s, 3H), 1.83 - 1.69 (m, 1H), 1.24 - 1.19 (m, 6H). MS (ESI): mass calcd. For C22H26BN5O3, 419.21, m/z found 420.3[M+H]+. HPLC: 96.10% (220 nm), 98.52% (254 nm). 900 mg of this material was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O MEOH]; B%: 35%-35%,7min) to give (trans)-3-((2-((2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin-6-yl)amino)-5- methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (172.3 mg, 97.49 % purity, 99.92% ee, first peak, Rt = 3.457 min) stereoisomer one as a white solid. 1H NMR (400 MHz, DMSO-d6) δ =8.87 (s, 1H), 8.61 (s, 1H), 8.07 (s, 1H), 7.81 - 7.71 (m, 2H), 7.10 (d, J = 9.2Hz, 1H), 6.58 (d, J = 9.2Hz, 1H), 5.94 (s, 1H), 4.45 - 4.48 (m, 1H), 3.84 - 3.87 (m, 2H), 3.29 - 3.08 (m, 4H), 2.32 – 2.15 (m, 1H), 1.91 (s, 3H), 1.87 - 1.73 (m, 1H), 1.26 - 1.21 (m, 6H). MS (ESI): mass calcd. For C22H26BN5O3, 419.21, m/z found 420.2[M+H]+. HPLC: 97.49% (220 nm), 98.76% (254 nm) and (trans)-3-((2-((2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin-6- yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (170.5 mg, 97.45 % purity, 98.50% ee, second peak, Rt = 3.902 min) stereoisomer two as a white solid.1H NMR (400 MHz, DMSO-d6) δ =8.83 (s, 1H), 8.62 (s, 1H), 8.08 (s, 1H), 7.76 - 7.74 (m, 2H), 7.13 (d, J = 8.8Hz, 1H), 6.59 (d, J = 8.8Hz, 1H), 5.94 (s, 1H), 4.48 - 4.42 (m, 1H), 3.88 - 3.84 (m, 2H), 3.29 - 3.12 (m, 4H), 2.23 - 2.14 (m, 1H), 1.98 - 1.92 (m, 3H), 1.88 - 1.76 (m, 1H), 1.26 - 1.21 (m, 6H). MS (ESI): mass calcd. For C22H26BN5O3, 419.21, m/z found 420.3[M+H]. HPLC: 97.45% (220 nm), 98.66% (254 nm).
[0575] 40. Preparation of (trans)-3-((2-((8-chloro-2-hydroxy-4-isopropyl-2H-benzo[e][1,2] oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile Cl O O OH N B [0576] 40.1 Preparation of 2-ch
[0577] Two reactions were carried out in parallel. For each a solution of 2-chlorophenol (12 g, 93.3 mmol, 9.5 mL, 1 eq) in DCM (120 mL) was added TEA (18.9 g, 186 mmol, 25.9 mL, 2 eq) and 2-methylpropanoyl chloride (10.9 g, 102 mmol, 10.7 mL, 1.1 eq). The mixture was stirred at 25 °C for 1 h. TLC showed the reaction was complete. The two parallel reactions were combined and diluted with H2O (100 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 10:1 to 5:1) to give 2-chlorophenyl isobutyrate (26.3 g, 70.9% yield) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ = 7.57 (dd, J = 1.6, 8.0 Hz, 1H), 7.43 - 7.36 (m, 1H), 7.30 (t, J = 8.0 Hz, 1H), 2.95-2.80 (m, 1H), 1.27 (d, J = 7.6 Hz, 6H). [0578] 40.2 Preparation of 1-(3-chloro-2-hydroxyphenyl)-2-methylpropan-1-one [0579] To a solution o
g, . , . , . q ,2-dichlorobenzene (131 g, 891 mmol, 100 mL, 17.7 eq) was added 2-chlorophenyl isobutyrate (10 g, 50.3 mmol, 1 eq) at 25°C. The mixture was stirred at 140°C for 3 h. TLC showed the reaction was complete. The
reaction mixture was diluted with ice-water (100 mL) at 0°C and extracted with EtOAc (50 mL ×3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 100:1 to 10:1) to give 1-(3-chloro-2-hydroxyphenyl)-2-methylpropan-1-one (3 g, 30% yield) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ = 12.79 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.01 (t, J = 8.0 Hz, 1H), 3.80 - 3.70 (m, 1H), 1.15 (d, J = 6.8 Hz, 6H). [0580] 40.3 Preparation of 1-(3-chloro-2-hydroxy-5-nitrophenyl)-2-methylpropan-1-one [0581] Two reactions w
of HNO3 (4.98 g, 51.3 mmol, 3.56 mL, 65% purity, 2.04 eq) and acetyl acetate (5.14 g, 50.3 mmol, 4.71 mL, 2 eq) was stirred at 25°C for 1 h, then drop-wised added 1-(3-chloro-2-hydroxy-phenyl)-2-methyl-propan- 1-one (5 g, 25.1 mmol, 1 eq) at 0oC. The mixture was stirred at 25°C for 1 h. TLC showed the reaction was complete. The two parallel reactions were combined, diluted with H2O (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 100:1 to 10:1) to give 1-(3-chloro-2-hydroxy-5-nitro-phenyl)-2-methyl-propan-1-one (8.4 g, 68% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.63 (d, J = 2.8 Hz, 1H), 8.55 (d, J = 2.8 Hz, 1H), 3.85-3.75 (m, 1H), 1.16 (d, J = 6.8 Hz, 6H). [0582] 40.4 Preparation of 1-(5-amino-3-chloro-2-hydroxyphenyl)-2-methylpropan-1-one
[0583] To a solution of 1-(3-chloro-2-hydroxy-5-nitro-phenyl)-2-methyl-propan-1-one (8.3 g, 34.0 mmol, 1 eq) in EtOH (90 mL) and H2O (30 mL) and EtOAc (90 mL) was added Fe (5.71 g, 102 mmol, 3 eq) and NH4Cl (5.47 g, 102 mmol, 3 eq) at 25°C in one portion. The mixture was stirred at 80°C for 2 hr. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was quenched with H2O (100 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 100:1 to 10:1) to give 1-(5-amino-3-chloro-2-hydroxyphenyl)-2-methylpropan-1- one (2.5 g, 34% yield) as brown oil. 1H NMR (400 MHz, DMSO-d6) δ = 7.14 (d, J = 2.8 Hz, 1H), 7.01 (d, J = 2.4 Hz, 1H), 5.04
( 2H), 3.60 - 3.50 (m, 1H), 1.15 - 1.12 (m, 6H). [0584] 40.5 Preparation of tert-butyl (3-chloro-4-hydroxy-5-isobutyrylphenyl)carbamate [0585] To a solution
lpropan-1-one (11.6 g, 54.2 mmol, 1 eq) in THF (110 mL) was added Boc2O (17.7 g, 81.4 mmol, 18.7 mL, 1.5 eq). The mixture was stirred at 60°C for 2.5 hr. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 5:1 to 3:1) to give tert-butyl N-[3-chloro-4- hydroxy-5-(2-methylpropanoyl)phenyl]carbamate (14 g, 82% yield) as brown oil.1H NMR (400 MHz, DMSO-d6) δ = 12.18 (s, 1H), 9.43 (s, 1H), 8.00 (s, 1H), 7.81 (s, 1H), 3.60-3.50 (m, 1H), 1.47 (s, 9H), 1.16 (d, J = 6.8 Hz, 6H). [0586] 40.6 Preparation of tert-butyl (8-chloro-2-hydroxy-4-isopropyl-2H-benzo[e][1,2] oxaborinin-6-yl)carbamate
[0587] ed N'-[2-
(dimethylamino)ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 20.7 g, 119 mmol, 24.9 mL, 7.5 eq) and 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]- 1,3,2-dioxaborolane (29.8 g, 111 mmol, 7 eq) at 0oC, and then the mixture was stirred at 0°C for 20 min under N2 atmosphere. Then to above mixture was drop-wise added a solution of tert- butyl N-[3-chloro-4-hydroxy-5-(2-methylpropanoyl)phenyl]carbamate (5 g, 15.9 mmol, 1 eq) in THF (50 mL) at 0°C. The mixture was stirred at 0°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with NH4Cl (200 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: EtOAc = 100:1 to 10:1) to give tert-butyl (8-chloro-2-hydroxy-4-isopropyl-2H-benzo[e][1,2]oxaborinin- 6-yl)carbamate (1.4 g, 26% yield)as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 9.45 (s, 1H), 9.03 (s, 1H), 7.81 (s, 1H), 7.73 (s, 1H), 6.03 (s, 1H), 3.20 - 3.00 (m, 1H), 1.48 (s, 9H), 1.15 (s, 6H). [0588] 40.7 Preparation of 6-amino-8-chloro-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol hydrochloride Cl Cl O OH O OH [0589] To a sol
[e][1,2]oxaborinin- 6-yl)carbamate (2 g, 5.92 mmol, 1 eq) in EtOAc (10 mL) was added HCl/EtOAc (4 M, 21 mL, 14.2 eq) at 20°C. The mixture was stirred at 20°C for 1 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give 6-amino-8-
chloro-4-isopropyl-2H-benzo[e][1,2]oxaborinin-2-ol hydrochloride (1.1 g, 67% yield, HCl salt) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.09 (m, 3H), 7.75 (d, J = 2.0 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 6.13 (s, 1H), 3.19 - 3.05 (m, 1H), 1.22 (d, J = 6.8 Hz, 6H). [0590] 40.8a Preparation of (trans)-3-((2-((8-chloro-2-hydroxy-4-isopropyl-2H-benzo[e][1,2] oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0591] ol
hydrochloride (300 mg, 1.10 mmol, 1 eq, HCl salt) in i-PrOH (3 mL) was added TFA (188 mg, 1.65 mmol, 0.12 mL, 1.5 eq) and (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile (250 mg, 990 umol, 0.9 eq). The mixture was stirred at 80°C for 4 hr. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (30 mL × 3). The residue was purified by prep-TLC (SiO2, Petroleum ether: EtOAc = 5:1) to give a crude product. The crude product was purified by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [water (formic acid-FA)-ACN]; B%: 20%-50%,8min) to give (trans)-3-((2-((8-chloro-2-hydroxy-4-isopropyl-2H- benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (388 mg, 77% yield, 96.16 % purity, 100% ee, first peak, Rt = 2.008 min) stereoisomer one as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.45 (s, 1H), 9.03 (s, 1H), 8.09 (s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.78 (s, 1H), 7.15 (d, J = 5.0 Hz, 1H), 6.04 (s, 1H), 4.53 - 4.40 (m, 1H), 3.92 - 3.79 (m, 2H), 3.27 - 3.12 (m, 4H), 2.18 (d, J = 10.0 Hz, 1H), 1.97 (s, 3H), 1.90-1.80 (m, 1H), 1.22 (d, J = 6.8 Hz, 6H). MS (ESI): mass calcd. For C22H25BClN5O3453.17, m/z found 452.0 [M-H]-. HPLC: 96.16% (220 nm), 98.11% (254 nm). [0592] 40.8b Preparation of (trans)-3-((2-((8-chloro-2-hydroxy-4-isopropyl-2H-benzo[e][1,2] oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0593
hydrochloride (300 mg, 1.10 mmol, 1 eq, HCl) in i-PrOH (3 mL) was added TFA (188 mg, 1.65 mmol, 122 uL, 1.5 eq) and (trans)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (249 mg, 985 umol, 0.9 eq). The mixture was stirred at 80°C for 4 hr. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (10 mL × 3). The residue was purified by prep-TLC (SiO2, petroleum ether: EtOAc = 5:1) to give a crude product. The crude product was purified by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [water (formic acid-FA)-ACN]; B%: 20%-50%,8min) to give (trans)-3-((2-((8-chloro-2-hydroxy-4-isopropyl-2H- benzo[e][1,2]oxaborinin-6-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (310 mg, 62% yield, 98.80 % purity, 97.52% ee, second peak, Rt = 2.397 min), stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.38 (s, 1H), 9.02 (s, 1H), 8.10 (s, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.78 (s, 1H), 7.08 (s, 1H), 6.04 (s, 1H), 4.52 - 4.41 (m, 1H), 3.92 - 3.79 (m, 2H), 3.28 - 3.10 (m, 4H), 2.22 - 2.13 (m, 1H), 1.97 (s, 3H), 1.83-1.80 (m, 1H), 1.23-1.21 (d, J = 6.8 Hz, 6H). MS (ESI): mass calcd. For C22H25BClN5O3453.17, m/z found 452.0 [M-H]-. HPLC: 98.80% (220 nm), 99.47% (254 nm). [0594] 41. Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-7-methyl-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0595] 41.1 Preparation of methyl 2-bromo-3-methyl-5-nitrobenzoate
[0596] To a solutio mol, 1 eq) in H2SO4
(98% purity,200 mL) was added HNO3 (19.2 g, 275 mmol, 90% purity, 3.15 eq) at 0°C. The mixture was stirred at 20°C for 1 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was poured into ice-water (200 mL) at 0oC, and large amount of solid formed and was collected by filtration to give a crude product. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate(EtOAc) = 100:1 to 10:1) and triturated with DCM (20 mL) at 25oC for 30 min to give methyl 2-bromo-3-methyl-5-nitro-benzoate (18 g, 75.2% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.35 (d, J = 2.8 Hz, 1H), 8.21 (d, J = 2.8 Hz, 1H), 4.00 (s, 3H), 2.60 (s, 3H). [0597] 41.2 Preparation of methyl 5-amino-2-bromo-3-methylbenzoate [0598] To a sol
3.6 mmol, 1 eq) in EtOH (150 mL) and H2O (30 mL) was added Fe (12 g, 214 mmol, 4 eq) and NH4Cl (12 g, 214 mmol, 4 eq) at 25°C. The mixture was stirred at 80°C for 1 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was diluted with H2O (300 mL) and extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (100 mL × 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-amino-2-bromo-3-methyl-benzoate (12.3 g, 93.9% yield) as yellow oil.1H NMR (400 MHz, DMSO-d6) δ = 6.66 (s, 2H), 5.43 (s, 2H), 3.79 (s, 3H), 2.23 (s, 3H). [0599] 41.3 Preparation of (5-amino-2-bromo-3-methylphenyl)methanol
[0600] To a solutio 20.5 mmol, 1 eq) in
THF (50 mL) was drop-wise added DIBAL-H (1 M in THF, 82 mL, 4 eq) at 0°C. After the addition, the reaction was allowed to warm to 25°C and stirred for 1 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was quenched with saturated aq. seignette salt (100 mL) and extracted with EtOAc (50 ×3 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give (5-amino-2-bromo-3-methyl- phenyl)methanol (1 g, 22.5% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ = 6.64 (d, J = 2.4 Hz, 1H), 6.41 (d, J = 2.4 Hz, 1H), 5.21 (t, J = 5.6 Hz, 1H), 5.17 - 5.07 (m, 2H), 4.36 (d, J = 5.6 Hz, 2H), 2.18 (s, 3H). [0601] 41.4 Preparation of (trans)-3-((2-((4-bromo-3-(hydroxymethyl)-5-methylphenyl)amino)-5- chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [060
ol, 1 eq) in i-PrOH (9 mL) was added TFA (713 mg, 6.26 mmol, 463 uL, 1.5 eq) and (trans)-3-[(2,5- dichloropyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (1 g, 3.75 mmol, 0.9 eq) at 25°C. The mixture was stirred at 80°C for 4 h. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was triturated with MTBE (10 mL) at 25oC for 20 min to give (trans)-3-((2-((4-bromo-3-(hydroxymethyl)-5-methylphenyl)amino)-5- chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (1.5 g, 79.4% yield) as an off- white solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.38 (s, 1H), 8.33 - 8.20 (m, 2H), 7.70 - 7.60
(m, 2H), 4.54 - 4.40 (m, 3H), 3.90 - 3.80 (m, 2H), 3.80 - 3.70 (m, 1H), 3.50 - 3.40 (m, 1H), 3.30 - 3.20 (m, 2H), 2.37 (s, 3H), 2.22 - 2.11 (m, 1H), 1.90 - 1.80 (m, 1H). [0603] 41.5 Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-7-methyl-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0 omo-
3-(hydroxymethyl)-5-methylphenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran- 4-carbonitrile (500 mg, 1.10 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5- dimethyl-1,3,2-dioxaborinane (994 mg, 4.40 mmol, 4 eq), KOAc (324 mg, 3.30 mmol, 3 eq), Pd(PPh3)2Cl2 (77.2 mg, 110 umol, 0.1 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120 °C for 1 hr under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The two parallel reactions were combined and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 35%-35%,13min) to give (trans)-3-((5-chloro-2-((1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (300 mg, 34.0% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.48 (s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.61 (s, 1H), 7.41 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 4.95 - 4.85 (m, 2H), 4.50 - 4.40 (m, 1H), 3.94 - 3.83 (m, 2H), 3.40 - 3.30 (m, 1H), 3.31 - 3.24 (m, 2H), 3.18 (t, J = 10.8 Hz, 1H), 2.39 (s, 3H), 2.20 - 2.10 (m, 1H), 1.85 - 1.74 (m, 1H). This material was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 35%- 35%,13min) to give (trans)-3-[[5-chloro-2-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (63.4 mg, 98.73% purity, 100% ee, first peak, Rt = 1.453 min), stereoisomer one as a white soild. 1H NMR (400 MHz, DMSO- d6) δ = 9.47 (s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.61 (s, 1H), 7.41 (s, 1H), 7.31 (d, J = 8.4 Hz, 1H), 4.89 (s, 2H), 4.50 - 4.40 (m, 1H), 3.94 - 3.83 (m, 2H), 3.40 - 3.30 (m, 1H), 3.31 - 3.24 (m,
1H), 3.20 - 3.10 (m, 1H), 2.39 (s, 3H), 2.20 - 2.10 (m, 1H), 1.90 - 1.77 (m, 1H). MS (ESI): mass calcd. For C18H19BClN5O3399.13, m/z found 400.2 [M+H]+. HPLC: 98.73% (220 nm), 99.46% (254 nm).and (trans)-3-[[5-chloro-2-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (94.7 mg, 96.68% purity, 99.64% ee, second peak, Rt = 1.864 min), stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.48 (s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.61 (s, 1H) 7.41 (s, 1H), 7.32 (d, J = 8.8
Hz, 1H), 4.95 - 4.85 (m, 2H), 4.50 - 4.37 (m, 1H), 3.97 - 3.82 (m, 2H), 3.40 - 3.30 (m, 1H), 3.30 - 3.23 (m, 1H), 3.18 (t, J = 10.8 Hz, 1H), 2.40 (s, 3H), 2.20 - 2.10 (m, 1H), 1.90 - 1.77 (m, 1H). MS (ESI): mass calcd. For C18H19BClN5O3399.13, m/z found 400.1 [M+H]+. HPLC: 96.68% (220 nm), 95.86% (254 nm). [0605] 42. Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile [0606] 42.1 Preparation of (5-am
hyl)phenyl)methanol [0607] To a solutio
oate (5 g, 16.8 mmol, 1 eq) in THF (100 mL) was added DIBAL-H (1 M in THF, 42 mL, 2.5 eq) dropwise at -60°C. The mixture was stirred at -60°C for 30 min. Then the mixture was stirred at 0°C for 1 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of aq. seignette salt (100 mL) at 0°C, and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/petroleum ether gradient @ 75 mL/min) to give (5-amino-2-bromo-3-(trifluoromethyl)
phenyl) methanol (3.2 g, 70.6% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ = 7.01 (d, J = 2.4 Hz, 1H), 6.94 (d, J = 2.8 Hz, 1H), 4.74 (s, 2H). [0608] 42.2 Preparation of (trans)-3-((2,5-dichloropyrimidin-4-yl)amino)tetrahydro-2H-pyran- 4-carbonitrile [0609] To a soluti
g, 20.9 mmol, 1 eq, HCl) in dioxane (40 mL) was added 2,4,5-trichloropyrimidine (3.07 g, 16.7 mmol, 0.8 eq), DIPEA (5.4 g, 41.8 mmol, 7.3 mL, 2 eq) at 25°C. The mixture was stirred at 100°C for 12 hr. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was poured into saturated aq. NH4Cl (40 mL), extracted with EtOAc (40 mL x 3) and the combined organic layers were washed with brine (40 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0~25% ethyl acetate/petroleum ethergradient @ 50 mL/min) to give (trans)3-[(2,5-dichloropyrimidin-4- yl)amino] tetrahydropyran-4-carbonitrile (1.7 g, 29.8% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ = 8.13 (s, 1H), 5.97 (d, J = 6.8 Hz, 1H), 4.40 (d, J = 3.2 Hz, 1H), 4.11 (dd, J = 2.4, 12.4 Hz, 1H), 3.89 (dd, J = 3.2, 7.6 Hz, 2H), 3.81 (dd, J = 2.4, 12.4 Hz, 1H), 3.28 - 3.25 (m, 1H), 2.19 - 2.11 (m, 1H), 1.90 - 1.85 (m, 1H). [0610] 42.3 Preparation of 3-((2-((4-bromo-3-(hydroxymethyl)-5-(trifluoromethyl)phenyl) amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0611] To a mixture of (5-amino-2-bromo-3-(trifluoromethyl) phenyl) methanol (1.6 g, 5.9 mmol, 1 eq) and (trans)-3-[(2,5-dichloropyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (1.62 g, 5.9 mmol, 1 eq) in i-PrOH (20 mL) was added TFA (1.35 g, 11.9 mmol, 877 uL, 2 eq) in one portion at 25°C. The mixture was stirred at 25°C for 10 min, then heated to 80°C and stirred for 12 hours. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filter cake was washed with saturated aq. NaHCO3 (10 mL) to give a residue. The residue was triturated with MTBE (10 mL) at 25oC for 30 min to give (trans)-3-((2- ((4-bromo-3-(hydroxymethyl)-5-(trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (2.23 g, 74.2% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ = 8.26 (s, 1H), 8.02 (s, 1H), 7.67 (s, 1H), 7.25 (s, 1H), 5.72 (d, J = 8.0 Hz, 1H), 4.84 (s, 2H), 4.49 - 4.46 (m, 1H), 4.20 - 4.16 (m, 1H), 3.96 - 3.90 (m, 1H), 3.84 - 3.79 (m, 1H), 3.67 (dd, J = 4.8, 12.4 Hz, 1H), 3.17 - 3.13 (m, 1H), 2.23 - 2.15 (m, 1H), 1.96 - 1.87 (m, 1H), 1.59 - 1.52 (m, 1H). [0612] 42.4 Preparation of 3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- (trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile CF3 CF3 O Cl Br TBSOTf N O Cl Br TBS [0
(trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (2 g, 3.95 mmol, 1 eq) and 2,6-dimethylpyridine (1.06 g, 9.90 mmol, 1.2 mL, 2.5 eq) in THF (40 mL) was added TBSOTf (1.57 g, 5.9 mmol, 1.4 mL, 1.5 eq) at 0°C. The mixture was stirred at 30°C for 3 hr. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was quenched by addition saturated aq. NH4Cl (50 mL) at 0°C, and then extracted with EtOAc (30 mL x 3) and the combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=10/1 to 0/1) to give (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-
(trifluoromethyl)phenyl) amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (971 mg, 39.6% yield) as a white solid.1H NMR (CDCl3, 400 MHz) δ = 9.95 (s, 1H), 8.37 (d, J = 2.4 Hz, 1H), 8.06 (s, 2H), 7.38 (d, J = 8.8 Hz, 1H), 4.73 (s, 2H), 4.47 - 4.44 (m, 1H), 3.90 - 3.81 (m, 2H), 3.36 - 3.16 (m, 3H), 2.19 - 2.16 (m, 1H), 1.82 - 1.78 (m, 1H), 0.95 (s, 9H), 0.14 (s, 6H). [0614] 42.5 Preparation of 3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5-(trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile
[0615] Seven reactions were carried out in parallel. For each a mixture of (trans)-3-((2-((4- bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-(trifluoromethyl)phenyl)amino)-5- chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (500 mg, 805 umol, 1 eq), 2- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (909 mg, 4.03 mmol, 5 eq), KOAc (237 mg, 2.42 mmol, 3 eq), Pd(PPh3)2Cl2 (57 mg, 80.5 umol, 0.1 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 1 hr under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The seven parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150x40mmx10um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 65% - 95%, 8 min) to give (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)-5-(trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (1.2 g, 32.55% yield) as a purple solid. [0616] 42.6 Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile
[0617] dimethyl-
1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)phenyl)amino)-5-chloropyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (1.2 g, 1.8 mmol, 1 eq) in THF (12 mL) was added aq. HCl (4 M, 1.8 mL, 4 eq). The mixture was stirred at 25°C for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was triturated with MeCN (10 mL) at 25°C for 30 min to give the residue. The residue was purified by prep-HPLC (column: Phenomenex Luna 80 x 30mm x 3um; mobile phase: [water (HCl)-ACN]; B%: 10%-40%, 8min) to give (trans)-3-((5-chloro-2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (755 mg, 90.7% yield, 97.88% purity) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ = 9.91 (s, 1H), 8.96 (s, 1H), 8.13 (s, 1H), 8.06 (s, 2H), 7.42 (d, J = 8.8 Hz, 1H), 5.06 - 4.97 (m, 2H), 4.49 - 4.38 (m, 1H), 3.91 - 3.84 (m, 2H), 3.30 - 3.24 (m, 2H), 3.18 (t, J = 10.8 Hz, 1H), 2.18 (d, J = 9.6 Hz, 1H), 1.90 - 1.80 (m, 1H). MS (ESI): mass calcd. For C18H16BClF3N5O3 453.10, m/z found 452.0 [M-H]-. HPLC: 97.88% (220 nm), 97.77% (254 nm). This material was separated by SFC (column: ChiralPak IH, 250x30mm, 10um; mobile phase: [0.1%NH3H2O ETOH]; B%: 25%-25%,6min) to give (trans)-3-((5-chloro-2-((1-hydroxy-7-(trifluoromethyl)- 1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (184.1 mg, 99.14% purity, 100% ee, first peak, Rt = 1.077 min) stereoisomer one as a white solid.1H NMR (DMSO-d6, 400 MHz) δ = 9.91 (s, 1H), 8.95 (s, 1H), 8.13 (s, 1H), 8.10 - 8.00 (m, 2H), 7.45 - 7.40 (m, 1H), 5.12 - 4.90 (m, 2H), 4.52 - 4.35 (m, 1H), 3.99 - 3.76 (m, 2H), 3.31 - 3.23 (m, 2H), 3.20 - 3.10 (m, 1H), 2.18 (d, J = 11.6 Hz, 1H), 1.90 -1.80 (m, 1H). MS (ESI): mass calcd. For C18H16BClF3N5O3453.10, m/z found 452.0 [M-H]-. HPLC: 99.14% (220 nm), 99.06% (254 nm) and (trans)-3-((5-chloro-2-((1-hydroxy-7-(trifluoromethyl)-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (201.5 mg, 99.76% purity, 99.16% ee, second peak, Rt = 1.146 min) stereoisomer two as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ = 9.91 (s, 1H), 8.95 (s, 1H), 8.13 (s, 1H),
8.06 (s, 2H), 7.41 (d, J = 8.8 Hz, 1H), 5.12 - 4.90 (m, 2H), 4.52 - 4.35 (m, 1H), 3.99 - 3.76 (m, 2H), 3.31 - 3.23 (m, 2H), 3.19 (t, J = 10.8 Hz, 1H), 2.18 (d, J = 11.6 Hz, 1H), 1.90 - 1.80 (m, 1H). MS (ESI): mass calcd. For C18H16BClF3N5O3453.10, m/z found 451.9 [M-H]-. HPLC: 99.76% (220 nm), 99.82% (254 nm). [0618] 43. Preparation of (trans)-4-((2-((1-hydroxy-7-(trifluoromethyl)-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile
[004] 43.1 Preparation of 6-tosyl-3-oxa-6-azabicyclo[3.1.0]hexane [0619] Three reactio
f 2,5-dihydrofuran (10 g, 142 mmol, 10.8 mL, 1 eq) and phenyltrimethylammonium tribromide (8.0 g, 21.4 mmol, 0.15 eq) in MeCN (100 mL) was added Chloramine-T (48.7 g, 214 mmol, 1.5 eq) at 25°C, then the reaction mixture was stirred at 25°C for 12 h. TLC showed the reaction was complete. The three parallel reactions were combined and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (Phenomenex Titank C18 Bulk 250*150mm 10u) ;mobile phase: [water (NH4HCO3)-MeCN]; B%: 30%-60%,20min) to give 6-(p-tolylsulfonyl)-3-oxa-6-azabicyclo[3.1.0]hexane (27 g, 26.3% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 3.99 (d, J = 10.0 Hz, 2H), 3.73 - 3.64 (m, 4H), 2.45 (s, 3H). [0620] 43.2 Preparation of N-((trans)-4-cyanotetrahydrofuran-3-yl)-4- methylbenzenesulfonamide
[0621] To a sol
26 g, 108 mmol, 1 eq) in THF (150 mL) was drop-wise added TMSCN (32.3 g, 326 mmol, 3 eq) and TBAF (1 M in THF, 43.4 mL, 0.4 eq) at 25°C under N2. And then the resulting mixture was stirred at 70°C for 3 hrs. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (500 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether: EtOAc=100:1 to 1:1) to give N-((trans)-4-cyanotetrahydrofuran-3-yl)-4-methyl- benzenesulfonamide (17 g, 58.7% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ = 7.80 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 5.89 - 5.66 (m, 1H), 4.10 - 4.00 (m, 1H), 3.95 - 3.85 (m, 2H), 3.70 - 3.60 (m, 1H), 3.19 - 3.04 (m, 1H), 2.46 (s, 3H). [0622] 43.3 Preparation of tert-butyl ((trans)-4-cyanotetrahydrofuran-3-yl)(tosyl)carbamate [0623] A mixture of
enzenesulfonamide (17 g, 63.8 mmol, 1 eq), Boc2O (20.9 g, 95.7 mmol, 1.5 eq), DMAP (2.34 g, 19.1 mmol, 0.3 eq) in MeCN (100 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 40°C for 2 hrs under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (100×3 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum:EtOAc = 100:1 to 1:1) to give tert-butyl ((trans)-4- cyanotetrahydrofuran-3-yl)(tosyl)carbamate (22.5 g, 96.1% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.82 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 5.47 - 5.29 (m, 1H), 4.19 - 4.15 (m, 1H), 4.09 - 3.91 (m, 2H), 3.87 - 3.75 (m, 1H), 3.66 (m, 1H), 2.42 (s, 3H), 1.30 (s, 9H).
[0624] 43.4 Preparation of tert-butyl ((trans)-4-cyanotetrahydrofuran-3-yl)carbamate [0625] To a solution of ter syl)carbamate (22.5 g,
61.4 mmol, 1 eq) in MeOH (2000 mL) was added magnesium powder(12 g, 491 mmol, 8 eq) in portions carefully at 25°C. Accompanied by generation of heat (exothermic) and bubbling, the resulting suspension was stirred at 25°C for 1 h. TLC showed the reaction was complete. The reaction was diluted with DCM (400 mL) and poured into cold water (200 mL), then adjust pH=5 with aq. HCl (2N). The organic phase was washed twice with saturated aq. NaHCO3 (100 mL x 2) and brine (100 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give tert-butyl ((trans)-4-cyanotetrahydrofuran-3-yl)carbamate (12 g, crude) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 7.61 - 7.38 (m, 1H), 4.31 - 4.17 (m, 1H), 4.02 - 3.91 (m, 2H), 3.91 - 3.83 (m, 1H), 3.55 - 3.45 (m, 1H), 3.18 (m, 1H), 1.40 (s, 9H). [0626] 43.5 Preparation of (trans)-4-aminotetrahydrofuran-3-carbonitrile [0627] A solution of t
rbamate (12 g, 56.5 mmol, 1 eq) in EtOAc (20 mL) was added HCl/EtOAc (4 M, 120 mL, 8.49 eq) at 25°C, and stirred at 25°C for 1 hr. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give (trans)-4-aminotetrahydrofuran-3-carbonitrile hydrochloride (8 g, 95.2% yield) as a white solid. [0628] 43.6 Preparation of (trans)-4-((2-chloro-5-methylpyrimidin-4-yl)amino) tetrahydrofuran- 3-carbonitrile
[0629] A mixt q), 4-
aminotetrahydrofuran-3-carbonitrile hydrochloride (4 g, 26.9 mmol, 1 eq), DIEA (20.8 g, 161 mmol, 6 eq) in DMA (80 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 140°C for 12 hrs under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with H2O (250 mL) and extracted with EtOAc (50×3 mL). The combined organic layers were washed with brine (100 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude product. The crude product was trituration with MTBE (20 mL) to give (trans)-4-((2-chloro-5- methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile (8 g, crude) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 7.91 (s, 1H), 7.49 (d, J = 6.0 Hz, 1H), 4.86 - 4.77 (m, 1H), 4.16 - 4.05 (m, 2H), 3.94 (m, 1H), 3.75 (m, 1H), 3.44 - 3.37 (m, 1H), 3.17 (d, J = 5.2 Hz, 1H), 2.01 (s, 3H). [0630] 43.7 Preparation of (trans)-4-((2-((4-bromo-3-(hydroxymethyl)-5-(trifluoromethyl) phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile [0631] A
furan-3- carbonitrile (2.2 g, 9.2 mmol, 1 eq), [5-amino-2-bromo-3-(trifluoromethyl)phenyl]methanol (2.5 g, 9.2 mmol, 1 eq), TFA (1.6 g, 13.8 mmol, 1.5 eq) in i-PrOH (50 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 °C for 12 hrs under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was trituration with MTBE (20 mL) to give (trans)-4-[[2-[4-bromo-3-(hydroxymethyl)-5-(trifluoromethyl)anilino]-5-methyl-pyrimidin-4- yl]amino]tetrahydrofuran-3-carbonitrile (4.4 g) as a yellow solid. 1H NMR (400 MHz, DMSO-
d6) δ = 10.90 (s, 1H), 8.57 (s, 1H), 8.09 (d, J = 2.0 Hz, 2H), 7.90 (s, 1H), 5.05 - 5.00 (m, 1H), 4.59 (s, 2H), 4.17 (t, J = 8.0 Hz, 1H), 4.15 - 4.05 (m, 1H), 3.90 - 3.85 (m, 1H), 3.81 - 3.62 (m, 2H), 2.06 (s, 3H). [0632] 43.8 Preparation of (trans)-4-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- (trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile [0 -5-
methyl-pyrimidin-4-yl]amino]tetrahydrofuran-3-carbonitrile (4.4 g, 9.3 mmol, 1 eq) in THF (50 mL) was added 2,4-dimethylpyridine (4 g, 37.2 mmol, 4 eq) and TBSOTf (4.9 g, 18.6 mmol, 4.3 mL, 2 eq) at 0°C degassed and purged with N2 for 3 times, and then the mixture was stirred at 20°C for 2 hrs under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was diluted with saturated aq. NH4Cl (50 mL) and extracted with EtOAc (50 x 3 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 100:1 to 1:1) to give (trans)-4-((2- ((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-(trifluoromethyl)phenyl)amino)-5- methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile (5.5 g, crude) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ = 9.54 (s, 1H), 8.39 (d, J = 2.4 Hz, 1H), 8.15 (s, 1H), 7.79 (s, 1H), 7.03 (d, J = 7.2 Hz, 1H), 5.05 - 4.95 (m, 1H), 4.73 (s, 2H), 4.20 - 4.10 (m 2H), 4.00 - 3.90 (m, 1H), 3.65 - 3.55 (m, 1H), 3.55 - 3.50 (m, 1H), 1.97 (s, 3H), 0.95 (s, 9H), 0.14 (s, 6H). [0634] 43.9 Preparation of (trans)-4-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4- yl)amino)tetrahydrofuran-3-carbonitrile
[0635] A yl)-5-
(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile (5 g, 8.52 mmol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (13.5 g, 59.6 mmol, 7 eq), KOAc (2.5 g, 25.5 mmol, 3 eq), Pd(PPh3)2Cl2 (598 mg, 852 umol, 0.1 eq) in dioxane (50 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 2 hrs under N2 atmosphere. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 60%-90%,8min). to give (trans)-4-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)-5-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3- carbonitrile (3 g, 56.8% yield) as a white solid. [0636] 43.10 Preparation of (trans)-4-((2-((1-hydroxy-7-(trifluoromethyl)-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydrofuran-3-carbonitrile [06
methyl- 1,3,2-dioxaborinan-2-yl)-5-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino) tetrahydrofuran-3-carbonitrile (2 g, 3.23 mmol, 1 eq) in THF (20 mL) was added aq. HCl (6 M, 2.15 mL, 4 eq) at 20°C, and then stirred at 40°C for 1 h. Large amount of solid formed. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and the filter cake was triturated with THF (10 mL), dried in vacuum to give (trans)-4-((2-((1- hydroxy-7-(trifluoromethyl)-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-
4-yl)amino)tetrahydrofuran-3-carbonitrile (1.4 g, 90% purity) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 9.54 (s, 1H), 8.89 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.84 (s, 1H), 7.04 (d, J = 7.6 Hz, 1H), 5.13 - 4.94 (m, 3H), 4.17 - 4.05 (m, 2H), 4.00 - 3.95 (m, 1H), 3.70 - 3.60 (m, 1H), 3.60 - 3.50 (m, 1H), 1.99 (s, 3H). This material (1 g) was separated by SFC (column: DAICEL CHIRALPAK AD(250mm*50mm,10um);mobile phase: [0.1%NH3H2O IPA]; B%: 30%- 30%,3.3min) to give (trans)-4-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol-5- yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydrofuran-3-carbonitrile (261.7 mg, 98.52% purity, 95.64% ee , first peak, RT=3.101 min) stereoisomer one as a white solid.1H NMR (400 MHz, DMSO-d6) δ 9.54 (s, 1H), 8.89 (s, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.84 (s, 1H), 7.03 (d, J = 7.2 Hz, 1H), 5.11 - 4.96 (m, 3H), 4.17 - 4.05 (m, 2H), 4.00 - 3.95 (m, 1H), 3.70 - 3.60 (m, 1H), 3.57 - 3.46 (m, 1H), 1.98 (s, 3H) MS (ESI): mass calcd. For C18H17BF3N5O3, 419.14, m/z found 418.0 [M-H]-.and (trans)-4-[[2-[[1-hydroxy-7-(trifluoromethyl)-3H-2,1-benzoxaborol-5- yl]amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydrofuran-3-carbonitrile (262.7 mg, 99.1% purity, 99.64% ee, second peak in SFC, RT=3.300 min) stereoisomer two as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 8.90 (s, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 7.83 (s, 1H), 7.04 (d, J = 7.6 Hz, 1H), 5.18 - 4.92 (m, 3H), 4.17 - 4.05 (m, 2H), 4.00 - 3.95 (m, 1H), 3.70 - 3.60 (m, 1H), 3.57 - 3.45 (m, 1H), 1.97 (s, 3H). MS (ESI): mass calcd. For C18H17BF3N5O3, 419.14, m/z found 420.1 [M+H]+. [0638] 44. Preparation of (trans)-3-((2-((1-hydroxy-7-methoxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0639] 44.1 Preparation of m
y y y y -benzoate
[0640] Two reactions were carried out in parallel. For each a solution of methyl 2-hydroxy-3- methoxy-benzoate (5 g, 27.4 mmol, 1 eq) in AcOH (30 mL) was added HNO3 (4.04 g, 41.6 mmol, 2.9 mL, 65% purity, 1.52 eq) at 10°C over 20 min. The mixture was stirred at 15°C for 40 min. TLC showed the reaction was complete. The two parallel reactions were combined and poured into ice water (90 mL) and then the yellow precipitate formed was collected, washed with H2O (50 mL x 3), Petroleum ether (50 mL x 2) to give methyl 2-hydroxy-3-methoxy-5-nitro- benzoate (11.8 g, 94.6% yield) as an off-white solid.1H NMR (DMSO-d6, 400 MHz) δ 11.30 - 11.20 (m, 1H), 8.19 (s, 1 H), 7.90 (s, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H). [0641] 44.2 Preparation of methyl 5-amino-2-hydroxy-3-methoxy-benzoate [0642] To a soluti g, 15.8 mmol, 1 eq)
in EtOH (50 mL) was added Pd/C (1.90 g, 10% purity) at 25°C. The mixture was stirred at 50°C for 12 h under H2 (15 Psi). TLC showed the reaction was complete. The reaction mixture was filtered and concentrated under reduced pressure to give methyl 5-amino-2-hydroxy-3-methoxy- benzoate (2.45 g, 78.4% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.75 (s, 1 H), 6.56 (s, 2 H), 4.79 (s, 2 H), 3.85 (s, 3 H), 3.72 (
3 H). [0643] 44.3 Preparation of methyl 5-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5- methyl-pyrimidin-2-yl]amino]-2-hydroxy-3-methoxy-benzoate [0644] To a
y y y y . g, 12.7 mmol, 1 eq) in i-PrOH (30 mL) was added (trans)-3-[(2-chloro-5-methyl-pyrimidin-4- yl)amino]tetrahydropyran-4-carbonitrile (3.22 g, 12.7 mmol, 1 eq) and TFA (2.18 g, 19.1 mmol,
1.41 mL, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 12 h. Solids precipitated out after 2 h reaction. TLC showed the reaction was complete. The reaction mixture was filtered and then the filter cake was triturated with saturated aq. NaHCO3 (50 mL) to give methyl 5-[[4- [((trans)-4-cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-2-hydroxy-3- methoxy-benzoate (4.9 g, 93.1% yield) as a gray solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.16 (s, 1 H), 8.78 (s, 1 H), 7.78-7.70 (m, 2 H), 7.53 (s, 1 H), 6.59 (d, J = 8.8 Hz, 1 H), 4.50-4.39 (m, 1 H), 3.93-3.82 (m, 5 H), 3.78 (s, 3 H), 3.31-3.18 (m, 2 H), 3.13 (t, J = 10.8 Hz, 1 H), 2.20-2.11 (m, 1 H), 1.93 (s, 3 H), 1.86-1.72 (m, 1 H). [0645] 44.4 Preparation of methyl 5-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5- methyl-pyrimidin-2-yl]amino]-3-methoxy-2-(trifluoromethylsulfonyloxy)benzoate [0646 l-
pyrimidin-2-yl]amino]-2-hydroxy-3-methoxy-benzoate (2.9 g, 7.01 mmol, 1 eq), 1,1,1-trifluoro- N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (PhNTf2, 3.76 g, 10.5 mmol, 1.5 eq), DMAP (85.7 mg, 701 umol, 0.1 eq) and TEA (3.55 g, 35.0 mmol, 4.88 mL, 5 eq) in DMF (30 mL) was stirred at 25°C for 4 h under N2 atmosphere. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (30 mL) at 0°C and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 5-[[4-[((trans)4- cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-3-methoxy-2- (trifluoromethylsulfonyloxy)benzoate (3.3 g, 86.2% yield) as a yellow solid. 1H NMR (DMSO- d6, 400 MHz) δ 9.51 (s, 1 H), 8.01 (d, J = 2.4 Hz, 1 H), 7.92 (d, J = 2.4 Hz, 1 H), 7.83 (s, 1 H), 6.79 (d, J = 8.8 Hz, 1 H), 4.54-4.42 (m, 1 H), 3.95-3.81 (m, 8 H), 3.29-3.18 (m, 2 H), 3.12 (t, J = 10.8 Hz, 1 H), 2.20-2.11 (m, 1 H), 1.97 (s, 3 H), 1.92-1.78 (m, 1 H). [0647] 44.5 Preparation of methyl 5-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5- methyl-pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methoxy-benzoate
[06 rans)-
4-cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-3-methoxy-2- (trifluoromethylsulfonyloxy)benzoate (0.5 g, 916 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (1.45 g, 6.42 mmol, 7 eq), Pd(PPh3)2Cl2 (96.5 mg, 137 umol, 0.15 eq) and KOAc (197 mg, 2.02 mmol, 2.2 eq) in dioxane (15 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100°C for 9 h under N2 atmosphere. TLC showed the reaction was complete. The eight parallel reactions were combined, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/1 to 0/1) to give methyl 5-[[4-[((trans)-4-cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-2- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-methoxy-benzoate (2.5 g, 53.5% yield, 80% purity) as a brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.19 (s, 1 H), 7.90 (s, 1 H), 7.79 (s, 1 H), 7.62 (s, 1 H), 6.69 (d, J = 8.8 Hz, 1 H), 4.55-4.43 (m, 1 H), 3.92-3.82 (m, 5 H), 3.74 (s, 3 H), 3.64 (s, 4 H), 3.29-3.18 (m, 2 H), 3.14-3.08 (m, 1 H), 2.20-2.11 (m, 1 H), 1.95 (s, 3 H), 1.88-1.75 (m, 1 H), 1.05 (s, 6 H). [0649] 44.6 Preparation of (trans)-3-[[2-[(1-hydroxy-7-methoxy-3H-2,1-benzoxaborol-5- yl)amino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile OH O
. trans)- 4-cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-3-methoxy-benzoate (0.5 g, 785 umol, 80% purity, 1 eq) in THF (20 mL) was added NaBH4 (89.1 mg, 2.36 mmol, 3 eq) at 0°C. After the addition, the reaction was
allowed to warm to 25°C and stirred at 25°C for 1 h. TLC showed the reaction was complete. The four parallel reactions were combined and quenched by addition of H2O (20 mL) at 0°C and adjust pH = 6 with aq. HCl (2N), then the precipitate formed was collected to give (trans)-3-[[2- [(1-hydroxy-7-methoxy-3H-2,1-benzoxaborol-5-yl)amino]-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (300 mg, 24.1% yield, 98.0% purity) as an off-white solid.1H NMR (DMSO-d6, 400 MHz) δ 10.52 (s, 1 H), 8.75 (s, 1 H), 8.33 (s, 1 H), 7.86 (s, 1 H), 7.18 (s, 1 H), 7.05 (s, 1 H), 4.97-4.86 (m, 2 H), 4.50-4.38 (m, 1 H), 3.95-3.85 (m, 2 H), 3.83 (s, 3 H), 3.42- 3.17 (m, 3 H), 2.22-2.14 (m, 1 H), 2.05 (s, 3 H), 1.88-1.75 (m, 1 H). MS (ESI): mass calcd. For C19H22BN5O4395.18, m/z found 396.2 [M+H]+. HPLC: 98.08% (220 nm), 99.12% (254 nm). This material was separated by SFC (column: DAICEL CHIRALPAK AD (250 mm x 30 mm, 10 um); mobile phase: [0.1% NH3H2O ETOH]; B%: 42%-42%, 9 min) to give (trans)-3-((2-((1- hydroxy-7-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-methylpyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (71.3 mg, 98.90% purity, 99.26% ee, first peak, RT = 4.034 min) stereoisomer one as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.17 (s, 1 H), 8.48 (s, 1 H), 7.79 (s, 1 H), 7.46 (s, 1 H), 7.24 (s, 1 H), 6.71 (d, J = 8.8 Hz, 1 H), 4.90-4.80 (m, 2 H), 4.53-4.41 (m, 1 H), 3.93-3.85 (m, 2 H), 3.78 (s, 3 H), 3.30-3.19 (m, 2 H), 3.12 (t, J = 10.4 Hz, 1 H), 2.21-2.14 (m, 1 H), 1.96 (s, 3 H), 1.89-1.76 (m, 1 H). MS (ESI): mass calcd. For C19H22BN5O4395.18, m/z found 396.2 [M+H]+. HPLC: 98.90% (220 nm), 99.28% (254 nm) and (trans)-3-((2-((1-hydroxy-7-methoxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5- methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (53.4 mg, 99.34% purity, 97.50% ee, second peak, RT = 4.255 min) stereoisomer two as a white solid. 1H NMR (DMSO- d6, 400 MHz) δ 9.33 (s, 1 H), 8.52 (s, 1 H), 7.80 (s, 1 H), 7.41 (s, 1 H), 7.20 (s, 1 H), 6.95 (s, 1 H), 4.92-4.81 (m, 2 H), 4.52-4.42 (m, 1 H), 3.93-3.85 (m, 2 H), 3.79 (s, 3 H), 3.30-3.20 (m, 2 H), 3.13 (t, J = 10.8 Hz, 1 H), 2.21-2.14 (m, 1 H), 1.97 (s, 3 H), 1.89-1.76 (m, 1 H). MS (ESI): mass calcd. For C19H22BN5O4395.18, m/z found 396.2 [M+H]+. HPLC: 99.34% (220 nm), 99.73% (254 nm). [0651] 45. Preparation of 5-((4-(((trans)-4-cyanotetrahydro-2H-pyran-3-yl)amino)-5- methylpyrimidin-2-yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile
[0652] 45.1 Preparation of 3-((2 xymethyl)phenyl)amino)-5-
methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0653] mmol, 1
eq) and 3-[(2-chloro-5-methyl-pyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (3.8 g, 15 mmol, 0.9 eq) in i-PrOH (40 mL) was added TFA (2.8 g, 25.1 mmol, 1.86 mL, 1.5 eq) at 25°C. The mixture was stirred at 80°C for 4 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was quenched with saturated.aq. Na2CO3 (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude product. The crude product was triturated with Petroleum ether (30 mL) at 25oC for 10 min to give (trans)-3-[[2-[4-bromo-3-cyano-5-(hydroxymethyl)anilino]- 5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (7.1 g, 95.6% yield) as a brown solid. 1H NMR (400 MHz, METHANOL-d4) δ = 8.24 (d, J = 2.8 Hz, 1H), 8.07 (d, J = 2.8 Hz, 1H), 7.77 (s, 1H), 4.67 (s, 2H), 4.01 - 3.97 (m, 1H), 3.95 (t, J = 3.2 Hz, 1H), 3.80 - 3.70 (m, 1H), 3.50 - 3.40 (m, 1H), 3.27 - 3.22 (m, 1H), 3.20 - 3.10 (m, 1H), 2.17 - 2.13 (m, 1H), 2.03 (s, 3H), 1.90 - 1.80 (m, 1H). [0654] 45.2 Preparation of (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- cyanophenyl)amino)-5-methylpyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[065 thyl-
pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (3.5 g, 7.90 mmol, 1 eq) in THF (40 mL) was added 2,6-dimethylpyridine (3.38 g, 31.5 mmol, 3.68 mL, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (4.17 g, 15.8 mmol, 3.63 mL, 2 eq) at 25°C. The mixture was stirred at 25°C for 2 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was triturated with petroleum ether (20 ml) at 25oC for 15 min to give 3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-cyano- anilino]-5-methyl-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (2.3 g, 52.2% yield) as a brown solid. 1H NMR (400 MHz, CDCl3) δ = 8.26 (d, J = 2.4 Hz, 1H), 7.84 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.00 (s, 1H), 5.03 (d, J = 7.6 Hz, 1H), 4.72 (s, 2H), 4.45 - 4.35 (m, 1H), 4.17 - 4.09 (m, 1H), 3.95 - 3.82 (m, 2H), 3.80 - 3.70 (m, 1H), 3.30 - 3.25 (m, 1H), 2.20 - 2.10 (m, 1H), 2.04 (s, 3H), 1.92 - 1.83 (m, 1H), 0.99 (s, 9H), 0.17 (s, 6H). [0656] 45.3 Preparation of (2-(((tert-butyldimethylsilyl)oxy)methyl)-6-cyano-4-((4-(((trans)-4- cyanotetrahydro-2H-pyran-3-yl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid [06
omo- 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-cyano-anilino]-5-methyl-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (500 mg, 897 umol, 1 eq) and 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (810 mg, 3.59 mmol, 4 eq) in dioxane (5 mL) was added Pd(PPh3)2Cl2 (62.9 mg, 89.6 umol, 0.1 eq) and K3PO4 (571 mg, 2.69 mmol, 3 eq). The mixture was stirred at 120°C for 10 min. LCMS showed the starting material was
consumed completely and desired MS was detected. The four parallel reactions were combined and concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (column: C18 (250*50mm*10 um);mobile phase: [water ( NH4HCO3)-ACN]; B%: 35%- 65%,10min) to give (2-(((tert-butyldimethylsilyl)oxy)methyl)-6-cyano-4-((4-(((trans)-4- cyanotetrahydro-2H-pyran-3-yl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid (0.8 g, 42.6% yield) as a white solid. [0658] 45.4 Preparation of 5-((4-(((trans)4-cyanotetrahydro-2H-pyran-3-yl)amino)-5- methylpyrimidin-2-yl)amino)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-7-carbonitrile [06
-4- cyanotetrahydro-2H-pyran-3-yl)amino)-5-methylpyrimidin-2-yl)amino)phenyl)boronic acid (400 mg, 765 umol, 1 eq) in THF (4 mL) was added aq. HCl (6 M, 5 mL). The mixture was stirred at 25°C for 2 hr. LCMS showed the starting material was consumed completely and desired MS was detected. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [water (formic acid-FA)-ACN]; B%: 1%-35%,8min) to give 5-[[4-[(4- cyanotetrahydropyran-3-yl)amino]-5-methyl-pyrimidin-2-yl]amino]-1-hydroxy-3H-2,1- benzoxaborole-7-carbonitrile (140 mg, 100% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 9.59 (s, 1H), 9.17 (s, 1H), 8.15 (s, 1H), 8.14 (s, 1H),
.12 (s, 1H), 7.84 (s, 1H), 6.82 (d, J = 8.8 Hz, 1H), 5.05 - 4.94 (m, 2H), 4.53 - 4.42 (m, 1H), 3.92 - 3.85 (m, 2H), 3.20 - 3.15 (m, 2H), 3.15 - 3.10 (m, 1H), 2.20 - 2.15 (m, 1H), 1.97 (s, 3H), 1.94 - 1.84 (m, 1H). MS (ESI): mass calcd. For C19H19BN6O3390.16, m/z found 389.0 [M-H]-. HPLC: 100.00% (220 nm), 100.00% (254 nm).
[0660] 46. Preparation of (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-fluoropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0661] 46.1 Preparation of (trans y-1,3-dihydrobenzo[c][1,2]
oxaborol-5-yl)amino)-5-fluoropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0662] 14 mmol,
1 eq, HCl salt) in i-PrOH (2 mL) was added (trans)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino) tetrahydro-2H-pyran-4-carbonitrile (205 mg, 798 umol, 0.7 eq), TFA (195 mg, 1.70 mmol, 1.5 eq) at 25°C , and then the mixture was stirred at 80°C for 1 h. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was quenched by addition H2O (0.5 mL) at 25°C, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18100x30mmx10um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 10%-40%,8min ) to give (trans)-3-((2-((7-chloro-1- hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-fluoropyrimidin-4-yl)amino) tetrahydro-2H-pyran-4-carbonitrile (7.3 mg, 97.48% purity) as a white solid.1H NMR (DMSO- d6, 400 MHz) δ = 9.62 (s, 1H), 8.05 (s, 1H), 7.80 - 7.78 (m, 1H), 7.75 (d, J = 5.6 Hz, 2H), 6.05 (s, 1H), 4.93 (s, 2H), 4.41 - 4.32 (m, 1H), 3.92 - 3.86 (m, 2H), 3.11 (m, 3H), 2.20 - 2.16 (m, 1H), 1.88 - 1.84 (m, 1H). MS (ESI): mass calcd. For C17H16BClFN5O3403.10, m/z found 402.0 [M- H]-. HPLC: 97.48% (220 nm), 98.66% (254 nm). [0663] 47. Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0664] 47.1 Preparation of meth rbonyl)amino)benzoate
[0665] To a m q) in EtOH (200
mL) was added Boc2O (31.3 g, 143 mmol, 1.5 eq) and stirred at 70°C for 12 hrs. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (100 mL) at 20°C for 2 hrs to give methyl 2-bromo-5-((tert-butoxycarbonyl)amino)benzoate (30 g, 95.0% yield) as a pink solid. 1H NMR (CDCl3, 400 MHz) δ 7.83 (s, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 6.55 (s, 1H), 3.93 (s, 3H), 1.52 (s, 9H). [0666] 47.2 Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)benzoate [0667]
mg, 3.02 mmol, 1 eq) in dioxane (20 mL) was added 5,5,5',5'-tetramethyl-2,2'-bi(1,3,2-dioxaborinane) (3.42 g, 15.1 mmol, 5 eq), KOAc (890 mg, 9.08 mmol, 3 eq) and Pd(PPh3)2Cl2 (212 mg, 302 umol, 0.1 eq) at 20°C and stirred at 120°C for 2 hrs under N2. LCMS showed the reaction was complete and desired MS observed. The reaction mixture was filtered and concentrated under reduced pressure to give methyl 5-((tert-butoxycarbonyl)amino)-2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)benzoate (1 g, crude) as brown oil. [0668] 47.3 Preparation of tert-butyl (1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)carbamate
[0669] To a mi yl-1,3,2-
dioxaborinan-2-yl)benzoate (1 g, 2.76 mmol, 1 eq, crude) in MeOH (10 mL) was added NaBH4 (518 mg, 8.28 mmol, 3 eq) at 20°C, and then the mixture was stirred at 20°C for 1 hr. LCMS showed the reaction was complete and desired MS was detected. The reaction mixture was quenched by addition aq. HCl (2N, 20 mL) at 0°C, and then extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/petroleum ethergradient @ 36 mL/min) to give tert-butyl (1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)carbamate (600 mg, crude) as yellow oil. [0670] 47.4 Preparation of 5-aminobenzo[c][1,2]oxaborol-1(3H)-ol (hydrogen chloride)
[0671] A mixture of tert-butyl (1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)carbamate (600 mg, 2.41 mmol, 1 eq) in HCl/EtOAc (10 mL, 4 M) was stirred at 20°C for 1 hr. LCMS showed the reaction was complete and desired MS was detected. The reaction mixture was concentrated under reduced pressure to give 5-aminobenzo[c][1,2]oxaborol-1(3H)-ol (370 mg, 82.8% yield, HCl) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.29 (s, 3H), 7.73 (d, J = 8.0 Hz, 1H), 7.21 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 4.97 (s, 2H). [0672] 47.5 Preparation of (trans)-3-((5-chloro-2-((1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0673] To a H-pyran-4-
carbonitrile (206 mg, 756 umol, 0.7 eq) in i-PrOH (5 mL) was added 5- aminobenzo[c][1,2]oxaborol-1(3H)-ol (200 mg, 1.08 mmol, 1 eq, HCl) and TFA (184 mg, 1.62 mmol, 119 uL, 1.5 eq), and stirred at 80°C for 2 hrs under N2. LCMS showed the reaction was complete and desired MS was detected. The reaction mixture was quenched by addition H2O (5 mL), filtered to obtain the filter cake as a crude product. The crude product was purified by prep-HPLC (column: Phenomenex luna C1880*40mm*3 um; mobile phase: [water (HCl)-ACN]; B%: 5%-30%, 7min) to give (trans)-3-((5-chloro-2-((1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (27.9 mg, 6.37% yield, 95.03% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.90 (s, 1H), 8.15 (s, 1H), 7.86 (s, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 5.01 - 4.89 (m, 2H), 4.47 - 4.36 (m, 1H), 3.90 - 3.86 (m, 2H), 3.43 - 3.17 (m, 3H), 2.19 - 2.16 (m, 1H), 1.89 - 1.80 (m, 1H). MS (ESI): mass calcd. For C17H17BClN5O3385.11, m/z found 383.9 [M-H]-. HPLC: 95.03% (220 nm), 99.70% (254 nm). [0674] 48. Preparation of (trans)-3-[[5-chloro-2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0675] 48.1 Preparation of (tran
5-(hydroxymethyl) phenyl)amino)- 5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0676] T mmol, 1 eq)
and (trans)-3-[(2,5-dichloropyrimidin-4-yl)amino]tetrahydropyran-4-carbonitrile (577 mg, 2.11 mmol, 1 eq) in i-PrOH (10 mL) was drop-wise added TFA (361 mg, 3.17 mmol, 1.5 eq) at 25°C. The resulting mixture was stirred at 80°C for 12 h. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered to give a residue. The residue was triturated with saturated aq. NaHCO3 (10 mL) and filtered to give 3-((2-((4-bromo-3-chloro-5- (hydroxymethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (0.5 g, 50% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.04 (s, 1 H), 8.17 (s, 1 H), 8.06 (s, 1 H), 7.78-7.71 (m, 2 H), 4.50 (s, 2 H), 4.49-4.45 (m, 1 H), 3.93-3.80 (m, 2 H), 3.38-3.28 (m, 1 H), 3.25-3.19 (m, 2 H), 2.21-2.15 (m, 1 H), 2.10-1.85 (m, 1 H). [0677] 48.2 Preparation of (trans)-3-[[2-[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5- chloro-anilino]-5-chloro-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0
-5- chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (0.5 g, 1.06 mmol, 1 eq) in THF (5 mL) was added 2,6-dimethylpyridine (452 mg, 4.23 mmol, 490 uL, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (419 mg, 1.59 mmol, 364 uL, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give (trans)-3-[[2-
[4-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-chloro-pyrimidin-4- yl]amino]tetrahydropyran-4-carbonitrile (0.6 g, 96.6% yield) as a white solid. [0679] 48.3 Preparation of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile o-3-
[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-anilino]-5-chloro-pyrimidin-4-yl]amino] tetrahydropyran-4-carbonitrile (250 mg, 425 umol, 1 eq), 2-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)-5,5-dimethyl-1,3,2-dioxaborinane (480 mg, 2.13 mmol, 5 eq), KOAc (125 mg, 1.28 mmol, 3 eq) and Pd(PPh3)2Cl2 (30 mg, 42.5 umol, 0.1 eq) in dioxane (5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 40 min under N2 atmosphere. TLC showed the reaction was complete. The two parallel reactions were combined, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-3- ((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2- yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (0.5 g, crude) as a white solid. [0681] 48.4 Preparation of (trans)-3-[[5-chloro-2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5- yl)amino]pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile Cl O Cl OH
[0682] To a solution of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (0.5 g, 806 umol, 1 eq) in THF (10 mL) was added aq. HCl (4 M, 2.0 mL, 10 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitate out. The reaction mixture was filtered to give a residue. The residue was triturated with MeCN (8 mL) and filtered to give (trans)-3-[[5-chloro-2-[(7-chloro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino] pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (80.2 mg, 23.7% yield, 98.31% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.82 (s, 1 H), 8.13 (s, 1 H), 7.74 (d, J = 6.8 Hz, 2 H), 7.49 (d, J = 8.8 Hz, 1 H), 5.00-4.90 (m, 2 H), 4.52-4.42 (m, 1 H), 3.93-3.80 (m, 2 H), 3.38- 3.28 (m, 2 H), 3.25-3.15 (m, 1 H), 2.21-2.15 (m, 1 H), 2.10-1.85 (m, 1 H). MS (ESI): mass calcd. For C17H16BCl2N5O3419.07, m/z found 420.1 [M+H]+. HPLC: 98.31% (220 nm), 99.12% (254 nm). [0683] 49. Preparation of (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile [0684] 49.1 Preparation of (tran
5-(hydroxymethyl)phenyl) amino)- 5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0685]
, . mol, 1 eq) in i-PrOH (5 mL) was added TFA (361 mg, 3.17 mmol, 1.5 eq) and (trans)-3-[[2-chloro-5- (trifluoromethyl)pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (647 mg, 2.11 mmol, 1 eq) at 25°C. The reaction mixture was stirred at 80°C for 4 hrs. Solids precipitated out. TLC
showed the reaction was complete. The reaction mixture was filtered and the filter cake was triturated with saturated aq. NaHCO3 (30 mL) and filtered to give (trans)-3-((2-((4-bromo-3- chloro-5-(hydroxymethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro- 2H-pyran-4-carbonitrile (670 mg, 62.7% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.12 (s, 1H), 8.34 (s, 1H), 8.09 (s, 1H), 7.79 (d, J = 2.8 Hz 1H), 7.20 (d, J = 8.8 Hz, 1H),
4.72 - 4.58 (m, 1H), 4.55 - 4.47 (m, 2H), 3.92 - 3.76 (m, 2H), 3.40 - 3.35(m, 1H), 3.31 - 3.18 (m, 2H), 2.21 - 2.08 (m, 1H), 1.98 - 1.79 (m, 1H). [0686] 49.2 Preparation of (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- chlorophenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile [
5- (trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (500 mg, 986 umol, 1 eq) in THF (20 mL) was added 2,6-dimethylpyridine (422 mg, 3.95 mmol, 4 eq) and [tert- butyl(dimethyl)silyl] trifluoromethanesulfonate (391 mg, 1.48 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 hrs. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (20 mL) at 0°C and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether/ethyl acetate = 5/1 to 3/1) to give 3-((2-((4- bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chlorophenyl)amino)-5- (trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (320 mg, 52.2% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 10.16 (s, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.72 (s, 1H), 7.16 (d, J = 8.8 Hz, 1H), 4.76 - 4.53 (m, 3H), 3.90 - 3.76 (m, 2H), 3.53 - 3.36 (m, 1H), 3.28 - 3.19 (m, 2H), 2.16 (d, J = 11.2 Hz, 1H), 1.90 - 1.80 (m, 1H), 0.94 (s, 9H), 0.13 (s, 6H).
[0688] 49.3 Preparation of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4- (5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0 omo-
3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chlorophenyl)amino)-5-(trifluoromethyl)pyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (277 mg, 446 umol, 1 eq), 2-(5,5-dimethyl-1,3,2- dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (503 mg, 2.23 mmol, 5 eq), Pd(PPh3)2Cl2 (31.3 mg, 44.6 umol, 0.1 eq) and KOAc (131 mg, 1.34 mmol, 3 eq) in dioxane (8 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 120°C for 10 min under N2 atmosphere. TLC showed the reaction was complete. The parallel reactions were combined, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-5-chloro-4-(5,5-dimethyl- 1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (600 mg, crude) as a yellow solid. [0690] 49.4 Preparation of (trans)-3-((2-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile To a
so u o o ans - - - - e - u y e y s y o y e y - -c o o- - , - dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-
yl)amino)tetrahydro-2H-pyran-4-carbonitrile (600 mg, 1.02 mmol, 1 eq) in THF (5 mL) was added aq. HCl (2 M, 10 mL) at 25°C. The mixture was stirred at 25°C for 2 hr. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered and the filter cake was triturated with THF (5 mL) and filtered to give (trans)-3-((2-((7-chloro-1- hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (7.3 mg) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.11 (s, 1H), 8.96 (s, 1H), 8.35 (s, 1H), 7.85 - 7.65 (m, 2H), 7.19 (d, J = 9.2 Hz, 1H), 5.06 - 4.90 (m, 2H), 4.68 - 4.54 (m, 1H), 3.93 - 3.80 (m, 2H), 3.45 - 3.40 (m, 1H), 3.28 - 3.19 (m, 2H), 2.17-2.15 (m, 1H), 1.94 - 1.80 (m, 1H). MS (ESI): mass calcd. For C18H16BClF3N5O3453.10, m/z found 452.0 [M-H]-. HPLC: 100% (220 nm), 100% (254 nm). [0691] 50. Preparation of (trans)-3-((5-chloro-2-((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0692] 50.1 Preparation of (tr
hydroxymethyl)anilino]-5-chloro- pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile [0693] To
, mmol, 1 eq) in i-PrOH (10 mL) was added TFA (350 mg, 3.07 mmol, 1.5 eq) and (trans)-3-((2,5- dichloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (558 mg, 2.05 mmol, 1 eq) at 25°C. The mixture was stirred at 80°C for 12 h. Solid was precipitate out. TLC showed the reaction was complete. The reaction mixture was filtered to give a residue. The residue was triturated with saturated aq. NaHCO3 (10 mL) and filtered to give (trans)-3-[[2-[4-bromo-3-
fluoro-5-(hydroxymethyl)anilino]-5-chloro-pyrimidin-4-yl]amino]tetrahydropyran-4-carbonitrile (600 mg, 64.2% yield) as a white solid. [0694] 50.2 Preparation of (trans)-3-((2-((4-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5- fluorophenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile [0 idin-
4-yl]amino]tetrahydropyran-4-carbonitrile (580 mg, 1.27 mmol, 1 eq) in THF (10 mL) was added 2,6-dimethylpyridine (544 mg, 5.08 mmol, 4 eq) and [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate (503 mg, 1.90 mmol, 1.5 eq) at 25°C. The mixture was stirred at 25°C for 2 h. TLC showed the reaction was complete. The reaction mixture was quenched by addition of H2O (10 mL) at 0°C and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 10/1 to 5/1) to give 3-((2-((4-bromo-3-(((tert-butyldimethylsilyl) oxy)methyl)-5-fluorophenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile (650 mg, 89.6% yield) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.82 (s, 1 H), 8.29 (t, J = 8.0 Hz, 1 H), 8.06 (s, 1 H), 7.89 (d, J = 8.0 Hz, 1 H), 7.61 (s, 1 H), 4.67 (s, 2 H), 4.52-4.42 (m, 1 H), 3.98-3.80 (m, 2 H), 3.38-3.28 (m, 2 H), 3.25-3.15 (m, 1 H), 2.35-2.05 (m, 1 H), 1.95-1.82 (m, 1 H), 0.93 (s, 9 H), 0.13 (s, 6 H). [0696] 50.3 Preparation of (trans)-3-((2-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluorophenyl)amino)-5-chloropyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile
[0697] Two reactions were carried out in parallel. For each a solution of (trans)-3-((2-((4- bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-fluorophenyl)amino)-5-chloropyrimidin-4- yl)amino)tetrahydro-2H-pyran-4-carbonitrile (340 mg, 744 umol, 1 eq) in dioxane (8 mL) was added Pd(PPh3)2Cl2 (52 mg, 74.4 umol, 0.1 eq), KOAc (182 mg, 1.86 mmol, 2.5 eq) and 2-(5,5- dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (840 mg, 3.72 mmol, 5 eq) at 25°C. The mixture was stirred at 120°C for 40 min. TLC showed the reaction was complete. The two parallel reactions were combined, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 3/1 to 1/1) to give (trans)-3-((2-((3-(((tert-butyldimethylsilyl) oxy)methyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluorophenyl)amino)-5- chloropyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (0.75 g, 88.2% yield) as a white solid. [0698] 50.4 Preparation of (trans)-3-((5-chloro-2-((7-fluoro-1-hydroxy-1,3- dihydrobenzo[c][1,2] oxaborol-5-yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4- carbonitrile [06
ethyl- 1,3,2-dioxaborinan-2-yl)-5-fluorophenyl)amino)-5-chloropyrimidin-4-yl)amino)tetrahydro-2H- pyran-4-carbonitrile (0.5 g, 828 umol, 1 eq) in THF (10 mL) was added aq. HCl (4 M, 2.0 mL, 10 eq) at 25°C. The mixture was stirred at 25°C for 1 h. Solid was precipitate out. The reaction mixture was filtered to give a residue. The residue was triturated with THF (8 mL) and filtered to give 3-((5-chloro-2-((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)amino)pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile (65.6 mg, 19.6% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.82 (s, 1 H), 8.13 (s, 1 H), 7.64 (s, 1 H), 7.53- 7.40 (m, 2 H), 4.96 (s, 2 H), 4.52-4.42 (m, 1 H), 3.98-3.80 (m, 2 H), 3.38-3.28 (m, 2 H), 3.25-
3.15 (m, 1 H), 2.35-2.05 (m, 1 H), 1.95-1.82 (m, 1 H). MS (ESI): mass calcd. For C17H16BClFN5O3403.10, m/z found 404.1 [M+H]+. HPLC: 99.04% (220 nm), 98.94% (254 nm). Comparator compounds [0700] Comparator compounds which are derivatives of Compound (II) having Y1-4 substituents (compounds C001-C020 as listed below) were prepared and the biological testing results for the comparator compounds are provided in Table 3b (Biological Examples). The comparator compounds may be made using the starting materials and synthetic procedures as outlined in PCT Application No. PCT/US2020/070234, which published as WO 2021/003501, and which is herein incorporated by reference with regard to such teaching. Y3 OH Y2 B I) Y1 Y2 3 4
Y Y C001 (Et)2CH- Me H H
BIOLOGICAL EXAMPLES [0701] The compounds of the present disclosure were tested in multiple assays as described below. Representative results from the compounds of the present disclosure are compiled in Table 3a. Results for Comparative Examples are provided in Table 3b. Biochemical Kinase Assay Protocol (JAK) [0702] Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% BrijTM 35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO, where required cofactors were added individually to each kinase reaction. [0703] Reaction Procedure: 1. Prepared indicated substrate in freshly prepared Base Reaction Buffer 2. Delivered any required cofactors to the substrate solution above 3. Delivered indicated kinase into the substrate solution and gently mix 4. Delivered compounds in DMSO into the kinase reaction mixture by Acoustic technology (Echo550; nanoliter range), incubated for 20 minutes at room temperature 5. Delivered 33P-ATP into the reaction mixture to initiate the reaction. 6. Incubated kinase reaction for 2 hours at room temperature 7. Reactions were spotted onto P81 ion exchange paper 8. Detected kinase activity by filter-binding method. Cytokine inhibition Assay Protocol for IL-4 and IL-31 [0704] The test compounds are solubilized in DMSO, then diluted to make appropriate stocks for use in the assay, and diluted in culture medium to 20X assay concentrations. PBMC’s are plated and allowed to settle for 1 hour at 37 °C, 5% CO2. Test compounds and controls are added to the settled PBMC’s and incubated for 1 hour at 37 °C, 5% CO2. The PBMC’s are then be treated with PHA (10 μg/mL) and incubated for 24 hours at 37 °C, 5% CO2. DMSO is used as a positive control and dexamethasone (100 nM) was used as a reference inhibitor control. After the main incubation, cell culture supernatants are harvested and assayed for the cytokines listed above, using standard Luminex protocols. Levels of cytokine induction are interpolated from standard curves using 5-parameter non-linear regression analyses, where y = (A+((B-A)/(1+(((B-E)/(E-
A))*((x/C)^D))))). The interpolated data is normalized to DMSO controls and analyzed to determine IC50 values using 4-parameter non-linear regression analyses, where y = (A+((B- A)/(1+((C/x)^D)))) Cytokine Function assay protocols for IL-4/pSTAT6 and GM-CSF/pSTAT5 [0705] GM-CSF/pSTAT5: Whole blood from a healthy donor was lysed to remove red blood cells. Cells were plated onto a 96 well plate. Compound was added and incubated for 1 hour (at 37°C). After 1 hour, cells were stimulated with GM-CSF for 15 minutes. Cells were fixed and stained with anti- pSTAT5 antibody. After staining, cells were read on a Beckman-Coulter CytoFLEX. [0706] IL-4/pSTAT6: PBMC from a healthy donor was plated onto a 96w plate. Compound was added and incubated for 1 hour (at 37°C). After 1 hour, cells were stimulated with IL-4 for 15 minutes. Cells were fixed and stained with anti-pSTAT6 antibody. After staining, cells were read on a Beckman-Coulter CytoFLEX. Cytokine Function assay protocol for IL-31 [0707] The protocol for the cytokine function assay for IL-31 is set forth below: 1. Plate DH82 cells at a density of 125,000 cells per well in a 96-well plate and incubate overnight in EMEM medium (ATCC® 30-2003) containing 15% FBS and 10 ng/mL canine IFNr (R&D, Cat# 781-CG-050, Lot#DIA1320011) at 37 °C. 2. After 24 hr, wash with 37 °C pre-warmed PBS (100 uL/well). 3. Add serum-free MEM, 90 uL per well, 2 hr, 37 °C. 4. Add 10 uL 10x IL-31 (40, 10, 2.5 ug/mL) in duplicate, 5 min, 37 °C. 5. Remove medium, add 60 uL lysis buffer per well. Agitate on a plate shaker (~350 rpm) for 10 min at RT. 6. Add 12 uL lysate/50%lysate to 384-well Opaque assay plate, 25% control lysate and lysis buffer were added to the assay plate in duplicate as positive and negative controls. 7. Add 6 uL Acceptor Mix, cover with aluminum foil, quickly spin at 1000 rpm, shake at 120 rpm for 2 min, then incubate at RT for 1hr.
8. Add 6 uL Donor Mix, cover with aluminum foil, quickly spin at 1000 rpm, shake at 120 rpm for 2 min, then incubate at RT for 1hr. 9. Measure the fluorescence using EnVisionTM plate reader. Dog LM (liver microsome) Assay [0708] The metabolic degradation of the test compound is assayed at 37°C with pooled liver microsomes from dogs (Beagle). The final incubation volume of 100 µl per time point contains TRIS buffer pH 7.6 at RT (0.1 M), magnesium chloride (5 mM), microsomal protein (1 mg/ml) and the test compound at a final concentration of 1 µM. Following a short preincubation period at 37°C, the reactions were initiated by addition of beta-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 1 mM) and terminated by transferring an aliquot into solvent after different time points. Additionally, the NADPH-independent degradation was monitored in incubations without NADPH, terminated at the last time point. The [%] remaining test compound after NADPH independent incubation is reflected by the parameter c(control) (metabolic stability). The quenched incubations are pelleted by centrifugation (10000 g, 5 min). An aliquot of the supernatant is assayed by LC-MS/MS for the amount of parent compound. The half-life (t1/2 INVITRO) is determined by the slope of the semilogarithmic plot of the concentration-time profile. The intrinsic clearance (CL_INTRINSIC) is calculated by considering the amount of protein in the incubation: CL_INTRINSIC [µl/min/mg protein] = (Ln 2 / (half-life [min] * protein content [mg/ml])) * 1000. For better across species comparison the predicted clearance is expressed as percent of the liver blood flow [% QH] in the individual species. In general, high stability (corresponding to low % QH) of the compounds across species is desired. Test Compounds [0709] The results of biological testing for the compounds according to the present disclosure are provided below in Table 3a. The Example Number entries formatted ##a represent stereoisomer one and entries formatted ##b represent stereoisomer two. A recitation of “-“ is intended as a designation of a compound of the present disclosure that is not yet tested for the respective assay.
TABLE 3a: Biological Testing Results Example IC50 IC50 IC50 IC50 IC50 IC50 Dog LM Number JAK1 JAK2 PDE4 IL-4 GM- IL-31 QH(%)
Example IC50 IC50 IC50 IC50 IC50 IC50 Dog LM Number JAK1 JAK2 PDE4 IL-4 GM- IL-31 QH(%)
[0710] Biological testing results for comparator compounds of structure (II) with variables Y1, Y2, Y3, and Y4 are provided in Table 3b:
Y3 OH Y2 B N I)
et: 88469-391203 (BAH-200-WO) [0711] TABLE 3b: Biological Testing Results, comparator compounds Y3 OH Y2
N Y1 N N N H H Comparato Y1 IC50 IC50 IC50 Dog LM r ID IL-4 GM- IL-31 QH(%) (nM) CSF (nM) (nM) C001 (Et)2 115.0 1718 - 73.8 C002 (Et)2 155.0 10000 - <19.9 C003 (Et)2 125.0 1156 - 41.0 C004 (Et)2 118.0 >10000 - 34.5 C005 (Et)2 6119.0 2254 - - C006 Cycl 293.0 270 - >86.6 C007 Cycl 300.1 3742 - 52.1 C008 Cycl 973.0 >10000 - 54.3 C009 Cycl 218.0 4221 - 83.4 C010 Cycl - - - - C011 Cycl 2494.0 7704 - 83.5 C012 Cycl 223.5 1783 - <19.9 C013 Cycl - - - - C014 Cycl 782.0 5354 - 78.5 C015 Cycl - - - 67.2 C016 Cycl 688.0 927 - 54.5 C017 Cycl 1638.0 10000 - 53.5 C018 Cycl - - - 56.0 C019 Cycl - - - 73.8 C020 Cycl - - - <19.9
Summary of Pharmacokinetic (PK) profile [0712] Three healthy male Beagle dogs were studied to determine a representative pharmacokinetic (PK) profile following a single oral administration of 1.0 mg/kg to each dog in a fasted state. Blood samples were collected at pre-dose, 0.25, 0.5, 1, 2, 4, 8, 24, 32, and 48 h post dose following oral administration (1 mg/mL in 10% Propylene glycol (PG), 45% PEG400, 7% Cremophor EL, 38% 50 mM citrate buffer pH 3.0 suspension or clear solution). [005] TABLE 4 Analyte Dose Median Mean Median Mean Mean Mean Mean
[0713] Ten healthy adult male Beagle dogs with no previous history of pruritus or skin disease were selected. All dogs first received intravenously recombinant canine IL-31 (1.75 ug/kg) to evaluate increased pruritic behaviors without any medications (IL-31 alone). Afterward, all dogs received repeated administration of oral solution and again intravenously recombinant canine IL- 31 injections to assess inhibition of IL-31 induced itch behavior. (See, e.g., Gonzales, Vet. Dermatol. 2016, 27, 34-e10 and Pearson, Vet. Sci. 2023, 10, 369) [0714] An oral solution of a representative compound of the present disclosure, Example 33a, at 1 mg/kg once daily in the morning for five (5) days, was administered to each dog in a crossover design for the five (5) consecutive days. All dogs were fasted during the oral administration and thirty minutes (30 min) post oral drug administration. On day 5, all dogs were administered a recombinant canine IL-31 intravenously at the dose of 1.75 µg/kg. [006] A comparative analysis between treatments (IL-31 baseline/alone, and representative compound/Example 33a) revealed that the representative compound of the present disclosure showed a significant anti-pruritic effect when compared to IL-31 baseline/alone. [0715] In some embodiments, the compounds of the present disclosure are potent JAK inhibitors. As such, the compounds may be used for the treatment or control of inflammation,
auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. [0716] All publications, patents, and patent applications cited in this specification are incorporated herein by reference for the teaching to which such citation is used. [0717] Test compounds for the experiments described herein were employed in free or salt form. [0718] The specific responses observed may vary according to and depending on the particular active compound selected or whether there are present carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present disclosure. [0719] Although specific embodiments of the present disclosure are herein illustrated and described in detail, the disclosure is not limited thereto. The above detailed descriptions are provided as exemplary of the present disclosure and should not be construed as constituting any limitation of the disclosure. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the disclosure are intended to be included with the scope of the appended claims.
[0720] The present disclosure is further supplemented by the following numbered paragraphs: [0721] #1. A compound of formula I: I), or a pharmaceutically accep
er thereof, wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be -O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R6)(R7)), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R6)(R7)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl; A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro-
1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro- 2H-1,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 : , A6, A7;
R5 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1- 3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl); wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring; R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen members of the above-mentioned R10 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more
substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0722] #2. A compound according to paragraph 1 wherein X1 is -C(R6)(R7)-; X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is-C(R6)(R7)- R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0723] #3. A compound according to one or more of paragraphs 1 to 2, wherein X1 is selected from the group consisting of -O-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen;
R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0724] #4. The compound according to any one or more of paragraphs 1-3, wherein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0725] #5. The compound according to any one or more of paragraphs 1-4, wherein R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl;
R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen. [0726] #6. A compound of formula (Ia) or (Ib): a), b), or a pharmaceutically a
ereof wherein
X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be –O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R7)(R8)-), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl; A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro- 1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro- 2H-1,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 : 2,
, A6, A7; R
oalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and - (C1-3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or
more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring; R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen members of the above-mentioned R10 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when
R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0727] #7. A compound according to paragraph 6, wherein X1 is -C(R6)(R7)-; X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)- R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of
one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0728] #8. The compound according to one or more of paragraphs 6-7, wherein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0729] #9. The compound according to any one or more of paragraphs 6-8, wherein R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen. [0730] #10. A compound selected from the group shown in the following Table 1: Table 1 Example Structure Example Number Number Structure
Example Structur Example Number e Number Structure
Example Number Structure Example Number Structure .
. , X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl. [0732] #12. The compound according to one or more of paragraphs 6 and 11, wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O- and -C(R6)(R7)-, except X1 and X2 may not both be -O-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-; R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members said R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. [0733] #13. The compound according to one or more of paragraphs 11 to 12, wherein X2 is -C(R6)(R7)-; X3 is -C(R6)(R7)-; R1, R2, and R3, are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen;
each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R12 is hydrogen; and each R13 is independently selected from the group consisting hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen. [0734] #14. A compound selected from the group shown in the following Table 2: Table 2 Example Struc Example Number ture Number Structure
Example Number Structure Example Number Structure
256
Example Number Structure Example Number Structure
[0735] #15. The compound according to any example in paragraph 10 and 14 which is a stereoisomer having trans relative stereochemistry as represented in formula (Ia) and (Ib):
a), b),
[0736] #16. The compound according to one or more of paragraphs 10 and 14, wherein the compound is a single stereoisomer having trans relative stereochemistry. [0737] #17. The compound according to claim 16, wherein the compound has trans stereochemistry as represented by either formula (Ia) or formula (Ib). [0738] #18. A process for preparing a compound according to any one of paragraphs 1-17. [0739] #19. A method for treating a patient having a disease or disorder susceptible to modulation of JAK including administering a therapeutically effective amount of a compound according to any one of paragraphs 1-17. [0740] #20. The method of paragraph 19, wherein the disease or disorder is a condition that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
[0741] #21. The method of paragraph 19, wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, inflammatory/autoimmune polyarthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, allergic rhinitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer. [0742] #22. The method of paragraph 21, wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis psoriasis, and rheumatoid arthritis. [0743] #23. The method according to any one of paragraphs 19-22, wherein the compound is administered in an amount to perturb an immune regulatory pathway in a cell. [0744] #24. The method of paragraph 23, wherein the perturbation results in an effect on the JAK-STAT pathway. [0745] #25. A method of inhibiting JAK in a mammalian cell including contacting the mammalian cell with a compound any one of paragraphs 1-17. [0746] #26. The method according to paragraph 25, wherein the mammalian cell is a cell from a subject having an inflammatory condition. [0747] #27. A composition including a compound of any one of paragraphs 1-17 and a pharmaceutically or veterinary acceptable carrier. [0748] #28. A combination including a compound of any one of paragraphs 1-17, and one or more other pharmaceutical or veterinary active substances.
[0749] #29. A method for treating one or more diseases or disorders of inflammation, auto- immune dysfunction, and cancer including administering to a subject in need thereof an effective amount of a compound of any one of paragraphs 1-17. [0750] #30. The method of paragraph 29, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis. [0751] #31. The method of paragraph 29 or paragraph 30, wherein the compound is administered orally, parenterally, or topically. [0752] #32. The method of any one of paragraphs 29-31, wherein the subject is a mammal. [0753] #33. The method of paragraph 32, wherein the mammal is selected from one or more of livestock mammals, domestic mammals, and companion animals. [0754] #34. The method of paragraph 32, wherein the mammal is selected from one or more of humans, cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs, and cats. [0755] #35. The method of paragraph 32, wherein the mammal is a human, dog, or cat. [0756] #36. A compound of any one of paragraphs 1-17 for use in medicine. [0757] #37. Use of a compound of any one of paragraphs 1-17 for the manufacture of a medicament for the treatment of one or more diseases or disorder of inflammation, auto-immune dysfunction, and cancer. [0758] #38. The use according to paragraph 37, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
[0759] #39. The use according to paragraph 37, wherein the disease or a disorder is ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2. [0760] #40. Use of a compound of any one of paragraphs 1-17 and a second active agent in the manufacture of a medicament for the treatment of a disease or a disorder that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2. [0761] #41. Use of a compound of any one of paragraphs 1-17 for the treatment of one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer. [0762] #42. The use according to paragraph 41, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis. * * * [0763] Having thus described in detail various embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
Claims
WHAT IS CLAIMED IS: 1. A compound of formula I: I), or a pharmaceutically accep
er thereof, wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be -O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R6)(R7)), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R6)(R7)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl; A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro-
1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro- 2H-1,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 : , A6, A7;
R5 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1- 3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl); wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring; R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen members of the above-mentioned R10 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more
substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
2. A compound according to claim 1 wherein X1 is -C(R6)(R7)-; X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is-C(R6)(R7)- R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
3. A compound according to one or more of claims 1 to 2, wherein X1 is selected from the group consisting of -O-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may
optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of: hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, - C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
4. The compound according to any one or more of claims 1-3, wherein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
5. The compound according to any one or more of claims 1-4, wherein
R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen.
6. A compound of formula (Ia) or (Ib): a), b),
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-, except X1 and X2 cannot both be –O-, and X2 and X3 cannot both be -O-; R1 is selected from the group consisting of hydrogen, halogen (when X3 is -C(R7)(R8)-), hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the of the above-mentioned R1 group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above- mentioned R2 group may optionally be substituted independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, halogen (when X1 is - C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -CHO, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, and partially or fully halogenated cyclopropyl; A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-dihydro- 1Hbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, 7,8 dihydro- 2H-1,6,9-trioxa-9-borabenzo[cd] azuline or a derivative thereof, such as a moiety selected from any one of A1-A7 : ,
and ;
R5 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the above- mentioned members of the R5 group, except hydrogen, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a heteroatom; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, - N(R8)(R9), -O(R10), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), - COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3- alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and - (C1-3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and wherein R6 and R7 may be linked together to form a ring; R8 and R9 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7- cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3- alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7- membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last fourteen members of the above-mentioned R8 and R9 groups may optionally be substituted independently of one another by one or more halogen, or R8 and R9 may be linked together to form a ring; R10 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3- alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6- cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the last thirteen
members of the above-mentioned R10 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except that said optional substitution may not be geminal; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R11 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, except when R11 is adjacent to oxygen, R11 is not halogen, and two adjacent R11 may be connected to provide a fused cycloalkyl, such as cyclopropyl; each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7- membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N- (R5)(R5), -SO2-(R5), -SO2-(R5)(R5), -S(O)-(R5), and -S-(R5), wherein the last fourteen members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
7. A compound according to claim 6, wherein X1 is -C(R6)(R7)-;
X2 is selected from -C(R6)(R7)-, or X2 comprises a bond between X1 and X3; X3 is-C(R6)(R7)- R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R2 group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R3 group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned R6 and R7 groups may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
8. The compound according to one or more of claims 6-7, wherein R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl;
R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein the C1-6 alkyl may optionally be substituted with one or more of halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy.
9. The compound according to any one or more of claims 6-8, wherein R1, R2, and R3 are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl may optionally be substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two substituents may optionally be substituted independently of one another by one or more halogen; R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen.
X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-, except X1 and X2 cannot both be -O-; R1 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R2 is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; each R3 is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned group may optionally be substituted independently of one another with one or more halogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the above-mentioned group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy, and R6 and R7 may be linked together to form a ring; and each R12 is independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl. 12. The compound according to one or more of claims 6 and 11, wherein X1 is selected from the group consisting of -O-, -N(R5)-, and -C(R6)(R7)-; X2 is selected from the group consisting of -O- and -C(R6)(R7)-, except X1 and X2 may not both be -O-, or X2 comprises a bond between X1 and X3; X3 is -C(R6)(R7)-; R1 is selected from the group consisting of hydrogen and C1-6 alkyl; R2 is selected from the group consisting of hydrogen and C1-6 alkyl; each R3 is independently selected from the group consisting of hydrogen and C1-6 alkyl; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen;
R12 is hydrogen; and each R13 is independently selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-(C3-6- cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last seven members said R13 group may optionally be substituted independently of one another by one or more substituents selected from the group consisting of halogen and hydroxy. 13. The compound according to any one or more of claims 11 to 12, wherein X2 is -C(R6)(R7)-; X3 is -C(R6)(R7)-; R1, R2, and R3, are hydrogen; R4 is selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl; R6 and R7 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more of halogen; each R11 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R11a is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R11 group may optionally be substituted independently of one another with one or more halogen; each R12 is hydrogen; and each R13 is independently selected from the group consisting hydrogen, halogen, cyano, C1-6 alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of the above-mentioned R13 group may optionally be substituted independently of one another by one or more halogen. 14. A compound selected from the group shown in the following Table 2:
Example Number Structure Example Number Structure .
15. The compound according to any example in claims 10 and 14 which is a stereoisomer having trans relative stereochemistry as represented in formula (Ia) and (Ib): a), b),
16. The compound according to one or more of claims 10 and 14, wherein the compound is a single stereoisomer having trans relative stereochemistry.
17. The compound according to claim 16, wherein the compound has trans stereochemistry as represented by either formula (Ia) or formula (Ib).
18. A process for preparing a compound according to any one of claims 1-17.
19. A method for treating a patient having a disease or disorder susceptible to modulation of JAK comprising administering a therapeutically effective amount of a compound according to any one of claims 1-17.
20. The method of claim 19, wherein the disease or disorder is a condition that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
21. The method of claim 19, wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic arthritis, inflammatory/autoimmune polyarthritis, Bechet’s disease, pityriasis rubra pilaris, alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous disease erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus, rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren’s syndrome, dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic dermatitis, allergic rhinitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular disease, artherosclerosis, and cancer.
22. The method of claim 21, wherein the disease or disorder is one or more of atopic dermatitis, flea allergy dermatitis psoriasis, and rheumatoid arthritis.
23. The method according to any one of claims 19-22, wherein the compound is administered in an amount to perturb an immune regulatory pathway in a cell.
24. The method of claim 23, wherein the perturbation results in an effect on the JAK-STAT pathway.
25. A method of inhibiting JAK in a mammalian cell comprising contacting the mammalian cell with a compound any one of claims 1-17.
26. The method according to claim 25, wherein the mammalian cell is a cell from a subject having an inflammatory condition.
27. A composition comprising a compound of any one of claims 1-17 and a pharmaceutically or veterinary acceptable carrier.
28. A combination comprising a compound of any one of claims 1-17, and one or more other pharmaceutical or veterinary active substances.
29. A method for treating one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-17.
30. The method of claim 29, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
31. The method of claim 29 or claim 30, wherein the compound is administered orally, parenterally, or topically.
32. The method of any one of claims 29-31, wherein the subject is a mammal.
33. The method of claim 32, wherein the mammal is selected from one or more of livestock mammals, domestic mammals, and companion animals.
34. The method of claim 32, wherein the mammal is selected from one or more of humans, cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs, and cats.
35. The method of claim 32, wherein the mammal is a human, dog, or cat.
36. A compound of any one of claims 1-17 for use in medicine.
37. Use of a compound of any one of claims 1-17 for the manufacture of a medicament for the treatment of one or more diseases or disorder of inflammation, auto-immune dysfunction, and cancer.
38. The use according to claim 37, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
39. The use according to claim 37, wherein the disease or a disorder is ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
40. Use of a compound of any one of claims 1-17 and a second active agent in the manufacture of a medicament for the treatment of a disease or a disorder that can be ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
41. Use of a compound of any one of claims 1-17 for the treatment of one or more diseases or disorders of inflammation, auto-immune dysfunction, and cancer.
42. The use according to claim 41, wherein the disease or disorder is atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263366535P | 2022-06-17 | 2022-06-17 | |
US63/366,535 | 2022-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023244775A1 true WO2023244775A1 (en) | 2023-12-21 |
Family
ID=89191888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/025516 WO2023244775A1 (en) | 2022-06-17 | 2023-06-16 | Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023244775A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100130486A1 (en) * | 2007-07-17 | 2010-05-27 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
WO2021003501A1 (en) * | 2019-07-03 | 2021-01-07 | Boragen, Inc. | Chemical compounds |
US20210000847A1 (en) * | 2006-02-16 | 2021-01-07 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as anti-inflammatory agents |
-
2023
- 2023-06-16 WO PCT/US2023/025516 patent/WO2023244775A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210000847A1 (en) * | 2006-02-16 | 2021-01-07 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as anti-inflammatory agents |
US20100130486A1 (en) * | 2007-07-17 | 2010-05-27 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
WO2021003501A1 (en) * | 2019-07-03 | 2021-01-07 | Boragen, Inc. | Chemical compounds |
Non-Patent Citations (2)
Title |
---|
DATABASE PUBCHEM SUBSTANCE ANONYMOUS : "AKOS033956620", XP093122795, retrieved from PUBCHEM * |
FLEMING ET AL.: "Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore", J MED CHEM., vol. 53, no. 22, 2010, pages 7902 - 7917, XP002695035, DOI: 10.1021/jm100762r * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021237841B2 (en) | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | |
US9206176B2 (en) | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | |
EP2800565B1 (en) | Carbamate compounds and methods of making and using same | |
US8372854B2 (en) | Pyrrolo[2,3-D]pyrimidine compounds | |
EP2864318B1 (en) | 2-aminopyrazine derivatives as csf-1r kinase inhibitors | |
JP2016537369A (en) | Substituted 4,5,6,7-tetrahydropyrazolo [1,5-A] pyrazine derivatives as casein kinase 1D / E inhibitors | |
US9296703B2 (en) | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | |
BR112015009168B1 (en) | COMPOUND OF STRUCTURAL FORMULA XI OR A SALT THEREOF, USE OF A COMPOUND AND PHARMACEUTICAL COMPOSITION | |
US20220242886A1 (en) | Chemical compounds | |
US11827657B2 (en) | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | |
AU2020300689A1 (en) | Chemical compounds | |
KR20220140515A (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
WO2023244775A1 (en) | Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof | |
CN107849042A (en) | Bicyclic heterocycle derivatives | |
US20240132525A1 (en) | Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof | |
KR20230096026A (en) | CFTR modulator compounds, compositions and uses thereof | |
WO2017198159A1 (en) | Imidazole derivative containing bridge ring | |
US11970493B2 (en) | Autotaxin inhibitor compounds | |
US20220106311A1 (en) | Autotaxin inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23824629 Country of ref document: EP Kind code of ref document: A1 |